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Abstract 
 
Background:  Although well documented in tobacco smokers, there is little empirical 
evidence on self-titration (i.e. adjusting puffing patterns to obtain desired blood nicotine 
levels) in e-cigarette users.  The primary aim was to explore the inter-relationships 
between e-cigarette puffing topography, nicotine concentrations and e-cigarette 
characteristics.  Other aims were to identify the possible predictors of smoking cessation 
in smokers attempting to quit using an e-cigarette.   
Methods:  Study 1 (N = 12 experienced e-cigarette users) employed a within-
participants design and measured how puffing topography differs between high (24 
mg/mL) and low (6 mg/mL) nicotine concentrations in 2 separate ad lib vaping 
sessions.  Study 2 used a mixed-participants design in which e-cigarette naïve smokers 
(N = 70; 62.9% female) were randomly allocated to a cigalike (18mg/mL) or a tank 
containing either 18 or 6 mg/mL nicotine concentrations to obtain profiles of puffing 
topography characteristics associated with each of the aforementioned conditions and 
how these evolve over a 2-week period (in 3 separate 20-minute ad lib vaping sessions).  
Puff duration, number and inter-puff intervals (IPI) were recorded along with exhaled 
carbon monoxide (CO), cigarette dependence, craving and withdrawal, and subjective 
effects at each session.  Participants were given the e-cigarette to take home and asked 
to record cigarettes smoked per day (CPD) and subjective symptoms.  In Study 3, Study 
2 participants were followed up at 1, 3 and 6 months.  Logistic regression analyses 
explored whether device type, nicotine concentrations, craving reduction, mean puff 
duration, cigarette dependence and motivation to quit could predict cessation.  
Results:  Study 1: Liquid consumption and puff number were higher and puff duration 
longer in the low nicotine concentrations condition (all ps < 0.01). There were no 
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statistically significant differences between conditions in self-reported craving, 
withdrawal symptoms, satisfaction, hit or adverse effects.  Nicotine plasma levels was 
significantly higher in the high nicotine concentration condition.  Study 2: Puff duration 
significantly increased one week post e-cigarette initiation whilst puff numbers and IPI 
decreased.  Cigalikes were associated with longer puff duration, shorter IPI and greater 
number of puffs; the use of Tank 18 led to longer IPI and shorter puff duration but this 
was not statistically significant when compared to Tank 6.  The Tank 18 and cigalikes 
were more efficient in reducing craving compared to the Tank 6 at baseline.  
Participants rated both Tanks (18 and 6 mg/mL) as more satisfying at baseline and Time 
1 compared with the cigalike.  CPD, CO and nicotine dependence reduced significantly 
at week 1 then plateaued between week 1 and 2, but did not differ between conditions.  
Study 3: Lower cigarette dependence, greater craving reduction with e-cigarette use 
reported at baseline and reports of tank use at follow up were significant predictors of 
cessation at 1, 3 and 6 months respectively.  Nicotine concentrations, mean puff 
duration and motivation to quit at baseline were not significant predictors.   
Conclusion:  Consistent with the self-titration theory, e-cigarette users engaged in 
compensatory puffing with lower (6 mg/mL) nicotine concentration liquids, nearly 
doubling their consumption.  Although self-titration was incomplete with significantly 
higher plasma nicotine levels in the high condition, compensatory puffing was sufficient 
to reduce craving and withdrawal discomfort.  The rapid adjustment in puffing 
topography and the more erratic puffing regimen in the cigalike condition both lend 
support to the self-titration theory. Whilst higher nicotine concentrations are more 
effective in reducing craving, tank systems are preferable in achieving satisfaction. This 
suggests an important role for device type in providing satisfaction and equally 
important role for nicotine concentrations to reduce craving.  Delineating the 
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mechanisms by which device types play a role in providing satisfaction and its subtle 
difference with craving should be one area to concentrate for future research.  Those 
with lower cigarette dependent scores were more likely to quit at 1 month, whilst those 
who reported greater craving reduction following e-cigarette use in the lab were more 
likely to have quit at 3 months; the predictive utility of measures of craving reduction at 
first use can be fostered to inform smoking cessation programmes.  The odds of quitting 
at 6 months were higher for those using a tank device at the time of follow-up compared 
to those using a cigalike, which is in line with previous studies suggesting that tank 
systems are associated with greater likelihood of successful cessation.  Key findings 
suggest that e-cigarettes have good potential in helping reduce tobacco smoking.   
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CHAPTER I 
THE BIOLOGICAL VERSUS THE PSYCHO-BEHAVIOURAL 
MODEL OF SMOKING ADDICTION: AN INTRODUCTION 
TO E-CIGARETTES 
 
Brief History of Tobacco Use  
As a genus of the Solanaceae family, the tobacco plant contains more than 50 
species; of these, Nicotiana Tabacum, the principal source of tobacco,  first originated in 
South and Central America, prior to its introduction into Europe (Stewart, 1967).  
Chewed, snuffed, burnt or consumed as a beverage, the custom of using tobacco leaves 
and inhaling the smoke, stems from religious ceremonies by the Mayans who attributed 
healing powers to the plant (Doll, 1999) and the Aztecs who credited it for its godly 
puissance (Elferink, 1983).  Early accounts of the medicinal uses of tobacco and its 
therapeutic applications to cure a number of ailments from ulcerated abscesses, earaches, 
constipation to healing wounds and burns, were documented in the 1500s and beyond 
(Hajdu & Vadmal, 2010; Stewart, 1967).  Although in the early 1600s, concerns were 
raised vis-à-vis its widespread and indiscriminate use, these were not sufficient to warrant 
its removal from pharmacopoeias (Charlton, 2004).  However, at the end of the fifteenth 
century, the medicinal use of tobacco was soon replaced by the ritual of smoking for 
pleasure which spread to the Caribbean Islands ports leading to its further propagation 
into Europe and the East by the Spaniards and the Portuguese.  Subsequently, Jean Nicot 
de Villemain a French ambassador to Lisbon, convinced that the plant held medicinal 
properties, introduced it to the French court in 1560 and to Portugal, whilst Sir Walter 
Raleigh propagated pipe smoking in England in 1578 (Corti, 1931 cited in Doll, 1999).   
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Following the original work of a French chemist Vauquelin, a colourless and 
viscous alkaloid, nicotine (named after the French ambassador Jean Nicot), was first 
isolated from the tobacco plant in 1828 by Posselt and Reimann.  This discovery 
furthered the understanding of the pharmacological potency of tobacco and the 
realisation of the potential dose-dependent toxicity of nicotine (Stewart, 1967).   
Cigarette smoking superseded pipe tobacco, cigars and snuff to only become 
popularised following the invention of the cigarette-rolling machine in 1880 which 
allowed their commercialisation (Dani & Balfour, 2011).  The first tobacco companies 
namely Philip Morris & Co, Imperial Tobacco in the UK, and in the US, American 
Tobacco Company, R.J. Reynolds, Ligget & Myers Tobacco Company, Lorillard, and 
British-American Tobacco started to emerge.  Tobacco became a protected crop and 
free cigarettes were included in soldiers’ rations.  By the end of World War II, cigarette 
smoking saw such a dramatic increase that its prevalence amongst adult males reached 
80% of the UK population (Doll, 1999).  By then, the realisation of the adverse health 
effects of tobacco smoking started to emerge (Doll, 1999).  Through correlational and 
epidemiological studies the link between tobacco smoking and cancer was becoming 
apparent.  The large predominance of smokers amongst lung cancer patients (Doll & 
Hill, 1950; Hoffman, 1931) and alarming mortality rates caused by coronary disease 
and various cancers amongst smokers (Hammond & Horn, 1958) came to light, despite 
significant efforts by the tobacco industry to suppress adverse media coverage and 
influence public perceptions (Brandt, 1990; TIRC, 1954).  Public awareness and the 
growing consensus vis-á-vis the harmful effects of smoking peaked at the beginning of 
the 1960s with the Royal College of Physicians report in 1962 followed by the first US 
surgeon General report in 1964, both suggesting a causal link between smoking and 
lung cancer, other lung and heart diseases and calling for the implementation of public 
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health measures to reduce smoking rates (Royal College of Physicians of London, 1962; 
Stanhope et al., 1964); this would eventually lead to a ban on cigarette advertisements 
in 1965 and 1970 in the UK and the US respectively, and the introduction of health 
warnings albeit timid, on packs of cigarettes (Action on Smoking and Health, 2015; 
Brandt, 1990).  This was followed by the foundation of anti-tobacco groups such as 
ASH (Action on Smoking and Health) by a lawyer called John Banzhaf III who 
following a court hearing secured free air time on radio networks for the advertisement 
of anti-smoking messages (Brandt, 1990).  This period marked the beginning of a shift 
toward a broad consensus about the health risks associated with smoking.   
Harms and costs of smoking  
Today, there is greater recognition that tobacco smoking is the leading cause of 
preventable disabilities and mortalities.  The differences in mortality rates in continuing 
smokers are consistently greater compared to ex- and non- smokers (Doll, Peto, 
Boreham, & Sutherland, 2004).  Smoking has been responsible for the premature death 
of approximately 6 million people worldwide every year, including 80% in lower 
income countries and 600,000 non-smokers from exposure to environmental tobacco 
smoke (The Tobacco Atlas, 2010).  Should the current trends continue, it is forecasted 
that the death toll may rise to one billion in the twenty-first century (Cancer Research 
UK, 2014).  Despite its known harmful effects, the current smoking prevalence remains 
at approximately 7.6 million which represents 15.6% of the UK population (Office for 
National Statistics, 2017).  Although this represents a significant and encouraging 
decline, with smoking rates continuing to increase in low and middle income countries, 
the global death toll is predicted to increase (Cancer Research UK, 2014).  In the UK, 
smoking is responsible for around 100,300 deaths annually, and, in England alone, an 
approximate 474,000 hospital admissions between 2015 and 2016 (Office for National 
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Statistics, 2017).  In England, smoking is estimated to cost an approximate £11 billion 
annually.  However, this figure is likely to be an underestimation due to a wide range of 
long term illnesses which impact on the social care system combined with the costs 
related to policing the illicit tobacco trade (Department of Health, 2017). 
Smoking is the leading cause of cardiovascular disease, Chronic and Obstructive 
Pulmonary Disease (COPD) and deaths related to cancer, and the extent of its adverse 
direct and indirect (environmental tobacco smoke) health consequences are extensively 
documented.  Smoking causes harms through multiple and complex mechanisms.  By 
exposing target sites within the body to more than 7 000 chemicals from which many 
are known human carcinogens (Pryor, Stone, Zang, & Bermúdez, 1998), it increases the 
risks of developing pneumonia, Cardiovascular Disease (CVD) (Ambrose & Barua, 
2004) such as emphysema, chronic bronchitis, and exacerbates asthma symptoms 
(Center for Disease Control and Prevention, 2010).  While smoking is more often 
associated with lung cancer, there is mounting evidence which suggests that exposure to 
tobacco smoke may lead to various other cancers, including but not exhaustive, cancer 
of the larynx, oesophagus, mouth, kidneys, cervix, bladder and so on (United States 
Department of Health and Human Services, 2014).  By convention, tobacco smoke is 
characterised by 2 phases, the tar (or particulate) which is long-lasting and the gaseous 
phase which is short lived (Pryor et al., 1998).  Although, nicotine is present in both 
phases (Hoffmann & Hoffmann, 1997), epidemiological data suggest no causal link 
between nicotine and cancer (Shields, 2011); it is the tar and exposure to carcinogens in 
the smoke that are associated with the harms of smoking (Center for Disease Control 
and Prevention, 2010).  To enable the establishment of toxicological profiles and the 
assessment of risks related to the exposure of tobacco smoke, its most potent 
constituents have been identified.  Tobacco smoke comprises a highly complex mixture 
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of i) chemical compounds for example, tobacco-specific N-nitrosamines (TSNAs) and 
polynuclear aromatic hydrocarbons (PAHs) (Hoffmann & Hoffmann, 1997), ii) 
chemicals specific to the tobacco leaves and iii) non-tobacco specific organic 
compounds which are the products of the combustion process (such as aldehydes) 
(Fowles & Dybing, 2003; Jefferson Fowles, Bates, & Noiton, 2000).  Carbon monoxide 
(CO), nitrogen oxides and other gaseous ingredients play an important role in CVD 
(Kjeldsen, Thomsen, & Astrup, 1974).  Amongst the harmful compounds present in the 
tobacco smoke, 1,3-butadiene represents the greatest risk of developing cancer (Fowles 
& Dybing, 2003) whilst cyanide, arsenic, and the cresols increase the risk  of CVD 
(Smith & Fisher, 2001).  Of equal concern, other metals, TSNAs, and PAHs have been 
identified as harmful chemicals in tobacco smoke while acrolein and acetaldehyde are 
known respiratory irritants (Talhout et al., 2011).    
Pharmacological and non-pharmacological factors, and nicotine delivery  
Many lines of evidence suggest nicotine to be the primary addictive component 
of tobacco smoking, and the main contributor of continued use despite the known 
harmful consequences (Balfour, Wright, Benwell, & Birrell, 2000; Dani & De Biasi, 
2001; Dani & Heinemann, 1996; Gaetano Di Chiara, 2000).  In fact, despite the well-
known harmful effects of smoking and early suggestions that smoking cessation 
significantly reduces the risks of smoking-related death and disease (Hammond & Horn, 
1958), and despite the fact that annually, a third of smokers in the UK make a quit 
attempt, the rate of long term successful attempts remain quite low (Royal College of 
Physicians & Group, 2016).  The large discrepancy between desire to quit and cessation 
success is testimony of the addictive nature of tobacco use.  Failed attempts to market 
nicotine free cigarettes (United States Department of Health and Human Services, 2014) 
further supports the concept that nicotine is the primary reinforcer of smoking 
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behaviours due to its addictive properties.  The notion that nicotine dependence drives 
smoking behaviour is based upon the premise of drug-seeking and -taking behaviours 
(Dani & Balfour, 2011).  Many definitions of addiction have been proposed, thus for the 
purpose of clarity, the term ‘addiction’ as referred to throughout is based on Professor 
Robert West and Dr Jamie Brown’s Theory of Addiction and is quoted verbatim: 
“Addiction is a chronic condition involving a repeated powerful 
motivation to engage in a rewarding behaviour, acquired as a result of 
engaging in that behaviour that has significant potential for unintended 
harm. Someone is addicted to something to the extent that they 
experience this repeated powerful motivation” (West & Brown, 2013, 
pp.15-18).   
 
Although some argue for a distinction between ‘addiction’ and ‘dependence’ (West & 
Brown, 2013), since they both describe similar neurochemical and psychological 
processes and involve characteristics of loss of control over drug self-administration 
(US Surgeon General, 1988),  these terms are used interchangeably in the current thesis.  
 
Nicotine: Principal mechanisms of actions in the brain 
 In conjunction with its addictive properties, the mechanisms underpinning the 
interactions of nicotine with brain receptors have been a focus of research with the 
central assumption that the binding of nicotine to specific brain receptors is the key 
mediator of tobacco dependence and positive reinforcement (Leshner & Koob, 2015).  
The resemblance of nicotine molecules to the natural neurotransmitter, acetylcholine 
(ACh) allows it to bind easily to and activate nicotinic ACh receptor (nAChR) subunits 
in the extracellular cleft allowing a flow of ions (Dani & De Biasi, 2001).  These 
receptor subunits are ligand-gated ion channels and are ubiquitous in the central nervous 
system (CNS),  autonomic division of the peripheral nervous system (PNS) (McKay, 
Placzek, & Dani, 2007) and at the neuromuscular junction (NMJ) (Millar & Gotti, 2009; 
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Millar & Harkness, 2008)  accounting for the complexity and multiplicity of the effects 
of nicotine.  In the autonomic division of the peripheral nervous system (PNS), nicotine 
raises heart rate and blood pressure whilst causing skin blood vessels constriction and 
releasing adrenaline from the medulla adrenal glands which mediate physiological and 
biochemical stress responses (Al-Safi, 2005; Grassi, Seravalle, Calhoun, Giannattasio, 
Marabini, & Del Bo, Mansia, 1994). Neuronal nAChR subunits vary in binding 
characteristics, their heteromeric (that is, α (2-7) β (2-4) and homomeric (for example 
α7) types can form various combinations and differ in pharmacological and biophysical 
properties (Wonnacott, Sidhpura, & Balfour, 2005), which in turn differentially 
influence their affinity and potency of agonists and antagonists (Grilli, Parodi, Raiteri, 
& Marchi, 2005).  These nAchR undergo three conformational states, i) open (or 
active), ii) closed (or non-conducting) and iii) desensitised in which receptors are 
rendered unresponsive following a prolonged and repetitive stimulation (Quick & 
Lester, 2002).  Agonists binding to the nAChR subunits occur via both stimulation and 
deactivation of these receptors and a complex mechanism of desensitisation.  Nicotinic 
AChRs’ permeability to Na2+ and Ca2+ through local depolarisation allow the 
modulation of neurotransmitters release (Fucile, 2004).  The opening of the ion channel 
creates a change at the conducting pathway passing through the membrane through 
reversal potential and allowing a flux of positively charged sodium and potassium ions 
(Dani & De Biasi, 2001).  A further change of the state of the receptors causes the ion 
channel to close rendering the receptors in a resting desensitised phase.  Desensitisation 
therefore corresponds to the gradual closure of these receptors due to continuous 
exposure to nicotinic agonists.  Animal studies suggest that desensitisation is produced 
by repeated activation of the nAChR, and repetitive or prolonged exposure to nicotine 
leads to an increased number of nicotinic receptor binding sites known as upregulation 
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(Buisson & Bertrand, 2001; Gentry & Lukas, 2002); this is also evidenced in post-
mortem studies of brains of human smokers  (Benwell, Balfour, & Anderson, 1988; 
Breese et al., 1997).  Other animal studies suggest that chronic nicotine injections cause 
a proportion of low affinity nAChRs to convert into high affinity receptors (Romanelli, 
Öhman, Adem, & Nordberg, 1988).  In contrast, an excess of nicotine may lead to 
down-regulation or to a loss of nAChR functional activity.  For instance, a study found 
that in rats (weighing 200-250g), chronic infusion of 1 mg/kg/h of nicotine over a 
period of 10 days dramatically affected the function of nAChR subtypes in the CNS, 
with a down-regulation of nAChR in the hippocampal synaptosomes (Grilli et al., 
2005).  Thus, the binding of nicotine, mediation and modulation of these nAChR release 
are dose- and time-dependent (Grilli et al., 2005; Ulrich, Hargreaves, & Flores, 1997), 
which has significant implications for the role played by nicotine in tobacco tolerance 
and dependence.  In fact, studies have found that levels of nicotine present in smokers’ 
blood are able to activate and desensitise multiple nAChRs and that whilst initial 
applications increase activities of DA neurons, prolonged exposure will cause 
desensitisation of these nAChRs which may explain smokers’ reported biases for their 
first tobacco cigarette in the morning over later cigarettes of the day (Pidoplichko, 
DeBiasi, Williams, & Dani, 1997).   
Of all the neuronal nAChR subtypes, the subunit with the highest affinity for 
nicotine is the α4β2 and has therefore been of key interest in this area of research.  
Indeed, whilst genetically modified mice lacking β2 receptors (‘knockout’ (KO) mice) 
fail to engage in nicotine-seeking behaviour, mice which have been engineered to have 
hypersensitive α4 subunits, display nicotine seeking behaviour (Maskos et al., 2005).  
Although most preclinical studies suggest that β2 receptors activation is necessary for 
the reward pathway and nicotine reinforcement (Picciotto et al., 1998); by selectively 
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activate α4 nicotinic acetylcholine receptors with low doses of agonist, it is possible to 
induce nicotine reward, tolerance, and sensitization (Tapper et al., 2004).  
Administration of low nicotine doses (usually insufficient to activate other nAChRs) 
into selectively activated α4 receptors have shown to induce nicotine related reward in 
mice (Tapper et al., 2004).  Likewise, in other studies, in which the α4 and β2 subunits 
were selectively re-expressed in the ventral tegmental area (VTA) exclusively, KO mice 
also displayed prompt nicotine self-administration (Pons et al., 2008); while others 
demonstrated that attenuating the α4 nAChR subunit function in the ventral mid-brain 
can lead to an increase in nicotine intake (Peng et al., 2017).  Data obtained from human 
smokers also provide convincing evidence for the importance of the α4β2.  A study 
utilising Positron Emission Tomography (PET) scanning found that the smoking of a 
tobacco cigarette increases the occupancy of nicotinic receptor subunits α4β2 (Brody et 
al., 2006), remarkably, a subsequent study found that in habitual smokers, the smoking 
of a denicotinised cigarette can also lead to an increase in the aforementioned receptors 
albeit to a much lesser extent (Brody et al., 2009).  This suggests that factors other than 
nicotine such as psychomotor or other ingredients in the smoke my also affect these 
receptor subunits, which questions the assumption of nicotine as the sole component to 
the pharmacological effects of smoking.     
Other nAChR subunits with high affinity to nicotine have been identified.  The 
α6β2 nAChR subunits are widely distributed in the mesolimbic DA system but 
restricted mainly to the ventral tegmental (VTA) and Substantia Nigra pars compacta 
DA neurons (Pons et al., 2008) and have generated great interest in nicotine research.  
Using transgenic mice in which the α6 nAChR subunits were engineered to be 
hypersensitive to ACh and nicotine, a study found that selectively activating the α6 
nAChR leads to stimulation of action potential firing of DA neurons in the VTA and 
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enhances synaptic plasticity, which is critical in the development of nicotine 
dependence (Berry, Engle, Mcintosh, & Drenan, 2016).  This is in line with a separate 
study in which the α6 nAChR subunits were re-expressed in the VTA of KO-mice; 
these mice displayed acute self-administration of nicotine versus saline (Pons et al., 
2008), suggesting an  important role of the α6 nAChR subunits in the VTA in nicotine 
self-administration behaviour.  Others found that nicotine can stimulate the α6 nAChR 
subunit at lower concentrations than is required for nicotine induced activation, which 
may partly explain how low doses of nicotine may reinforce smoking (Salminen et al., 
2007).  The ability of nicotine to stimulate the α6 at low concentrations may be 
explained by the formation of α4α6β2 nAChR subunits in the midbrain dopamine (DA) 
areas (McKay et al., 2007).   
The actions at the neuronal level are extremely complex and dynamic, and, 
given that  receptor subtypes differ in their ability to respond to nicotine in both 
activation and desensitisation phases (Olale, Gerzanich, Kuryatov, Wang, & Lindstrom, 
1997), these actions strongly relate to the pattern and level of nicotine delivery (Rose, 
Behm, Westman, & Coleman, 1999).   
 On the other hand, receptor sub-types with low affinity, for instance the α7 receptor 
subunit, by virtue of its inverse relationship with nicotine may offer a promising route 
for smoking cessation medicine.  For instance, selectively stimulating this receptor may 
diminish nicotine reward and ultimately the motivation to self-administrate nicotine 
(Brunzell, Mcintosh, & Papke, 2014).   
 Altogether, research studies suggest that nicotine can regulate and activate several 
nAChRs subtypes, releasing ACh at the presynaptic axon terminals.  Several lines of 
evidence suggest that chronic exposure of nicotine differentially affects the function of 
these release-regulating nAChR subtypes and these nAChR subunits have high 
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importance for the self-administration of nicotine (Pons et al., 2008).  Although other 
receptors are expressed in the CNS (amongst others α2 and α3), in this section, the 
focus has been on primary receptors that are expressed in great quantity and interact 
with DA neurons in the VTA and nucleus accumbens (NAcc) since dopamine appears 
to hold a central role in mediating addiction.   
 
Nicotine as a positive reinforcer: Mesolimbic dopamine reward pathways 
The areas of the brain that have been identified to act as mediators of nicotine 
discrimination are the prefrontal cortex, the ventral striatum and the hippocampus 
(Ando et al. 1993; Miyata et al. 1999; 2002; Rosecrans and Meltzer 1981).   The 
complex mechanisms of  action and effects exerted by nicotine is underpinned by its 
ability to promote the release of multiple neurotransmitters, which produce multiple 
effects on the CNS and PNS varying from mood modulation and arousal to pleasure 
(Benowitz, 2008).  Because nicotine alters the concentrations of multiple 
neurotransmitters, its administration triggers many physiological responses including 
acute increased heart rate and blood pressure, vasoconstriction in the skin (Grassi et al., 
1994) and coronary arteries (Balfour et al., 2000).  Aside from the release of 
noradrenaline (NA) (Clarke & Reuben, 1996) and glutamate (McGehee et al., 1995) at 
pre- and post-synaptic levels and GABA (Yang, Criswell, & Breese, 1996), nAChRs 
chiefly promote the release of ACh (Reid, Lloyd, & Rao, 1999) and DA (Wonnacott et 
al., 2005) and, the core pathway which has been advanced to explain the actions and 
effects of nicotine associated with the reinforcement of nicotine addiction is the 
mesolimbic dopamine (DA) reward pathway (Leshner & Koob, 2015; Tanner, 
Chenoweth, & Tyndale, 2015).  It is proposed that nicotine is able to stimulate 
dopamine (DA) secreting cells in the NAcc by attaching to ACh receptors in the ventral 
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tegmental area (VTA) of the mid-brain which project to the limbic structures. These 
projections may involve the locomotor excitatory properties of nicotine and its ability to 
reinforce self-administration (Corrigall, Coen, & Adamson, 1994; Di Chiara, 2000; 
Leshner & Koob, 2015).  Studies have found that animals are capable of learning to 
self-stimulate electrodes implanted in the DA reward pathways (Bozarth, Pudiak, & 
KuoLee, 1998); however, pre-treatment with nicotine to enhance DA overflow in the 
NAcc was found to reduce the threshold previously required to evoke a reward 
response; this suggests nicotine long-term exposure causes desensitisation of the 
nicotinic receptors in the mesolimbic DA system (Pidoplichko et al., 1997).  Located at 
the terminal field of the mesolimbic DA system, the NAcc is comprised of two major 
anatomically distinct subdivisions called the shell and the core (Zham & Brog, 1992) 
which seemingly play complementary roles central to nicotine dependence (Balfour, 
2004).  Much of the evidence available on the reinforcing properties of nicotine can be 
found in studies in which the delivery of nicotine is paired with a stimulus that is 
engineered to become a conditioned stimulus.  For example, animal studies found that 
responses to a visual conditioned stimulus were enhanced by increases in DA overflow 
in the NAcc (Donny et al., 2003).  In rats, Donny (1999) has also reported robust 
nicotine self-administration when lever pressing for nicotine was paired with a light cue 
(Harvey et al., 2004).  Functional Magnetic Resonance Imaging (fMRI) studies looking 
at the effects of smoking related cues, also highlight how the mesolimbic system is 
implicated in nicotine discrimination.  In a study in which abstinent habitual smokers 
matched to control non-smokers were shown smoking-related and neutral images, 
pictures of cigarette smoking evoked greater activation in the ventral striatum (including 
the NAcc) in smokers compared to non-smokers (David et al., 2007), suggesting that 
these subcortical areas of the brain are important in nicotine craving and reinforcement. 
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These findings indicate that stimuli associated with the delivery of nicotine may be very 
important for the effectiveness of nicotine as a reinforcer. 
Earlier studies found that local nicotine injections lead to significant increases of 
DA release in the striatum and in the NAcc but have modest effects in the frontal cortex 
(Marshall, Redfern, & Wonnacott, 1997).  Interestingly, others found that whilst 
infusions of the nicotine antagonist dihydro-ß-erythroidine in the VTA reduce nicotine 
self-administration, the same dosage in the NAcc produces no effect compared to 
operant responding for cocaine self-administration, food or locomotor activity 
(Corrigall et al., 1994).  Shedding light on the complex structure of the NAcc, later 
studies demonstrated that acute nicotine injections are able to evoke stimulation of DA 
overflow in the accumbal shell (Cadoni & Di Chiara, 2000) (Benwell & Balfour, 1992; 
Iyaniwura, Wrigt, & Balfour, 2001), but not in the accumbal core, unless experimental 
animals had been subject to sensitisation by receiving daily injections prior to the 
experiment (Iyaniwura, Wright, & Balfour, 2001).  Increases in DA overflow may 
therefore play an important role in the development of habit forming associated with 
reward (Di Chiara, 2000a,b, 2002).  Nonetheless, repetitive injections in the media shell 
diminish DA response (Cadoni & Di Chiara, 2000).  Thus, the accumbal DA responses 
are contingent upon the delivery of the drug (whether chronic or repeated exposure), 
and these sensitised responses are dependent upon DA neurons which project to the 
accumbal shell (Balfour, 2004).  In contrast, extracellular DA in the core subdivision of 
the NAcc serves to enhance the effects of conditioned stimuli on drug seeking 
behaviours.  This is supported by a study in which lesions to the NAcc core but not the 
shell led to the attenuation of the effects of the conditioned cue on responding to food 
reward (Hall, Parkinson, Connor, Dickinson, & Everitt, 2001).  Similarly, blockade of 
DA receptors have shown to inhibit nicotine self-administration in animals (Corrigall & 
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Coen, 1991) including using nicotine antagonists such as mecamylamine in the striatum, 
the NAcc and the frontal cortex (Ji, Lape, & Dani, 2001; Marshall et al., 1997).  
Likewise, re-expressing nAChR DA neurons in the VTA of KO mice have shown to 
evoke DA release and successfully reinstate nicotine self-administration (Maskos et al., 
2005).  Therefore, continued and increased levels of DA overflow in the accumbal 
medial shell causes the rewarding value of the behaviour or stimuli (nicotine/smoking) 
to increase, and renders the behaviour itself (act of smoking) to become pleasurable 
whilst promoting an association between the stimuli or behaviour and reward.  
Meanwhile, in the accumbal core, increased extracellular DA levels enhance responding 
for a conditioned cue which has been previously associated with the delivery of nicotine 
(Balfour, 2004).  Taken together, the evidence presented here indicates that the 
increased DA overflow in both the accumbal core and shell, is instrumental in the 
rewarding properties of nicotine.  
 
Evidence for nicotine discrimination  
 The role of nicotine as the primary reinforcer promoting the maintenance of 
smoking is well established.  A large number of studies support the notion that nicotine 
has the ability to elicit behaviours that are characteristics of addictive drug use by 
promoting self-administration, enhancing locomotor activity and reward from brain 
stimulation (Clarke, 1990; Corrigall & Coen, 1991; Corrigall et al., 1994) and 
reinforcing place preference (Gaetano Di Chiara, 2000), including studies of human 
smokers in which nicotine is delivered in forms other than  tobacco smoke (Harvey et 
al., 2004).  Key to the reinforcing properties of nicotine is the ability to perceive the 
effects of the drug following administration and discriminate the drug.   
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Behavioural drug discrimination procedures in animals are very useful as dosage 
of the drug can be administered in a careful and controlled manner.  This enables 
reliable matching of differential responses with each dose administered.  Contrary to 
experimental drug discrimination studies in animals, self-report effects in humans 
provide in-depth qualitative knowledge of the effects experienced following drug 
administration.  Both procedures have been useful in furthering our understanding of the 
psycho-behavioural effects of nicotine.  Nicotine is able to produce interoceptive 
stimulus effects, that is physiological and autonomic responses (e.g. hedonic sensations) 
elicited by external stimuli, thought to be positively reinforcing (Perkins, Kunkle, 
Michael, Karelitz, & Donny, 2016).  For instance, animals can be trained to reliably 
discriminate nicotine from saline systematically by pressing a lever to obtain food 
reward or to avoid punishment (e.g. an electric shock) (Solinas, Panlilio, Justinova, 
Yasar, & Goldberg, 2006) and, treatments with nicotine antagonists extinguish their 
ability to discriminate nicotine from saline (Morrison & Stephenson, 1969).     In 
another study exploring the effects of varying treatment time and the onset of the effects 
of various doses of nicotine, higher nicotine (0.4 versus 0.2 mg/kg-1) doses were 
preferentially selected by the rats and the effects of this higher dose were visible as 
early as 5 min following subcutaneous injections and lasted up to 60 minutes.  Others 
suggest that nicotine discriminative functions can be long lasting and endure several 
weeks following discrimination training, but are influenced by motivation (Troisi, 
Bryant, & Kane, 2012).  These findings clearly indicate that nicotine can serve as a 
reinforcer.  However, some have expressed reservations about the reinforcement 
properties of nicotine to maintain smoking by pointing to the inconsistencies in study 
findings in both humans and animals (Dar & Frenk, 2004).  Among these 
inconsistencies are the ability of the nicotine antagonist mecamylamine to induce 
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withdrawal symptoms in rodents but not in human smokers (Rose, Behm, & Westman, 
2001).  This suggests that the effects of nicotine on human smokers differ greatly from 
those on rodents.  In addition to the inconsistent findings concerns have been raised vis-
à-vis the use of food-deprived and trained animals and experimental conditions 
employed in past studies (Dar & Frenk, 2002).  It is worth noting however that differing 
methodologies including the use of varied doses of nicotine between studies are likely 
to generate different results, specifically the use of different strains of rat species which 
likely to differ in sensitivities.  Indeed, the experimental conditions employed in drug 
discrimination paradigm studies are of crucial importance and, inadequate pace and 
duration of nicotine injections and the use of nicotine dependent primed rodents such as 
those used in past studies may have rendered some past results erroneous (Le Foll, 
Wertheim, & Goldberg, 2007).  Subsequently, later studies have employed naïve-
experimental primates as opposed to rodents to assess the reinforcing properties of 
nicotine.  In one  study, five naïve-experimental monkeys were trained to respond to a 
fixed- or a progressive-ratio schedule which was paired with a stimulus light and 
required numerous presses on an ‘active’ or an ‘inactive’ lever to obtain a nicotine drug 
reward (Le Foll et al., 2007).  The monkeys displayed clear preference for responding 
on the ‘active’ lever thereby self-administrating nicotine even in instances when 600 
presses were required per injection, reiterating that nicotine is a robust reinforcer (Le 
Foll et al., 2007).  This bias for the ‘active’ lever presser was not present at the initial 
sessions but developed only after repeated sessions, which echoes the theory of 
sensitisation discussed previously.  Experiments in human smokers also provide strong 
evidence that nicotine acts as a reinforcer and promotes drug-seeking and -taking 
behaviours.  For example, in a study, using intravenous self-administration, regular 
smokers were given the choice to pull on two levers which linked to the delivery of 
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either nicotine or saline both paired with a stimulus light (Harvey et al., 2004).  Lever-
pull responses corresponding to nicotine injections were significantly greater than those 
for saline including when the response requirement for nicotine injections increased.  
Interestingly, responses to the nicotine lever positively correlated with nicotine doses.  
Nicotine lever-pull responses increased in conjunction to the  response requirement for 
nicotine injections (Harvey et al., 2004), suggesting that smokers adjusted their 
responses in order to maintain constant blood nicotine levels.  Indeed, studies using 
dose-response paradigms also suggest that dependent smokers are able to discriminate 
nicotine and prefer higher doses of nicotine.  In a counterbalanced double-blind 
experiment, 10 abstinent human smokers sampled 3 assigned doses of nicotine 
intravenously (0.7, 0.4, 0.1 mg/5mL of nicotine) and a matching dose of sodium 
chlorine as the placebo condition in 4 separate experimental sessions of 90 minutes each 
(Sofuoglu, Yoo, Hill, & Mooney, 2008).  Following sampling, participants were 
instructed to choose a condition on six instances.  Participants demonstrated clear 
preference for the highest doses over the 0.1 mg/5mL and the placebo condition, and 
these higher doses were associated with self-reports of ‘drug liking’ and ‘high’ 
(Sofuoglu et al., 2008).   Likewise, the potency of the actions of nicotine on the CNS to 
reinforce smoking behaviours has also been documented in earlier studies in which the 
administration of the nicotine antagonist mecamylamine produced a 30% increase in 
smoking, decrease in blood pressure, impairment in cognitive tasks and reports of 
dysphoria (Stolerman, Goldfarb, Fink, & Jarvik, 1973).  Altogether these findings 
provide clear evidence that even when removed from its conventional mode of delivery 
(that is smoking), nicotine produces effects that are analogous of those seen in other 
potent drugs of abuse (such as cocaine or amphetamine) which reiterates that nicotine 
itself is a robust reinforcer.    
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 Nicotine discrimination paradigms play an important role in understanding the 
abuse liability of nicotine that is relevant to the development of nicotine agonists and 
antagonists for smoking cessation medications.  The reinforcing properties of nicotine is 
also evidenced in smoking cessation studies demonstrating the efficacy of nicotine 
containing products over placebo (Fiore, Smith, Jorenby, & Baker, 1993).  Furthermore, 
historically, tobacco cigarettes from which the nicotine content has been considerably 
reduced or removed have fallen short of receiving public acceptance in comparison to 
other forms of nicotine products delivering larger amount of nicotine (Everitt, 1996).   
The important role of nicotine in reinforcing smoking is apparent when 
considering the heavy investments made by tobacco companies to further their 
understanding of the role of nicotine in shaping smoking behaviours.  In the past, many 
tactics were used to maximise the pharmacological and physiological effects (including 
sensory effects) of smoking thereby enhancing satisfaction to maintain addiction 
(Carpenter, Wayne, & Connolly, 2007).  Such tactics included manipulating nicotine 
dosage and continuously modifying cigarettes (the use of additives and ventilation 
holes).  For example, the 1980s saw the development of tobacco cigarettes which were 
manufactured from air-cured Burley tobacco blend as a means to enhance their nicotine 
content two-fold of that of conventional cigarettes and alter their nicotine to tar ratio 
(Chakraborty, 1985 in Wayne & Carpenter, 2009).  Furthermore, specific chemicals 
were also added to alter the harshness of the product whilst enhancing the nicotine yield 
to maximise sensory effects (Keithly, Ferris Wayne, Cullen, & Connolly, 2005).  These 
remarks are consistent with the notion that cigarette manufacturers have long 
understood that nicotine is chiefly responsible for the continuation of smoking.  
 Hitherto, the discussion has focused on the positive reinforcement properties of 
nicotine in promoting smoking by i) presenting empirical evidence that experimental 
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animals and human smokers are able to perceive and discriminate doses of the drug, and 
ii) briefly discussing how nicotine containing tobacco cigarettes have been engineered 
to promote the continuation of smoking.  Although many theories have been proposed 
to explain nicotine dependence, in the following two sections the discussion will focus 
on the most prominent theories;   theories that describe nicotine as a positive reinforcer, 
those which describe nicotine as  a negative reinforcer and the contribution of non-
nicotine cues that contribute to reinforcing smoking behaviours.   
 
Nicotine as a Negative Reinforcer: Dependence, Craving and Withdrawal symptoms  
In addition to the positive physiological and autonomic responses (e.g. hedonic 
sensations) described above, continued smoking may be driven by the avoidance of 
negative psychological and physiological effects that are contingent upon smoking 
abstinence.  Prior to turning to a discussion on the negative reinforcement theory, 
definitions of the key concepts relevant here will be offered.   For the purposes of this 
thesis, craving refers to the experience of a powerful motivation to engage in a specific 
behaviour; in this thesis craving may also be referred to as ‘urge’ or ‘desire’.  Early 
studies to document drug dependence were based on the observations that following the 
development of tolerance of a drug, falling levels of that drug in the blood 
systematically induce a withdrawal state (Wikler, 1980), thus drug dependence can be 
defined as a process wherein regular intake of a psychoactive substance results in a 
cycle of increased tolerance characterised by neuroadaptations, which in turn causes an 
increase in the motivation to self-administer.  The central tenet of this early theory 
posited that drug intake is primarily driven by avoidance of aversive states such as 
withdrawal which can be evoked by associative cues.  It was further explicated that 
environmental cues which were initially neutral, develop reinforcing properties to 
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become conditioned cues, subsequently, exposure to these conditioned cues will induce 
cravings and withdrawal in turn increasing the likelihood of relapse, even after a long 
period of abstinence (Wikler, 1948).  That smoking abstinence is typically followed by 
a range of negative signs and symptoms is widely documented (Hughes et al. 1991; 
Hughes and Hatsukami 1986).  Indeed, cessation of nicotine use (Hughes & Hatsukami, 
1986) or reducing the nicotine content in tobacco cigarettes typically induce a state of 
withdrawal in regular smokers, whilst reinstating nicotine intake (for example with 
nicotine replacement therapy) tend to attenuate the intensity of these symptoms (West, 
Russell, Jarvis, & Feyerabend, 1984).  Because withdrawal ensues upon cessation and 
withdrawal state can be reversed by smoking, the smoker learns to avoid the discomfort 
by continuing to smoke.  Likewise, reduction in dosage will successfully reinforce drug 
taking behaviours even in the absence of positive subjective effects (Lamb et al., 1991; 
Panlilio et al., 2005).   Interestingly, the negative correlation between blood nicotine 
levels and craving may indicate that smoking behaviour is driven not just by a need to 
avoid the discomfort of withdrawal but equally to satisfy craving (Jarvik et al., 2000).   
A state of withdrawal may comprise a wide range of affective, somatic and 
cognitive symptoms including depressed mood, cravings for tobacco, anhedonia, 
anxiety, irritability, drowsiness, nausea, increased hunger, headache, inability to 
concentrate amongst others (West & Hajek, 2004).  Since nicotine administration 
alleviates these symptoms, it is reasonable to assume that withdrawal is a significant 
motivational drive for the perpetuation of nicotine dependence and continued smoking 
behaviours.  Moreover, studies suggest that although withdrawal peaks as early as two 
days following cessation, some symptoms can last up to six months (Le Foll & 
Goldberg, 2005) increasing the risk of relapse and providing evidence that nicotine 
dependence may be negatively reinforced.   
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Drawing from the central assumption of negative reinforcement, later models 
added more emphasis to the associative processes involved, arguing that smoking 
behaviours are reinforced not by withdrawal-related stimuli as advanced by Wikler, 
rather by cues that were previously paired with administration (Siegel, 1983).  This 
concords with a later theory, the opponent-process theory which posits that smoking 
behaviour is negatively reinforced via an intrinsic homeostasis mechanism (Solomon, 
1997).  This was described as compensatory responses that are elicited by cues in order 
to counteract the appetitive effects of the drug.  For example, encountering a 
conditioned cue may lead to an increase in positive mood, resulting in turn in an 
increase in negative mood in anticipation as an attempt to compensate and reinstate 
homeostasis; and, because this behavioural mechanism is unopposed, withdrawal ensues 
(Solomon, 1977).   
Though there is substantial evidence suggesting that avoidance of aversive 
withdrawal symptoms is the primary driver of smoking, criticisms vis-à-vis negative 
reinforcement accounts would eventually render it to fall in disfavour.  Firstly, the 
suggestion that drugs can evoke responses in the absence of withdrawal; for instance, 
that in many cases relapse occurs even after withdrawal has subsided (Robinson & 
Berridge, 1993), concords with self-reports of street addicts (McAuliffe, 1982).  
Secondly, a large body of evidence which points to the importance of, and the role 
played by, smoking related cues.  Some animal studies have found that exposure to drug 
cues is sufficient to reinstate self-administration even following a period of extinction in 
which the drug was no longer available (Stewart, 1984); this challenges the key 
assumption that avoiding withdrawal is the chief motivator for smoking behaviours. 
Although there is convincing empirical evidence to attribute the 
pharmacological reinforcement effects of nicotine to smoking maintenance, several 
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lines of evidence suggest that there may be other candidates that contribute to the 
reinforcing effects of smoking.   For example, combined with nicotine, monoamine 
oxidase inhibitors (MAOIs) are able to exert reinforcing effects (Villégier et al., 2006; 
Villégier, Blanc, Glowinski, & Tassin, 2003).   
Following the discovery of the important role of MAOs in the regulation of 
various monoamine neurotransmitters including DA and serotonin, MAOIs have been 
implicated in the regulation of mood and anti-depressant properties of smoking (Glover 
et al, 1980 in Fowler et al, 1996).  Since monoamine oxidase (MAO) enzymes are 
involved in the oxidation of serotonin (5-HT), MAOIs promote the prolongation of 
these neurotransmitters release, potentially through inhibiting their oxidation (Lewis, 
Miller, & Lea, 2007).  One likely explanation might be that smokers have significantly 
reduced brain MAO levels compared to non-smokers (Fowler et al., 1996) thus smoking 
may be the manifestation of a self-medication mechanism that helps regulate negative 
affective states  (Cohen, McCarthy, Brown, & Myers, 2002).  Moreover, animal 
experiments suggest that inhibiting the subtype MAO-A with an antidepressant drug, 
results in increased extracellular release of serotonin (Celada, Bel, & Artigas, 1994).  
One possible mechanism by which MAOIs act with nicotine may be through prolonging 
the release of DA neurotransmitters thereby potentiating the reinforcing effects of 
nicotine (Glover et al, 1980 in Fowler et al, 1996).  This is supported by studies which 
found that pre-treatment with tranylcypromine (a MAOI) produced robust nicotine self-
administration, but this was not the case in tranylcypromine-naïve rats (Villégier et al., 
2006). Rats are also able to re-establish behavioural sensitization following concurrent 
injections of MAOIs and nicotine (Villégier et al., 2003).  Thus, it appears that MAOI 
combined with nicotine has reinforcing properties.  
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Non-nicotine stimuli as reinforcers: Incentive models 
Thus far, the discussion suggests that it is likely that smokers continue to engage in 
smoking behaviours primarily to experience the rewarding and pleasurable effects of 
nicotine or to avoid the aversive effects experienced upon abrupt cessation.  However, 
although the evidence to support the positive and negative reinforcement models is 
robust, both models fail to fully account for the continuation of, or relapse to, smoking 
i) when these subjective pleasurable effects are minimal and ii) in the absence of 
withdrawal  (Robinson & Berridge, 1993).  Amongst its multiple mechanisms of 
actions, through its conditioning properties, nicotine is able to enhance the rewarding 
value of smoking cues (Donny et al., 2003).  Aside from components of the smoke, 
smoking addiction is also context-dependent pointing more specifically at the sensory 
and motor cues associated with smoking (Balfour, 2004; Caggiula et al., 2002a; Donny 
et al., 2003; Palmatier et al., 2006; Rose, Behm, & Levin, 1993).  Indeed, it is argued 
that smokers’ liking for the sensory attributes of  tobacco smoke such as the smell, taste, 
olfactory and respiratory tract sensations, and the tactile aspects of smoking are major 
reinforcers of smoking in their own right (Parrott & Craig, 1995).   When decoupled 
from the traditional mode of delivery that is the smoking of a cigarette, nicotine does 
not always provide positive mood effects (Dar & Frenk, 2004).  Amongst the methods 
utilised to disassociate the sensory from the nicotine effects from smoking is comparing 
the effects of nicotine administered intravenously and the smoking of cigarettes from 
which nicotine content was removed.  For instance, it has been demonstrated that the 
smoking of denicotinised cigarettes is capable of alleviating smoking withdrawal 
symptoms and reducing craving (Barrett, 2010; Caggiula et al., 2002b; Perkins, 
Karelitz, Conklin, Sayette, & Giedgowd, 2010), as well as providing levels of 
satisfaction greater than those elicited by intravenous nicotine (Rose, Behm, Westman, 
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& Johnson, 2000; Rose, Salley, Behm, Bates, & Westman, 2010).  In contrast, 
attenuating these sensory cues seems to diminish self-rating satisfaction (Perkins et al., 
2001; Rose, Tashkin, Ertle, Zinser, & Lafer, 1985).  As noted earlier, the NAcc 
core/ventral striatum has been implicated in mediating the positive responses to 
conditioned stimuli and visual cues, such as images of a burning cigarette, have been 
demonstrated to activate the ventral striatum in smokers but not in non-smokers (David 
et al., 2007).  David and colleagues further suggested that activation of the ventral 
striatum elicited by smoking related stimuli and other physiological effects (such as 
craving) may be caused by neuroadaptations (or persistent changes) in the 
mesoaccumbens DA area (David et al., 2007).  These neuroadaptations derive from 
sensitisation thought to be caused by long term and repeated exposure to nicotine 
(Balfour, 2002) and, because sensitisation is amenable to conditioned stimuli, 
presenting the cues which have, a priori, been paired with smoking, may themselves 
become reinforcers even with no or negligible doses of nicotine (Rose et al., 2006).  
This proposition corroborates with a long-established theory, advanced by Robinson 
and Berridge, the ‘Incentive sensitization theory’. This theory posits that the ability of 
addictive drugs to activate the mesolimbic DA system induces attentional bias and 
affects perceptions related to the drug or the drug-related stimuli (Robinson & Berridge, 
1993; 2008).  This psychological mechanism which is referred to as incentive salience, 
is defined as a pathological motivation to seek and self-administer a given drug and, and 
is understood to be manifested implicitly via ‘wanting’ or explicitly through ‘craving’ 
(Robinson & Berridge, 1993; 2008).  It is further suggested that chronic administration 
of the drug creates increasing neuroadaptations thereby sensitising the DA system 
incrementally, increasing the incentive value of the drug and drug-related cues and 
rendering drug ‘wanting’ into ‘excessive craving’ (Robinson & Berridge, 1993).  
 
 
25 
 
Indeed, it has been demonstrated that drug related cues elicit increases in DA release in 
the mesolimbic pathway in animals, but also presentation of these stimuli can induce 
craving in human smokers (Di Chiara, 2000).  Thus, aside from its directly reinforcing 
properties, it appears that nicotine is able to amplify the incentive and reward value of 
stimuli (such as sensory, motor and visual) that have been previously paired with its 
administration.  Although this model has received substantial support and provides a 
comprehensive explanation of cravings and the persistent motivation to self-administer, 
it does not provide a full account of the compulsive nature of drug-seeking and -taking 
that are typical in addicted individuals despite the known adverse consequences.   
Although non-nicotine stimuli (for example nicotine-free tobacco smoke) have 
shown to reduce craving and induce positive subjective effects (Rose, Behm, Westman, 
& Johnson, 2000), aside the fact that these are contrived to the laboratory settings and 
standardised protocols that arguably may not be a true reflection of the real world 
smoking behaviours, these positive effects remain significantly modest compared to 
nicotine-containing conventional cigarettes, which typically evoke greater levels of 
euphoria and reduction in withdrawal symptoms (Rose, Behm, Westman, Bates, & 
Salley, 2003; Westman, Behm, & Rose, 1996).  That higher levels of nicotine can be 
discriminated against lower or no nicotine-content cigarettes underlines the primacy of 
the pharmacological over the sensory stimuli which act in concert to reinforce smoking 
behaviours.  This is in keeping with findings from a study in which a standardised 
puffing regime was used to delineate the rewarding effects of nicotine from that of 
tobacco smoke constituents by measuring self-reported reward within 7 seconds of 
inhalation (before nicotine reaches the brain and the pharmacological effects are felt) 
(Naqvi & Bechara, 2005).  Puffs from the nicotine-containing cigarettes were found to 
elicit greater reward compared to puffs from the denicotinised cigarettes (Naqvi & 
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Bechara, 2005).  The notion that the pharmacological rewards may be more driven by 
nicotine per se compared to the airway sensory effects is also supported in earlier 
studies which found that blocking peripheral nAChRs (with an antagonist trimethaphan) 
diminishes smoking satisfaction (Rose, Westman, Behm, Johnson, & Goldberg, 1999), 
whilst increasing nicotine concentrations in tobacco cigarettes increases satisfaction 
(Pritchard, Robinson, Guy, Davis, & Stiles, 1996b, 1996a).  These manipulations 
indicate that subjective effects are dose-dependent, but also that the route of nicotine 
delivery (i.e. inhalation) is of equal importance for reward.  Indeed, throughout the 
current discussion the primacy of nicotine per se becomes evident, but it is also apparent 
that stimuli other than nicotine are of key importance in the maintenance of smoking.  
Henceforth, the focus of the discussion will turn to the importance of the delivery of 
nicotine in reinforcing smoking behaviours.  The first part will offer a brief description 
of the importance for a rapid nicotine absorption before discussing how the route and 
pace of delivery (that is inhalation) render the act of smoking a cigarette the most 
effective vehicle for nicotine contributing to most of the addictiveness of smoking.    
 
The mode of nicotine delivery as a key reinforcer: The Bolus theory 
An average cigarette contains between 3 and 10 mg, and following the smoking 
of a cigarette an average of 1 to 1.5 mg of nicotine is absorbed in the course of taking 10 
puffs per cigarette (Benowitz & Jacob, 1984).  The amount delivered can vary between 
0.3 and 3.2 mg per cigarette (Benowitz & Henningfield, 1994) (Benowitz & Jacobs, 
1984; Gori & Lynch, 1985; Jones, 1987), and this not determined by the cigarette 
content but largely by the way the cigarette is smoked (Benowitz & Jacob, 1984b; 
Benowitz, Kuyt, & Jacob, 1982).  This is supported by empirical evidence suggesting 
that smokers of low yield tobacco cigarettes (determined by machine estimations) do 
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not systematically consume less nicotine and blood nicotine concentrations do not 
correlate with machine yield estimations (Benowitz et al., 1983).  Furthermore, the 
inter-variabilities in biomarkers of nicotine absorption, with some smokers capable of 
achieving 100 ng/mL arterial nicotine levels following the smoking of a single cigarette 
(Henningfield & Keenan, 1993), whilst others’ peak at 20 ng/mL (Rose, Behm, 
Westman, & Coleman, 1999), suggest wide inter-individual variabilities in puffing 
topography also.   
With each puff and tobacco smoke particles inhaled, nicotine passes through the 
arterial circulation and quickly reaches the alveoli of the lungs due to the large surface 
of the lungs and the elevated pulmonary capillary blood circulation.  This facilitates a 
rapid absorption and allows nicotine to reach the brain in approximately 10 to 20 
seconds, which is followed by sharp increases in arterial blood nicotine concentrations 
levels and an ultimate peak at the end of the cigarette (Benowitz, 1990).  The average 
nicotine concentrations vary between 20 and 60 ng/mL, but can reach up to 100 ng/mL 
(Henningfield & Keenan, 1993).   
The fast nicotine absorption combined with the high nicotine concentration levels 
achieved are of particular importance in producing what is referred to as a ‘hit’ or 
‘bolus’ the intense psychoactive effect of the drug and desired effect sought by the 
smoker (Benowitz, 1990).  That the remarkably fast transit from the lungs to the brain 
and high arterial nicotine concentration are central to the reinforcing properties of 
nicotine, is known as the ‘bolus theory’ (Russell & Feyerabend, 1978).  The act of 
inhaling provides a unique route for nicotine to be delivered rapidly and efficiently to 
target organs and is thought to mediate the pharmacological effects of nicotine as 
reflected in the greater levels of arterial versus venous nicotine concentrations 
(Henningfield, Stapleton, Benowitz, Grayson, & London, 1993). The greater magnitude 
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and higher pace of the arterial route enhances the reinforcing effects of nicotine.  
Inhalation produces more rapid and pronounced physiological and psychological effects 
than nicotine delivered transdermally or via the buccal mucosa (Cone, 1995; Evans et 
al., 1996; Fant et al., 1999; Henningfield et al., 2004; Henningfield & Benowitz, 2004).  
This is reflected in the differences in kinetic profiles of the transdermal and oral nicotine 
products compared to tobacco cigarettes; the latter are typically characterised by a sharp 
peak at around the end of a cigarette and is followed by a sudden drop, whilst use of the 
former is associated with a steadier and more gradual release of nicotine (Benowitz, 
Hukkanen, & Jacob Iii, 2009).  As a consequence, biomarkers of nicotine absorption in 
nicotine products are typically lower than those related to tobacco cigarettes (Schneider, 
Olmstead, Franzon, & Lunell, 2001), with the exception of high content nicotine 
products which can exceed levels reached with tobacco cigarettes albeit at a much 
slower pace (McNabb, 1984; Schneider et al., 2001).   
The ability to fully control the pace and amount of the drug delivered through each 
puff provides a highly effective mode of delivery which allows a rapid absorption 
through the lungs and produces a desired nicotine concentration bolus to the brain.  
With each puff, the smoker can regulate their nicotine intake to a desired, satisfactory 
and constant level (Russell, 1980) thereby achieving optimal level of cognitive arousal 
and mood regulation (Benowitz, 2001).  This rapid absorption is thought to be key in 
regulating smoking and puffing topography.  The hypothesis that regular smokers seek 
to regulate their blood nicotine levels is apparent in the fact that supplementary nicotine 
administration suppresses smoking.   For instance, a study by Benowitz and Jacob 
(1990) found that cigarette consumption could be significantly reduced following 
intravenous nicotine administration, likewise increasing the dosage of nicotine 
replacement therapy products (hereafter referred to as NRT) could further decrease 
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cigarette consumption (Benowitz, Zevin, & Jacob Iii, 1998).  Although plasma nicotine 
concentrations tend to fluctuate considerably, since nicotine accumulates over a period 
of six to eight hours including during sleep, by regulating their smoking, smokers are 
able to maintain their nicotine blood levels (Benowitz, Kuyt, & Jacob, 1982).  This 
further supports the notion that smokers need to regulate their nicotine intake.  In line 
with this, a typical smoker does not allow his/her blood nicotine to drop below habitual 
levels thereby avoiding withdrawal by continuing smoking; and abstinence periods are 
characterised by increases in craving and withdrawal symptoms quickly followed by a 
rapid escalation in desire to smoke sometimes in remarkably short succession of a 
cigarette (Schuh & Stitzer, 1995).   
NRT formulated to assist an equilibrium in blood nicotine levels, prevent relapse in 
the short term only; this disappointing outcome may reflect the absence of a nicotine 
bolus. Conversely higher doses better promote smoking cessation (Hughes et al., 1999).  
This provides further credence to the notion that smokers’ puffing behaviours are driven 
by their nicotine needs.  Moreover, it is recognised that NRT is not used long term and 
does not cause dependence.  NRT’s low abuse liability potential may be largely due to 
the slow nicotine delivery and the fact that the user has little or no control over the 
nicotine release at least in the case of transdermal patches.  There is substantial evidence 
supporting the hypothesis that the reinforcing properties of addictive drugs can be 
greatly enhanced by a rapid and direct delivery to the brain in high concentrations 
(Benowitz, 1990b; Benowitz, 1999; Henningfield & Keenan, 1993).  Notably, smokers 
typically report greater levels of craving for cigarettes and nicotine dependence 
compared to snuff users (Dole, 1980).  This theory suggests that the sudden high level 
of nicotine in the brain acts as a positive reinforcer thereby contributing to smoking 
maintenance.   
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In summary, the evidence pointing to inhalation as an important reinforcer partly 
explains why smoking is a unique and preferred mode of delivery.  By providing greater 
control over the pace and flux of nicotine, it allows the smoker to regulate the intake of 
the drug thereby ensuring individualistic and satisfactory blood nicotine levels which is, 
arguably, at the heart of smoking reinforcement. 
 
Self-titration and compensatory puffing  
 
The evidence cited thus far suggests that smoking behaviours are largely driven by a 
need to achieve rapid blood nicotine hit, and, to maintain a constant blood nicotine level 
that is sufficiently high to be satisfactory and prevent withdrawal but also falls below 
their individualistic threshold not to produce aversive or toxic effects.  One mechanism 
by which smokers achieve individual and satisfactory blood nicotine levels is by 
adjusting their puffing topography (e.g. puff number, duration and inter-puff intervals) 
according to the nicotine content of each tobacco cigarette.   Evidence for the 
idiosyncratic nature of puffing topography in smoking is reflected through the stark 
contrast between the inter-variability (Benowitz et al., 1982) and intra-consistency in 
nicotine absorption and puffing topography (Gust, Pickens, & Pechacek, 1983).  This 
bio-behavioural mechanism reiterates that smokers need to maintain constant and 
satisfactory nicotine blood levels by adjusting their puffing topography; this forms the 
basis for the theory of self-titration.   The terminology self-titration is commonly 
defined as a smoker’s individual need to maintain characteristic nicotine levels in the 
body, whilst compensation or compensatory puffing behaviours denotes active changes 
in puffing behaviours in response to alterations of nicotine exposure in an effort to 
maintain characteristic nicotine levels in the body (McMorrow & Foxx, 1983). 
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Evidence for the self-titration theory is well documented (Ashton et al., 1979, 1970; 
Herning et al., 1981; Russell, Jarvis, Iyer, & Feyerabend, 1980; Strasser et al., 2007; 
West, Russell, Jarvis, & Feyerabend, 1984; Woodward & Tunstall-Pedoe, 1993).  By 
increasing the length and frequency of puffs, increasing the number of cigarettes, 
smoking more intensively (Kolonen, Tuomisto, Puustinen, & Airaksinen, 1991) or 
smoking each cigarette to a shorter butt length, manipulating vent holes (Kozlowski, 
Pillitteri, & Sweeney, 1994; Kozlowski, Pope, & Lux, 1988) and cigarette filters (Zacny 
& Stitzer, 1996), smokers will attempt to compensate for the lower nicotine delivery 
from low-yield (light) cigarettes (machine-measured yield) (Ashton et al., 1979, 1970; 
Collins et al., 2010; Hammond et al., 2005; Kolonen, Tuomisto, Puustinen, & 
Airaksinen, 1992; Strasser et al., 2007; Woodward & Tunstall-Pedoe, 1993).  In a cross-
sectional survey of 2754 smokers, an increase in exhaled carbon monoxide (CO) was 
positively correlated with tar yield, whilst being inversely correlated with nicotine yield, 
which implies that a decrease in nicotine availability ensues in an increase in smoke 
intake (Woodward & Tunstall-Pedoe, 1993).  Additional evidence reveals that 
switching to low nicotine yield cigarettes can induce an increase in the number of 
cigarettes smoked, whereas a switch to high nicotine yield cigarettes lead to a decrease, 
which supports the notion that smokers adjust their puffing patterns to regulate their 
nicotine uptake (Russell, Wilson, Patel, Cole, & Feyerabend, 1973).  Likewise, 
smokers’ puffing patterns increase when nicotine is blocked through nicotine antagonist 
administration (Stolerman et al., 1973); conversely, smoking decreases when nicotine is 
supplemented via oral route with nicotine gums (Ebert, McNabb, & Snow, 1984).   
In line with the titration theory, the way in which each tobacco cigarette is smoked 
also suggests a drive to maintain desired blood nicotine levels.  There is robust evidence 
that the first puffs on a single cigarette are typically longer and larger and inter-puff 
 
 
32 
 
intervals (intervals between puffs) are shorter compared with the subsequent puffs; as a 
cigarette is smoked, puff duration and volume decrease and inter-puff intervals increase 
(Chait & Griffiths, 1982; Kolonen et al., 1992). This is suggestive of  an attempt to raise 
fallen blood nicotine levels since the last cigarette (Collins et al., 2010).  Likewise, the 
smoking of two succeeding tobacco cigarettes typically results in a decrease in puff 
intensity and frequency as the subsequent cigarette is smoked, suggesting a satiation 
effect (Kolonen et al., 1992).  Conversely, abstinence of a few hours may lead to a more 
intensive puffing regimen.  Thus, the behavioural mechanism of compensation is not 
strictly defined as an adjustment of nicotine intake by consuming more or fewer 
cigarettes but rather extends to a seemingly perpetual mechanism exerted on a puff-by-
puff basis (Woodward & Tunstall-Pedoe, 1993).    
Another prediction of this theory posits a propensity for heavier smokers to 
smoke soon after waking proposedly in response to depleted blood nicotine levels owed 
to overnight abstinence (Kozlowski, Director, & Harford, 1981); and, the latency of this 
first cigarette of the day seems a good predictor of nicotine exposure and dependency 
(Heatherton, Kozlowski, Frecker, Rickert, & Robinson, 1989).  This may account for 
the many self-reports that the first cigarette of the day is  the most satisfactory and also 
concords with the aforementioned findings that the latency of the first cigarette of the 
day correlates with nicotine dependency and nicotine exposure (Baker et al., 2010; 
Fagerström, 2003).  Although contrary to the previous assumption that the first cigarette 
of the day would be puffed on more intensively, some have found that cigarettes 
smoked during the night and the first cigarette of the day are smoked less intensively 
(Grainge, Shahab, Hammond, O’Connor, & McNeill, 2009) and this coincides with the 
fact that craving peaks are typically observed at midday as opposed to mornings in 
highly deprived smokers (Teneggi et al., 2005).  It has been proposed that this 
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adjustment in puffing topography could be driven by a reduction in nicotine tolerance 
due to the overnight prolonged period of abstinence (Grainge et al., 2009).  Of note, the 
sample used in Grainge et al.’s study was comprised of smokers with the characteristics 
of a median time to first cigarette of 30 minutes, a sample of heavier smokers with 
shorter time (that is ≤ 5 minutes) could have yielded opposite results.  Equally, it could 
be argued that cigarettes smoked during the night are smoked less intensively because 
of a satiation effect of nicotine and that the less intensive puffing is a reflection of the 
smoker’s need to maintain, rather than to raise, blood nicotine levels.  Likewise, 
although current evidence suggests that light cigarette smokers are less dependent 
compared to heavy smokers, some studies suggest that due to more intensive puffing 
they may be subject to greater exposure to nicotine (Krebs et al., 2016), suggesting that 
the fewer cigarettes smoked may lead to a need to puff more intensively on each 
cigarette, which again lends support to the self-titration theory.    
The most commonly used investigative approach to explore the phenomenon of self-
titration in tobacco smokers has been to manipulate the nicotine yield of cigarettes. This 
has been achieved through various methods, i) altering the size of the experimental 
cigarettes and observing puffing topography following the smoking of the experimental 
versus the full-size cigarette (Goldfarb, Jarvik, & Glick, 1970 in McMorrow & Foxx, 
1983), ii) using manufactured cigarettes for which the nicotine yield was predetermined 
by smoking machines.  A large body of research has suggested that smoking machine- 
determined nicotine yield are not valid estimates of relative human exposure to 
toxicants.  Whilst smoking machines produce uniform and consistent sets of toxicant 
yields, the differing nature of smokers’ puffing patterns will result in varying levels of 
toxicants emission so any claims on reduced human exposure based on smoking 
machines maybe erroneous (Burns et al., 2008).  Invalid claims vis-à-vis the reduced 
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harms associated with the use of low tar low nicotine yield cigarettes have led to a 
plethora of studies utilising biomarkers such as human blood, urine and saliva whilst 
measuring puffing topography.  Such an approach represents a powerful metric to 
investigate real human exposure to nicotine as well as toxicants aerosolised.  A more 
complete discussion on compensatory puffing behaviours including further evidence is 
offered in Chapter II. 
Harm Reduction: Nicotine Replacement Therapy Products (NRT)  
 
The renowned Professor Michael Russell stated in 1976 that “People smoke for 
the nicotine but die from the tar” (Russell, 1976, p. 1431). This often quoted dicta 
continues to be the basis, not only for the core theories and models related to smoking 
behaviours, but has also for the development of NRT.  In addition to comprehensive 
tobacco control strategies (through media education campaigns, excise taxes, prevention 
and cessation services and so on), it has become apparent that nicotine could play a key 
role in reducing the harms of smoking.  NRT emerged as a means to support smokers in 
their attempt to quit.  Because nicotine can be absorbed through cell membranes albeit 
not as fast as through inhalation, various forms of NRT (patches, gums, lozenges, 
sprays, inhalators and so on) have been developed to enhance cessation.  To enhance 
their absorption, NRTs were made of an aqueous nicotine solution buffered to alkaline 
pH (Hukkanen et al., 2005).  Transdermal patches are placed on the skin and nicotine 
release to the blood is constant but  very slow with a Tmax (Time at which maximum 
concentration peaks) varying between 3 and 8 hours depending on the dose (Fant, 
Henningfield, Shiffman, Strahs, & Reitberg, 2000).  As a result the user has no control 
over the nicotine release and is unable to self-titrate (Balfour & Fagerström, 1996).  In 
contrast, nicotine gum allows the user a modest degree of self-titration; mastication 
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causes rise and troughs in blood nicotine levels and time to peak can be achieved after 
approximately 30 minutes (Balfour & Fagerström, 1996) but control over the nicotine 
intake is modest and not comparable to smoking a cigarette (Benowitz, 1988).  
Compared to the transdermal patch, the nicotine delivery profile resembles cigarette 
smoking albeit at much lower levels (Keenan, Henninfield & Jarvik, 1995).  The nasal 
spray is the fastest nicotine delivery amongst all NRT; with a Tmax of 5-10 min, its 
nicotine delivery peak curve is the closest to resemble that of a tobacco cigarette 
(Sutherland et al., 1992).  Although designed to emulate tobacco cigarettes by drawing 
through a mouthpiece, nicotine inhalators have poor nicotine delivery and rewarding 
effects compared with cigarette smoking (Balfour & Fagerström, 1996).   
Nicotine inhaled via smoking is quickly absorbed and characterised by a peak 
blood nicotine level at 5 minutes thereby providing a ‘hit’ to the smoker.  By contrast, 
evidence suggests that such speed of delivery is not achievable via transdermal route 
(Hukkanen et al., 2005).  Nonetheless, some evidence suggests that a higher dosage of 
NRT can increase one year smoking cessation rate (Tonnesen et al., 1999).  That said, if 
nicotine was the sole cause of smoking maintenance, one might have expected the 
development of such safer nicotine products to have had a much greater impact on 
smoking cessation rates.  Instead despite many decades on the market, long term 
smoking cessation using NRT remain fairly modest (Rose, Lokitz, Garg, Turkington, & 
Minton, 2006) and NRT has increasingly become the least preferred smoking cessation 
aid (West, Beard, & Brown, 2018; West & Brown, 2018).  Although combining NRT 
with regular behavioural support can increase its efficacy for smoking cessation (Moore 
et al., 2009), their success rate has been modest with fewer than 20% of users remaining 
abstinent for a year (Stead et al., 2012).  Only 1 in 10 users remain abstinent after 1 year 
(Etter & Stapleton, 2006), and more recent data suggest that the expected 1 year 
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abstinence rates using licensed nicotine products is only 5% (Kotz, Brown, & West, 
2014).  This could be due to the slow and gradual release of nicotine which completely 
differs from the pharmacokinetic profile of combustible cigarettes typified by a sharp 
peak as opposed to a flatter and lower curve (Digard, Proctor, Kulasekaran, Malmqvist, 
& Richter, 2013).  A further drawback is their inability to provide the sensory and 
behavioural cues associated with the ritual of smoking which are deemed highly 
significant in reinforcing smoking (Perkins, Karelitz, Giedgowd, Conklin, & Sayette, 
2010; Rose, 2006) as previously discussed.  Empirical evidence suggests the way in 
which nicotine is delivered plays a major role in the reinforcement of nicotine use and 
tobacco addiction (Henningfield et al., 1993; Henningfield & Keenan, 1993).  As noted 
previously, smoke inhalation directly through the lungs optimises nicotine delivery and 
the positive effects of nicotine (Henningfield & Keenan, 1993).  Indeed, since many 
smokers are unwilling or unable to quit, there is a growing consensus that new and more 
effective cessation methods are needed.  Given the literature reviewed above, effective 
nicotine delivery and replacement of the behavioural aspects of smoking are likely to be 
key features of a successful cessation method.  This sets the context for the emergence 
of the new ‘disruptive’ technology: e-cigarettes.  
 
The Emergence of E-cigarettes  
First developed in 2004 by the Ruyan Group (Holdings) Ltd, a Chinese company 
in 2004 (Bullen, McRobbie, Thornley, Glover & Laugesen, 2010; Bullen, et al., 2013; 
Dawkins, Turner, Roberts & Soar, 2013), electronic-cigarettes (hereafter referred to as 
e-cigarettes) are today the most popular (West, Beard, & Brown, 2017) and amongst the 
most effective at supporting smoking reduction in the UK (McRobbie et al., 2014; 
Brown, Beard, Kotz, Michie, & West, 2014; Beard, West, Michie, & Brown, 2016; 
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Farsalinos, Poulos, Voudris, Le Houezec, 2016).  Although there remains concerns vis-
á-vis their use (including the notion that e-cigarettes may renormalize smoking and 
preclude or reverse tobacco control efforts).  Since their introduction they have 
dramatically increased in popularity from 700000 in 2012 (ASH, 2016) to 2.9 million 
users in the United Kingdom in 2017 (ASH, 2017).   
E-cigarettes are battery-powered devices which closely emulate the action of 
smoking by releasing an inhalable aerosol through pressurising a solution commonly 
comprising propylene glycol, vegetable glycerine, and flavourings (Bullen et al., 2013).   
Although this solution (hereafter referred to as e-liquid) does not contain tobacco, it 
may contain nicotine (extracted from tobacco leaves), with levels varying from 0 
mg/mL up to 20 mg/mL as sold in Europe since the introduction of a cap by the 
European Union Tobacco Product Directive regulations (EU-TPD) in May 2016.  Prior 
to the EU-TPD, concentrations could range from 0 to 36 mg/mL (European Union, 
2014).    
Although there is considerable variation between device types, commonly e-
cigarettes comprise i) a lithium-ion battery (which can be pre-filled or rechargeable); ii) 
a micro-electrical circuit containing a sensor which can be activated upon a single draw 
or button press; iii) a heating component called atomiser which houses a wick and 
vaporises the nicotine solution; iv) a mouthpiece which acts as the e-liquid reservoir and 
delivers the aerosol to the mouth (in the earliest models it incorporates the cartridge); in 
early models v) an optional LED diode which simulates the lighting of a tobacco 
cigarette upon activation of the sensor, and vi) a manual switch (Bullen et al., 2010; 
Etter, Bullen, Flouris, Laugesen & Eissenberg, 2011; Goniewicz, Kuma, Gawron, 
Knysak & Kosmider, 2012; Polosa et al., 2011) (see Figure 1.1, appendix 1).  A draw or 
button press activates the atomiser which is detected by the airflow sensor, in turn 
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prompting the wick to become saturated with e-liquid, before releasing the inhalable 
aerosol (Goniewicz, Kuma, Gawron, Knysak & Kosmider, 2012).  
Early models were made to resemble conventional tobacco cigarettes in size and 
shape and housed relatively smaller batteries (in comparison to later models).  These are 
commonly referred to as cigalikes, first generations or closed systems (see Figure 1.2, 
appendix 1) (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013a). When 
first introduced, cigalikes could be single or two-piece units with re-chargeable or pre-
filled cartridges (thus can be rechargeable or disposable); however, in the later cigalikes, 
the fluid-filled reservoir cartridge and the atomizer were merged into a single cartomizer 
(Dawkins, Turner, Roberts & Soar, 2013).   
Later e-cigarette models have evolved considerably and differ significantly from 
cigalikes, this indeed reflects the highly heterogeneous nature of e-cigarettes; the 
differences in function and effectiveness between models will be discussed in the ‘e-
cigarette characteristics’ section later on.  Second generation e-cigarettes differ from the 
appearance of conventional cigarettes however operate and share many of the 
characteristics of the cigalikes in terms of internal components.  They tend to be slim in 
appearance, typically resembling pens hence the term  ‘pen-like’, they contain a fillable 
reservoir for the e-liquid, and operate on a manual switch (refer to Figure 1.3 and 1.4 in 
appendix 1).  Although considered as tank systems because of their fillable reservoirs, 
for the sake of clarity, these will be referred to as second generation or pen-likes in this 
thesis.  This will allow for a clear distinction between second and third generations.  
Third generations on the other hand will be referred to as tank systems.  
Third (hereafter referred to as tank systems) generation e-cigarettes depart 
considerably from the appearance of conventional cigarettes, are bulkier and larger than 
cigalikes and pen-likes, and house more optimal and larger capacity batteries (Figure 
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1.5, appendix 1).  Referred to as open, tank systems (or mods), they can be modified 
and mounted on various combinations of tanks and mouthpieces.  Indeed, this category 
also includes devices which contain rebuildable atomisers (Grana, Benowitz, & Glantz, 
2014).  Tank systems have sophisticated features which allow the user to adjust the 
voltage and/or wattage output, control the temperature, whilst some tanks contain an 
adjustable airflow rate and are compatible with atomisers of varied voltage resistance.  
Third generation tank systems also encompass devices for which the e-liquid can be 
added directly to the heating coil to allow for dripping, this is commonly referred to as 
‘drip-tip’ or ‘direct dripping’ (Talih, Balhas, Salman, Karaoghlanian, & Shihadeh, 
2016).  Some models are equipped with downloadable software or memory chips 
allowing data collection such as history of puff counter.  These additional features are 
thought to considerably enhance the user’s experience (Baweja et al., 2016; Yingst et 
al., 2015).  For example, the coil and wick material and arrangement (parts of the 
atomiser), and the atomiser resistance combined with the voltage output conducted 
through the atomiser will affect the velocity, density and quality of the aerosol produced 
as well as the temperature of the device during use (Brown & Cheng, 2014).   
Fourth generation e-cigarettes also known as sub-ohm devices are seen as an 
enhancer of the third generations.  They do not differ dramatically from their 
predecessors (third generation tank systems), are similar in size and shape but differ in 
terms of their ability to be compatible with atomisers of very low resistance (< 1 ohm) 
(Figure 1.6, see appendix 1).  This allows a greater wattage output to be conducted 
through the coil thereby resulting in an increase in power and greater volume and 
density of the aerosol. 
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E-cigarettes in the context of Smoking cessation  
In the UK, smoking prevalence has been in decline from approximately 19% in 
2010 to 15.8% (around 7.6 million adults over the age of 18) in 2017 (Office for 
National Statistics, 2017).  In contrast, e-cigarettes uptake has soared to an estimated 2.9 
million adult users (ASH, 2017). Males and adults aged 35 to 49 were more likely to be 
users (Office for National Statistics, 2017).  Their ability to closely simulate the psycho-
motor actions and rituals of cigarette smoking, and to provide a comparable method of 
nicotine delivery have certainly contributed to their surge in popularity (Polosa et al., 
2014).  There is empirical evidence which suggests that in comparison to NRT users, e-
cigarette users have greater odds to achieve and sustain abstinence (Brown et al., 2014).  
Though it cannot be said that e-cigarettes are the main contributor, the decline in 
smoking prevalence has coincided with the rise in EC use (Office for National 
Statistics, 2017).  Recent statistical data suggest e-cigarettes as the most popular method 
of smoking cessation over NRT, prescribed medicines and behavioural support (Brown 
et al., 2014; West et al., 2017).  Similarly, in England, an estimated 2.5% 
(approximately 22,000 smokers) achieved complete cessation using an e-cigarette where 
they would have failed using no aids or a licensed nicotine product purchased over the 
counter (West, Shahab, & Brown, 2016).  Although past studies do not attribute the 
decrease in use of more conventional licensed medicinal products to the rapid rise in e-
cigarette use (Beard, Brown, McNeill, Michie, & West, 2015), they have certainly 
coincided.  Such coincidences add to concerns that e-cigarettes may detract from the use 
of licenced nicotine products and impede tobacco control efforts by renormalizing 
smoking thereby attracting youths and non-smokers and causing a gateway effect to 
smoking (Bell & Keane, 2014; Kozlowski & Warner, 2017; Leventhal et al., 2015).  
Some of the opponents expressing concerns, have cited  cross sectional study data  
(Dutra & Glantz, 2014) to conclude that youths who ‘ever used’ an e-cigarette (even 
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one puff) were more likely to later become smokers.  Such causal inferences are highly 
inappropriate, ignore many possible confounders whilst failing to consider plausible 
alternative explanations.  Besides, recent statistical data suggest otherwise.  For 
instance, the prevalence in youth smoking in  the UK (Bauld et al., 2017; Bauld, 
MacKintosh, Ford, & McNeill, 2016) and the US (Harrell, Naqvi, Plunk, Ji, & Martins, 
2017; Kozlowski & Warner, 2017) suggests that the modest increase in e-cigarettes use 
has coincided with a decrease in smoking prevalence amongst youths, which is 
indicative of a gateway from smoking.  In fact, many studies alluding to a gateway 
effect, use flawed methodologies including questionnaire items measuring ‘ever use’ or 
‘past 30 day use‘ which fail to capture actual frequency and intensity of use (Polosa, 
Russell, Nitzkin, & Farsalinos, 2017).  In fact longitudinal data suggest that ‘ever use’ 
rarely translates into regular use but rather relates to experimentation (Bauld et al., 
2017; Greenhill, Dawkins, Notley, Finn, & Turner, 2016).  This is in agreement with the 
fact that the prevalence of e-cigarette use amongst youths (Jamal et al., 2017) as well as 
amongst non-smoker adults in the EU (Farsalinos, Poulas, Voudris, & Le Houezec, 
2016) remains fairly low and appear to be decreasing.  Furthermore, longitudinal data 
from the US found that prohibition of e-cigarettes sale to adolescents in some States 
tended to be positively associated with increased smoking rates amongst these groups 
(Friedman, 2015; Pesko, Hughes, & Faisal, 2016).  In addition, the number of ex-
smokers using e-cigarettes rose to 52% (approximately 1.5 million) compared to 45% of 
dual users (smokers using e-cigarettes) (ASH, 2017), this adds further evidence that e-
cigarettes are providing a route away from smoking.  Of particular interest, in 2014, of a 
total of 27 460 of EU current and former e-cigarette users, only 10.8% reported being 
former smokers against 31.1% classified as dual users (Farsalinos, Poulas, Voudris, & 
Le Houezec, 2016).  Altogether this suggests a clear trend of an increase in departure 
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from smoking to dual use which translates into complete cessation.   This is supported 
by the Eurobarometer data, which found an estimated 35.1%  and 32.2% of current e-
cigarette users reporting smoking cessation and reduction (respectively) with the help of 
an e-cigarette, based on 48.5 million EU e-cigarette users (Farsalinos, Poulas, et al., 
2016).  Of particular importance to this thesis, most of this sample (76.8%) used 
nicotine containing e-cigarettes as opposed to nicotine-free-ones; the widespread use of 
nicotine in this sample could be seen as a continued nicotine dependence and a 
willingness to substitute a well-known harmful mode of nicotine delivery for a safer 
one.  Encouragingly, studies suggest that e-cigarette use may be less addictive than 
smoking.  This is supported by studies comparing nicotine dependence as an e-cigarette 
vaper against dependence as a smoker; former smokers who made a complete 
substitution were found to be less dependent on their devices compared to their tobacco 
smoking (Foulds et al., 2015).  This is in agreement with findings suggesting that the 
latency of the first cigarette of the day, a good indicator of dependence (Heatherton et 
al., 1989), is longer for e-cigarettes than for tobacco cigarettes (Dawkins, Turner, 
Roberts, & Soar, 2013; Farsalinos et al., 2013a,b; Goniewicz et al., 2013). 
Evidence on the effectiveness of e-cigarettes has not always been so clear and, 
as they have gained in popularity, opinions have become more polarised.  Although 
early studies suggesting that e-cigarettes could promote cessation were deemed too few 
thus inconclusive (McRobbie, Bullen, Hartmann-Boyce, & Hajek, 2014), as e-cigarettes 
have gained in popularity worldwide (Brown et al., 2014; de Lacy, Fletcher, Hewitt, 
Murphy, & Moore, 2017; Delnevo et al., 2015; Giovenco & Delnevo, 2018; Hummel et 
al., 2015; King, Patel, Nguyen, & Dube, 2015) including in unfavourable regulatory 
climates wherein sales of nicotine-containing e-cigarettes are prohibited unless 
classified as medicinal (Li, Newcombe, & Walton, 2015), the evidence has mounted and 
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strengthened considerably.   In fact findings of early clinical studies (Bullen et al., 2010; 
Vansickel, Cobb, Weaver, & Eissenberg, 2010) suggested they were inefficient at 
delivering nicotine, whilst early randomised controlled trials (RCT) and cohort studies 
found they had very modest effects on abstinence rates (Bullen et al., 2013) casting 
doubt on their efficiency to become viable as nicotine replacements products.   The 
2014 Cochrane review, based on evidence from two RCTs with just under 1000 
smokers, suggested that 6 months abstinence was more likely in smokers using nicotine 
e-cigarettes compared to those using placebo e-cigarettes whilst one study found no 
difference between transdermal nicotine products and e-cigarettes (McRobbie, Bullen, 
Hartmann-Boyce, & Hajek, 2014).  In contrast, evidence from nine cohort studies of 
just under 2000 smokers did suggest that e-cigarettes could reduce smoking 
significantly; the limited number of studies and lack of certainty in the results rendered 
the evidence inconclusive (McRobbie, Bullen, Hartmann-Boyce, & Hajek, 2014).  
However, one of the key issues with these early studies involved the use of early 
generation models with poor nicotine delivery highlighting the need to consider device 
efficiency and reliability more carefully (Lopez & Eissenberg, 2015).  Since these early 
trials and clinical studies, the technology has advanced considerably, and better 
developed and more efficient devices have enhanced nicotine delivery (Farsalinos et al., 
2016).  Substantial numbers of experimental studies have found that e-cigarettes can, 
not only deliver nicotine efficiently (D’Ruiz, Graff, Yan, Sherwin Yan, & Yan, 2015; 
Dawkins & Corcoran, 2014; Farsalinos et al., 2014; Farsalinos, Spyrou, Tsimopoulou, 
et al., 2015; Hajek, Przulj, Phillips, Anderson, & McRobbie, 2017; Lee, Gawron, & 
Goniewicz, 2015; Lopez et al., 2016; Wagener et al., 2016) but sometimes at levels that 
exceed tobacco cigarettes (Ramôa et al., 2015).  Subsequently, it became apparent that 
measuring the impact of e-cigarettes on smoking cessation using RCTs may have 
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inherent limitations.  E-cigarette use is a highly complex phenomenon.  Given the rapid 
and constant evolution of the product (Lopez & Eissenberg, 2015), the considerable 
choice in products, the large variation within and between devices combined with the 
changing trends in use patterns and the possible peer-influence encountered via e-
cigarette forums and social media, RCTs may be subject to non-compliance.  Thus, as 
many confounders may arise, it becomes apparent that RCTs are not always appropriate 
and may not reflect ‘real life’ scenarios.  In fact, in a small (N = 40) ‘real life’ 
observational study, in which smokers were followed up for two years, 27.5% of the 
sample reduced their smoking by more than 50% (reducing their cigarettes smoked per 
day from 24 to 4), whilst 40% were abstinent at 2 years (Polosa et al., 2014).   Further 
controversies adding to the misconceptions about e-cigarettes’ efficiency as smoking 
cessation aids, stem from a meta-analysis from the US which included cross-sectional 
and prospective cohort studies (Kalkhoran & Glantz, 2016).   The odds of quitting were 
28% lower using e-cigarette compared to those who did not.  However, this meta-
analysis failed to capture crucial variables related to participants’ past quit attempts, 
such as models used, frequency and duration of use (that is casual versus regular use) 
conflating all different types of e-cigarette users and devices.  Firstly, many of the 
studies included, suffered a sample selection bias wherein ex-smokers who quit using an 
e-cigarette would have been excluded, whereas smokers who may have made many 
attempts to quit and used an e-cigarette prior to taking part in the study could be 
included.  In addition, the study did not take into account reasons for e-cigarettes use.  
For example, one study included reported low cessation rates amongst those who used 
e-cigarettes for a purpose other than cessation (Vickerman et al., 2017).  Secondly, 
frequency and duration of use were not captured; in fact research suggests that greater 
frequency of use is associated with a higher likelihood to quit (Hitchman, Brose, 
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Brown, Robson, & McNeill, 2015).  Finally, in the analysis, all devices were treated as 
one type, a number of studies have found that considerable variations between e-
cigarette types in terms of their efficiency (Caponnetto et al., 2017; Farsalinos, Spyrou, 
et al., 2014; Hajek et al., 2017; Hitchman et al., 2015; Kozlowski, Lynn Homish, 
Homish, Homish, & Homish, 2017); and that most successful attempts will involve 
transitioning from one type of device to a more efficient one (Yingst et al., 2015).  
Clearly, all the aforementioned are crucial components when determining the 
effectiveness of e-cigarettes, and have all been neglected in this meta-analysis.  Given 
the highly heterogeneous nature of e-cigarettes and e-liquid disparity combined with the 
different materials and varied methodologies similarly to RCTs, meta-analysis are 
highly susceptible to misinterpretations.  Thus, population level studies may be better 
suited to assess the true impact of e-cigarettes on the population.  In contrast, the 2014 
PATH study using a methodology that allows distinguishing between casual and regular 
use and the inclusion of former smokers who used e-cigarettes, found clear differences 
between experimentation and former smokers who used their devices on a daily basis 
(Rodu & Plurphanswat, 2017a); this highlights the need for careful consideration to 
clearly discriminate users such as regular users versus from experimenters.   
A substantial number of studies suggested e-cigarettes to have the potential to 
promote cessation (Beard, West, Michie, & Brown, 2016; Bell & Keane, 2012; Koch, 
2012; Meier, Tackett & Wagener, 2013; Weinberg & Segelnick, 2011), including a 
large English cross-sectional study (N = 5863), which found that those using an e-
cigarette were more than twice as likely to remain abstinent at one year compared to 
those who used NRT or no aid (Brown et al., 2014).  This was echoed in a recent US 
study which, using the National Health Interview Survey (NHIS) (and a sample of 
current and former smokers, N = 15,532), found that those using an e-cigarette daily 
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were more likely to have quit compared to those who did not use an e-cigarette 
(Giovenco & Delnevo, 2018).  In the UK, the emerging evidence has accompanied a 
growing consensus that e-cigarettes can help reduce smoking and promote cessation.  
For instance, in 2015, based on a review of 158 studies, Public Health England (PHE) 
have endorsed them as less harmful than smoking and state that their use should be 
encouraged for those who are unable or unwilling to quit (McNeill et al., 2015).  The 
Royal College of Physicians echoed PHE’s endorsement, other public organisations 
(such as NICE and NCSCT the National Centre for Smoking Cessation and Training) 
followed to endorse e-cigarettes and encourage smokers who are unable to quit using 
conventional cessation aids to try the products.  The fact that PHE incorporated e-
cigarettes in national cessation campaigns such as ‘Stoptober’, suggest a change in 
attitudes with regard to advertisement regulations (NHS, n.d.).  Evidence on the 
effectiveness of e-cigarettes to be helpful in a quit attempt is also captured in qualitative 
data which suggest that e-cigarettes can help prevent complete relapse to smoking 
(Notley, Dawkins, Holland, Jakes, & Ward, 2017).  The potential of e-cigarettes to help 
reduce and promote cessation (Etter & Bullen, 2014) more so than NRT (Beard, 
Bruguera, McNeill, Brown, & West, 2015; Brown et al., 2014) is also reflected in self-
reports from long term users stating that they are more effective than NRTs in 
promoting to smoking cessation and reducing withdrawal symptoms (Nelson et al., 
2015).  
Based on the International Tobacco Control (ITC) Netherlands Survey and data 
collected between 2008 and 2014 (N = 1820; N = 1550) the reported chief reason for 
trying an e-cigarette was to reduce the number of cigarettes smoked per day (hereafter 
referred to as CPD) (Hummel et al., 2015).  In the UK, the ASH report highlighted 
some distinctions, but clear similarities, between current (dual users) and former 
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smokers.  Reducing and stop smoking were the main reasons reported by dual users and 
former smokers respectively; whilst for both groups ‘saving money’ was the second 
reason, followed by “to help me stop smoking entirely” and “to help keep me off 
tobacco” given by former and current smokers respectively (ASH, 2017).  Other reasons 
for using an e-cigarette include seeking health improvements (Brown et al., 2014), past 
failed attempts and concerns regarding  the consequences of passive smoking (ASH, 
2017).   
Aside from reasons for using e-cigarettes, it is relevant to briefly note the key 
characteristics sought after in e-cigarettes.  Past studies have noted that for smokers who 
have tried e-cigarettes, features such as the design would contribute to increase their 
appeal (Dawkins, Kimber, Puwanesarasa, & Soar, 2015); whilst for experienced e-
cigarette users i) the ergonomics, ii) the compatibility with varied components, iii) the 
ability to adjust the voltage and wattage, iv) durability and reliability are key desirable 
characteristics (Baweja et al., 2016; McQueen, Tower, & Sumner, 2011).  Of key 
importance is the ‘more satisfying hit’, battery capabilities and the affordability to 
greater e-liquid choice seem highly important features (Baweja et al., 2016; Yingst et 
al., 2015).  The latter will be later discussed in the context of nicotine delivery and 
differences in device types.  These factors are important as they may further the 
understanding of dissatisfaction and product discontinuation or the need to transition to 
other models (Yingst et al., 2015); this can be informative to smokers who are yet to 
transition away from smoking.   
E-cigarettes Safety  
As there is no combustion and tar, and far fewer toxicants compared with 
tobacco cigarettes (Goniewicz et al., 2014; McAuley, Hopke, Zhao, & Babaian, 2012; 
Schripp, Markewitz, Uhde, & Salthammer, 2013; Stephens, 2017), e-cigarettes are 
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deemed a safer alternative to tobacco smoking (McNeill et al., 2015).  This is echoed 
through discourses amongst vapers who report significant health improvements after 
switching to e-cigarettes (Dawkins, Turner, Roberts, & Soar, 2013; McQueen, Tower, 
& Sumner, 2011).   
Data from toxicological studies suggest that e-cigarette use is far less harmful 
than smoking  combustible cigarettes (Farsalinos & Polosa, 2014) and subtituting 
smoking for e-cigarettes use significantly reduces exposure to selected toxicants and 
carcinogens (Goniewicz et al., 2017) as well as leads to considerable health benefits 
(Caponnetto, Polosa, Morjaria, Caruso, Strano, & Russo, 2015).  Encouragingly, a 
recent study shows that biomarkers of exposure to selected toxicants and carcinogens in 
exclusive e-cigarette users are equivalent to those found in exclusive NRT users and 
significantly lower than those found in smokers (Shahab et al., 2017).  Furthermore, 
several studies (Caponnetto et al., 2015; Farsalinos et al., 2016; Polosa et al., 2016) 
have found that in individuals with asthma, chronic obstructive pulmonary disease 
(COPD) or high blood pressure, patients who switched to e-cigarettes, showed a 
significant improvement in symptoms and physical activity levels.  In 2015, PHE 
estimated that e-cigarette use would unlikely exceed 5% of the risks associated with 
smoking. This was based on an assessment of 185 studies (McNeill et al., 2015) and the 
estimate was supported in the Royal College of Physicians subsequent report (Royal 
College of Physicians & Group, 2016).  It is worth noting that the widely cited estimate 
that e-cigarettes are 95% safer than smoking has received criticisms (The Lancet, 2015; 
McKee & Capewell, 2015) and these have been addressed in a comprehensive response 
by the authors (McNeill, Brose, Calder, Hitchman, et al., 2015; McNeill & Hajek, 
2014). 
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 The mechanism by which e-cigarettes operate consists of heating a solution at a 
temperature not exceeding 290oC, which involves little chemical alterations under 
commonly used operating temperature (Pankow et al., 2017). Conversely, side- and 
mainstream smoke from tobacco cigarettes involve combustion which can reach up to 
900oC and creates physical and chemical alterations generating more than 7000 known 
and potentially harmful chemicals (United States Department of Health and Human 
Services, 2014).   In fact, studies suggested that many of the chemicals present in 
tobacco smoke appear to be absent, at trace levels or much lower levels in e-cigarette 
aerosols in comparison (Flora et al., 2016; Goniewicz et al., 2014; Pankow et al., 2017; 
Tayyarah & Long, 2014).  However, specific circumstances such as long puff duration 
in combination with high voltage applied to the coil can lead to over-heating the 
atomizer (Geiss, Bianchi, & Barrero-Moreno, 2016) which can in turn produce 
carbonyls (Farsalinos, Voudris, & Poulas, 2015; Kosmider et al., 2014; Pankow et al., 
2017) listed as harmful or potentially harmful constituents (HPHC) in tobacco products 
and tobacco smoke (FDA, 2012).  
Though e-cigarette aerosols have been found to yield greater number of particles 
compared to aerosols produced by tobacco cigarettes, studies suggest minimal risks 
from first and second hand compared to tobacco cigarettes smoke given that the particle 
concentrations deposited onto surfaces are significantly lower (Scungio, Stabile, & 
Buonanno, 2018).   Likewise, based on previously published chemical analyses, a recent 
study suggested the potential for carcinogenic cell production from e-cigarette aerosols 
exposure was found to be only one percent of that from tobacco cigarettes smoke 
(Stephens, 2017).    
Conflicting studies can also be found in the literature with regards to their 
safety.  In one study, sputum samples from e-cigarette users, smokers and non-smokers 
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were analysed to measure total and individual mucins concentrations and neutrophil 
extracellular trap formation rates.  Findings of greater levels of the target analytes in the 
e-cigarette group in relation to the smoking group allowed the authors to conclude that 
the use of e-cigarettes may increase the risk of immune system alteration in the lung 
system (Reidel et al., 2017).  However, it is unclear if and how smoking history of the e-
cigarette users was accounted, treated or adjusted for in the analysis.  Indeed a sample 
which included heavy smokers who switched to e-cigarettes would have influenced the 
results.  Moreover, some ex-smokers in the e-cigarette user group were reported to 
smoke occasionally which alludes to a possible conflation between smokers and e-
cigarette users and raises further concerns in relation to the interpretations of these 
findings.  A better sampling method would include e-cigarette users with no history of 
smoking or the introduction of a control group (for example smokers who quit with the 
aid of NRT or medication).  Further limitations are that sputum cultures may not be the 
best specimen to determine causative organisms in lung disease as they have not always 
yielded clear conclusions (García-Vázquez et al., 2004).  More importantly, previous 
studies suggest that increases in mucins concentrations and sputum neutrophils in 
COPD suffering quitters with inflamed airway may be part of a repair mechanism of 
tissue damage and this was found to persist a year following cessation (Willemse et al., 
2005).  Therefore, the authors’ interpretation that e-cigarettes use may lead to alterations 
of the immune system may be premature.  
Other critics refer to concerns vis-á-vis the e-liquid safety following publications 
that some flavours may be associated with high levels of toxicants due to oxidation or 
thermal degradation (Behar et al., 2016; Leigh, Lawton, Hershberger, & Goniewicz, 
2016); whilst others found greater levels of aldehyde in e-cigarette aerosols compared to 
that of combustible cigarettes (Jensen, Luo, Pankow, Strongin, & Peyton, 2015).  
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However, it appeared that occurrences of thermal degradation often relate to extreme 
temperature and misuse of the voltage (Farsalinos, Kistler, et al., 2017; Gillman, Kistler, 
Stewart, & Paolantonio, 2016).  Replicating the methodologies used in these studies, it 
was later demonstrated that in many instances, the investigators failed to employ 
realistic conditions replicating how these devices are used in everyday lives, namely a 
failure to change the coil after each replicate and excessive power applied to the coil, 
which resulted in greater toxicants and carbonyls production (Stephens, 2017); referred 
to as the ‘dry puff’ phenomenon (Farsalinos, Voudris, & Poulas, 2015).   Besides, 
empirical research has shown that dry puffs  are discernible and aversive thus avoided 
by e-cigarette users (Farsalinos, Voudris, Spyrou, & Poulas, 2017) which highlights the 
need for continued research and more importantly for the inclusion of realistic usage 
conditions.   
Thus altogether, although it may be a little premature to determine the long term 
health effects associated with e-cigarettes, there is substantial evidence to suggest that e-
cigarettes are much safer than smoking, and it is this existing evidence that is informing 
the current regulatory framework applied in the UK.   
 
E-Cigarette Regulations 
 
The evidence thus far that e-cigarettes are a viable substitution to smoking is 
vastly encouraging, thus they are likely to play a favourable role in tobacco harm 
reduction.  To this effect, regulations should ensure a minimum quality product 
standard.  The European commission introduced a range of regulations through article 
20 from the EU-TPD, with the intentions of ensuring safety and a minimum standard of 
quality product (European Union, 2014).  These included limiting the tank and cartridge 
sizes to 2 mL and a restriction on nicotine concentrations to 20 mg/mL unless subject to 
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an application to be classified and sold as medicinal devices which can be an onerous 
procedure.  Although intended to ensure safety, these restrictions may deter potential 
users (i.e. current smokers) rendering e-cigarettes less appealing.  Although, many e-
cigarettes users gradually reduce their nicotine concentration over time (Polosa, 
Caponnetto, Cibella & Le-Houezec, 2015), highly dependent smokers may need to 
increase their nicotine concentration in order to achieve complete smoking abstinence at 
least in the early stages of a cessation attempt (Farsalinos, Romagna, Tsiapras, 
Kyrzopoulos & Voudris, 2013).  Although data suggest that only a small proportion of 
e-cigarette users use nicotine e-liquid higher than the EU-TPD cap (ASH, 2017), given 
the large population of e-cigarette users overall (2.9 million), the number affected 
remains large (approximately 170 000 users) and must not be ignored.  However, the 
recent decision to exit the EU might provide some flexibility for the UK to respond to 
emerging evidence with regards to evaluating the legislative provisions introduced 
within the TPD.  Besides, other countries have gradually softened their stance and 
started to recognise the potential benefit of e-cigarettes in reducing the burden of 
smoking.   In the process of legalising e-cigarettes, Canada has published an amendment 
to its Tobacco Act to allow for a clear differentiation between the act of smoking from 
vaping (Senate Government Bill, 2017), whilst New Zealand, recognising the potential 
of e-cigarettes to contribute towards the Smoke free 2025 target, is adopting regulations 
more in line with the UK (New Zealand Ministry of Health, 2017).  In contrast, e-
cigarettes are still banned in many other countries including in Brazil, Argentina, 
Colombia and Indonesia.  
Ensuring policies in place remain appropriate and proportionate are highly 
important, since studies show that the regulatory environment may influence the impact 
of e-cigarettes on smoking cessation (Yong et al., 2017).  A comparison was made on 
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the real-world effectiveness of e-cigarettes in two countries (Canada and Australia) 
wherein nicotine e-cigarettes sales are prohibited, with two countries (USA and UK) 
with far less restrictive policies (Yong et al., 2017).  It was found that smokers in less 
restrictive policy climate were more likely to quit using e-cigarettes, compared with 
making an attempt unaided.  In contrast, those using e-cigarettes to quit in more 
restrictive policy climate were less likely to succeed in their quit attempt (Yong et al., 
2017).   
 
Nicotine concentrations, puffing topography, and user’s experience 
As previously mentioned, the slow and gradual release of nicotine from NRT 
(Digard et al., 2013) may not be so appealing to smokers and may explain NRT’s low 
abuse liability (Henningfield & Keenan, 1993; Nelson et al., 2015) and the desire for 
smokers to have greater control over their nicotine delivery at a ‘finger-tip’ level.  
Indeed, the troughs and peaks observed following the smoking of a cigarette tend to be 
strongly associated with greater satisfaction levels (Berridge et al., 2010) and reversal of 
withdrawal symptoms (Nelson et al., 2015) compared to NRT, which suggests the need 
for immediate reward namely a ‘hit’ and lends support to the bolus and titration theory.  
Nicotine Delivery and Puffing Topography 
Similar to smoking, nicotine delivery in e-cigarettes use is likely to be a key 
determinant to dictate puffing topography, blood nicotine levels and satisfaction.  Early 
studies to investigate the effectiveness of e-cigarettes found that the devices delivered 
no to little levels of nicotine compared to tobacco cigarettes (Bullen et al., 2010; 
Eissenberg, 2010; Vansickel et al., 2010).  Differences between tobacco cigarettes’ and 
e-cigarettes’ nicotine delivery could be largely attributed to the differences in 
mechanism suction between cigarette smoking and e-cigarette use with e-cigarettes 
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requiring a stronger vacuum than combustible cigarettes (Trtchounian, Williams, & 
Talbot, 2010).   This relates to the delay between the activation of the atomiser and the 
time of the aerosol generation, and to the lower volume of aerosols produced compared 
with tobacco cigarettes (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 
2013).  Indeed some found that despite a higher frequency in e-cigarette puffs compared 
to tobacco smokers, e-cigarettes failed to match the nicotine delivery of tobacco 
cigarettes (Hajek et al., 2017). It is worth noting though, that many other variables could 
have contributed to these differences namely differences between individuals’ nicotine 
absorption, the type of the devices, and so on.   
Whilst early studies suggested that e-cigarettes had poor nicotine delivery in 
naïve users (Bullen et al., 2010; Eissenberg, 2010), subsequent studies in experienced 
users both, with cigalikes (Dawkins & Corcoran, 2014) and tank systems (Vansickel & 
Eissenberg, 2013) have yielded significantly higher blood nicotine levels, providing 
craving relief and satisfaction compared to naïve users using cigalikes or tanks 
(Farsalinos et al., 2014; Farsalinos et al., 2015).  This might be explained by different 
puffing topographies between experienced users who reportedly take longer puffs 
compared to naïve users (Farsalinos, Spyrou, Stefopoulos, et al., 2015).  Likewise, naïve 
users tend to increase their puffing over time, possibly to optimise blood nicotine 
delivery (Lee et al., 2015).  Aside from puffing patterns, higher nicotine concentrations 
in e-cigarette liquids may be preferable to maximise effective blood nicotine delivery.  
Indeed, studies found that high nicotine concentrations are associated with more 
effective nicotine delivery (Farsalinos et al., 2013a; Hajek et al., 2017; Lopez et al., 
2016), greater satisfaction and greater reduction in withdrawal and desire to smoke 
(D’Ruiz et al., 2015) and, many studies suggest that the addictiveness of nicotine 
delivery systems is dependent upon the speed at which nicotine is delivered (Le 
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Houezec, 2003).  That said, e-cigarette users tend to decrease their nicotine 
concentrations over time (Lechner et al, 2015), however the drivers of this phenomenon 
are currently unclear.  This shift in behaviours may be driven by the negative perception 
surrounding the long term use of nicotine, the regulatory environment (that is the cap on 
nicotine concentrations imposed by the EU-TPD) or the increasing popularity of ‘sub-
ohming’.   
To reverse the negative effects of withdrawal symptoms (e.g. lack of 
concentration, depressed mood and irritability) experienced during abstinence, smokers 
need to maintain a constant plasma nicotine level by means of continued nicotine intake 
(Collins et al., 2010). This is supported by the large body of evidence which shows that 
smokers regulate levels of nicotine in their blood system by adjusting their puffing 
behaviours when given a lower or higher nicotine concentrations compared to their 
habitual ones, as discussed earlier (Ashton et al., 1979, 1970; Herning et al., 1981; 
Strasser et al., 2007; Woodward & Tunstall-Pedoe, 1993).  The hypothesis that e-
cigarette users may similarly titrate to regulate their blood nicotine levels, although not 
explicitly, is alluded to in empirical studies.  Large individual differences were found in 
plasma nicotine levels in e-cigarettes users using the same device, concentrations and 
prescribed standardised puffing protocols (Dawkins & Corcoran, 2014).  This suggests 
that participants may have adjusted the way they puffed by taking more, longer and/or 
more intensive puffs compared to others in order to extract their desired amount of 
nicotine.  If e-cigarette users are able to self-titrate in the same manner as smokers do 
with tobacco cigarettes, enabling ‘finger-tip’ control over their nicotine intake, this 
might explain the increased appeal of e-cigarettes over traditional NRT.    
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Nicotine concentrations 
Aside from puffing topography and device efficiency, another key driver in 
nicotine delivery is the concentration of nicotine in the e-liquid.  Likewise, 
pharmacokinetic studies suggest that greater craving and withdrawal relief are 
associated with high-powered tank systems, more intensive puffing patterns and higher 
nicotine concentration e-liquids (Etter, 2015).  That higher nicotine concentrations are 
associated with greater craving relief is of some importance, given that the second 
reason for discontinuation of e-cigarettes was their inefficiency to deal with craving 
relief (ASH, 2017).  Indeed, like nicotine yield in tobacco cigarettes (Hammond, Fong, 
Cummings, & Hyland, 2005; Russell, Epstein, & Dickson, 1983), e-liquid nicotine 
concentration is an important factor that is likely to influence puffing topography.  In a 
later study, researchers compared puffing topography between 0, 8, 18 and 36 mg/mL 
and the interactions with plasma nicotine levels following two vaping bouts of ten puffs 
each in experienced users (Ramôa et al., 2015).  Participants increased their puff 
duration in the 0 mg/mL condition compared with the 36 mg/mL nicotine concentration 
(however not in the 8 or 18 vs. 36 mg/mL condition), suggesting an attempt to 
compensate for the deprivation of nicotine (Ramôa et al., 2015).  However, although the 
study supports the hypothesis of compensatory puffing, utilising a standardised ten-puff 
protocol may have influenced users’ natural puffing behaviours and/or reduced their 
ability to compensate fully.   
There is also evidence that higher nicotine concentrations products (including 
NRT) can increase smoking cessation (Tunnesen et al., 1999); and that in the early stages 
of a cessation attempt, smokers need to increase their nicotine concentration in order to 
achieve and sustain complete smoking abstinence (Farsalinos, Romagna, Tsiapras, 
Kyrzopoulos & Voudris, 2013).  This highlights the importance of high nicotine 
concentrations over low concentrations.  
 
 
57 
 
Longitudinal studies suggest whilst long term e-cigarettes users gradually reduce 
their nicotine concentration over time (Farsalinos et al., 2013a; Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos, & Voudris, 2014), this tends to be associated with an increase in 
nicotine intake (Etter, 2016).  Indeed, in a sample of 98 experienced users, although 
nicotine concentrations decreased from a median cotinine level of 11 to 6 mg/mL after a 
period of 8 months, salivary cotinine levels increased from 252 ng/mL to 307 ng/mL at 
follow-up (Etter, 2016).  This increase in nicotine consumption may be explained by a 
need to compensate for the drop in nicotine concentrations and self-titrate in order to 
maintain a satisfactory and constant level of blood nicotine level.  In fact, similarly to 
smoking (Gritz, Rose, & Jarvik, 1983), the number of puffs do not determine 
consumption, rather volume consumed is a better predictor; this is acknowledged by e-
cigarette users (Baweja et al., 2016), suggesting that other components of puffing 
topography such as duration may dictate consumption.  This adds further evidence for 
the inter-variability in puffing topography and that self-titration may occur in e-cigarette 
use.  
 
Differences in device types 
Another key element of nicotine delivery is the proficiency of the device used.  
In recent years, e-cigarettes have evolved and improved considerably.  Recent studies 
using tank systems as opposed to cigalikes have demonstrated rapid nicotine delivery 
approximating tobacco cigarettes (D’Ruiz, Graff, Yan, Sherwin Yan, & Yan, 2015; 
Farsalinos et al., 2014; Farsalinos, Spyrou, Tsimopoulou, et al., 2015; Hajek, Przulj, 
Phillips, Anderson, & McRobbie, 2017; Lee, Gawron, & Goniewicz, 2015; Lopez et al., 
2016; Wagener et al., 2016).  Nonetheless, there are still marked variations in devices’ 
efficacy to deliver nicotine and their ability to induce a satisfactory hit (Baweja et al., 
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2016), and to alleviate craving and withdrawal symptoms (Farsalinos et al., 2014; Hajek 
et al., 2017; Yingst et al., 2015).  Furthermore, studies suggest that successful quit 
attempts are seldom associated with cigalikes (Brose, Hitchman, Brown, West, & 
McNeill, 2015; Brown et al., 2014) and the use of tanks are more likely to lead to a quit 
attempt (Hitchman et al., 2015).  The popularity of tank systems over cigalikes with 
experienced users (Dawkins, Turner, Roberts, & Soar, 2013; Hitchman, Brose, Brown, 
Robson, & McNeill, 2015; Polosa, Caponnetto, Cibella, & Le-Houezec, 2015; Polosa, 
Caponnetto, Maglia, Morjaria, & Russo, 2014) may be partly due to their added 
features, sophistication and more importantly their superiority in delivering nicotine 
(Farsalinos et al., 2014; Farsalinos, Yannovits, Sarri, Voudris, & Poulas, 2016).  This 
accords with empirical findings suggesting that successful quit attempts often involve 
and may require transitioning from cigalikes to tanks systems (Yingst et al., 2015). 
Although e-cigarettes address both the pharmacological and the psycho-
behavioural aspects of smoking, for many smokers they are not as satisfying as 
smoking.  Forty-five percent are dual users whilst 65% of smokers who have tried have 
discontinued use. Of these 25% reported that they do not feel like smoking and 20% 
reported they did not help reducing craving for tobacco cigarettes (ASH, 2017).  
Altogether, the need to monitor, report and ensure efficiency across all device types is 
warranted. 
Furthermore, as previously mentioned, there are key characteristics that are 
favourable to e-cigarette users (Baweja et al., 2016; Dawkins et al., 2015; McQueen et 
al., 2011; Yingst et al., 2015) and which may help increase the appeal of these devices 
to existing smokers.  The following characteristics, the compatibility with varied 
components, the ability to adjust the voltage and wattage, (Baweja et al., 2016; 
McQueen et al., 2011), ‘more satisfying hit’, battery capabilities and the affordability to 
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greater e-liquid choice (Baweja et al., 2016; Yingst et al., 2015) are associated with tank 
systems and are absent from the cigalikes.  
 
User experience: Effects on puffing topography and nicotine delivery 
Similarly to tobacco cigarettes smokers (Hammond et al., 2005), there are inter-
individual variabilities in e-cigarette users’ puffing topography whilst puff number and 
duration tend to remain constant within individuals across brands or days (Behar, Hua, 
& Talbot, 2015).  Consistency in puffing behaviours within each e-cigarette user may be 
indicative of a need to maintain steady and constant blood nicotine levels as per the self-
titration theory (Russell, 1980; Russell & Feyerabend, 1978).    
A key factor in the efficacy of delivering nicotine and in providing satisfaction is 
the way in which the device is used.   Experienced users typically achieve higher levels 
of plasma nicotine, craving relief and satisfaction compared to naive users; they do so 
by taking longer and larger puffs thus drawing greater volume of nicotine liquid 
compared to e-cigarette naïve smokers (Farsalinos, Spyrou, Stefopoulos, et al., 2015b).  
The efficacy of obtaining satisfactory blood nicotine levels also depends upon the way 
the e-cigarette is used and studies have shown that both are likely to improve with 
practise (Hajek et al., 2015). Naïve users tend to increase their puffing patterns over 
time (Hajek et al., 2015; Polosa et al., 2014), which can lead to marked improvements 
in blood nicotine levels (Hajek et al., 2015; Lee et al., 2015).  This long term adjustment 
in puffing patterns support the notion that e-cigarette use is a learning curve (McQueen 
et al., 2011) and practise is required in order to obtain satisfaction.   
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Puffing Topography Measurements and Methods 
For the purpose of the current thesis, the focus here will remain on 
measurements and methods used to collect human data in e-cigarettes use as opposed to 
smoking machines which mimic human puffing patterns for the purpose of compounds 
(smoke/aerosol) analyses.  Puffing topography data provide direct evidence of a change 
in puffing patterns thus is central to compensatory puffing behaviours research (Scherer, 
1999).   Though puffing topography measures may comprise several variables (i.e. puff 
duration, numbers, inter-puff intervals, puff volume/velocity, inhalation/exhalation 
time, pressure drop, flow rate and peak flow rate (see Table 1.1), studies documenting e-
cigarette users’ behaviours have put more emphasis on puff duration (Hua et al., 2013) 
and puff number (Farsalinos et al., 2013b, 2015, 2017; St Helen et al., 2016; Strasser et 
al., 2016) in addition to volume consumed (Norton et al., 2014).  However, there is 
evidence to suggest puff number as a poor indicator of puffing topography and volume 
consumed and puff duration as stronger assessors for compensatory puffing (Baweja et 
al., 2016).   
Historically, a variety of different methods have been used to capture puffing 
topography data in smokers; these include observational methods and more precise 
computerised systems, for instance instruments measuring flow and pressure rate and 
puff velocity in milliseconds (e.g. Puustinen, Olkkonen, Kolonen, & Tuomisto, 1987). 
In the nascent era of e-cigarettes research, observational methods such as Youtube 
videos (Hua et al., 2013) and frame-by-frame analysis (Farsalinos et al., 2013b) were 
used to report puffing behaviours of e-cigarette users.  These methods (Hua et al., 2013; 
Farsalinos et al., 2013) were in good agreement in that they both suggested differences 
in puffing characteristics between e-cigarettes users and smokers (Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos, Voudris, 2013b; Hua et al., 2013).  Although frame-by-frame 
time analysis of video recordings is a useful and reliable method, it present some 
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limitations.  It does not allow the measurements of puff velocity and volume and is 
susceptible to visual interpretation bias.  This is reflected in earlier reports which found 
longer puff duration compared to mouth-piece devices (Blank et al., 2009).  Moreover, 
the frame-by-frame time analysis renders this method relatively onerous.    
Attempts have been made to employ the handheld machine CReSS (Clinical 
Research Support System) to capture puff count, duration, IPI, puff volume, rate and 
peak flow rate in e-cigarette users (Behar et al., 2016).  However, since the machine was 
originally developed for tobacco cigarettes and due to in-built features such as a cut-off 
point for the number of puffs and other technical issues such as leakages, use of the 
device has led to underestimation of puff counts and duration in some instances (see 
Behar et al., 2016 for example).  Eventually with technological advancement, some 
studies have been able to overcome these issues by the addition of a manufacturer 
adaptor for e-cigarettes (Norton et al., 2014).  Portable mouth-piece instruments have 
also been used to capture real world (and daily) puffing topography outside of the lab 
(e.g. Robinson et al., 2015); and these have been found to offer a more pragmatic and 
less intrusive method compared to desktop computerised systems (Spindle et al, 2015).  
However, findings that such modes of data collection may be intrusive thereby 
confound puffing behaviour data (Ross & Juliano, 2016; Spindle et al., 2015), these 
have highlighted a need for technologies that offer greater ecological validity.   For 
instance, it has been found that the use of mouth-piece devices negatively affects 
experiences in many ways including making e-cigarette use difficult (Spindle et al., 
2015) and diminishing pleasure from smoking (Blank et al., 2009).  Thus, the need for 
reliable, pragmatic and cost-effective methods with good ecological validity is 
warranted.   Equipped with an in-built downloadable software and memory chip that 
automatically records and stores the start and end of single puff upon each button press, 
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the eVic e-cigarette has recently entered the market (at the time of Study 1 planning); 
these features make the e-Vic a well suited choice of instrumentation to measure puffing 
topography.   Table 1.1 offers an overview of publications reporting used methods and 
measures in chronological order of methods used; note that care has been taken to 
differentiate publications that preceded Study 1 planning and data collection and 
publications that followed.
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Table 1.1  
Publications reporting puffing topography measures and methods in e-cigarettes research 
Author (s) / Publication date Variables measured Method used  Study settings 
Observational methods  
Hua et al., 2013* Puff duration Youtube videos Real world / Ad lib 
Farsalinos et al., 2013b* Puff number and duration Video recordings Lab / Ad lib 
St Helen et al., 2016 Puff number and duration, IPI Video recordings Lab / Ad lib 
Strasser et al., 2016 Puff number and duration, IPI Video recordings Lab / Standardised 
protocol 
    
Mouth-piece connecting instruments  
Norton et al., 2014* Puff number and duration, IPI, Puff 
volume 
CReSS Micro Lab / Ad lib 
Spindle et al., 2015 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial 
computerised instrument  
Lab / Standardised 
protocol 
Behar, Hua & Talbot, 2015 Puff number and duration, IPI, Total 
volume, Volume/puff, Flow rate, Peak 
flow rate 
CReSS pocket device with 
EC adaptor 
Lab /  2 separate days of 2 
ad lib sessions consisting 
of 10-min bouts  
Lee et al., 2015 Puff number and duration, IPI, Puff 
volume, Flow rate 
CReSS micro Lab / Ad lib 
Robinson et al., 2015 Puff number and duration, Number of 
puff/day, IPI, Puff volume, Flow rate 
Wireless portable monitor  Real world / Ad lib 
Ramôa et al., 2015 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial 
computerised  instrument 
Lab / Standardised 
protocol 
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Spindle et al., 2016 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial 
computerised  instrument 
Lab / Standardised 
protocol 
Robinson et al., 2016 Puff duration, Number of puff/day, Puff 
volume, Flow rate 
Wireless portable monitor  Real world / Ad lib 
Cunningham et al., 2016 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial SA7 puff 
flow-induced device 
Lab / Ad lib 
Lopez et al., 2016 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial 
computerised  instrument 
Lab / Standardised 
protocol 
Hiler et al., 2017 Puff number and duration, IPI, Puff 
volume, Flow rate 
Non-commercial 
computerised  instrument 
Lab / Standardised 
protocol 
Lee et al., 2017 Puff number and duration, IPI, Puff 
volume, Flow rate 
Wireless portable monitor Real world / Ad lib 
    
Integrated e-cigarette devices 
Farsalinos et al., 2015 Puff number and duration EVic e-cigarette  Lab / Standardised 
protocol 
Dautzenberg & Bricard, 2015 Puff duration, IPI, Number of puff/day  Smokio monitor (Smokio®; 
http://us.smokio.com) 
Real world / Ad lib 
Farsalinos et al., 2017 Puff number and duration EVic e-cigarette  Lab / Standardised 
protocol 
Note * indicates publications available at the time of study planning and data collection of Study 1.  
Real world signifies real world environment; IPI signifies inter-puff intervals; Lab signifies Laboratory; Ad lib signifies ad libitum 
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Summary of Rationale and Primary Aims  
 
Altogether, evidence suggests users’ experience, device characteristics and 
nicotine concentrations as likely factors influencing nicotine delivery and the way a 
device is puffed on (e.g. puff duration and frequency) (Talih et al., 2014).  As 
previously discussed, nicotine delivery in e-cigarettes use is likely to be a key 
determinant to dictate puffing topography, satisfactory blood nicotine levels and craving 
reduction for tobacco cigarettes.  Effective nicotine delivery therefore is likely to 
promote sustained e-cigarette use and tobacco cigarettes substitution, and eventually 
lead to a successful smoking cessation.  In this chapter it has also come to light that 
similarly to smoking, e-cigarette use may involve self-titration; this is reflected in the 
stark differences in puffing topography between e-cigarette use and the smoking of a 
tobacco cigarette (Farsalinos et al., 2013b).  Others have found some evidence (albeit 
not direct due to the use of prescribed protocol puffing) of compensatory puffing under 
the use of 0 compared to 36 mg/mL nicotine concentrations (Ramôa et al., 2015).  There 
is further evidence to suggest that blood nicotine under the use of low nicotine 
concentrations (including 18 mg/mL) do not equate levels delivered via tobacco 
cigarettes (Farsalinos, Spyrou, Tsimopoulou, et al., 2014) and this concords with the 
fact that e-cigarette users are more likely to achieve complete cessation when initiating 
use with higher nicotine concentration prior to a gradual reduction over time (Farsalinos 
et al., 2013a).    
Aside higher nicotine concentrations, tank devices that allow power adjustment, 
have been found to be associated with more effective nicotine delivery compared to 
cigalikes (Farsalinos, Spyrou, Tsimopoulou, et al., 2014).  Thus it follows that the use 
of tank devices combined with higher nicotine concentrations will be more likely to 
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promote levels of satisfaction close to that achieved under tobacco smoking and 
alleviate cigarette craving and withdrawal symptoms more effectively compared to 
cigalikes.   
In the same light, given that tank devices and higher nicotine concentrations 
have been found to be associated with greater craving reduction (Etter, 2015), which in 
turn is associated with more intensive use, these factors will be more likely to be 
associated with greater odds of smoking cessation in the long term.  Whilst there is 
ample studies that suggest motivation and cigarette dependence as predictors of 
smoking cessation, to date, very few studies have explored the potential factors that can 
help predict quit with the aid of e-cigarettes. Given the difficulty of quitting and 
remaining abstinent, the struggle for many to achieve a complete transition away from 
smoking remains.  Thus, further understanding of the factors that can predict successful 
cessation outcomes will be informative and can add to the support provided to smokers 
and dual users to facilitate complete cessation.   
The current thesis aims to shed light on the inter-relationships between puffing 
topography of e-cigarette users, nicotine concentrations and e-cigarette characteristics.  
Further aims are to further the understanding of the complementary roles of subjective 
effects namely satisfaction, the alleviation of craving and reduction of withdrawal 
symptoms in e-cigarette use.  The findings of this thesis will be informative to smoking 
cessation services, smokers, e-cigarette users and policy makers, specifically vis-à-vis 
regulatory decisions on nicotine concentrations in e-liquid including assessing whether 
the decision to restrict nicotine concentrations to 20 mg/mL (Article 20 of the EU-TPD) 
has merit.   
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Study 1 will ascertain whether e-cigarette users are able to self-titrate by 
exploring compensatory puffing behaviour when regular users are given a lower 
nicotine concentration compared to the one they are accustomed to.    
Study 2 will explore how puffing behaviours and nicotine delivery in naïve e-
cigarette users (that is, smokers who have no or very little experience in e-cigarette use) 
change over time and vary according to device type and nicotine concentration.  It will 
also explore effects of device type/nicotine concentration on satisfaction, craving 
alleviation, product acceptability.   
In Study 3, factors such as device types, nicotine concentrations, craving 
reduction and satisfaction at initial use, baseline motivation to quit and cigarette 
dependence will be explored in a logistic regression model to assess whether they have 
any predictive value for smoking cessation with e-cigarettes use.   
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CHAPTER II 
“SELF-TITRATION BY E-CIGARETTE USERS: PUFFING 
TOPOGRAPHY, PLASMA NICOTINE AND SUBJECTIVE 
EFFECTS” 
 
Abstract 
Background:  Self-titration is well documented in the tobacco literature.  The extent to 
which e-cigarette users self-titrate is unknown.  This study explored the effects of high 
and low nicotine concentrations on puffing topography, nicotine delivery and subjective 
effects in experienced vapers.   
Methods:  Pilot study:  In order to inform the procedural aspects of the main 
experiment, between October and December 2014, a pilot study (N = 5) was conducted 
using a single-blinded within-participants design to compare resulting puffing 
topography in a low (6 mg/mL) versus a high (18 mg/mL) nicotine concentration.  Puff 
duration, number and IPI were recorded via video-recordings and an eVic™ e-cigarette 
with an in-built puff timer/counter.  Craving, withdrawal symptoms were measured at 
the start and end of the 45 min ad lib vaping session, and other subjective (positive and 
adverse) effects at the end of the session.   Study 1:  In a double-blind within-
participants design experiment, between June and July 2015, 12 experienced e-cigarette 
users completed 1 hour of ad libitum e-cigarette use under low (6 mg/mL) and high (24 
mg/mL) nicotine concentrations.  An eVic™ e-cigarette mounted with an Aspire tank 
containing 2 mL of e-cigarette liquid recorded, puff number and duration.  Blood 
samples and subjective craving/withdrawal symptoms were collected at baseline, 10, 30 
and 60 minutes from the first puff.   Adverse (e.g. nausea, headache) and positive 
effects (e.g. hit and satisfaction) were reported at 60 minutes.    
Results:  Pilot study:  Means in puff number, duration and volume were greater 
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in the low condition as per the eVic and also as per the video recording data; conditions 
did not differ in craving and withdrawal symptoms alleviation or subjective effects.  
Puffing topography data recorded from the eVic correlated highly with the video 
recordings data in the low condition for puff number r = .98, p = .005 and puff duration 
r = .90, p = .037, and in the high condition for puff number r = 1.00, p < .0001, but not 
for puff duration r = .67, p =.22.  There was a statistically significant correlation 
between volume consumed and puff duration in the low condition only [r = .90, p = 
.037].   Study 1:  Liquid consumption and puff number were higher and puff duration 
longer in the low nicotine concentrations condition (all ps < 0.01).  Mean (SD) nicotine 
boost for the high nicotine condition from baseline were 32.35 (34.88) ng/mL, 35.48 
(28.31) ng/mL and 43.00 (34.78) ng/mL.  Corresponding values for the low nicotine 
condition were 8.74 (7.52) ng/mL, 16.75 (11.72) ng/mL and 21.96 (16.19) ng/mL at 10, 
30 and 60 minutes respectively (ps < 0.05).  There were no statistically significant 
differences between conditions in self-reported craving, withdrawal symptoms, 
satisfaction, hit or adverse effects.   
Conclusion:   That both methods correlated highly suggest good reliability of the eVic 
as an instrument to measure puffing topography and the frame-by-frame time analysis. 
Both the pilot study and Study 1 found direct evidence of compensatory puffing with 
lower (6 mg/mL) nicotine concentration liquids.  Although self-titration was incomplete 
with significantly higher plasma nicotine levels in the high condition, compensatory 
puffing was sufficient to reduce craving and withdrawal discomfort.    
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Introduction: Self-Titration and Nicotine Delivery - Effects on Puffing 
Topography 
 
One mechanism by which smokers are able to control their nicotine intake and 
compensate for a decrease or increase in nicotine availability is by altering their puffing 
patterns in order to obtain and maintain desired and constant levels of nicotine.  There is 
ample evidence in the literature which provides support to this hypothesis (Scherer, 
1999; Scherer & Lee, 2014).  Other factors likely to be central to effective nicotine 
delivery and acceptance of e-cigarettes as a substitution for tobacco smoking are 
nicotine concentrations and the speed and absorption rate of nicotine.  
In Chapter 1, differences between nicotine delivery from tobacco cigarettes and 
e-cigarettes were described.  It was noted that tobacco cigarettes are generally 
associated with higher and faster blood nicotine delivery although more recent studies 
using newer generation devices have found better nicotine delivery. 
 
Differences in puffing topography  
Whilst early studies reported poor nicotine delivery by e-cigarettes, later studies 
in long term users (Dawkins & Corcoran, 2014) found that later models can be effective 
in increasing blood nicotine levels (Farsalinos et al., 2014a; Nides, Leischow, Bhatter, 
& Simmons, 2014; Vansickel & Eissenberg, 2013), and, experienced users can achieve 
50% higher blood nicotine levels compared with naïve users (Farsalinos et al., 2015) in 
parallel with significant craving alleviation (Etter, 2015; Fearon et al., 2017).  This 
suggests that e-cigarette types differ in their efficacy to deliver nicotine and effective 
delivery depends largely on the manner in which the device is used (that is puffing 
patterns).  This is in line with later studies which found that regular use and practice can 
significantly increase blood nicotine levels (Hajek et al., 2015).  Using a sample of 
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naïve users to explore the effects of practice on nicotine absorption, a significant 
increase in nicotine intake was observed following a four-week period practice, which 
resulted in a significant increase in blood nicotine levels (Hajek et al., 2015).  This 
increase in nicotine intake may be explained by a need to compensate for the less 
effective nicotine delivery of e-cigarettes which is characterised by a greater draw 
resistance in comparison with tobacco cigarettes.  Although the nicotine delivery from 
e-cigarettes appears less effective compared to combustible cigarettes, increasingly it 
becomes evident that this could be reversed with practice; by adjusting puffing patterns 
(for example, increasing the duration and intensity of each puff), e-cigarette users can 
maintain constant and satisfactory blood nicotine levels, and withdrawal and craving 
relief (Dawkins & Corcoran, 2014; Dawkins, Turner, Hasna, & Soar, 2012; Etter & 
Bullen, 2011). 
Puffing topography (such as puff duration, volume and frequency) therefore, 
plays a large role in the effectiveness of nicotine delivery.  Experienced users typically 
take longer puffs and exhale larger volume of aerosols (Hua, Yip, & Talbot, 2011) 
compared with smokers (inexperienced e-cigarette users) using tobacco cigarettes or e-
cigarettes (Farsalinos et al., 2013; Talih et al., 2014).  Smokers however, tend to adjust 
their puffing patterns within a week of adopting e-cigarettes, chiefly by increasing their 
puff duration and adjusting each puff to a slower pace which in turn, result in a decrease 
in puff flow rate (Lee et al., 2015).  Others found that experienced e-cigarette users’ 
inhalation time is shorter compared to that of smokers when smoking combustible 
cigarettes (Farsalinos et al., 2013).  In a study comparing experienced users’ puffing 
topography versus smokers’ smoking and vaping topography, experienced users’ 
puffing duration were two-fold higher (M = 4.2, SD =  0.7 s) compared with smokers 
smoking a tobacco cigarette (M = 2.1, SD = 0.4 s) and smokers using an e-cigarette (M 
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= 2.3, SD = 0.5 s).  These results are in agreement with previous findings (Hua, Yip, & 
Talbot, 2011) and in line with the hypothesis that there is a “learning curve” involved in 
vaping (McQueen et al., 2011), and suggest that the required adjustment in puff 
duration is largely dictated by the need to compensate for the poorer nicotine delivery. 
 
Pharmacokinetic profiles of e-cigarettes and nicotine delivery 
Likewise, pharmacokinetic (PK) studies suggest that more effective craving and 
withdrawal relief are  associated with high-powered tank systems, more intensive 
puffing patterns and higher nicotine concentration e-liquids (Etter, 2015).  Indeed, like 
nicotine yield in tobacco cigarettes (Hammond, Fong, Cummings, & Hyland, 2005; 
Russell, Epstein, & Dickson, 1983), e-liquid nicotine concentration is an important 
factor that is likely to influence puffing topography.  Indeed, studies found that high 
nicotine concentrations are associated with more effective nicotine delivery (Farsalinos 
et al., 2013a; Hajek et al., 2017; Lopez et al., 2016), greater satisfaction and greater 
reduction in withdrawal and desire to smoke (D’Ruiz et al., 2015).  
Of particular interest, in a clinical study, documenting the pharmacokinetic effects 
of an early e-cigarette device, experienced e-cigarette users were invited to a one-hour 
ad libitum vaping session followed by an hour resting period (Dawkins & Corcoran, 
2014).  Following a ten-minute ten-puff standardised puffing protocol, large individual 
variabilities were observed, with a maximum peak of 13.4 ng/mL plasma nicotine levels 
and a minimum of 2.50 ng/mL despite maintaining the device (a cigalike model) and 
nicotine concentration (18 mg/mL) constant across all participants and sessions 
(Dawkins & Corcoran, 2014).  This suggests that although participants took the same 
number of puffs, their puffing patterns differed through adapting each puff to suit their 
nicotine intake needs (manipulating their puff duration and intensity) which led to the 
wide individual variability in plasma nicotine levels.  The ten-minute standardised 
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protocol was followed by an ad lib vaping session in which individual variabilities 
further increased with one participant reaching 25.6 ng/mL and another participant only 
achieving 4.35 ng/mL plasma nicotine levels at the end of the 60 minute ad lib puffing 
period (Dawkins & Corcoran, 2014), suggesting  that similar to smokers, vapers have 
desirable blood nicotine levels and titrate their nicotine intake to adapt to their personal 
nicotine needs.  In a later study, researchers compared puffing topography between 0, 8, 
18 and 36 mg/mL and the interactions with plasma nicotine levels following two vaping 
bouts of ten puffs each in experienced users (Ramôa et al., 2015).  Participants 
increased their puff duration in the 0 mg/mL condition compared with the 36 mg/mL 
nicotine concentration (however not in the 8 or 18 vs. 36 mg/mL condition), suggesting 
an attempt to compensate for the deprivation of nicotine (Ramôa et al., 2015).  
However, although the study supports the hypothesis of compensatory puffing, utilising 
a standardised ten-puff protocol may have influenced users’ natural puffing behaviours 
and/or reduced their ability to compensate fully.  Compensatory puffing behaviours 
have also been documented in studies in which the nicotine levels were moderately 
reduced from 18 to 16 mg/mL (Behar et al., 2015).  In a within-participants design 
study, participants were provided a 18 (V2 Cig) and a 16 mg/mL (Blu Cig) cartomisers 
and asked to vape ad libitum during two ten-minute vaping sessions separated by 10-15 
minutes interval on two separate days.  Nicotine intake and puff volume were 
significantly higher in the 16 compared to the 18 mg/mL nicotine concentrations, which 
is indicative of compensatory puffing (Behar et al., 2015).  In contrast, others report 
opposing findings.  For instance, D’Ruiz’ group found no evidence of compensation 
between the use of 16 and 24 mg/mL (D’Ruiz et al., 2015) and Hajek et al. (2017) 
found that a 24 mg/mL nicotine content e-cigarette generated the same PK profile as a 
16 mg/mL concentration.  However, similar to Ramôa and colleagues’, D’Ruiz and 
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colleagues utilised a 30-minute standardised puffing protocol prior to the ad lib session 
which may have caused a saturation effect and influenced puffing behaviours.  
 
Self-titration model (in the smoking population)  
As discussed in Chapter I, the concepts of self-titration and compensation are well 
established in the tobacco literature.  Although puffing patterns remain fairly constant 
within a smoker (Gust et al., 1983), generally smokers tend to regulate their nicotine 
intake by altering their puffing patterns to adapt to the nicotine availability and obtain 
desired and satisfactory nicotine levels. 
Compensation does not necessarily occur through consuming more cigarettes but by 
smoking more vigorously (that is increasing puff duration and/or inhalation) 
(Woodward & Tunstall-Pedoe, 1993).  This is of high relevance when comparing 
tobacco smoking topography and puffing topography of e-cigarettes since the former 
could be defined as a finite activity (the smoking of a single cigarette lasting about five 
minutes) unlike the latter.  Thus, although smoking differs from e-cigarette use, it is 
reasonable to argue that, like a smoker compensating to raise blood nicotine levels 
through the first puffs on one cigarette, an e-cigarette user will display a similar pattern 
when availability of nicotine is reduced (for example, after a period of abstinence).    
However, the literature also suggests that compensation through alterations in 
puffing patterns, may not be driven by nicotine alone, but by the reduction in tar yield 
(Sutton, Russell, Iyer, Feyerabend, & Saloojee, 1982).  That said, studies show that in 
nicotine deprived states, smokers tend to exert more intensive puffing patterns (Sutton 
et al., 1982).  Likewise acceleration of nicotine renal elimination, induces smokers to 
augment their smoking patterns (Benowitz & Jacob, 1985).   In a study investigating the 
effects of accelerated nicotine clearance via ammonium chloride administration (or 
urinary acidification loading) in a 24-hour period, smokers’ nicotine intake resulted in 
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an 18 % increment compared to the placebo group (sodium bicarbonate) during the 
urinary acidification loading, which lends support to the compensation theory.   
 
Nicotine titration and metabolism 
Smoking topography and nicotine intake are also influenced by the rate at which 
smokers are able to metabolise nicotine.  In most smokers, seventy to eighty percent of 
nicotine absorbed is metabolised by C-oxidation into cotinine which is further 
metabolised by hydroxylation into trans-3-hydroxy-cotinine (Tricker, 2003).  The ratio 
of 3-hydroxy-cotinine to cotinine (therafter OH-cot/cotinine) determined in saliva or 
blood samples is commonly utilised as biological markers of nicotine metabolism and 
for phenotyping.  The lower ratio in body fluids is indicative of a slower nicotine 
metabolism.  The major enzyme involved in the clearance and partial conversion of 
nicotine to cotinine and OH-cot/cotinine has been identified as cytochrome P450-
dependent monooxygenases (CYP) or CYP2A6 (Benowitz, Swan, Jacob, Lessov-
Schlaggar, & Tyndale, 2006; Nakajima et al., 1996).  Smokers with reduced CYP2A6 
activity typically smoke fewer cigarettes, have lower plasma nicotine and carbon 
monoxide levels (Zhu et al., 2013) and, since cotinine levels accumulate faster, they 
achieve similar plasma cotinine levels compared to those with higher CYP2A6 activity 
(Strasser et al., 2011) despite smoking fewer cigarettes per day (Schoedel, Hoffmann, 
Rao, Sellers, & Tyndale, 2004).  Consistent with the titration theory, many studies have 
found that smokers with reduced CYP2A6 activity reduce the intensity of their puffing 
regimes presumably in order to maintain desired blood nicotine levels (Strasser, 
Malaiyandi, Hoffmann, Tyndale, & Lerman, 2007).  Altogether, the evidence suggests 
that CYP2A6 to a great extent influences smoking topography.  Due to the acute nature 
of the current study, it will not be possible to infer any effects of nicotine metabolism, 
nonetheless knowledge of participants’ nicotine metabolism profiles could be useful for 
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interpreting the current study’s findings.  Thus, baseline cotinine and OH-cot/cotinine 
levels will be measured to confirm that any changes in puffing topography will not be 
solely explained by nicotine metabolism but largely due to the availibility of nicotine.   
Taken together, the aforementioned studies are suggestive, although not conclusive, 
of compensatory puffing behaviour in e-cigarette users.  Although, this is well 
researched in tobacco smoking, no such direct empirical evidence from ad libitum 
protocols in e-cigarette use has come to light yet.  
By increasing their puffing duration and intensity, users might increase their 
exposure to possible carbonyl compounds present in the emitted aerosol.  Although 
these levels are much lower than in tobacco cigarettes (Farsalinos & Polosa, 2014) and 
equivalent to levels found in NRT (Shahab et al., 2017), longer puff duration combined 
with higher voltage can lead to increasing temperature which can overheat the atomiser 
coil (Geiss et al., 2016), and result in increased toxicant emission (Kosmider et al., 
2014b).  Whilst e-cigarette users show a tendency to gradually reduce the nicotine 
concentration in their liquids over time (Polosa, Caponnetto, Cibella, & Le-Houezec, 
2015), in line with the titration model, studies suggest that the use of higher nicotine 
liquid is required in order to achieve satisfaction, obtain craving and withdrawal relief 
(Etter, 2015), and sustain abstinence specifically at the early stages of a cessation 
attempt (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2014).  The Tobacco 
Product Directive (EU-TPD) in Europe implemented in May 2016 imposes restrictions 
on high nicotine concentration (> 20 mg/mL).  This may compel long term e-cigarette 
users to reduce their nicotine intake or new users (smokers) to adopt a lower nicotine 
concentration, when switching from smoking, than one which may be optimal for 
craving reduction and sustained cessation.  If e-cigarettes are to be successful in 
promoting tobacco cigarette cessation, it is crucial that smokers are given the nicotine 
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concentration that they require.  Therefore, investigating the effects of a switch to lower 
nicotine concentrations on vapers’ puffing patterns and documenting the 
pharmacokinetic effects is warranted and will be informative to users, policy-makers 
and smoking cessation service advisors. 
Thus the primary aims are to explore whether and to what to extent experienced 
e-cigarette users self-titrate, that is, alter their puffing patterns to adapt to changes in 
availability of nicotine concentrations in order to achieve a desired blood nicotine level.  
In this chapter, two empirical studies will be presented.  In order to inform the 
procedural aspects of the main experiment, a pilot study was conducted with the specific 
aims of i) checking the eVic e-cigarette puffing topography reliability against the frame-
by-frame time analysis of video recordings ii) calculating the sample size that would be 
required for the main study iii) testing the functionality of the eVic, features such as 
voltage and air hole settings against preferences of experienced e-cigarette users, iv) 
testing the parameters for the main study such as the blinding process for the nicotine 
concentrations, and, v) informing the mitigation plan for the main study (e.g. spillages 
and timing issues of questionnaires administration and weighing of tanks at the 
commencement and end of each session).  
 
Aims and Hypotheses 
It is hypothesised that participants will attempt to compensate by consuming 
more liquid and take longer and more frequent puffs in the lower nicotine concentration 
condition.  To this effect, puffing topography (puff number and duration), and self-
reported (positive and adverse) effects will be measured in the pilot study on two 
separate occasions under two conditions:  a ‘high nicotine concentration liquid’ (18 in 
the pilot study and 24 mg/mL in Study 1) and a ‘low nicotine concentration liquid (6 
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mg/mL)’.  Plasma nicotine concentrations will be measured in addition in Study 1.  
Additional aims are to explore the effects of condition (high vs. low nicotine 
concentration e-liquid) on subjective effects (craving, withdrawal symptoms, positive 
and adverse effects).  
Hypothesis 1 (H1): 
Puffing topography will differ across conditions with a higher number of puffs and 
longer puff duration in the 6 mg/mL condition.  
Hypothesis 2 (H2): 
Plasma nicotine levels will remain similar across both conditions, (i.e. 24 and 6 mg/mL) 
evidencing compensatory behaviours and complete self-titration.  
Hypothesis 3 (H3): 
Craving and withdrawal symptoms should show equivalent levels of reduction across 
both conditions, evidencing self-titration.   
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Pilot Study - Do E-Cigarette Users Compensate? 
 
Methods 
Design and ethical considerations 
Ethical approval was granted (reference number: UREC_1415_02; approval 
date: 8th October 2014; see appendix 3) from the University of East London’s ethics 
committee (UREC_1415_40) and was conducted in accordance with the ethical 
standards outlined in the 1964 Declaration of Helsinki.  A single blind within-
participants design with two conditions: ‘high strength’ (18mg/ml) and ‘low strength’ 
(6mg/ml) nicotine e-liquid was used.  The order of presentation was counterbalanced. 
Participants 
Participants were all daily e-cigarette users recruited via word-of-mouth or 
known to the researcher.  The sample comprised five former smokers (2 females and 3 
males), all above 18 years of age, fluent in English and currently using a second or third 
generation e-cigarette and 18 mg/ml nicotine concentration minimuma.  Exclusion 
criteria included current smokers, non-daily e-cigarette users, under the age of 18, 
pregnant or lactating females, of those with neurobiological or heart conditions. 
Measurements and Materials 
• Carbon Monoxide (CO) levels were measured using the Bedfont piCO 
Smokerlyzer®  
• The third generation e-cigarette device has many useful features which allows 
research data collection with the aid of a downloadable software which records 
the duration, frequency and times in seconds per puff. The device comprises the 
following 2 components:  
                                                 
a Note, 18mg/ml was first selected on the basis that, at the time of the study, it was the most commonly 
used strength amongst e-cigarette users (Dawkins, Turner, Roberts, Soar, 2013; Etter & Bullen, 2011). 
 
 
80 
 
1. The main component the ‘eVic Supreme’ from ‘Joyetech’ comprises a 
battery tube which houses a lithium-ion battery, has a manual button and 
a OLED display screen  (see figure 2.1, see appendix 2)  
2. A ‘Nautilus’ Pyrex glass tank has a capacity to hold 5ml of fluid, is 
equipped with a measuring gauge and a four-port adjustable airflow 
control system (figure 2.2, appendix 2).  The tank housed a BVC 
atomiser (Bottom Vertical Coil) of 1.8 ohm resistance which is built to 
withstand high wattages, therefore is less likely to lead to overheat 
(figure 2.3, appendix 2).  
• Nicotine e-liquid:  6 bottles of 10 ml nicotine e-liquid of 6 and 18 mg/mL 
nicotine concentration were purchased from an e-cigarette website, ‘Totally 
Wicked’.  The following flavours, lemon sherbet, Columbian coffee, ‘Tutti 
Frutti’ were chosen based on participants’ preferred choices.  
• Precision scales were used to weigh the tank at baseline prior to and at the end 
of each session to measure the amount of liquid consumed. 
• A questionnaire (see appendix 6) was used to collect e-cigarette daily patterns of 
use from each participant and other information such as type of device used, e-
liquid concentrations and daily consumption.  Examples of items included 
“Which strength of nicotine fluid/cartridge are you currently using?”  The latter 
part of the questionnaire contained one item from the Fagerström Test for 
Cigarette Dependence (thereafter referred to as FTCD) (Fagerström, 2012) 
which was modified and renamed eFTND to apply dependence related to e-
cigarettes use and asked “How soon after you wake up do you use your 
electronic cigarette?”.  The available options were ‘within 5 minutes’ 
(corresponds to the highest possible score of 4), whilst the option ‘after 60 
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minutes’ scores the lowest as per the FTND (Heatherton et al., 1991).  The 
higher overall scores signify a higher dependence.  
• The Mood and Physical Symptoms Scale (thereafter referred to as MPSS) (West 
& Hajek, 2004) was altered to measure ‘urge to vape’, as opposed to ‘desire to 
smoke’, measured on a scale from 1 to 7 (appendix 7).  This questionnaire also 
measure the presence and severity of the five DSM-IV nicotine withdrawal 
symptoms.  These were ‘depressed mood’, ‘irritability’, ‘anxiety’, ‘restlessness’, 
‘hunger’ and ‘inability to concentrate’, each measured using a five-point rating 
scale (scores range from 1 to 5 “Not at all” to “Extremely”).  Thus, total score 
can range from 5 to 25. 
• Subjective effects of nicotine were assessed using a two-part questionnaire 
measuring positive and adverse effects.   
1. ‘Positive’ effects were measured using an 11-item visual analogue scale 
(VAS) derived from Blank, Sams, Weaver, & Eissenberg’ s paper (2008) 
(appendix 8).  Participants were required to rate each statement by 
drawing a cross or a small line adjacent to the 20 cm-line with the far left 
representing ‘not at all’ and the opposite right end ‘extremely’.  
Examples include ‘I feel a definite hit from the e-cigarette’, ‘The e-
cigarette is satisfying.  Scoring is obtained by measuring from the far left 
corner to the drawn cross or line in millimetres then the score is 
translated in percentages.  A higher score is indicative of more positive 
effect. 
2. Adverse effects were measured with a 21-item visual analogue scale 
(appendix 8).  This has been used in previous work (Vansickel & 
Eissenberg, 2013).  Examples of items include ‘confused’, ‘dizzy’, 
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‘nausea’, ‘headache’, ‘salivation’, ‘sweaty’.  As per the positive effects, 
participants were required to place a cross or adjacent line through a 20 
cm-line.  Percentage score is obtained as per the positive effects 
questionnaire. 
 
Procedure: 
Based on participants’ preferences and following consultation with other 
experienced e-cigarette users, the e-cigarette was set to the following parameters across 
both sessions.  The voltage was set at 3.9 Volt for an atomiser with a resistance of 1.8 
ohms which resulted in 8.5 Watts.  The device was adjusted to the biggest airflow 
(following recommendation from vaping colleagues).  To obtain a measure of the liquid 
consumed, the tank was removed from the main unit and weighed using precision scales 
before and after filling up the tank, at the commencement and end of each session.  For 
hygiene purposes, each participant provided their own mouth-piece to be attached to the 
device. 
Participants were asked to abstain from all tobacco products and nicotine intake 
including use of e-cigarettes for a period of at least 10 to 12 hours prior to each session.  
Upon arrival, participants were provided with an information sheet then required to 
provide written informed consent.  Exhaled CO levels were collected from participants 
via a breathalyser to confirm non-smoker status (cut off: 10 ppm). 
Participants were given the e-cigarette with instructions to use the device ad 
libitum.  There was no practise period as all participants were current e-cigarette users 
with prior experience of a similar device.  Participants were reminded of their right to 
withdraw at any time and have a break before the session commenced.  The entire 
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session from the first puff to the last puff was videoed using a ‘Toshiba Camileo X400’ 
recorder.  At the end of the session, ‘urge to vape’ was measured and subjective effects 
of nicotine questionnaires were administered.  Following completion of the task, the e-
cigarette was attached to a secure and password protected UEL PC and all data on puff 
duration and frequency were downloaded and backed up onto university drives.   
The full session was repeated the following working day for each participant using the 
other nicotine concentration.   
 
Data and Statistical Analysis 
 
Outcome measurements 
  The primary outcomes were ‘puff number’, ‘puff duration’, ‘IPI’ in milliseconds 
and estimated ‘volume consumed’ in millilitres. Secondary outcomes were changes in 
‘urge to vape’, ‘withdrawal’ and each of the withdrawal symptom dimensions (e.g. 
depressed, irritable, anxious), ‘satisfaction’, ‘hit’ and other subjective positive and 
adverse effects.  Volume consumed was obtained by first calculating the mass of the 
liquid (in grams) added to the tank, which was calculated by subtracting the weight of 
the filled tank before use by the weight of the empty tank [mass1 = X (g) – Y (g)].  
Thereafter, liquid density was calculated by dividing the mass of the liquid (in grams) 
by the quantity of liquid (in mL) contained in the tank [d = mass1 (g) / Z (mL)].  Then, 
the weight of liquid consumed (in grams) was calculated by subtracting the weight of 
the filled tank prior to and at the end of the vaping session [mass2 = X (g) – N (g)].  
Lastly, the value of the volume consumed in mL was obtained by dividing the mass (in 
grams) by the density of the liquid consumed [Vol (mL) = mass2 / d].  
Due to the small sample size, Wilcoxon Signed Rank tests were used to compare 
scores between conditions.  Alpha level was adjusted to p < .10 to address the issue of 
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small sample size (eg. N < 20) and insufficient power, in accordance with Stevens 
(1996).   
Given ‘urge to vape’ was measured before and after using the device, variables 
were computed to obtain values of the changes between urge to vape at baseline and 
urge to vape at ‘Time 2’ by calculating the difference between scores at baseline minus 
the scores at ‘Time 2’.   Higher scores on ‘urge to vape’ are indicative of greater 
reductions.  Positive effects (Hit, Satisfied, Pleasant, etc) and subjective adverse effects 
(Nauseous, Dizzy, etc) under both conditions were compared to investigate the effects 
under ‘low’ and ‘high concentrations’.   
A frame by frame analysis of 29.97 fps using the ‘Adobe Premiere Pro CS5’ 
software was used to analyse timing measurements.  Puff duration was demarcated by 
the time at which the e-cigarette was clearly in the mouth with both lips closed (start of 
the puff) until the frame at which the e-cigarette was removed from the mouth.  The end 
of the puff was defined by the time frame preceding the first time frame of the start of 
the inter-puff interval (interval between each puff; hereafter referred to as IPI).  This 
coincided with the first time frame when the e-cigarette mouth tip could be clearly seen 
and the e-cigarette had left the lips.  There are instances wherein e-cigarette users press 
the activation button before (Behar et al., 2015) or whilst bringing the device to the 
mouth, whilst others may do the opposite (Farsalinos et al., 2013b).  In such instances, 
the time frame was captured only when the device was clearly seen in the mouth with 
both lips closed.  Extra care was taken to ensure clear visibility of the start and end of 
puff (start / end of inhalation and exhalation).  In cases where some aerosol escaped and 
was visible during a puff (and whilst the e-cigarette was still in the mouth and the user 
was clearly inhaling), the puff was considered as one puff.  To increase accuracy of 
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measurements from the video-recordings’ data, an inter-observer reliability were 
calculated by taking the average of scores obtained by two different researchers.    
Spearman’s Rank correlation tests were used to explore relationships between 
puffing topography variables as well as the relationship between the video and the eVic 
data (see Table 2.3).   
 
Results 
Participants’ characteristics 
Participants’ demographics and baseline characteristics are displayed in Table 
2.1.  All, except one participant, were current users of nicotine concentrations equal to 
or exceeding 18 mg/mL and accustomed to using a 3rd generation device, although the 
participant who reported currently using a cigalike was familiar with 3rd generation 
devices.  Based on the first item of the FTND questionnaire a mean (SD) of 3 (1.23) is 
indicative of relatively moderate e-cigarette dependence (possible scores range: 1 - 4). 
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Table 2.1  
Participants' Demographics and Baseline Characteristics 
 N % Mean SD Min Max 
Gender 5 - - - - - 
  Male 3 60 - - - - 
  Female 2 40 - - - - 
Ethnicity 5 - - - - - 
  White 4 80 - - - - 
  South Asian 1 20 - - - - 
Occupational status  5  - - - - - 
  Employed 2 40 - - - - 
  Studying/Part time employed 1 20 - - - - 
  Self-employed 2 40 - - - - 
eFTND1 - First puffs of the day 5 - 3.00 1.23 1.00 4.00 
  Within 5 mins 2 40 - - - - 
  6-30 mins 2 40 - - - - 
  31-60 mins 0 0 - - - - 
  After 60 mins 1 20 - - - - 
Baseline CO (ppm) high strength  5 - 3.40 2.07 1.00 6.00 
Baseline CO (ppm) low strength  5 - 3.00 1.23 2.00 5.00 
Daily Liquid Vol consumed (mL) 5 - 2.3 0.76 1.00 3.00 
Nicotine concentration most used 5 - - - - - 
  12mg/mL 1 20 - - - - 
  18mg/mL 3 60 - - - - 
  24 mg/mL 1 20 - - - - 
Current model most used 5 - - - - - 
  1st gen / Rechargeable cigalike 1 20 - - - - 
  2nd gen / Penlike/Clearomiser 2 40 - - - - 
  3rd gen / Tank/Mod systems  2 40 - - - - 
Note.  1 eFTND = First item of the Modified version of Fagerström Test of Nicotine 
Dependence for e-cigarettes use “How soon after you wake up do you use your 
electronic cigarette?”  
 
Puffing topography  
Table 2.2 presents the puffing topography data for: volume consumed, puff 
number and duration, and IPI (Inter-puff intervals) based on the video recording 
analysis as well as puff number and duration obtained from the eVic.  Minimum and 
maximum values as well as median scores are presented.  Means in puff number and 
puff duration were very slightly greater in the low condition as per the eVic and also as 
per the video recording data.   
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Table 2.2.  
Puffing topography data based on the Video analysis and the eVic 
 Mean (SD) Min Max Median 
 High Low High Low High Low High Low 
Vol. cons. 0.33 (0.20) 0.48 (0.24) 0.14 0.27 0.61 0.85 0.25 0.39 
         
Video Data 
P. Number 35.60 (15.52) 42.80 (11.69) 19 30 55 55 28 47 
         
P. Duration 3.71 (1.22) 4.52 (1.72) 1.96 2.27 5.10 6.63 3.54 4.61 
         
IPI 146.31 (150.11) 69.74 (29.48) 46.07 43.89 408.50 104.58 112.20 55.31 
         
eVic Data 
P. Number 38 (17.88) 43.20 (11.49) 20 31 63 55 30 47 
         
P. Duration  4.10 (0.68) 4.67 (1.04) 2.90 3.24 4.50 5.90 4.36 4.81 
Note.  Legend: Vol. cons.: volume consumed; P. Number: puff number; P. Duration: puff duration; IPI: 
inter-puff interval. 
Volume consumed is expressed in millilitre; Puff duration and IPI are expressed in seconds 
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Six instances of extremely short button presses (i.e. < 1s) were observed (in 3 separate 
sessions involving 3 individuals) in the data collected from the eVic.  These were 
verified against backup video data and deleted in cases where the device was not clearly 
in the mouth.  In all instances wherein a short puff (< 1 s) preceded or succeeded a puff 
of more than 1 second, the former was merged with the latter.  Based on the video data, 
six instances of extremely long puffs exceeding 10 seconds were observed.  Participant 
5, had the highest record of puffs exceeding 10 seconds, 5 were in the low condition and 
1 in the high condition. 
Based on the data analysed from the video recordings, there were significant 
differences between the high (18 mg/mL) and low (6 mg/mL) conditions in mean 
volume of liquid  consumed (mL) [z = -2.02, p = .04] with a large effect size where r = 
.64 (Figure 2.1), puff number [z = -1.83, p = .07, r = .58] (see Figure 2.2), puff duration 
[z = -1.75, p = .08, r = .55] (Figure 2.3) and IPI [z = -2.02, p = .04, r = .64] (Figure 2.4).  
Although very similar to the video recording data and in the same direction, puffing 
topography data collected from the eVic did not reach statistical significance, mean puff 
number [z = -1.21, p = .23] and puff duration [z = -1.48, p = .14]). 
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Figure 2.1 Mean (SE) in Volume 
consumed in high and low nicotine 
concentrations after the ad lib vaping 
session 
Figure 2.2 Mean (SE) puff number in 
high and low nicotine concentrations 
after the ad lib vaping session (Video 
datab) 
 
 
 
 
 
 
                                                 
b Graphs presented here are based on the data collected from the video recordings only, since values from 
the eVic were very similar   
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Figure 2.3 Mean (SE) puff duration in 
high and low nicotine concentrations 
after the ad lib vaping session (Video 
data2) 
 
 
Figure 2.4 Mean (SE) IPIs in high and 
low nicotine concentrations after the ad 
lib vaping session (Video data2) 
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Table 2.3 Correlations between mean scores in puff number, duration, volume consumed and between the video data 
and the eVic data 
  High Video High Evic Low Video Low eVic 
           
High 
 
 Puff no Puff d Puff no Puff d Vol. Puff no Puff d Puff no Puff d 
 
 
Video 
Vol. .70 .80 .70 .56 1.00 .70 1.00** .67 .90* 
          
Puff no - .50 1.00** .10 .70 1.00** .70 .98** .50 
          
Puff d - - .50 .67 .80 .50 .80 .56 .50 
           
eVic 
 
Puff no - - - .10 .70 1.00** .70 .98** .50 
          
Puff d - - - - .56 .10 .56 .24 .46 
Low 
 
 Puff no Puff d Puff no Puff d Vol. Puff no Puff d Puff no Puff d 
           
 
 
Video 
 
Vol. - - - - - .70 1.00** .67 .90* 
          
Puff no - - - - - - .70 .98** .50 
          
Puff d - - - - - - - .67 .90* 
           
eVic Puff no - - - - - - - - .41 
          
Note.  *p ≤ 0.05 (2-tailed), **p ≤ 0.01 (2-tailed) 
Legend:  High Video / eVic: Video / eVic data in the high condition; Low Video / eVic: Video / eVic data in the low condition; 
Vol. corresponds to Volume consumed; Puff no  corresponds to  puff number; Puff d  corresponds to puff duration 
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There was a statistically significant correlation between volume consumed and 
puff duration in the low condition only [r = .90, p = .037].  Puffing topography data 
recorded from the eVic correlated highly with the video recordings data in the low 
condition for puff number r = .98, p = .005 and puff duration r = .90, p = .037, and in 
the high condition for puff number r = 1.00, p < .0001, but not for puff duration r = .67, 
p =.22.   
 
Subjective effects 
Reduction in urge to vape and withdrawal 
Means (SD) in changes in ‘urge to vape’ (M = 2.8, SD = 1.30) and (M = 2.40, 
SD = 1.52) and changes in withdrawal symptoms (M = 2.8, SD = 1.79 and M = 5.4, SD 
= 3.78) in the high and low conditions respectively suggest that both nicotine 
concentrations equally reduced withdrawal symptoms (Note that higher scores are 
indicative of greater reductions).  There were no statistically significant differences in 
changes in ‘urge to vape’ (z = -1.00, p = .32) (see figure 2.8).  Differences in changes in 
withdrawal symptoms between conditions just fell short of statistical significance (z = -
1.83, p = .068) (see figure 2.9).  There were no significant differences between 
conditions in changes in depressed mood, irritability, anxiety, drowsiness, restlessness, 
hunger and inability to concentrate (all ps > .05). 
 
 
93 
 
 
 
Figure 2.5 Means (SE) in changes in 
‘urge to vape’ in the high and low 
concentrationsc 
 
Figure 2.6 Means (SE) in changes in 
withdrawal symptoms in the high and 
low concentrations 
 
 
Satisfaction, Hit and Other positive effects  
There were no statistically significant differences between conditions (all p 
values > 0.10) on self-reported positive effects.  Data on satisfaction, hit and other 
positive effects are presented in Table 2.4.   
 
 
 
 
 
 
 
 
 
                                                 
c The higher scores in ‘urge to vape’ and in ‘withdrawal symptoms’ indicate greater reductions  
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Table 2.4  
Mean (SD) and median (%) in subjective positive effects in the high and low conditions  
High Low  
Mean (SD) Median Mean (SD) Median      
‘Hit’ 65.5 (13.31) 73.5 51.25 (16.64) 54.5 
‘Satisfaction’ 70.85 (16.96) 72.25 54.35 (17.91) 54.5 
‘Pleasant’ 71.65 (12.87) 71.5 64.05 (16.59) 74.5 
‘Tastes good’ 68.65 (14.01) 67 70.4 (19.25) 66.75 
‘Reduced my craving’ 59.31 (23.52) 69 58.35 (19.34) 66.75 
‘helped my concentration’ 61.6 (16.27) 67 55 (22.21) 65 
‘helped me feel calmer’ 55.2 (21.88) 61.5 57.35 (18.10) 64.5 
‘feel more awake’ 47 (18.05) 42.5 51.41 (17.80) 41 
‘reduced my hunger’ 35.2 (9.39) 32.75 35.15 (30.54) 25 
‘tastes like my usual brand/model’ 34.3 (22.22) 33.5 48.3 (18.61) 45 
‘feels like using my usual 
brand/model’ 
38.3 (23.96) 23.5 42.57 (24.02) 31.1 
Note.  Values are mean scores in percentage for each dimension of the VAS 
questionnaire on positive subjective effects related to e-cigarette use.  
 
Adverse effects 
Wilcoxon signed rank tests revealed no statistical differences between conditions in 
adverse effects (all p values > .10) (all means and standard deviations are presented in 
Table 2.5). 
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Table 2.5  
Mean (SD) and median (%) in subjective adverse effects in the high and low conditions  
High Low  
Mean (SD) Median Mean (SD) Median      
Confused 9.25 (8.22) 7.5 11.5 (10.60) 10 
Dizzy 22.35 (24.53) 10 18.8 (18.37) 18.75 
Headache 15.55 (15.61) 10 16.4 (19.02) 9.25 
Pounding heart 15.4 (15.45) 10 11.3 (9.17) 9.5 
Light headed 29.3 (31.22) 15 26.2 (25.86) 21.5 
Nausea Feeling sick 20.6 (25.20) 9.5 12.3 (13.73) 9 
Nervous 12.7 (14.02) 5 7.1 (6.19) 6 
Salivation 6.8 (5.03) 6 11.4 (15.22) 6 
Sweaty 6.3 (4.98) 7 7.2 (5.89) 6 
Weak 10.35 (13.02) 6 6.504 (5.11) 6 
Mouth irritation 5.07 (4.20) 5.5 6.2 (3.90) 6 
Throat irritation 8.05 (6.36) 7.5 6.3 (3.90) 6.5 
Aching jaws 13.95 (21.41) 6 8.65 (9.31) 6 
Vomiting 15.25 (17.49) 9.5 9.24 (9.03) 6.5 
Flatulence bloating 9.65 (7.86) 9.5 7.6 (4.49) 9 
Stomach ache 7.75 (5.26) 9.5 7.6 (4.35) 9 
Heartburn 8.75 (6.76) 9.5 8.35 (5.42) 9 
Diarrhoea 5.1 (4.51) 4.25 6.35 (4.01) 7.75 
Hiccups 5.8 (4.62) 6 7.21 (4.13) 9 
Cold hands feet 7.1 (4.59) 9.5 12.81 (14.35) 9 
Palpitations 13.1 (12.68) 9.5 6.71 (3.93) 7.55 
Note.  Values are mean scores in percentage for each dimension of the VAS 
questionnaire on negative subjective effects related to e-cigarette use.  
 
 
Discussion 
Summary of findings  
The current pilot study was primarily designed to inform procedural aspects of 
Study 1.  To this effect, video recordings were used to measure puffing topography in 
conjunction with the eVic, to check for reliable eVic recordings, so any risk of data 
distortion due to pre-puffing instances could be minimised.  The eVic data were found 
to correlate highly with data collected via the video recordings in the low condition for 
puff number [r = .975, p = .005] and puff duration [r = .900, p = .037], and in the high 
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condition for puff number, r = 1.00, p < .0001, but not for puff duration, r = .67, p =.22. 
Video recordings have been used in previous studies and found to be reliable 
(Farsalinos et al., 2013b) against other automated puffing recorder machines for 
example the CReSS pocket device which consists of a mouthpiece equipped with a 
computerised system (Blank, Disharoon, & Eissenberg, 2009; Spindle, Breland, 
Karaoghlanian, Shihadeh, & Eissenberg, 2015).  In these previous studies, participants 
reported dislike of such automated machines, adding the device made use of the e-
cigarette difficult; such fact is likely to influence participants’ puffing patterns. Thus 
arguably, the eVic is a less invasive method and may have greater ecological validity 
compared to puffing machines such as the CReSS device.  In the current study, puff 
number and duration correlated highly in the low condition for puff number and puff 
duration as well as puff number in the high condition.  This strengthens the validity of 
the eVic as a method for puffing data collection.  The non-statistical significant 
relationship in the high condition for puff duration may be explained by a lack of 
statistical power given the shorter puff duration.   
Other aims of this pilot study, were to investigate whether and to what to extent 
experienced e-cigarette users alter their puffing patterns to adapt to changes in nicotine 
availability so they can achieve desired blood nicotine levels.  As per hypothesis H1, 
participants made an attempt to self-titrate by increasing their liquid consumption, puff 
duration and frequency in the lower nicotine concentration condition.  As per hypothesis 
H3, compensatory puffing behaviours were effective in relieving ‘urge to vape’ and 
withdrawal discomfort, there was no statistical difference between conditions.  
Similarly, there were no differences in subjective positive effects such as ‘satisfaction’ 
and ‘hit’.  Adverse effects did not differ between conditions.  These findings seem to 
support the titration theory and suggest that in the same manner as smokers, vapers have 
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a tendency to adjust their puffing patterns and obtain an optimal and satisfactory level 
of blood nicotine, sufficient to alleviate craving and withdrawal symptoms.  
 
Puffing topography  
Participants consumed a greater quantity of liquid, increased their puff numbers 
and duration, and took shorter inter-puff intervals in the low nicotine condition 
compared with the high nicotine concentration.  These findings concur with previous 
studies, average puff duration in the low condition observed here are similar to those 
previously reported in experienced users (Hua et al., 2011) with newer generation 
devices (Farsalinos et al., 2014), and longer than those reported for cigalike (first-
generation) devices (Behar et al., 2015) and combustible cigarettes (Hua et al., 2013).  
The proposition that longer puff durations and shorter IPI (Williams et al., 2011) are 
conducive to more efficient nicotine delivery (Hajek et al., 2015) seem to be supported 
by the current data.  The significant increase in puff duration suggest that participant did 
unconsciously or consciously felt the need to exert a more intensive puffing pattern in 
the low condition to obtain and maintain a constant and satisfactory nicotine blood 
level, likewise in the high condition, they adjusted their puff numbers and duration to 
regulate their nicotine intake.   
Effects on craving, withdrawal and subjective effects  
Means in changes in ‘urge to vape’ and withdrawal symptoms in the high and 
low conditions respectively suggest that both nicotine concentrations reduced 
withdrawal symptoms and ‘urge to vape’ equally.  Indeed, there were no differences 
between conditions in ‘depressed mood’, ‘irritability’, ‘anxiety’, ‘drowsiness’, 
‘restlessness’, ‘hunger’ and ‘inability to concentrate’.  This suggests that low nicotine 
concentration levels may be sufficient for the relief of craving and withdrawal 
discomfort at least subjectively.   
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There were no statistically significant differences in subjective positive effects.  
This suggests that, although participants scored fairly high on the nicotine dependence 
scale (as per ‘first puff of the day’ from the eFTND), the low nicotine concentration and 
efforts made to compensate were sufficient to achieve satisfaction and feel a hit from 
the low nicotine concentration, at least in the short term.  Likewise, there were no 
statistically significant differences in adverse effects.  
 
Concluding remarks 
This pilot study was set to inform the procedural aspects of Study 1 and, as such 
suggests that the e-cigarette eVic offers a reliable method of data collection.  These 
findings also suggest, that in line with the titration model, experienced e-cigarette users, 
like smokers, have a tendency to self-titrate by controlling their puffing patterns to 
maximise nicotine delivery and regulate their nicotine intake to a desired and constant 
level; this is supported by the large effect sizes for the puffing topography variables.  
Here, compensatory puffing appeared to be effective in alleviating subjective ‘urge to 
vape’ and withdrawal discomfort and achieving satisfaction, at least in the short term 
and under acute conditions.  However, in this pilot work, biomarkers were not measured 
thus there is no clear indication that greater quantity of liquid consumed and indeed the 
increase in puffing patterns translated into greater nicotine absorption.  This forms the 
focus of the subsequent study.   
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Study 1 - Nicotine Titration by E-Cigarette Users: Puffing Topography, 
Plasma Nicotine and Subjective Effects 
 
The pilot study has achieved two aims i) confirmed that the use of the eVic 
provides a reliable method for data collection on puffing topography, ii) informed other 
procedural aspects (including sample size) for Study 1, iii) suggested that experienced 
e-cigarette users adjust their puffing patterns in response to changes in nicotine 
availability.  To this effect, several methodological changes were implemented to 
strengthen the design of Study 1.  In Study 1, it is anticipated that the findings of the 
pilot study will be replicated using a series of biomarkers in addition to measuring 
puffing topography namely baseline salivary cotinine to ensure participants are 
habituated to high nicotine concentrations, plasma nicotine levels to observe differences 
between conditions and substantiate findings of compensatory behaviours and, 3-
hydroxy cotinine and 3-hydroxy-cotinine to cotinine ratio were measured to eliminate 
these possible confounders and ensure any indications of compensatory puffing 
behaviours observed were not the result of previous nicotine use or phenotypic status.  
In addition, unlike the pilot study which was single blinded, Study 1 used a double blind 
design to minimise expectancy effects and researcher bias.  A team of 3 researchers will 
be in place to facilitate the double blind procedure and ensure the smooth running of 
Study 1 (e.g. nicotine liquid and the eVic and questionnaires will be handled by one 
researcher whilst blood samples by another, a third researcher held responsibility for 
timings).  Statistical power of the study was increased with the inclusion of a larger 
sample (N = 12 from N = 5 in the pilot study).  Final changes included an increase in 
nicotine concentrations.  At the time of the pilot study planning, 18 mg/mL was the 
most commonly used concentration amongst e-cigarette users (Dawkins, Turner, 
Roberts, Soar, 2013; Etter & Bullen, 2011).  However due to the imminent EU-TPD 
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legislations to limit nicotine concentrations to 20 mg/mL, the decision was made to 
increase the nicotine concentration to 24mg/ml in Study 1, as it was a worthwhile 
opportunity to document puffing behaviours in the EU with nicotine concentrations that 
would soon be in excess of the legal limit. 
The aims of Study 1 are to observe how experienced e-cigarette users respond to 
a high versus a low nicotine concentration by measuring i) puffing topography, ii) urge 
to vape and withdrawal symptoms, ii) subjective effects (positive and adverse effects) 
and iii) plasma nicotine levels.   
Methods 
Design  
A double-blind within-participants, counterbalanced design with 2 conditions: 
‘low’ (6 mg/mL) and ‘high’ (24 mg/mLd) nicotine concentration liquid, was employed.   
 
Ethical considerations  
The study received full ethical approval from the University of East London’s 
ethics committee (UREC_1415_40; approval date: 29th January 2015, see appendix 9) 
and was conducted in accordance with the ethical standards outlined in the 1964 
Declaration of Helsinki.  All participants provided written informed consent 
(appendices 10 and 11) to take part in the study.   
Full risk and COSHH assessments were conducted in addition to the ethics 
consideration.  The week leading to the first study session, laboratory walk-through 
were performed in consultation with the technical laboratory support staff.  Prior to the 
                                                 
d Note, 18mg/ml was first selected on the basis that, at the time of the study, it was the most commonly 
used strength amongst e-cigarette users (Dawkins, Turner, Roberts, Soar, 2013; Etter & Bullen, 2011). 
However due to the EU-TPD legislations that nicotine concentration will be capped at 20 mg/mL, the 
decision was made to increase the nicotine concentration to 24mg/ml which were subsequently used in 
study 1. 
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commencement of each session, the research team and qualified doctor or phlebotomist 
nurse discussed all aspects and each step of the study’s procedure so all were fully 
informed and aware of each person’s remit.  All medical equipment was checked by the 
phlebotomist prior to participants’ arrival.   
All data were coded, treated confidentially and retained in accordance with the 
Data Protection Act, stored on password protected hard drives.  To facilitate any 
withdrawal, each participant was given an identification number which they had to 
memorise should they wish to withdraw.  Hard copies of questionnaires were stored in a 
locked filing cabinet in a lockable room then destroyed in accordance with the 
university’s data protection policies.  Signed consent forms were stored separately from 
questionnaires and video data were accessible to only the research team.  Video 
recordings were analysed then entered into a computerised dataset before being 
disposed of securely.  
Participants 
Twelve regular e-cigarette users (11 male and 1 female, all ex-smokers; see 
sample size calculation below), attended 2 separate sessions between 2 and 7 days apart 
at the University of East London.  Participants responded to advertisements on social 
media sites, e-cigarette forums and emails.  Eligibility criteria were: aged 18+; 
experienced e-cigarette user (daily use for > 3 months); currently using a second or third 
generation e-cigarette; familiar with 24 mg/mL nicotine concentration liquid (i.e. used 
24mg/mL at least once in the last 6 months); baseline salivary cotinine levels > 100 
ng/mL; CO levels ≤ 10 ppm; willing to provide saliva and blood samples and abstain 
from using nicotine for 12 hours prior to study commencement. 
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Randomisation and Masking 
A double-blind design was utilised.  To facilitate the double blind process, 
nicotine liquid was decanted into plain bottles and re-labelled X and Y, so brand and 
nicotine concentration were unknown to participants and participant-facing researchers.  
Ten most popular brands of nicotine liquid were selected using various e-cigarette 
review internet sites, during January and February 2015.  One brand (Halo Smokers’ 
Angels) was selected at random by one member of the research team with nicotine 
concentrations of 6 and 24 mg/mL (both 60/40 propylene glycol and glycerine).  Order 
of presentation was counterbalanced and participants were randomly allocated to 
receive either nicotine concentration on their first session. 
 
Statistical analysis 
An a priori estimation of power for the required sample size and to detect an 
effect on puffing topography was calculated using the statistical software GPower 3.1 
with the pilot data.  To detect a difference between conditions in mean number of puffs, 
puff duration and volume consumed with > 80% power at p < 0.05 with 95% CI, a 
sample of between N = 9 and 17 was required.  The initial target was set to recruit 
fifteen participants but due to participant drop out and failure to meet required baseline 
criteria, twelve were tested. 
Data were analysed using ‘IBM SPSS Statistics 23’.  Normality of the 
distribution of scores was checked using the following approaches, Skewness and 
Kurtosis values, Kolmogorov-Smirnov and Shapiro-Wilk tests and, histograms and 
normal quantile-quantile (Q-Q) plots.  Given the sample size (N < 20) combined with 
the lack of normality in various variables, transformations were not appropriate (Field, 
2013) and non-parametric statistics were conducted to compare means between the high 
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and low nicotine conditions.   Two-tailed Wilcoxon signed-rank tests were performed to 
explore differences in puffing topography (puff number, duration and volume 
consumed), nicotine boost, changes in self-report craving and withdrawal symptoms 
and subjective (positive and adverse) effects.  Spearman’s correlations coefficients were 
used to explore the relationship between a) plasma nicotine levels (nicotine boost) and 
puffing topography data at each time point, b) between cotinine to 3-hydroxy-cotinine 
ratio and plasma nicotine levels and c) cotinine to 3-hydroxy-cotinine ratio and puffing 
topography.  The accepted alpha level was p < .05.  
 
Outcomes 
The primary outcomes were puffing topography: i) mean number of puffs; ii) 
mean puff duration (as recorded by the eVic) and, iii) volume of liquid consumed (in 
millilitres) and nicotine boost.  Nicotine boost, a measure of nicotine exposure, was 
calculated by subtracting plasma nicotine levels at each time points from baseline levels 
(Patterson et al., 2003).  Secondary outcomes were subjective effects which include: 
changes in craving (urge to vape) and withdrawal symptoms and, self-reported hit, 
satisfaction, other positive and adverse effects.  Changes in craving, withdrawal and 
each dimension of the MPSS were computed by subtracting baseline levels from levels 
at each time point. Volume consumed was calculated in the same way as for the pilot 
study.  
 
Measures  
In addition to the materials, apparatus and measures in the pilot study, the 
following measures were employed (For a full list of materials and apparatus used for 
the blood collection, handling and storage as well as for the collection of the puffing 
topography data refer to Appendix 12).  
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Questionnaires: 
• Baseline questionnaire to collect demographic information including age, 
gender, ethnicity, occupational status and highest qualification (appendix 13). 
• The Fagerström Test for Cigarette Dependence (hereafter referred to as FTCD) 
measuring Cigarette dependence (Fagerström, 2012) was modified and renamed 
eFTND to measure dependence on e-cigarette, vaping history and e-cigarette 
use.  Examples of items include measurements of self-report behavioural 
markers such as “How soon after you wake up, you use your e-cigarette?”  The 
available option ‘within 5 minutes’ corresponds to the highest score, whilst the 
option ‘after 60 minutes’ scores the lowest as per the FTCD 3 (appendix 14).  
High scores signify high dependence.  Other items were more subjective and 
aimed at measuring dimensions of loss of control, for instance: “Do you find it 
difficult to refrain from using your electronic cigarette in places where it is 
forbidden?”    
• A single-item rating of addiction from 0-100% (scored from 0 = low addiction to 
5 = very high addiction taken from the Cigarette Dependence Scale (CDS) 
(Etter, Le Houezec & Perneger, 2003) was also used (see appendix 14). 
 
Procedure 
Figure 2.7 illustrates the design of the study.  Prior to testing, participants were 
sent an information sheet and screened via email and telephone.  Pre-test saliva samples 
were collected by post and assessed for cotinine at Advanced Bioanalytical Service 
(ABS) Laboratories Ltd in order to verify that participants were habitual users of high 
nicotine concentrations and minimise the risks of aversive effects.  Consistent with the 
pilot study, the e-cigarette was set at 3.9 Volt for an atomiser with a resistance of 1.8 
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ohms resulting in 8.5 Watts.  The device was adjusted to the biggest airflow.  To obtain 
a measure of the liquid consumed, the tank was removed from the main unit and 
weighed using precision scales before and after filling up the tank, at the 
commencement and end of each session.  Liquid was pipetted in the tank prior to the 
start of each session.  
Participants were asked to abstain from all tobacco products and nicotine intake 
including use of e-cigarettes for a period of at least 10 to 12 hours prior to each session 
and were tested individually.  Upon arrival, each participant was welcomed by the 
research team, introduced to the phlebotomist and invited to take a seat on a medical 
plinth.  Participants were offered a glass of water and provided written informed 
consent.  Smoking status was verified via carbon monoxide breath test (cut off was < 10 
ppm) and nicotine abstinence via baseline blood sample.  
Baseline and demographic characteristics including vaping history, e-cigarette 
dependence, current craving (‘urge to vape’) and withdrawal symptoms were collected 
before a phlebotomist inserted a venous cannula into the participant’s forearm and 
collected a baseline blood sample.  Thereafter, the participant was presented with the 
eVic™ e-cigarette and asked to vape ad libitum for 60 minutes.  During this time the 
participant read quietly, worked, engaged with social or other media via his/her own 
device.  Further blood samples were taken, and craving and withdrawal symptoms 
recorded, at 10, 30 and 60 minutes after the first puff.  Only the phlebotomist dealt with 
the blood samples collection assisted by a researcher, whilst another member of the 
research team handled data collection, running of the video recordings and the eVic™.  
At the commencement of each session and prior to replenishment, the tank was 
removed so the e-cigarette could be thoroughly cleaned and a new atomiser mounted.  A 
third member of the research team was responsible for time monitoring and overseeing 
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the smooth running of the study’s procedures.  Puffing topography (puff number and 
puff duration) was recorded by the eVic™ and downloaded to ‘My Vapors Joyetech 
1.4’.  The venous catheter was removed following the last blood sample collection at 60 
minutes, before completion of a Visual Analogue Scale assessing positive (including hit 
and satisfaction) and adverse effects associated with nicotine and e-cigarette use 
(Dawkins & Corcoran, 2014).  Participants were then offered a snack and refreshment, 
thanked and reimbursed financially for their time (£50 compensation) at the end of the 
second session.  
 
Blood collection and nicotine analysis 
Blood samples were collected using 4 mL BD K2EDTA vacutainer tubes and 
put on ice upon collection in an polystyrene igloo with the lid tightly closed at all times.  
All pre-labelled vacutainer tubes were kept in a closed container away from the vaping 
area.  Only the phlebotomist and a designated researcher handled blood samples.  Prior 
to handling vacutainer tubes, hands were disinfected (with Virucidal alcohol hand gel) 
and gloves were worn and changed every time to avoid contamination.  A different 
researcher was responsible for handling the e-cigarette and loading with liquid to avoid 
blood sample contamination.  After each testing session all blood samples were 
transported to an on-site forensic laboratory for plasma extraction, using PPE (gloves, 
safety spectacles) within 5 hours maximum of being collected.  
Surface was disinfected using clinell and Blue roll.  The MSE Falcon 6/300R 
centrifuge system was set and pre-run as follows, 2000 RCF, Temperature 4o Celsius, 
for 10 minutes.  All blood samples were weighed and arranged in pairs before being 
placed in centrifugation machine diagonally to render samples acellular.  The latter was 
set to run for 10 minutes at 4o Celsius, (2000 RCF).  Thereafter, plasma was extracted 
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from the cell pellet using sterile Pasteur pipette heads and pipetted into sterile pre-
labelled microvials.  All samples were kept at -20oC pending transportation to ABS 
Laboratories Ltd. for analysis using a validated LC-MS/MS method with a lower limit 
of quantification (LOQ) of 0.5 ng/mL. 
 
 
Figure 2.7 Experimental procedure (repeated at both sessions)  
 
 
Results 
Participant Characteristics 
Table 2.6 provides demographics baseline characteristics of the sample.  
Pre-study
Screening
•Salivary Cotinine ≥ 100 ng/mL
•Overnight ( ≥ 10 - 12hours) abstinence
•Exhaled Carbon monoxide ≥ 10 ppm
Baseline
•Blood sample collection
•Craving
•Withdrawal symptoms
10 minutes
•Blood sample collection
•Craving
•Withdrawal symptoms
30 minutes 
•Blood sample collection
•Craving
•Withdrawal symptoms
60 minutes
•Blood collection
•Craving 
•Withdrawal symptoms
•Positive and adverse effects
60-
minute 
ad 
libitum 
vaping 
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Table 2.6  
Participants' demographics and Baseline characteristics (Study 1) 
 N % Mean SD Min Max 
Age (years) 12   42.33 12.60 21 56 
Gender       
  Male 11 91.67  -  -  -  - 
  Female 1 8..33  -  -  -  - 
Ethnicity      -  -  -  - 
  White 12 100  -  -  -  - 
Qualification      -  -  -  - 
 GSCEs level 5 41.7  -  -  -  - 
 A levels 2 16.7  -  -  -  - 
 Undergraduate level (5 to 6) 5 41.7  -  -  -  - 
Occupational status       -  -  -  - 
 Employed 7 58.3  -  -  -  - 
 Non-employed 2 16.7  -  -  -  - 
 Self-employed 3 25.0  -  -  -  - 
eFTND1 12   3.83 1.12 2 6.00 
E-cig Addiction2 12  3.25 1.13 1 5.00 
Baseline cotinine (ng/mL) 12   451.97 243.93 134.2 890.6 
3-hydroxy-cotinine (ng/mL) 12  159.33 124.00 41.90 458.10 
Cotinine to 3-hydroxy-cotinine 
ratio  12    0.37 0.22 0.09   .86 
Baseline CO (ppm) high strength  12   2.00 1.21 1.00 4.00 
Baseline CO (ppm) low strength  12   2.08 1.31 1.00 5.00 
Daily Liquid Vol consumed (mL) 12   4.00 1.73 2.00 7.00 
  6 mg/mL 4 33.3  -  -  -  - 
  10 mg/mL 1 8.3  -  -  -  - 
  11mg/mL 1 8.3  -  -  -  - 
  18mg/mL 1 8.3  -  -  -  - 
  24 mg/mL 3 25  -  -  -  - 
  30 mg/mL 2 16.7  -  -  -  - 
Current model most used      -  -  -  - 
  Rechargeable non-cigalike (2nd 
gen) 1 9.1  -  -  -  - 
  Modular systems (incl.sub-ohms4) 11 90.9  -  -  -  - 
Note. 1 eFTND = Modified version of Fagerström Test for Cigarette Dependence for e-
cigarettes use with item regarding consumption removed (score range: 0-7) 
2 Self-rated addiction: 0-20% = 1; 21-40% = 2; 41-60% = 3; 61-80% = 4; 81-100% = 5 
3Note: Most participants indicated using multiple strengths. 
4 i.e. atomiser resistance < 1ohm used with higher wattage 
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Puffing Topography 
Some instances of extremely short puffs/button presses (i.e. < 1s) (9/568 puffs in 
the high condition and 15/887 puffs in the low condition; 1.58% and 1.69% 
respectively) were observed.  These were verified against backup video data and deleted 
in cases where the device was not clearly in the mouth (N = 4).  In all other instances 
wherein a short puff (< 1 sec) preceded or succeeded a puff of more than 1 second, the 
former was merged with the longer puff.  Individual puffing topography data are 
presented in Tables 2.7 and depicted graphically in Figures 2.8 to 2.12.  All participants 
(with the exception of P.4) increased their number of puffs and puff duration (with the 
exception of P1) from the high to the low condition.  Likewise, volume consumed (mL) 
increased from the high to low condition for all participants.   
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Table 2.7  
Puffing topography (individual and overall scores in mean number of puffs and duration during the 60 mins ad lib vaping period) 
 Puff number  
(SD) 
Puff Duration (s)  
(SD) 
Volume consumed 
(mL) (SD) 
 High Low 
 
High Low High Low 
       
P1 51 85 4.60 4.51 .61 1.19 
P2 17 32 4.00 7.31 .84 1.74 
P3 61 89 4.02 6.77 .70 1.46 
P4 80 61 5.76 6.84 .56 1.34 
P5 65 97 3.94 4.53 .82 .97 
P6 63 131 3.94 5.17 .88 2.38 
P7 50 94 2.15 3.20 .45 .73 
P8 36 109 2.36 3.35 .43 .85 
P9 12 14 3.50 5.09 .41 .45 
P10 16 31 1.92 3.62 .34 .50 
P11 57 66 2.01 4.00 .58 .99 
P12 60 78 3.80 6.16 .82 1.77 
       
Overall means  47.33 
(22.08) 
73.92 
(34.66) 
3.76 
(1.01) 
5.04 
(1.43) 
0.62 
(0.18) 
1.20 
(0.57) 
Note.  Values are mean scores on puff number and duration (in seconds) and volume consumed  
(in millilitre). Standard deviations are presented for the overall sample
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Figure 2.8 Puff number per participant and overall means at each 
time point in the high conditione 
 
 
Figure 2.9 Puff number per participant and overall means  
at each time point in the low condition 
 
                                                 
e Figures 2.8 and 2.9 Means here are cumulative scores and represent total number of puffs taken from baseline to the end of the 60 min ad lib session 
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Figures 2.10 Average puff duration per participant and overall 
means at each time point in the high conditionf 
 
  
 
 
Figures 2.11 Average puff duration per participant and overall 
means at each time point in the low condition 
 
                                                 
f Figures 2.10 and 2.11 Means here are cumulative scores from baseline to the end of the 60 min ad lib session 
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Figure 2.12 Volume consumption (in mL) per participant in high and low 
conditions (p < 0.05) 
 
A Wilcoxon Signed Rank Test revealed statistically significant differences 
between the high and low conditions in mean puff number [z = -2.59, p < .05] (see 
figure 2.8 and 2.9) with a large effect size (r = .53), in mean puff duration [z = -3.06, p 
= .002] (figure 2.10 and 2.11) with a large effect size (r = .62), and mean volume of 
liquid (mL) consumed [z = -3.06, p = .002] (Figure 2.12) and a large effect size (r = 
.62).  The median scores in volume consumed Md = .59 mL increased almost two-fold 
from the high to the low condition Md = 1.08 mL.  Median scores in puff number also 
increased from Md = 54 to Md = 81.50, and in puff duration from Md = 3.84 to Md = 
4.81 from the high and to the low condition respectively, indicative of compensatory 
puffing. 
  Spearman’s rank correlation tests indicated a statistical strong relationship 
between volume consumed and overall means in puff duration, in the high, r = .63, n = 
12, p < .05 and in the low condition respectively, r = .69, n = 12, p < .05.  There was no 
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statistically significant correlation between volume consumed and overall means in puff 
numbers in the high or in the low condition (all p > .05).  
In order to explore how participants adjusted their puffing topography in 
response to the given nicotine concentrations, means in non-cumulativeg puff numbers 
and duration in high versus low condition were compared using Wilcoxon Signed Rank 
tests.  Detailed puffing topography data at each time points with mean (SD) puff 
numbers and duration are presented in Table 2.8.  There was a statistically significant 
difference between conditions in mean puff numbers at 30 [z = -2.35, p < .05] and 60 
minutes [z = -2.83, p < .05], and in puff duration at 10 [z = -3.06, p < .05], at 30 [z = -
3.06, p < .05] and at 60 minutes [z = -3.06, p < .05].  The greater mean values in puff 
duration in the low compared to the high condition suggest that participants increased 
their puff duration in response to the drop in nicotine concentration (see Table 2.8 for 
means (SD).  The difference between conditions in mean puff number at 10 minutes 
was not statistically significant (p > .05).  From the high to the low condition 
respectively, median scores in puff number at 10 minutes increased from Md = 14 to Md 
= 16.50, at 30 minutes from Md = 17 to Md = 27, at 60 minutes from Md = 19.5 to Md = 
31.5, and in puff duration at 10 from Md = 3.87 to Md = 4.90, at 30 from Md = 3.98 to 
Md = 4.75 and at 60 minutes from Md = 3.62 to Md = 4.66 suggesting compensatory 
puffing at all time points.
                                                 
g Non-cumulative puff number scores correspond to the total of puffs taken at each vaping sequence 
(from baseline to 10, from 10 to 30 and from 30 to 60 minutes), and non-cumulative scores in puff 
duration correspond to averages in puff duration per vaping sequence. 
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Table 2.8  
Individual scores in mean puff numbers and duration at each time point  
 
 Puff number 
(SD) 
Puff duration 
(SD) 
 High Low 
 
High Low 
 10 
mins 
30 mins 60 mins 10 
mins 
30 
mins 
60 mins 10 
mins 
30 
mins 
60 mins 10 
mins 
30 
mins 
60 
mins 
             
P1 16 35 51 27 53 85 4.61 4.20 4.23 4.75 4.49 4.51 
P2 6 11 17 8 17 32 4.00 5.54 5.00 5.79 8.11 7.31 
P3 15 36 61 21 51 89 4.02 4.73 5.29 5.93 6.45 6.77 
P4 18 49 80 13 31 61 5.76 4.74 4.88 5.88 8.11 6.85 
P5 12 34 65 17 50 97 3.94 3.94 4.12 4.53 4.44 4.53 
P6 24 43 63 27 71 131   3.94 4.02 3.98 5.48 5.00 5.17 
P7 13 24 50 22 50 94 2.15 2.86 2.57 2.85 3.28 3.20 
P8 7 21 36 27 62 109 2.36 2.95 2.89 3.06 3.46 3.35 
P9 5 8 12 10 12 14 3.50 3.70 3.50 5.05 5.70 5.09 
P10 5 10 16 9 21 31 1.92 1.86 2.11 2.86 3.78 3.62 
P11 15 37 57 15 40 66 2.01 3.16 2.88 2.93 4.00 4.00 
P12 26 41 60 16 47 78 3.80 4.60 3.70 6.18 6.07 6.16 
Overall 
means  
13.50 
(7.03) 
29.08 
(13.91) 
47.33 
(22.08) 
17.67 
(7.08) 
42.08 
(18.31) 
73.92 
(34.66) 
3.50 
(1.17) 
3.86 
(1.02) 
3.76 
(1.01) 
4.61 
(1.33) 
5.24 
(1.67) 
5.04 
(1.43) 
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Nicotine boost: Changes in Plasma Nicotine levels 
All plasma nicotine level (nicotine boost) results and correlational analyses 
included eleven participants due to exclusion of one participant due to an inability to 
withdraw blood (N = 11).   
A Wilcoxon Signed Rank Test revealed a statistically significant increase in 
nicotine boost at all time points in the high (10 mins: Z = -2.85, p = .04; 30 mins: Z = -
2.70, p = .007; 60 mins: Z = -2.58, p = .01 with large effect sizes, r = .61, r = .59, r = 
.55 at 10, 30 and 60 minutes respectively) compared with the low condition.  The 
median scores in the high condition increased from 10 (Md = 18.12) to 30 (Md = 36.11) 
and 60 minutes (Md = 37.23).  Mean (SD) nicotine boost for the high nicotine condition 
from baseline were 32.35 (34.88) ng/mL, 35.48 (28.31) ng/mL and 43.00 (34.78) 
ng/mL.  Corresponding values for the low nicotine condition were 8.74 (7.52) ng/mL, 
16.75 (11.72) ng/mL and 21.96 (16.19) ng/mL at 10, 30 and 60 minutes respectively 
(see Figure 2.13).  This suggests that compensatory puffing was not complete with 
significantly higher plasma nicotine boost in the high condition.  
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Figure 2.13 Plasma nicotine concentration at baseline, 10, 30 and 60 mins from 
baseline, for the high and low nicotine conditions (N = 11; Error bars are ± 1 SE)  
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Correlation between plasma nicotine boost and cumulative scores in puffing 
topography  
Spearman’s Rank correlation tests indicate that plasma nicotine boost correlated 
with mean scores in puff number at all time points, and with mean puff duration only at 
10 minutes in the high condition.  Correlations were significant only at 30 minutes in 
the low condition (see Table 2.9).  
Table 2.9  
Correlations between the cumulative mean scores in puff number, duration, liquid 
consumption and plasma nicotine boost, at each vaping sequence in the high and low 
nicotine conditions.   
 
High Nicotine 
Liquid 
Plasma Nicotine Boost 
 10 mins 30 mins 60 mins 
 
Total scores 
Puff number  .91** .86** .85** .85** 
Puff Duration .62* .59  .56 .63* 
     
Low Nicotine 
Liquid 
 
10 mins 30 mins 60 mins Total scores 
Puff number .49  .61* .56  .56 
Puff duration .39 .33  .35 .32 
     
Note.  *p ≤ 0.05 (2-tailed); **p ≤ 0.01 (2-tailed).  Mean scores on Puff 
number and duration are averaged from baseline at each time point. 
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Individual puffing topographies in relation to plasma nicotine levels  
In order to explore how participants adjusted their puffing behaviours in 
response to the given nicotine concentrations and resulting rise in their plasma nicotine 
levels, non-cumulative puff numbers and duration are plotted at each time point and 
presented per individual graphs (Figures 2.14 to 2.37 in appendix 15).  The graphs 
suggest fairly similar fluctuations in puffing patterns per vaping sequence across both 
conditions.  In the low condition it seems that means in puff number and duration 
accompanied an increase in plasma nicotine levels in most cases.  Whereas in the high 
condition, increases in plasma nicotine levels were followed by downward trends in 
puffing patterns but not for all participants.  Two participants (P6 and P10) seemed to 
achieve complete self-titration raising their plasma nicotine in the low condition to 
similar levels achieved in the high condition (see Figures 2.24 - 2.25 and 2.32 - 2.33, 
appendix 15).   
 
Correlations between plasma nicotine and puffing topography (in non-cumulative 
scores) 
Puff number correlated with plasma nicotine boost at each vaping sequence in 
the high (all ps < .01, see Table 2.5) and only at 30 minutes in the low condition.  Puff 
duration correlated with plasma nicotine boost at 10 minutes in the high condition and 
not at all in the low condition.  Volume consumed also correlated positively with 
nicotine boost at 60 minutes in the low condition only (see Table 2.10).   
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Table 2.10  
Correlations between the non-cumulative mean scores in puff number, duration, liquid consumption and 
plasma nicotine boost, at each vaping sequence in the high and low nicotine conditions.   
 
High Nicotine 
Liquid 
Plasma Nicotine Boost 
 10 mins 30 mins 60 mins 
 
Total scores 
Puff number  .91** .78** .61* .85** 
Puff Duration .62* .59  .56 .63* 
Volume (mL) 
consumed 
- - - .47 
 
 
    
Low Nicotine 
Liquid 
 
10 mins 30 mins 60 mins Total scores 
Puff number .49  .68* .57  .56 
Puff duration .39 .36  .35 .32 
Volume (mL) 
consumed 
 
- - - .75** 
Note.  *p ≤ 0.05 (2-tailed); **p ≤ 0.01 (2-tailed).  Volume (mL) consumed was only 
measured at 60 mins. 
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Correlational analysis between 3-hydroxy-cotinine to cotinine ratio and plasma 
nicotine 
There was a statistically significant positive correlation between 3-hydroxy-
cotinine and non-cumulative scores in puff numbers at 30 [r = .62, p < .05] and at 60 
minutes [r = .66, p < .05].  Baseline cotinine, 3-hydroxy cotinine and 3-hydroxy-
cotinine to cotinine ratio did not correlate with plasma nicotine boost under high or low 
conditions at any time point (all ps > .05) or with puffing topography variables (all ps > 
.05) which suggest that previous nicotine use or phenotypic status to metabolise nicotine 
did not affect puffing behaviours.  
 
Changes in ‘Urge to vape’ and withdrawal symptoms 
For ‘changes in urge to vape, median scores indicated that participants generally 
reported greater reduction in the high versus low conditions at 10 minutes Md = 2 
versus Md = 1, 30 minutes Md = 2.5 versus Md = 2 and 60 minutes Md = 3 versus Md = 
2.5.  However, these differences were not statistically significant [at 10 z = -.51, 30 z = -
.67 or 60 minutes z = -.79, all p < .05].  There was no statistically significant differences 
between conditions in ‘changes in overall withdrawal symptoms’ at any time points [10 
z = -.36, 30 z = -.42 and 60 minutes z = -.56, all p < .05].  There was no statistically 
significant differences between conditions in changes in depressed mood, irritability, 
anxiety, drowsiness, restlessness, hunger and inability to concentrate (all ps > .05).  
These results suggest that although plasma nicotine levels failed to equate those 
achieved in the high condition, compensatory puffing was sufficient to alleviate craving 
and withdrawal symptoms. 
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Subjective Effects: Self-report positive effects 
Mean (SD) and median scores are presented in table 2.11.  There were no 
statistically significant differences between conditions for hit z = 1.726, p = .084 and 
satisfaction z = 1.883, p = .060 nor for any other positive effects (all ps > .05).  
Table 2.11  
Mean (SD) and Median scores in the high and low conditions in changes in positive effects 
associated with e-cigarette use.   
 
 Low condition High condition 
 Mean (SD) Median Mean (SD)  
 
Median 
‘Hit’ 45.21 (22) 45 61.96 (30.03) 68.5 
‘Satisfaction’ 47.31 (16.21) 46.25 62.02 (17.11) 64.38 
‘Pleasant’ 46.46 (23.77) 49.25 48.06 (15.26) 49 
‘Tastes good’ 41.33 (23.38) 38.25 27.07 (22.41) 27.75 
‘Reduced my 
craving’ 
59.63 (19.76) 60.75 71.33 (22.83) 74 
‘helped my 
concentration’ 
48.29 (15.81) 46.75 57.93 (21.47) 59.50 
‘helped me feel 
calmer’ 
48.40 (18.35) 51 51.35 (20.97) 50.25 
‘feel more awake’ 37.83 (20.16) 34.75 45.46 (25.23) 45 
‘reduced my hunger’ 25.77 (15.19) 23.25 29.02 (23.80) 27.75 
‘tastes like my usual 
brand/model’ 
15.08 (18.36) 9 13.79 (17.69) 9.75 
‘feels like using my 
usual brand/model’ 
25.01 (27.16) 19.75 38.08 (25.14) 42.25 
Note.  Values are mean scores in percentage for each dimension of the VAS 
questionnaire on positive subjective effects related to e-cigarette use.  
 
Self-report adverse effects 
Overall mean adverse effect self-ratings did not differ statistically across 
conditions: z = -1.33, p = 0.18. Analysis of individual symptoms revealed no significant 
differences across conditions (all ps > 0.05; see Table 2.12).  There was one incident in 
which a participant felt unwell and vomited 30 minutes into his first testing session 
following use of the e-cigarette in the high condition.  To prevent such incidents and 
ensure that participants were daily users and accustomed to the high nicotine 
concentration specified in the inclusion criteria, all were pre-screened with a cut-off 
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point for cotinine ≤ 100mg/mL and advised to drink plenty and to eat breakfast.  This 
participant admitted failing to follow these recommendations.  His previously 
experienced anxiety over difficulty locating the study venue on a very hot day, may 
have also contributed to his sickness.  After a period of 20 minutes symptoms eased 
away and the participant chose to continue with the study.   
Overall adverse effects did not correlate with plasma nicotine boost at any time 
points (all ps > .05).  
 
Table 2.12  
Mean (SD) and Median scores in the high and low conditions in adverse effects associated with 
e-cigarette use (in order from the most to the least severe symptoms based on means).   
 
 Low condition High condition 
 Mean (SD) Median Mean (SD)  
 
Median 
‘Sweaty’ 11.71 (14.17) 5.00 18.46 (15.73) 12.50 
Throat irritation 13.58 (19.28) 10.50 18.25 (26.76) 11.75 
‘Light headed’ 11.92 (12.23) 8.25 16.17 (16.16) 12.75 
‘Mouth irritation’ 14.79 (19.04) 12.75 15.35 (27.10) 9.00 
Nausea, feeling sick 8.71 (9.38) 5.50 14.88 (17.46) 11.00 
‘Dizzy’ 7.56 (6.48) 6.00 14.25 (14.39) 10.75 
‘Weak’ 10.21 (11.84) 5.00 13.98 (14.37) 11.88 
‘Salivation’ 10.19 (15.21) 4.63 12.50 (13.91) 8.50 
‘Confused’ 7.04 (5.61) 5.75 11.96 (14.07) 9.00 
‘Pounding heart’ 10.44 (11.47) 8.75 6.79 (7.14) 6.00 
‘Nervous’ 9.08 (8.28) 7.75 9.79 (13) 6.00 
‘Cold hands and feet’ 6.21 (5.63) 5.00 9.04 (13.96) 4.50 
‘Palpitations’ 6.29 (5.73) 5.00 9.00 (13.29) 5.00 
‘Stomach ache’ 6.17 (5.50) 5.00 8.15 (7.80) 6.00 
‘Headache’ 7.04 (5.63) 6.00 6.96 (6.73) 6.00 
‘Aching jaws’’ 6.17 (5.50) 5.00 6.13 (6.63) 4.75 
‘Hiccups’ 6.94 (6.85) 5.00 5.96 (6.52) 4.25 
‘Diarrhoea’ 6.31 (5.62) 5.00 6.04 (6.64) 4.25 
‘Heartburn’ 6. 29 (5.52) 5.00 6.25 (6.70) 5.00 
‘Flatulence, Bloating’ 5.96 (5.21) 5.00 6.19 (6.73) 5.00 
‘Vomiting’ 6.00 (5.30) 5.00 5.96 (6.65) 4.25 
Note.  Values are mean scores in percentage for each dimension of the VAS questionnaire 
on negative subjective effects related to e-cigarette use.  
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Discussion 
 
Summary of findings  
The aims of the current study were to investigate whether and to what to extent 
experienced e-cigarette users adjust their puffing patterns to adapt to changes in nicotine 
availability so they can achieve desired blood nicotine levels.  As per hypothesis H1, 
participants made an attempt to self-titrate by increasing their liquid consumption, puff 
duration and frequency in the lower nicotine concentration condition.  However, as for 
hypothesis H2, which posited that there will be no differences between conditions, 
plasma nicotine levels were significantly higher in the high nicotine concentrations 
suggesting that titration was only partial and that compensatory puffing was not 
sufficient to raise plasma nicotine levels to match levels achieved in the high condition.  
On the other hand, as per hypothesis H3, the use of both nicotine concentrations were 
equally effective in alleviating ‘urge to vape’ and withdrawal discomfort.  Similarly, 
there were no differences in subjective positive effects such as ‘satisfaction’ and ‘hit’ or 
in adverse effects. 
Puffing topography and plasma nicotine levels 
Participants consumed almost double the amount of liquid in the low compared 
with the high nicotine concentration, increased their puff numbers and duration.  Mean 
puff durations found here are in good agreement with previous documentations of 
experienced e-cigarette users’ puff duration (Farsalinos et al., 2013b; Hua et al., 2013).  
Others found much shorter puffs whilst comparing plasma nicotine levels with 0, 8, 18 
and 36 mg/mL nicotine concentrations.  Following the first 10-puff (30s IPI) 
standardised protocol, mean scores in puff duration (across 0, 8, 18 and 36 mg/mL 
conditions) differed statistically only between 0 and 36 mg/mL; the significant increase 
in puff duration from 36 mg/mL to the placebo nicotine condition is suggestive of 
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compensatory puffing (Lopez et al., 2016).  However, the same group later reported 
similar differences in mean puff duration between 0 and 36 mg/mL (Ramôa et al., 
2015).  The argument that longer puff duration and shorter IPI (Williams et al., 2011) 
are conducive to more efficient nicotine delivery (Hajek et al., 2015) seem to be 
supported by the current data; mean puff durations were significantly longer in the low 
condition and here significantly higher plasma nicotine levels were achieved with 
6mg/mL nicotine e-liquid compared to previous studies.  In a previous study, following 
a 60 min ad lib puffing session, a mean puff duration of (M = 2.3, SD = 0.2 s) yielded an 
average plasma nicotine level of 13.8 ng/mL (SD = 1.6) in naïve e-cigarette users 
(Farsalinos et al., 2015), which are moderate compared to the mean level seen here 
21.96 ng/mL (SD = 16.19) at 60 minutes.  The higher number of puffs taken in the 6 
mg/mL condition in an attempt to compensate is echoed in previous findings.  
Following a 30-minute controlled, rapidly succeeded by a 60-minute ad lib, puffing 
session, higher puff numbers were associated with lowest nicotine e-liquid 
concentrations and with cartridge models (Hajek et al., 2017) which typically have a 
poor nicotine delivery compared with tank models (Farsalinos et al., 2014).  
These puffing topography results concur with previous findings; the average 
puff duration in the high condition observed here was slightly longer than those 
previously reported in experienced users (Hua et al., 2011) using newer generation 
devices (Farsalinos et al., 2014) and longer than those reported for cigalike (first-
generation) devices (Behar et al., 2015) and combustible cigarettes (Hua et al., 2013).  
Previous studies have found longer puff duration in first-generation cigalike models to 
be associated with greater discomfort compared with second-generation eGo models 
(Dawkins, Kimber, Puwanesarasa, & Soar, 2015) suggesting that the increased 
sophistication of the newer generation devices may promote longer puffing patterns.  
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Nevertheless, there is emerging data which suggests that puffing patterns may be 
influenced by factors other than nicotine concentration such as the ingredients present in 
the liquids.  For instance, studies have found a higher ratio of propylene glycol 
(compared to vegetable glycerine) to be associated with shorter puff number and 
duration, but result in higher plasma nicotine levels suggesting that a combination of 
propylene glycol (PG) and vegetable glycerine (VG) is a better vehicle for nicotine 
compared to vegetable glycerine alone (Yan & D’Ruiz, 2015).  Here this was controlled 
by using a 60/40 (PG/VG) ratio across both conditions.  In the same light, the high ratio 
of PG may have contributed to the unusually high plasma nicotine observed here. 
These findings suggest that, in line with the self-titration model, experienced e-
cigarette users will compensate by adjusting their puffing patterns to maximise nicotine 
delivery from a lower nicotine concentration liquid.  Furthermore, statistically 
significant differences in mean values of non-cumulative puffing number and duration 
suggest that participants had to adjust their puffing patterns across time points during 
the course of using the e-cigarette according to the nicotine availability; this provide 
support for the ‘finger-tip’ control that is often ascribed to smoking. 
 
Nicotine boost 
Nicotine boost was significantly higher in the high compared with the low 
nicotine concentration (see Figure 2.7).  Although puffing topography data are an 
indication of attempts to compensate for the low nicotine concentration, from the latter 
results it is clear that self-titration was not complete with significantly higher levels in 
the high nicotine content concentration.  This is in line with previous reports from 
tobacco cigarette studies.  Self-titration tend to be complete when smoking higher yield 
cigarettes, but only partial when smoking lower yield cigarettes (Scherer, 1999).  A 
likely explanation for the partial titration could be that the high nicotine concentration 
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was sufficiently high to exceed desired levels.  This is supported by the non-cumulative 
puffing data which shows that as plasma nicotine boost increased, participants 
decreased their puffing intensity.      
Plasma nicotine levels achieved here were unusually high compared to those in 
previous reports and equate to levels observed in tobacco smoking (Russell et al., 1980; 
Russell, Wilson, Patel, Feyerabend, & Cole, 1975).  These levels exceed those reported 
in previous studies in which similar (Farsalinos et al., 2014; Farsalinos et al., 2015; Yan 
& D’Ruiz, 2015) and higher nicotine concentrations (Hajek et al., 2017; Lopez et al., 
2016; Ramôa et al., 2015) were used.  For comparison, in a recent study the smoking of 
a tobacco cigarette in a five-minute puffing period (10 puffs, 30 seconds apart) resulted 
in Cmax of 13.4 ng/mL (Fearon et al., 2017), which seems negligeable compared to 
levels achieved by some individuals from the current study (means ranged from 5 to 
110.12 ng/mL); although much greater levels ( that is, ≥ 30 ng/mL following the 
smoking of 32 mg/mL nicotine yield tobacco cigarettes) are reported in earlier tobacco 
research studies (Russell et al., 1975).  In a study investigating PK profiles of a cigarette 
versus different e-cigarette brands, none of the e-cigarette matched the PK profile of the 
tobacco cigarette (Cmax = 17.9 ng/mL), that is including a 48 mg/mL nicotine 
concentration e-cigarette which yielded a mean Cmax of 13.6 (SD = 9.7) ng/mL 
following 19 puffs during a five-minute prescribed vaping protocol (Hajek et al., 2017).  
In one study, higher puff numbers tended to be associated with the lowest PK profiles 
and the lower nicotine concentrations (Hajek et al., 2017), which concurs with the 
compensatory puffing hypothesis.  Such high plasma nicotine levels may be due to the 
one hour ad libitum vaping design combined with the required 10 to 12 hour nicotine 
abstinence and a self-selective recruitment method of high nicotine concentration vapers 
with baseline salivary cotinine levels equal or exceeding 100 ng/mL.  Due to the rapid 
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advancement in technology, recent findings suggest that the shape of pharmacokinetic 
curve of the nicotine delivery of e-cigarettes is increasingly approaching that of 
combustible cigarettes (St Helen, Havel, Dempsey, Jacob 3rd, & Benowitz, 2015); 
findings of the present study certainly seem to support this trend. 
Nicotine boost and puff numbers were highly correlated at all time-points in the 
high but not in the low nicotine concentration condition.  The failure to reach statistical 
significance may be due to the small sample size or due to a saturation effect in the low 
nicotine concentration condition.  In the high condition, non-cumulative puffing data 
suggests that, as plasma nicotine boost was increasing, participants tended to decrease 
their puffing.  The number of puffs taken from baseline to 30 minutes was significantly 
lower than the number of puff taken during the remaining 30 minutes, and in some 
cases, the trajectory of the nicotine boost goes downwards after the 30 minutes, which is 
suggestive of an attempt to regulate (downwards) to a desired and satisfactory plasma 
nicotine levels.  Already the first 10 minutes were marked by a significant difference in 
puff duration, with a higher overall mean (SD) in the low (M = 4.61, SD = 1.33 s.) 
compared to the high condition (M = 3.50, SD = 1.17 s.) which lends support to the self-
titration theory.  
The notion of self-titration (or self-regulation) is well established and 
extensively evidenced in smokers, typically in up-regulation attempts, titration is 
seldom complete (Scherer, 1999).  In the present study with vapers, despite the several 
fold reduction in the low nicotine concentration (24 to 6 mg/mL), corresponding 
nicotine boost was only two-fold lower at 30 and 60 minutes.  One possible explanation 
for the failure to fully self-titrate could be that the large difference in nicotine liquid 
content may require too great an effort to compensate fully combined with a time 
constraint of one hour which may have caused a satiation effect.  That is, any given time 
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period imposes a limit on the quantity of nicotine liquid that an individual is able to 
consume comfortably.  It is unknown whether a more prolonged ad libitum session 
would have led to similar plasma nicotine levels. 
 
Individual differences 
Puffing topography and plasma nicotine levels varied widely amongst 
participants as has previously been demonstrated in smokers (Hammond et al., 2005; 
Russell, 1980), and e-cigarette users (Dawkins & Corcoran, 2014; Farsalinos et al., 
2015; Yan & D’Ruiz, 2015).  However, like in the smoking population (Gust et al., 
1983), puffing patterns were consistent across conditions within participants (Behar et 
al., 2015).  As indicated by the standard deviations, individual variabilities were more 
pronounced in the low nicotine concentration with the lowest individual mean in puff 
number of 14 and the highest 131 puffs.  Mean volume consumed ranged from .45 to 
2.38 mL and mean puff duration ranged from 3.20 to 7.31 s, in some cases exceeding 10 
s.  Such extreme long puffs are not uncommon in e-cigarette use, Hua and colleagues 
observed puff duration of 8 s in experienced e-cigarette users (Hua et al., 2013).  As was 
the case for most of the sample, participant 6 increased his puffing frequency by almost 
double from 63 to 131 puffs and his puff duration from 3.94 to 5.17 s and his liquid 
consumption from 0.88 to 2.38 mL.  Likewise participant 4 increased his liquid 
consumption from 0.56 to 1.34 and his puff duration from 5.76 to 6.84 s, inversely his 
mean puff number reduced from 80 to 61 puffs.  Though, the latter must be interpreted 
with caution as participant 4 did feel unwell half way through the session and his 
puffing behaviour in the repeated session may have been impacted by a possible recall 
of the event in his previous session.  The lack of statistical significance in correlational 
analysis between puffing topography and plasma cotinine levels suggests that inhalation 
depth may have differed widely between participants and influenced nicotine 
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absorption.  The individual variations are likely to be due to the small size of the sample 
and also be a reflection of the variations in nicotine dependence within the sample with 
baseline cotinine levels varying from 134.2 to 890.6 ng/mL.   
Participants’ puffing patterns seemed to fluctuate in the same fashion across 
vaping sequence and conditions.  In the low condition, means in puff number and 
duration accompanied an increase in nicotine boost in most cases.  Whereas in the high 
condition, increases in nicotine boost were followed by downward trends in puffing 
patterns but not for all participants.  Two participants (P6 and P10) seemed to achieve 
complete self-titration raising their plasma nicotine in the low condition to similar levels 
achieved in the high condition, which suggests that it is possible for some e-cigarette 
users to self-titrate by adjusting their puffing patterns in order to obtain desired and 
satisfactory plasma nicotine levels.   
 
Relationships between nicotine metabolism, nicotine intake and puffing topography 
Mean in trans-3-hydroxy-cotinine to cotinine ratio (M = .37, SD = .22) fell 
within the common range amongst smokers (.2 to .75) (Dempsey et al., 2004), however, 
the sample varied widely with 3-hydroxy cotinine to cotinine ratio ranging from .09 to 
.86.  As per previous reports in tobacco smokers (Levi, Dempsey, Benowitz, & Sheiner, 
2007), puffing patterns were not influenced by 3-hydroxy-cotinine to cotinine ratios.  
Puff number and duration were not associated with baseline cotinine levels, 3-hydroxy 
cotinine or 3-hydroxy-cotinine to cotinine ratio.  Neither did baseline cotinine, 3-
hydroxy cotinine or 3-hydroxy-cotinine to cotinine ratio correlate with plasma nicotine 
boost under high or low conditions at any time point.  This suggests that previous 
nicotine use or phenotypic status to metabolise nicotine did not affect puffing 
behaviours.  This is in line with previous studies in tobacco smokers, the wide 
individual variabilities in the relationships between nicotine intake, saliva cotinine and 
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could be largely explained by i) the individual differences in percentages in nicotine to 
cotinine conversion (usually between 55 - 92 %) and also ii) individual differences in 
the rate of cotinine metabolism (Benowitz & Jacob, 1994).  Besides, whilst nicotine 
metabolism has been shown to influence nicotine intake, the one hour ad libitum vaping 
session would not allow sufficient time for the metabolism of nicotine or cotinine 
conversion to exert any effect on puffing behaviours.  
 
Effects on craving, withdrawal and subjective effects  
Although compensatory plasma nicotine levels in the low nicotine concentration 
failed to equate to those in the high nicotine concentration, in line with tobacco smoking 
(Sutton et al., 1982), such attempts to self-titrate appeared to be effective in alleviating 
subjective urge to vape and withdrawal discomfort.  Median scores in reduction in ‘urge 
to vape’ were greater in the high conditions compared with the low condition, but, these 
differences did not reach statistical significance.  Similarly, there was no statistically 
significant differences between conditions in any of the individual withdrawal 
symptoms.  These results suggest that although plasma nicotine levels failed to equate 
those achieved in the high condition, compensatory puffing was sufficient to alleviate 
craving and withdrawal symptoms.  Findings of the current study concur with others 
who found significant differences in plasma nicotine levels from tobacco cigarettes 
smoking versus e-cigarettes use, but no differences between groups in reduction in 
‘desire to smoke’ (Fearon et al., 2017);  this suggests that low nicotine concentration 
levels may be sufficient for the relief of craving and withdrawal discomfort, 
nonetheless, with the caveat of consuming a much greater amount of liquid and exerting 
a more intensive puffing regime.  In contrast, previous studies found craving alleviation 
to be associated with more intensive puffing patterns (that is greater puff numbers and 
volume consumed) and the use of higher nicotine concentrations and are in turn linked 
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to achieving higher satisfaction (Etter, 2015).  Likewise, early studies also report greater 
relief of ‘urge to smoke’ in e-cigarettes which contain nicotine compared with placebo 
e-cigarettes (Dawkins et al., 2012).  Others found that higher plasma nicotine levels 
were associated with greater reduction in craving relief and higher ‘satisfaction’ and 
‘throat hit’ (Farsalinos et al., 2014).  However, the small sample size could not be 
dismissed as an alternative explanation for the lack of differences between conditions, 
since the study was powered to detect an effect on puffing topography variables but not 
on subjective effects. 
There were no significant differences in subjective effects, although both, means 
in hit and satisfaction were numerically higher in the high compared with the low 
condition and in the high.  These results reiterate that although self-titration was 
incomplete with significantly lower plasma levels in the low condition, compensatory 
puffing was sufficient to achieve subjective satisfaction at least in the short term.  In 
fact, differences could have emerged from a longer ad libitum session or a larger 
sample.  Likewise, there were no statistically significant differences in adverse effects 
and the highest means tended to be in the high nicotine condition however.   
 
Limitations 
This study is one of the first (Farsalinos et al., 2015) to use an e-cigarette with a 
downloadable software to record puffing topography data, which, unlike the CReSS 
machine (Ross & Juliano, 2016; Spindle et al., 2015) is non-evasive and may have 
greater ecological validity.  However, the device used here has its limitations, it does 
not measure puff velocity and volume and has a safety cut off point which prevent any 
presses of more than 10 seconds.  That said, previous studies suggest that puff volume 
(Kosmider, Madej, Garwon, Sobczak, 2016) and velocity alone do not influence liquid 
evaporation (Talih et al., 2014) and, here, liquid consumption was measured using other 
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means.  Moreover, the current study was conducted in a controlled laboratory 
environment which may not be a true reflection of real puffing behaviour (Robinson et 
al., 2015).  For instance, previous studies suggest that smokers and e-cigarette users 
have a tendency to display more intensive puffing patterns in laboratory settings 
compared to when in their natural environment (June et al., 2012; Robinson et al., 
2015).  However, to postulate that the intensive puffing patterns and unusually high 
plasma nicotine levels could be an over-estimation of real puffing behaviour, may not 
hold true since the current study is concerned with changes in puffing patterns within 
individuals and the same controlled laboratory setting across both conditions was 
utilised.  Similarly, in an attempt to hold variables constant and maintain experimental 
control, the e-cigarette device was set with fixed parameters, however this may not 
reflect real-life use of third generation e-cigarettes, specifically given the surge in the 
use of sub-ohm tanks (mounted with atomisers with less than one ohm resistance) which 
are typically used with very low nicotine concentrations.  In fact, participants stated that 
in natural conditions they would alter device parameters (increase the voltage/wattage 
and reduce atomiser resistance) when using a lower nicotine concentration e-liquid.  
Thus, these findings cannot be generalised to other e-cigarette device types given the 
wide variability in puffing patterns across device types (Behar et al., 2015).  
Furthermore, to maximise the true effect of the ad libitum session, participants were not 
allowed to get accustomed to the eVic™, however, this may have been offset by the fact 
that all were experienced and regular e-cigarettes users accustomed to third generation 
devices.  A further limitation may lie in the use of 6 and 24 mg/mL nicotine 
concentrations only which are at opposing extremes of the nicotine concentration 
spectrum.  It is not clear whether the use of 18 and 24 mg/mL for example would have 
allowed participants to self-titrate fully and achieve matching plasma nicotine levels.  
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Finally, participants were mostly all Caucasian 91.67 % males; this does not reflect the 
wider population, given that studies suggest gender differences in nicotine dependence 
(Dawkins et al., 2012), in e-cigarette use (Jorenby, Smith, Fiore, & Baker, 2017) and 
ethnic variations in nicotine disposition kinetics (Benowitz, Hukkanen, & Jacob III, 
2009). 
Concluding remarks 
Findings here suggest that, similar to smokers, experienced e-cigarette users 
have a tendency to self-titrate by altering their puffing patterns when switching to a 
lower nicotine concentration liquid.  Similarly to previous tobacco cigarette studies 
which suggest that upwards regulation is more commonly achieved compared to 
downwards regulation, titration was not complete; despite significantly lower puff 
number and duration, plasma nicotine levels were significantly higher in the high 
nicotine concentration condition.  However, it is unclear whether a more prolonged ad 
libitum session would have led to equal plasma nicotine levels; future work may focus 
on more naturalistic settings to obtain more realistic puffing topography data and 
biomarkers. 
There were no differences in subjective craving, withdrawal, satisfaction and other 
positive effects, which infers that participants were able to obtain satisfactory plasma 
nicotine levels at least subjectively. This suggests that matching plasma nicotine levels 
and indeed very high nicotine content liquids may not be an absolute necessity for 
alleviation of craving or withdrawal at least for experienced vapers in acute conditions 
in the laboratory. However, the findings suggest that when given lower nicotine 
concentrations, vapers would (consciously or subconsciously) exert compensatory 
puffing behaviours which carry greater financial expense (consuming a greater quantity 
of e-liquid) and potential health risks.  Whilst studies suggest that e-cigarette emissions 
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carry only 5 % of the health risks of tobacco cigarettes (Mcneill et al., 2015), more 
intensive puffing pattern as documented here, may lead to increased toxicant exposure 
and adverse long term health effects (Kosmider, Kimber, Kurek, Corcoran & Dawkins, 
2017).   
Findings of the current study also suggests that under certain conditions, 
extremely high plasma nicotine levels can be achieved; this is indicative of a remarkable 
improvement in e-cigarette nicotine delivery.  Thanks to the rapid advancement in 
technology, recent findings suggest that the shape of pharmacokinetic curve of the 
nicotine delivery of e-cigarettes can match and indeed exceed that of combustible 
cigarettes.  This is encouraging given the importance of nicotine delivery in the 
maintenance of tobacco use and the ability of alternative products such as e-cigarettes to 
rival tobacco cigarettes.  
 
Summary of Chapter II 
Whilst previous studies have used standardised puffing protocols either 
exclusively or preceding an ad lib session, here it is argued that the use of prescribed 
puffing regimes do not reflect real-life device use and will affect nicotine delivery and 
absorption.  Thus, although they are suggestive of compensatory puffing behaviours, 
they do not provide clear evidence of titration.  This study is the first to directly explore 
self-titration by allowing experienced e-cigarette users, customarily using high nicotine 
concentration e-liquid, to use an e-cigarette device ad libitum in the lab.  In fact, the 
findings provide direct empirical evidence of a clear attempt to self-titrate; when given a 
lower nicotine concentration, users increased their puff frequency and duration and 
consumed more e-liquid.  As with tobacco smoking, compensation was partially 
effective; users reported equivalent reduction in craving and withdrawal symptoms 
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between conditions although blood nicotine levels remained significantly higher in the 
high nicotine condition.  Indeed, the current study shows that experienced users using 
third generation e-cigarettes and a 24 mg/mL nicotine concentration e-liquid can 
achieve high blood nicotine levels very quickly, matching and even exceeding those 
reported in tobacco smokers.  Such patterns of nicotine delivery, approximating those 
achieved in cigarette smoking may bolster cessation rates, but may raise concerns over 
nicotine dependence for some.  
When considering the phenomenon of self-titration or nicotine regulation there 
is a need for longitudinal studies.  Furthering the understanding of how smokers adapt 
their smoking and puffing behaviours in response to nicotine availability certainly merit 
attention.  Study 3 (in the following chapter) is not investigating the compensation 
theory directly, rather is exploring the self-titration theory through the lens of inter-intra 
variability of puffing topography in response to varying nicotine concentration levels in 
e-cigarettes and, to what extent if any smokers alter their puffing topography over time 
to adapt to nicotine delivery.   
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CHAPTER III 
“CIGALIKES VERSUS TANK SYSTEMS: EFFECTS OF 
PUFFING TOPOGRAPHY, DEVICE CHARACTERISTICS 
AND NICOTINE CONCENTRATION DURING THE EARLY 
STAGE OF A QUIT ATTEMPT” 
 
 
Abstract 
Background:  Although the previous study demonstrated evidence of self-titration 
through compensatory puffing, this was in experienced users and only over a short 
duration in the lab.  There is also a need to understand how smokers adapt their smoking 
and puffing behaviours in response to nicotine availability and different e-cigarette 
models over time as this may have implications for e-cigarette satisfaction, acceptance 
and ultimately cessation.  This study aimed to measure changes in puffing topography 
over 2 weeks in naïve e-cigarettes smokers and subsequent cigarette reduction, 
comparing cigalikes and tanks and low versus high nicotine concentrations. 
Methods:  E-cigarette naïve smokers, (N = 70; 62.9% female) were randomly allocated 
to 1 of 3 conditions, cigalike (18mg/mL), tank-high (18mg/mL) or tank-low (6mg/mL).  
Participants were given the e-cigarette to take home and recorded cigarettes smoked per 
day (CPD) and subjective symptoms in a diary during the 2-week period.  In three 
additional lab sessions, they used the e-cigarette ad lib for 20 min, at baseline, one week 
later (Time 1) and 2 weeks later (Time 2). Puff duration, puff number and inter-puff 
intervals (IPI) were recorded along with exhaled carbon monoxide (CO), cigarette 
dependence, craving and withdrawal (pre- and post- e-cigarette use), and subjective 
effects at each session.   
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Results:  Puff duration increased significantly between Baseline and Time 2, whilst puff 
numbers and IPI decreased.  Cigalikes were associated with longer puff duration, 
shorter IPI and greater number of puffs; the use of tank-high led to longer IPI and 
shorter puff duration.  The tank-high and cigalikes were more efficient in reducing 
craving compared to the tank-low at baseline.  Participants rated the tanks (both high & 
low) as more satisfying at baseline and Time 1 compared with the cigalike.  CPD, CO 
and nicotine dependence reduced significantly, but did not differ between conditions 
Conclusion:  Smokers increased their puff duration over time, presumably as they 
learned puff-technique in order to obtain satisfactory blood nicotine levels in line with 
the self-titration theory.  Whilst higher nicotine concentrations were more effective in 
reducing craving, tanks were associated with higher satisfaction.  Although nicotine 
concentration did not have a direct effect on puffing topography, the longer puff 
duration and puff number associated with the cigalike suggest nicotine delivery is a 
primary determinant of puffing topography.  E-cigarettes helped reduce tobacco 
smoking in the initial weeks of a quit attempt regardless of the device and, the effects on 
long term smoking reduction and abstinence are reported in Chapter IV. 
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Introduction 
 
Differences in device types 
A key element of nicotine delivery is the proficiency of the device used, and as 
devices have evolved, so has nicotine delivery improved (D’Ruiz, Graff, Yan, Sherwin 
Yan, & Yan, 2015; Farsalinos et al., 2014; Farsalinos, Spyrou, Tsimopoulou, et al., 
2015; Hajek, Przulj, Phillips, Anderson, & McRobbie, 2017; Lee, Gawron, & 
Goniewicz, 2015; Lopez et al., 2016; Wagener et al., 2016).   
Long term users can also achieve 50% higher blood nicotine levels compared 
with naïve users (Farsalinos et al., 2015) coupled with significant craving alleviation 
(Etter, 2015; Fearon et al., 2017).  Thus, there are marked differences in device efficacy 
to deliver nicotine and their ability to induce a satisfactory hit (Baweja et al., 2016) and 
alleviate craving and withdrawal symptoms (Farsalinos et al., 2014; Hajek et al., 2017; 
Yingst et al., 2015).  This indicates that the type of e-cigarette plays a significant role in 
nicotine delivery and subjective effects, and, variations in efficiency are also contingent 
upon the manner in which the device is used (that is puffing patterns).   
In England, e-cigarettes have enhanced cessation rates by an estimated 2.5% 
(22,000 of smokers) (West, Shahab, & Brown, 2016), however the likelihood of 
cessation does not seem to be associated with cigalikes but rather, with tank systems 
(Hitchman et al., 2015).  In a survey of 1643 smokers, those using a tank device on a 
daily basis were more likely to quit than those using cigalikes or using any device types 
on a non-daily basis.  Furthermore, although most smokers initiate use with a cigalike 
(at least prior to 2016), most successfully reduce their smoking to eventually quit only 
after transitioning to a more advanced later generation model to achieve ‘a more 
satisfying hit’ (Yingst et al., 2015).  Thus, it soon became evident that these initial 
reports of poor nicotine delivery were an attribute of cigalike models.   
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In the UK, in 2017, the number of regular e-cigarette users, that is former 
smokers who completely switched to solely using e-cigarettes, exceeded  the proportion 
of smokers using e-cigarettes concurrently (hereafter referred to as dual users) (52% 
versus 45% respectively) (ASH, 2017).  Since a reduction in smoking compared to 
complete cessation does not necessarily reduce mortality risks (Inoue-Choi et al., 2017), 
this is an encouraging trend and, equally further reiterates that e-cigarettes use can 
promote cessation.  In contrast, in the US, where cigalikes has occupied a large 
proportion of the market share (Department of Health et al., 2016; Shiffman, 
Sembower, & Kim, 2018), the number of dual users is still greater than the proportion 
of former smokers who quit using an e-cigarette (54% versus 34% respectively) (Rodu, 
2017).  Though there may be several factors at play, the greater prevalence of cigalikes 
in the US compared to the UK may partly explain these opposite trends.  It is worth 
noting however that due to the fast evolving nature of this market, the figures reported 
herein are likely to fluctuate thus become rapidly outdated.  
In 2017, the Eurobarometer found that of the 15% of European smokers who 
declared trying an e-cigarette, 9% did so only once or twice, whilst 4% who used them 
regularly in the past had discontinued their use (Eurobarometer, 2017).  That smokers 
try an e-cigarette once or twice or even regularly before discontinuing use suggests 
dissatisfaction of the product.  This is alluded to in the recent ASH Fact sheet in which 
dissatisfaction, more explicitly that ‘the device did not feel like smoking’ or that ‘it did 
not help dealing with craving for smoking’, was reported as an important driver for 
discontinuation of use (ASH, 2017).  Although, these data do not provide information 
that enables one to attribute device type to discontinuation, this highlights the 
importance for all e-cigarette devices to be efficient in delivering nicotine, reduce 
craving for tobacco cigarettes and successfully replace smoking.  The implications for 
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these continuing smokers are that first negative encounters with e-cigarettes may deter 
future cessation attempts using an e-cigarette.  Consequently, that some smokers who 
succeed in their cessation attempts with the aid of e-cigarettes whilst others fail, 
certainly warrants further investigation to assist this population.   
Importantly, the visual appearance of the device may have a role to play in 
enhancing their appeal and acceptability to smokers.  In a previous study, it was found 
that when offered a choice of cigalike or tank model, smokers were equally likely to 
choose either (50% opted for cigalike; 50% tank-like) but following use of the device, 
tank models were associated with greater satisfaction compared to the cigalikes 
(Dawkins, Kimber, Puwanesarasa, & Soar, 2015).  Qualitative data from the same study 
included reports from smokers that it is important that the device ‘feels and looks like 
smoking’; this highlights the high importance of the behavioural aspects of smoking 
addiction.   On the other hand, there are reports that the complexity associated with tank 
systems may be a deterrent and impedes acceptability of e-cigarettes (Mckeganey & 
Dickson, 2017), hampering smoking cessation.  Qualitative studies suggest that the 
bulky and oversize appearance combined with the complex technology of the tank-
models may be a barrier for some users (Wadsworth, Neale, Mcneill, & Hitchman, 
2016).  This therefore provides a strong rationale for smaller cigarette-type devices such 
as cigalikes to remain on the market as well a large variety of devices to reflect the 
heterogeneity of preferences from different users.  Given the appeal for their close 
resemblance to conventional cigarettes for some smokers, investigating whether cigalike 
models can be well received is therefore important.   
User’s Experience: the Effect of Practise  
The efficacy of obtaining satisfactory blood nicotine levels also depends upon 
the way the e-cigarette is used and studies have shown that both are likely to improve 
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with practise (Hajek et al., 2015).  Although the nicotine delivery from e-cigarettes 
appears less effective compared to combustible cigarettes, at least for some models, it is 
becoming increasingly  evident that this could be reversed with practice; by adjusting 
puffing patterns (for example, increasing the duration and intensity of each puff), e-
cigarette users can maintain constant and satisfactory blood nicotine levels, withdrawal 
and craving alleviation (Dawkins & Corcoran, 2014; Dawkins, Turner, Hasna, & Soar, 
2012; Etter & Bullen, 2011).  This is in line with later studies which found that regular 
use and practice can significantly increase blood nicotine levels (Hajek et al., 2015).    
This increase in nicotine intake may be explained by a need to compensate for the less 
effective nicotine delivery of e-cigarettes which is characterised by a greater draw 
resistance in comparison with combustible cigarettes.   
Puffing topography (such as puff duration, volume and frequency) therefore, 
plays a large role in the effectiveness of nicotine delivery.  Experienced users typically 
take longer puffs and exhale larger volume of aerosols (Hua, Yip, & Talbot, 2011) 
compared with smokers (inexperienced e-cigarette users) using tobacco cigarettes or e-
cigarettes (Farsalinos et al., 2013; Talih et al., 2014).  Smokers however, tend to adjust 
their puffing patterns within a week of adopting e-cigarettes, chiefly by increasing their 
puff duration and adjusting each puff to a slower pace which in turn, results in a 
decrease in puff flow rate (Lee et al., 2015).  Others found that experienced e-cigarette 
users’ inhalation time is shorter compared to that of smokers when smoking 
combustible cigarettes (Farsalinos et al., 2013).  In a study comparing experienced 
users’ puffing topography versus smokers’ smoking and vaping topography, 
experienced users’ puffing duration were two-fold higher (M = 4.2, SD = 0.7 s) 
compared with smokers smoking a tobacco cigarette (M = 2.1, SD = 0.4 s) and smokers 
using an e-cigarette (M = 2.3, SD = 0.5 s).  These results are in good agreement with 
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online video data (Hua, Yip, & Talbot, 2011) and accords with the hypothesis that there 
is a ‘learning curve’ involved in vaping (McQueen et al., 2011), which suggests that the 
required adjustment in puff duration is largely dictated by the need to compensate for 
the lesser effective nicotine delivery or more demanding suction mechanism. 
The importance of nicotine concentrations in the e-liquid: a key factor in nicotine 
delivery  
Another factor influencing how e-cigarette use is likely to be effective and 
accepted as a substitute to smoking is the nicotine concentration in the e-liquid.  Although 
e-cigarette users tend to gradually reduce the nicotine concentration in their e-liquids over 
time (Farsalinos et al., 2014), higher concentrations of nicotine may be  important in the 
initial stages of transitioning from smoking to vaping.  In a study of 111 experienced e-
cigarette users, 42% using nicotine concentration liquids exceeding 15 mg/mL, and 
16.2% reported that they had to increase the initial nicotine levels used in order to achieve 
complete smoking abstinence (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 
2013).  There is also evidence that higher nicotine concentrations in alternative nicotine 
delivery products (ANDS) and NRT can increase smoking cessation (Tunnesen et al., 
1999). 
Likewise, pharmacokinetic studies suggest that greater craving and withdrawal 
relief are  associated with high-powered tank systems, more intensive puffing patterns 
and higher nicotine concentration e-liquids (Etter, 2015).  In a cross-sectional survey of 
374 regular users, greater craving relief were associated with the use of more advanced 
models and higher voltages, as well as higher nicotine concentrations and greater 
puffing frequency (Etter, 2015).  That higher nicotine concentrations are associated with 
greater craving relief is of some importance given that the second cause of 
discontinuation of the product was reported as the inability of the product to relieve 
craving (ASH, 2017).   
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Indeed, like nicotine yield in tobacco cigarettes (Hammond, Fong, Cummings, 
& Hyland, 2005; Russell, Epstein, & Dickson, 1983), e-liquid nicotine concentration is 
an important factor that is likely to influence puffing topography.  Clinical studies, and 
Study 1 of this thesis, suggest that experienced e-cigarette users may adjust their puffing 
in response to nicotine concentrations in the e-liquid.  However, whether naïve e-
cigarette users can do so, is unclear.  
Longitudinal studies suggest whilst long term e-cigarettes users gradually reduce 
their nicotine concentration over time (Farsalinos et al., 2013a; Farsalinos, Romagna, et 
al., 2014; Polosa et al., 2015), this tends to be associated with an increase in nicotine 
intake (Etter, 2016).  Indeed, in a sample of 98 experienced users, although nicotine 
concentrations e-liquids decreased from 11 to 6 mg/mL after a period of 8 months, 
salivary cotinine levels increased from 252 ng/mL to 307 ng/mL at follow-up; of 
particular interest the author also report an increase in the volume of liquid consumed 
(Etter, 2016).  This increase in nicotine intake may be explained by a need to 
compensate for the drop in nicotine concentrations from the e-liquid and to self-titrate 
via compensatory puffing in order to maintain a satisfactory and constant level of blood 
nicotine level.  Similarly to smoking (Gritz et al., 1983), the number of puffs do not 
determine consumption, rather volume consumed is a better predictor in comparison 
and this is acknowledged by e-cigarette users (Baweja et al., 2016), suggesting that 
other components of puffing topography such as puff duration may be a better predictor 
of consumption.   
Altogether, much evidence suggests users’ experience, device characteristics and 
nicotine concentrations are likely factors influencing nicotine delivery and the way a 
device is used or puffed on (Talih et al., 2014).  Given that nicotine is the primary 
reinforcer of smoking behaviour (Harvey et al., 2004), the implications are that e-
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cigarette devices with poor nicotine delivery will preclude product acceptability, 
influence puffing behaviour and possibly put users at risk of relapsing to tobacco 
smoking.  If e-cigarettes are to help in alleviating the huge burden of smoking 
prevalence, it is important to further explore their potential as smoking cessation aids.  
To date there is little evidence which helps understand the dynamic interplay of the 
factors and mechanisms which influence nicotine delivery positively or negatively and 
result in success at quitting smoking.  Although previous studies (Dawkins & Corcoran, 
2014; Dawkins, Kimber, Doig, Feyerabend, & Corcoran, 2016; Farsalinos et al., 2015) 
have documented the influence of puffing patterns and device characteristics on blood 
nicotine delivery (Farsalinos et al., 2014) and also suggest that puffing behaviours 
evolve over time (Hajek et al., 2017), how all these factors influence smoking cessation 
success has not been explored. 
Although e-cigarettes address both the pharmacological and the psycho-
behavioural aspects of smoking, for many smokers they are not as satisfying as 
smoking.  Forty-five percent are dual users whilst 65% of smokers who have tried have 
discontinued use. Of these, 25% reported that they do not feel like smoking and 20% 
reported they did not help reduce craving for tobacco cigarettes (ASH, 2017).  
Altogether, the need to monitor, report and ensure efficiency across all device types is 
warranted. 
Furthermore, as previously mentioned, there are key characteristics that are 
favourable to e-cigarette users (Baweja et al., 2016; Dawkins et al., 2015; McQueen et 
al., 2011; Yingst et al., 2015) and may help increase the appeal of these devices to 
existing smokers.  The following characteristics, customisability, the ability to adjust 
the voltage and wattage, (Baweja et al., 2016; McQueen et al., 2011), more satisfying 
hit, battery capabilities and the affordability to greater e-liquid choice (Baweja et al., 
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2016; Yingst et al., 2015) are associated with tank systems and are absent in cigalike 
models.  These factors are important as they may further the understanding of 
dissatisfaction and product discontinuation or the need to transition to other models 
(Yingst et al., 2015); this can be informative to smokers who are yet to transition away 
from smoking.   
There is increasing concerns that e-cigarettes may re-normalise smoking, 
preclude smoking cessation and reverse efforts made by tobacco control.  Indeed, due to 
their close similarity to combustible cigarettes, these worries could be more justified in 
the case of cigalikes.  Concerns that e-cigarettes may re-normalise smoking and act as a 
gateway to smoking have remained despite the evidence suggesting otherwise.  
Opponents fear that they may preclude smoking cessation and reverse tobacco control 
efforts.  Specifically given the close similarity of the cigalike model to combustible 
cigarettes, these concerns could be more justified.   
Although the evidence outlined above suggests that cigalikes may not be as 
effective in promoting cessation, they are clearly serving as an introductory product and 
facilitating the transitional phase to more advanced devices to subsequently increase the 
likelihood to quit.  Thus, this next study will explore how puffing behaviours and 
nicotine delivery in naïve e-cigarette users (that is, smokers who have no or very little 
experience in e-cigarette use) change over time (as a user becomes more experienced in 
vaping) and vary according to device type and nicotine concentration.  It will also 
explore satisfaction, craving and withdrawal symptoms alleviation, and other subjective 
effects. Study 3 (Chapter IV) will continue to follow up this cohort of smokers over a 6-
month period to explore factors associated with smoking cessation.  
Taking a more naturalistic approach (relative to Study 1; Chapter II), the aims of 
this current study are threefold, to explore:  i) how naïve users’ puffing behaviours a) 
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differ between devices (cigalike vs. tank), and b) change over time, c) differ according 
to nicotine concentration (high vs. low); ii) to explore smoking reduction over a two-
week period, and the effects of device type and nicotine concentrations on smoking 
reduction and, iii) to explore a) satisfaction, craving and withdrawal symptoms 
alleviation and product acceptability.   
A sample of 70 current smokers, willing to initiate a quit attempt were recruited.  
Participants were randomly allocated (using ‘IBM SPSS Statistics 22’ software) to 
either condition:  1) a cigalike, 2) a tank with low nicotine concentration (6 mg/mL; 
Tank 6), 3) a tank with high nicotine concentration (18 mg/mL; Tank 18). Participants 
were invited to attend 3 sessions: at baseline, week-1 and week-2.  They were given the 
e-cigarette to keep along with refill cartridges/bottles at baseline and week-1 and told to 
substitute as many cigarettes as possible with the e-cigarette.  Each participant was 
given a diary to record their daily e-cigarette use, cigarettes smoked per day (CPD) and 
subjective effects associated with the e-cigarette.  Socio-demographic data, craving and 
information on cigarette dependence were collected.  At the 2-week session participants 
were invited to keep the device and encouraged to continue use, substituting for as 
many cigarettes as they can in order to be followed up for Study 3.  
Aims and Hypotheses 
Aside higher nicotine concentrations, tank devices that allow power adjustment, 
have been found to be associated with more effective nicotine delivery compared to 
cigalikes (Farsalinos, Spyrou, Tsimopoulou, et al., 2014).  Thus it follows that the use 
of tank devices combined with higher nicotine concentrations will be more likely to 
promote levels of satisfaction close to that achieved under tobacco smoking and 
alleviate cigarette craving and withdrawal symptoms more effectively compared to 
cigalikes.   
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Hypothesis 1 (H1):  
Puff duration will increase overtime from baseline to Time 2 across all conditions 
evidencing an attempt to self-titrate.  
Hypothesis 2 (H2): 
Puffing topography will differ across conditions with a higher number of puffs, longer 
puff duration and shorter IPI in Tank 6 compared to Tank 18 and Cigalike in order to 
compensate for the lower nicotine concentration.  Tank 18 will be associated with few 
and shorter puffs and longer IPI.  
Hypothesis 3 (H3): 
CPD and Cigarette dependence will reduce overtime.  
Hypothesis 4 (H4): 
The Tank 18 will be associated with greater reduction in craving and withdrawal 
symptoms and greater levels of satisfaction and other positive effects.   
 
 
Methods  
 
Design 
The study received full ethical approval by the University ethics committee 
(UREC 1516-04_5th October 2015, see appendix 16).  A mixed-participants design with 
the between-subject factor (cigalikes, tank 18 and tank 6) and the within-subject factors 
of time: baseline, one-week and two-week period was used (Figure 3.1).  Participants 
were randomly allocated to one of the following conditions: 1) a cigarette-like model 
(referred to as cigalike thereafter) with a high nicotine concentration liquid housed in a 
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cartomiser, (18 mg/mL), each participant received a week supply of 15 cartridges; 2)  a 
tank model with a high nicotine concentration of 18 mg/mL, and a supply of 20 mL of 
liquid per week; 3)  a tank model with a low nicotine concentration (6 mg/ml), and a 
supply of 30 mL of liquid per week (see Figure 3.1).   
 
Participants 
Seventy (62.86% female) smokers (smoking 5 cigarettes or more per day for at 
least in the preceding year), not currently using an e-cigarette (i.e. have not used an e-
cigarette more than 5 times in the past) and willing to make a quit attempt, were 
recruited between December 2015 to December 2016.  Other inclusion criteria included 
aged 18 or over, fluent in English.  Exclusion criteria were pregnant or lactating 
females, any known neurobiological or heart conditions.  Participants were included 
regardless of their gender, ethnicity and SES (collected via questionnaires).  
Recruitment was conducted via advertisements on social media (Twitter and Facebook), 
leaflets distribution and posters on and outside the University of East London premises.  
 
Questionnaires / Measures: 
 
Puffing topography preliminary analysis 
As the devices used in this study did not have inbuilt puff counters, puffing 
topography (number of puffs, puff duration and IPI) was measured by video-recording 
at each session then using a frame by frame analysis of 29.97 fps (frame per second) to 
analyse timing measurements (using the ‘Adobe Premiere Pro CS5’ software).  Puff 
duration was demarcated as the time at which the e-cigarette was clearly placed in the 
mouth with both lips closed until the first frame capturing when the e-cigarette was 
removed from the mouth.  IPI was demarcated as the time frame when the e-cigarette 
was removed from the mouth until the time at which the e-cigarette was repositioned in 
 
 
150 
 
the mouth with both lips closed.  This method has high inter-rater-reliability as observed 
in the pilot study for Study 1.   
Measures: 
• CO measured before each ad libitum lab session to calculate smoking reduction 
from Baseline to Time 1 and Time 2. 
• Puffing topography (puff number, duration and IPI) at Baseline, Time 1 and 
Time 2 (1 and 2 weeks after first use; measured via video-recordings during the 
20-minute ad libitum puffing lab sessions). 
• CPD (Self-reported cigarette per day) at Baseline, Time 1 and 2 
• Volume consumed measured in mL 
• Baseline socio-demographic questionnaire (appendix 13). 
• Smoking history questionnaire (appendix 19) to collect information such as 
number of years of smoking, number of cigarette smoked per day, ever use of an 
e-cigarette.  
• A single item from the Motivation To Stop Scale  (MTSS) (Kotz, Brown, & 
West, 2013) to assess motivation to stop smoking, measured on a 7-point Likert 
scale.  It contains items such as “I don’t want to stop smoking” (coded as 1 the 
lowest possible score) and “I REALLY want to stop smoking and intend to in 
the next month” (coded as 7 the highest possible score) (appendix 19).  The 
highest score reflects ‘a strong desire and short term intention’ to initiate a quit 
attempt whilst the lowest reflects the absence of any desire or intention to do so. 
• A single item to measure self-confidence to be successful in a quit attempt 
(appendix 19). 
• The Fagerström Test for Cigarette Dependence (Fagerström, 2012) (appendix 
20). 
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• Craving reduction (urge to smoke) and Withdrawal symptoms relief at Baseline, 
Time 1 and 2.  These were measured via the Mood and Physical Symptoms 
Scale (MPSS) questionnaire (West & Hajek, 2004) (See Chapter II, p. for further 
details, appendix 7).  
• Subjective effects at Baseline, Time 1 and 2, positive such as satisfaction, hit 
and adverse effects rated on the VAS for positive and negative effects associated 
with nicotine use as described in Chapter II. Possible maximum scores are 100 
(see appendix 8).   
• A diary to record daily e-cigarette use, number of cigarettes smoked per day, 
craving and withdrawal symptoms related to tobacco cigarettes, other subjective 
effects associated with the use of nicotine (e.g. satisfaction, hit, pleasant, based 
on the VAS questionnaire (appendix 21).  These dimensions were collected and 
measured at Week 1 and 2. 
• Follow-up Interview questions for Study 3 (appendix 22)  
Equipment: 
A carbon Monoxide (CO) Bedfont piCO Smokerlyzer® was used to measure carbon 
monoxide.  ‘Salivette’ kits were procured through ABS Labs to measure salivary 
cotinine.  A Samsung video recorder was used to record each session.  The Totally 
wicked mini curve tank system e-cigarette by Totally Wicked was mounted with a 2 mL 
capacity tank which housed a standard atomiser of 1.8 ohm resistance; the kit contained 
a charger and a manual instructions.  Initially, the TECC ‘Go e-cigarette’ was used (N = 
11), however due to repeated issues of leakages, this model was replaced by the BLU 
cigalike model device (N = 13).  Participants in the two respective cigalike conditions 
were recorded and allocations were taken into account during data collection and entry.  
Repeated measures ANOVA revealed a statistically significant difference between the 
‘TECC’ and ‘Blu’ cigalikes in CO reduction over time (p = .027).  Whilst means 
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stagnated for the TECC cigalike model (M = 8.88, SD = 3.40 at baseline to M = 7.13, 
SD = 4.08 at 2-week follow up), those allocated the BLU cigalike device saw a decrease 
in CO from 21.25 at baseline (SD = 14.66) to 13.75 (SD = 12.06) at 2-week follow up. 
There were no further statistically significant difference for all the remaining measures.  
Thus primary analyses were conducted and presented with both cigalike models 
collapsed.  Both cigalike kits contained a user manual, battery (main body) and charger.  
Tobacco flavour ‘Go e-cig’ Refill cartridges 18 mg/mL nicotine concentration and refill 
bottles tobacco flavour ‘Totally Wicked Red Label’ 18 and 6 mg/mL nicotine 
concentration were provided to the participants in the cigalike, tank-high and tank-low 
condition respectively.  All e-cigarette products were purchased online between July 
2015 and October 2016.   
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Figure 3.1. Outline of Study 2 (yellow gradient boxes) and Study 3 (green gradient boxes)  
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Procedure 
Potential participants who responded to the advert via email or phone calls, were 
screened via phone interviews to ensure all inclusion criteria were met and an 
information sheet was provided via email.  Participants were invited to attend baseline 
and 1 and 2-week individual testing sessions.  Sessions followed a one hour abstinence 
period, so participants would not feel satiated before the start of the vaping session.  
Upon arrival, the researcher went through the information sheet (appendix 17) and 
ensured all aspects of the procedure were understood. Participants were asked to 
provide written informed consent (appendix 18), informed of their right to withdraw and 
invited to ask further questions.  Salivary cotinine and exhaled CO tests were 
administered before collecting baseline, socio-demographic data and information about 
their nicotine/cigarette dependence.  Participants were asked to place the test swab in 
their mouth for 5 minutes, then the fully saturated cotton swab was placed in a capped 
centrifugation tube and in an individually sealed plastic bag for storage in a -20oC 
freezer.  The MPSS was completed at the start and end of each session.  Participants 
were allocated a condition, given the e-cigarette with instructions on how to use it and 
to vape ad libitum for 20 minutes.  The entire vaping session was recorded.  At the end 
of the first session, participants completed the subjective effects questionnaires.  Lastly, 
participants were instructed to keep a record of their e-cigarette use and number of 
cigarettes smoked in the diary at the end of each day, given a supply of e-liquid bottles 
(20 mL) or cartridges (10 units) and asked to return all used and unused refills.  The 
session was repeated one then two weeks later.  At week-2 (Time 2), supply of e-
liquid/cartridges ceased.  Participants were asked to keep the device and encouraged to 
continue use; there was no other reward or motivational incentives.  Participants were 
asked for their consent to be contacted via phone calls for further follow-up phone 
interviews at one, three and six months in order to provide information regarding their 
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smoking status and e-cigarette use (see Chapter IV).  See Figure 3.2 for an outline of the 
procedure of each of the sessions.
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Figure 3.2 Diagram of Experimental procedure  
Baseline session
• > 1 hour abstinence 
• Salivary cotinine & CO
• Demographic data
• Smoking history & Motivation to 
quit (MTTS)
• Cigarette dependence (FTCD)
• Craving & WS pre vaping
• ECIG allocation
• 20 min ad lib vaping
• Craving & WS post vaping
• Subjective effects 
• Diary instructions
• Provision of e-liquid supply
2nd Session Time 1
• > 1 hour abstinence 
• CO
• Cigarette dependence (FTCD)
• Craving & WS pre vaping
• 20 min ad lib vaping
• Craving & WS post vaping
• Subjective effects 
• Diary instructions
• Provision of e-liquid supply
• Collection of Diary data
•Weekly CPD 
•Puff frequency
•Daily Subjective effects 
3rd Session Time 2
• > 1 hour abstinence
• CO
• Cigarette dependence (FTCD)
• Craving & WS pre-vaping
• 20 min ad lib vaping
• Craving & WS post vaping
• Subjective effects
• Collection of Diary data (see Time 
1)
• Debrief
• Email instructions on how to 
maintain ECIG equipment
• Follow-up instructions for Study 3
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Salivary cotinine analysis 
Salivary cotinine is an accurate method that is highly correlated with blood 
cotinine levels (and can be detected in low range) for measuring active exposure to 
nicotine (Abrams, Follick, Biener, Carey, & Hitti, 1987; Benowitz, 1996; Etter, Due, & 
Perneger, 2000). More importantly, compared to blood sampling, it is less invasive and 
presents less difficulty in terms of collecting body fluids from a large sample of 
individuals.  
All analyses were conducted by ABS labs and disposed of in accordance with 
the MHRA, GLP (Good Laboratory Practise) and GCP (Good Clinical Practise) 
accreditation protocols.  Samples were frozen (-20oC) and stored in UH006/7 at on site 
forensic laboratory. All samples were sent in appropriate containers to the Advanced 
Bioanalytical Service (ABS) Laboratories Ltd., Welwyn Garden City, UK, for the 
determination and quantitation of cotinine in saliva. All samples were disposed of in 
accordance with the MHRA, GLP (Good Laboratory Practise) and GCP (Good Clinical 
Practise) accreditation protocols. A certificate of destruction was issued and provided by 
ABS laboratories Ltd.  
 
Statistical analyses 
Changes in scores 
Variables were computed to calculate reduction from pre- to post-use for 
craving, withdrawal symptoms, and cigarette dependence (Fagerström Test for Cigarette 
Dependence) overall mean scores at each time point.  In instances where variables were 
not normally distributed, and assumptions were violated, non-parametric tests were used 
and medians, as opposed to means were reported.  The number of outliers to remove 
was too great in relation to the sample size distribution for each of the group.  Thus, 
where appropriate, variables were transformed using logarithm transformation to avoid 
affecting the size of the sample and minimise Type 1 error.  
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Unless otherwise specified, each variable was analysed using a mixed analysis 
of variance, with the between subjects factor as condition (Cigalike, Tank 18 and Tank 
6)  and the within-subjects factor of time (Baseline, Time 1 and Time 2).  Given e-
cigarette type is the variable of key interest, Pairwise comparisons for the main effect of 
condition is reported. Where a significant interaction effect was found, post hoc t-tests 
were conducted.   
 
Results  
Participants Characteristics  
Table 3.1 displays the baseline characteristics for the whole sample (N = 70).  Eleven of 
the initial 70 participants failed to attend the follow-up sessions and were therefore 
excluded from further analyses.  Reported reasons for drop out included health, 
conflicting commitments, one participant wished not to vape during a second session 
due to sore throat, 3 participants wished to discontinue use of the device due to adverse 
effects (including sore throat and elevated depressed mood), and one did so following 
negative stories read in an online newspaper.  Others wished to withdraw whilst 
consenting for their data not to be discarded, others gave no reasons. A flow diagram of 
participation is presented below (see Figure 3.3).   
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Figure 3.3 Flow chart of study completion.  Flow chart representing the total of participants 
attending Session 2 and 3 differ as some participants were unable to attend the 2nd session but 
attended the baseline and 3rd session, whilst others attended the baseline and 2nd session only. 
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Table 3.1 Participants characteristics       
 N % Mean SD Min Max 
Age (years) 70 - 29.47 9.19 18 60 
Gender 70 - - - - - 
  Male 26 37.1 - - - - 
  Female 44 62.9 - - - - 
Ethnicity 70 - - - - - 
 White/Caucasian 42 60 - - - - 
 Black Afro-Caribbean 8 11.4 - - - - 
 Mixed Race 4 5.7 - - - - 
 Asian (Indian/Pakistani/Bangladeshi) 4 5.7 - - - - 
 Nth/Sth East Asian (Chinese) 1 1.4 - - - - 
 Arab-Nth African 1 1.4 - - - - 
 Greek/Turkish/Cypriot/Kurd 2 2.9 - - - - 
 Other 8 11.4 - - - - 
Qualification 70 - - - - - 
 None 1 1.4 - - - - 
 GSCEs or equivalent 5 7.1 - - - - 
 Vocational qualification (BTECs) 8 11.4 - - - - 
 A-levels/O-levels or equivalent 24 34.3 - - - - 
 Undergraduate level (5 to 6) 22 31.4 - - - - 
 Postgraduate study (≥ level 7) 10 14.3 - - - - 
Occupational status  70 - - - - - 
 Employed 19 27.1 - - - - 
 Non-employed 1 1.4 - - - - 
 Self-employed 2 2.9 - - - - 
 Studying 48 68.9 - - - - 
Tried an ecig before 70 - - - - - 
 Never used it 32 45.7 - - - - 
 Fewer than 5 times 37 52.9 - - - - 
 More than 10 times 1 1.4 - - - - 
Type of ecig tried before 36 - - - - - 
 Cigalikes 17 24.28 - - - - 
 Later generations 13 18.57 - - - - 
 Both 6 8.57 - - - - 
Past quit attempts 70 - - - - - 
 Yes 60 85.7 - - - - 
 No 10 14.3 - - - - 
Numbers of quit attempts 70 - 2.41 2.07 0 10 
Baseline cotinine (ng/mL) 70 - 140.33 84.84 4.70 438.20 
Baseline CO (ppm) 70 - 14.89 9.60 2 42 
Cigarettes smoked per day (CPD) 70 - 12.83 6.50 4 35 
Smoking history (years) 70 - 12.31 9.16 2 44 
1 FTCD 70 - 4.23 2.37 0 9 
2 MTSS 70 - 4.76 1.53 2 7 
3 Confidence in successful quit 70 - 2.07 .97 0 4 
1 FTCD = Fagerström Test for Cigarette Dependence (score range: 0-10) 
2 MTSS = Motivation to Stop Scale (Kotz, Brown & West, 2013) (score range:1 – 7) 
3 Self-rated confidence in quitting (score range: 0 – 4) 
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Puffing topography 
 
Ad libitum laboratory sessions  
A mixed analysis of variance (ANOVA) was conducted to assess the variability 
between conditions and changes in puffing patterns across Baseline, Time 1 and 2.   
Data on the puff number and IPI variables were not normally distributed, and the 
assumptions of the analysis of variance were violated.  Thus, variables were 
transformed using logarithm to avoid affecting the size of the sample and minimise 
Type 1 error as the number of outliers to remove was too great in relation to the sample 
size distribution for each of the group.  All means (SD) for the puffing topography 
variables are displayed per conditions and session in Table 3.2.  
Puff number  
ANOVA revealed a significant main effect of condition F(2,47) = 8.48, p = 
.001, ƞ2 = .27; suggesting that the device type influenced participants’ puff numbers.   
Post Hoc tests (Least Significant Difference LSD) revealed that overall across all 3 
sessions, participants took a greater number of puffs in the Cigalike (M = 39.51, SD = 
20.93, 95% CI [31.90, 47.12]) compared to participants in the Tank 18 (M = 19.87, SD 
= 11.80, 95% CI [14.22, 25.56]) (p < .0001) and those in the Tank 6 condition (M = 
22.97, SD = 11.31, 95% CI [17.17, 28.76]) (p = .003).  There was no statistically 
significant difference between the Tank 18 and Tank 6 conditions (p = .28).   
There was a main effect of time, Wilks Lambda F(2,46) = 5.13, p = .010, ƞ2 = 
.18.  Across all conditions, puff number was greater at Baseline (M = 31.39, SE = 2.59, 
95% CI [26.18, 36.59]) compared to Time 1 (M = 26.07, SE = 2.08, 95% CI [21.89, 
30.26]) (p = .004) and Time 2 (M = 24.89, SE = 1.62, 95% CI [21.63, 28.15]) (p = .017).  
This suggests that participants puffing frequency changed over time at least in the acute 
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laboratory session.  However, puff number did not differ between Time 1 and 2 (p = 
.604).  There was no significant interaction effect between time and condition on puff 
number, Wilks lambda F(4,92) = 0.69, p = .59, ƞ2 = .03.   
Puff duration 
Mauchly’s test indicated that the assumption of sphericity had been violated for 
the main effect of time, χ2 (2) = 6.87, p = .032.  Therefore, Greenhouse-Geisser 
corrected values are reported and revealed a main effect of time F(1.76, 82.55) = 5.91, p 
= .006, ƞ2 = .11.  Post Hoc tests (LSD) revealed that across all conditions, participants’ 
puff duration increased from Baseline (M = 2.52, SD = 1.09, 95% CI [2.23, 2.88]) to 
Time 1 (M = 2.82, SD = 1.46, 95% CI [2.48, 3.34]) and to Time 2 (M = 2.88, SD = 1.39, 
95% CI [2.64, 3.41]).  These increases were statistically significant between Baseline 
and Time 1, and Baseline and Time 2 (p = .026 and p = .004 respectively) but not 
between Time 1 and 2 (p = .310).    
There was no main effect of condition F(2, 47) = 2.14, p = .129, ƞ2 = .083.  
Although, mean puff duration in Cigalike were greater (Estimated Marginal Means; M = 
3.36, SE = .35, 95% CI [2.66, 4.07]) compared with Tank 18 (M = 2.47, SE = .26, 95% 
CI [1.95, 3.00]) (p = .048).  Cigalike did not differ from Tank 6 (p = .117) and the latter 
did not differ from Tank 18 (p = .626).  There was no significant interaction effect 
between time and condition on puff duration, Wilks lambda F(4,92) = 1.82, p = .133, ƞ2 
= .073. 
IPI (Inter-puff intervals) 
Using logarithm transformation for the IPI variable, ANOVA revealed a 
significant main effect of time, Wilks Lambda F(2,46) = 6.172, p = .004, ƞ2 = .212.   IPI 
increased significantly from Baseline (M = .62, SD = .47, 95% CI [,]) to Time 1 (M = 
1.03, SD = 16.22, 95% CI [,]) (p < .001) then significantly decreased at Time 2 (M = 
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.72, SD = .50, 95% CI [,] (p = .027).  (Means (SD) with all 3 conditions collapsed).  
There was no statistically difference between Baseline and Time 2 on IPI (p = .166).  
There was a main effect of condition, F(2,47) = 10.68, p < .0001, ƞ2 = .31.  Post 
Hoc tests (LSD) revealed that across all 3 sessions, participants took shorter inter-puff 
intervals in the Cigalike (Estimated marginal means, M = .36, SE = .15, 95% CI [0.06, 
0.66]) compared to those in the Tank 18 (M = 1.03, SE = .11, 95% CI [.81, 1.26]) (p < 
.0001) and those in the Tank 6 condition (M = .79, SE = .11, 95% CI [.57, 1.02]) (p < 
.001).  There was no statistically significant difference between the Tank 18 and Tank 6 
conditions (p = .208).   
There was no significant interaction effect between time and condition on IPI, 
Wilks lambda F(4,92) = 0.66, p = .67, ƞ2 = .025.   
Table 3.2   
Means (SD) for Puff Number, Puff Duration and IPI per condition at baseline, Time 1 
and 2 
Session Condition Puff 
Number 
Mean 
SD Puff 
Duration 
Mean 
SD IPI  
Mean 
SD N 
Baseline Cigalike 46.09 27.53 2.77 1.07 .31 .18 11 
 Tank 18 23.80 16.79 2.40 1.03 .80 .57 20 
 Tank 6 24.26 9.72 2.49 1.20 .62 .37 19 
 Total 28.88 19.60 2.51 1.09 .62 .47 50 
Time 1 Cigalike 39.09 20.32 3.46 1.55 .40 .36 11 
 Tank 18 17.65 11.98 2.57 1.46 1.38 1.15 20 
 Tank 6 21.47 12.03 2.71 1.38 1.04 .84 19 
 Total 23.82 16.22 2.82 1.46 1.03 .97 50 
Time 2 Cigalike 33.36 14.94 3.86 1.53 .36 .30 11 
 Tank 18 18.15 6.64 2.45 1.25 .92 .55 20 
 Tank 6 23.16 12.18 2.77 1.22 .72 .45 19 
 Total 23.40 12.27 2.88 1.39 .72 .50 50 
 
 
Self-reported daily puff number at Week 1 and Week 2  
Changes in weekly mean puff numbers were calculated by first computing the 
variables for the total number of self-reported puffs per day into weekly averages at 
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Week 1 (Time 1/Session 2) and Week 2 (Time 2/Session 3).  Exploratory analysis 
including Q-Q plots and Kolmogorov-Smirnov revealed clear deviations from a normal 
distribution with outliers at Time 1 and unusual cases at Time 2.  Removal of outliers 
and transformations of data did not rectify the distribution, therefore non-parametric 
tests were conducted to explore changes in self-reported daily puffing patterns and 
differences between conditions.  Friedman’s ANOVA revealed no statistically 
significant changes in scores over time (p > .05), daily puff number averaged at Week 1 
(M = 41.07, SD = 38.04; Md = 33.50) and Week 2 (M = 43.29, SD = 43.04, Md = 
29.64).  Kruskal-Wallis tests indicated no statistically significant differences between 
conditions (p > .05).   
Effects on Smoking reduction  
 
Changes in cigarettes smoked per day (CPD) per condition 
Table 3.3 displays Means (SE) in CPD for all time points are displayed in Figure 
3.4.  Mauchly’s test indicated that the assumption of sphericity had been violated, 
therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of 
sphericity (ɛ = .67 for the main effect of time).  There was a main effect of time, F(1.35, 
52.49) = 66.39, p < .0001, ƞ2 =  .63, a large effect size suggesting that self-report CPD 
reduced over time.  Pairwise comparison (LSD) tests revealed that CPD reduced from 
Baseline M = 12.53, SE = 1.04, 95% CI [10.44, 14.63] to Time 1 M = 6.61, SE = .88, 
95% CI [4.83, 8.39] (p < .0001) and Time 2 M = 5.82, SE = .81, 95% CI [4.18, 7.46] (p 
= .033).  Differences were also statistically significant between Baseline and Time 2 p < 
.0001.   However, there was no main effect of condition F(2,39) = .754, p = .477, ƞ2 = 
.037.  There was a significant interaction effect between time and conditions, 
Greenhouse-Geisser F(2.69, 52.49) = 2.88, p = .05, ƞ2 =  .129.  Means (SE) of CPD 
reduction were greater in the Tank 6 compared M = 9.68, SE = 1.26, 95% CI [7.12, 
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12.23] to the Tank 18 M = 8.00, SE = 1.80, 95% CI [5.37, 10.64] and the Cigalike M = 
7.28, SE = 1.74, 95% CI [3.77, 10.79] (p = .033) (all p < .05).  At Time 1, there were 2 
self-reports of complete cessation (CO < 10 ppm verified) in the Tank 18, 1 in the Tank 
6 and none in the Cigalike condition, these remained consistent at Time 2.   
 
 
Figure 3.4. CPD per condition at Baseline, Time 1 and 2. 
 
Changes in Carbon monoxide levels (CO) per conditions  
Means (SD) per conditions and across all sessions are displayed in Table 3.3. A 
mixed ANOVA revealed a main effect of time.  Participants’ CO reduced steadily 
across all 3 sessions; from Baseline M = 14.86, SE = 1.37, 95% CI [12.11, 17.63] to 
Time 1 M = 11.45, SE = 1.32, 95% CI [8.79, 14.11] (p < .001) and Time 2 M = 10.44, 
SE = 1.17, 95% CI [8.10, 12.79] (p < .0001).  The reduction between Time 1 and 2 was 
not statistically significant, p = .226.  Wilks’ Lambda indicates a main effect of time 
F(2, 49) = 14.12, p < .0001, ƞ2 =  .366 suggesting that CO significantly reduced over 
time.  However, there was no main effect of condition F(2, 50) = .245, p = .783, ƞ2 =  
.010.  There was no significant interaction effect Wilks’ Lambda, F(4, 98) = .513, p = 
.726, ƞ2 = .021.   
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Table 3.3.   
Mean (SD) in CPD (cigarette per day) and CO (Carbon Monoxide) per 
conditions at Baseline, Time 1 and 2 
  CPD  CO 
Session Condition Mean SD          N Mean SD N 
Baseline Cigalike 9.67 4.03 9 13 10.15 12 
 Tank 18 13.41 5.25 16 15.90 9.58 21 
 Tank 6 14.53 8.21 17 15.70 9.50 20 
 Total 13.06 6.56 42 15.17 9.57 53 
Time 1 Cigalike 6.52 4.00 9 10.83 11.28 12 
 Tank 18 6.02 5.68 16 11.52 10.12 21 
 Tank 6 7.29 5.88 17 12.00 6.91 20 
 Total 6.64 5.36 42 11.55 9.16 53 
Time 2 Cigalike 5.65 3.72 9 9.33 7.81 12 
 Tank 18 4.59 5.30 16 10.10 9.13 21 
 Tank 6 7.21 5.39 17 11.90 7.47 20 
 Total 5.88 5.07 42 10.60 8.15 53 
 
Craving reduction 
All means (SD) are displayed in Table 3.4 and Means (SE) per condition are 
illustrated in Figure 3.5. Within each session, change scores were computed by 
subtracting craving scores post e-cigarette use from pre e-cigarette use (i.e. 1 hr 
abstinence scores). A series of one-way ANOVAs were conducted to assess craving 
reduction at each time point.   
Within-session craving reduction at each time point 
A One way ANOVA revealed a statistically significant difference in craving 
reduction from pre to post e-cigarette use at baseline [F(2, 63) = 3.05, p = .05] with a 
small effect size Cohen’s d = .01.  Post Hoc comparisons Tukey HSD tests suggest a 
statistically significant difference between Tank 18, M = 2.17, SD = 1.77 and Tank 6, M 
= .95, SD = 1.63, p = .043.  Cigalikes did not differ from either conditions, M = 1.60, 
SD = 1.43. There were no statistically significant differences in craving reduction at 
Time 1 [F(2, 51) = 0.571, p = .568, ƞ2 = .022], nor were there any statistically 
significant differences in craving reduction at Time 2 [F(2, 53) = 1.422, p = .250, ƞ2 = 
.051].   
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Craving reduction across all sessions  
Mauchly’s test indicated that the assumption of sphericity had been violated, 
therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of 
sphericity (ɛ = .89 for the main effect of time).  A mixed ANOVA revealed no main 
effect of time, F(1.77, 85.02) = 0.204, p = .790, ƞ2 =  .004 suggesting that craving 
reduction did not differ across all 3 sessions.  There was no main effect of condition 
F(2, 48) = 2.259, p = .115, ƞ2 = .086, although Pairwise comparisons (LSD) indicated 
that Means (SD) in Tank 18 was significantly greater, M = 2.17, SE = .28, 95% CI 
[1.61, 2.72] compared to Tank 6, M = 1.33, SE = .28, 95% CI [.76, 1.90] (p = .041).  
This difference was less pronounced and not statistically significant (p > .05) in 
comparison with the Cigalike condition M = 1.37, SE = .45, 95% CI [.92, 2.36].  There 
was no significant interaction between Time and Condition, Greenhouse-Geisser, 
F(3.54, 85.02) = .165, p = .942, ƞ2 = .007.   
Table 3.4.   
Mean (SD) Craving reduction in the lab (pre vs. post e-cigarette use) by condition at 
Baseline, Time 1 and 2 
 Conditions Means SD N 
Baseline Cigalike 1.42 1.68 12 
 Tank 18 2.20 1.88 20 
 Tank 6 1.21 1.78 19 
 Total 1.65 1.82 51 
Time 1 Cigalike 1.83 1.70 12 
 Tank 18 2.05 1.90 20 
 Tank 6 1.37 1.34 19 
 Total 11.55 9.16 51 
Time 2 Cigalike 1.67 1.37 12 
 Tank 18 2.25 1.86 20 
 Tank 6 1.42 1.39 19 
 Total 1.80 1.60 51 
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Figure 3.5. Mean (SE) in Craving reduction per condition at Baseline, Time 1 and 
2 (i.e. pre e-cig use score minus post e-cig use score).  
 
 
Withdrawal symptoms  
As for craving, change scores were computed by subtracting withdrawal scores 
post e-cigarette use from pre e-cigarette use (i.e. following 1 hr abstinence).    
Within-session withdrawal symptoms at each time point 
A One way between-groups analysis of variance revealed no statistically 
significant differences in overall withdrawal symptoms reduction at baseline [F(2, 67) = 
1.786, p = .176, ƞ2 =  .051], Time 1 [F(2, 51) = 1.414, p = .253, ƞ2 =  .053] or Time 2 
[F(2, 53) = 0.956, p = .391, ƞ2 =  .035].   
Withdrawal symptoms across all sessions 
Exploratory analysis including Q-Q plots and Kolmogorov-Smirnov indicated a 
non-normal distribution.  The assumptions of analysis of variance were violated even 
following the removal of outliers, therefore non-parametric tests were conducted.  
Friedman test revealed a statistically significant difference across time χ2 (2, n = 51) = 
19.348, p < .0001.  Medians increased from Md = -1.00 at Baseline to Md = 1.00 at 
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Time 1 and Md = 0 at Time 2, suggesting that regardless of the device type, withdrawal 
states following use of the e-cigarette improved with time.  Kruskal-Wallis revealed no 
statistically significant differences between conditions at Baseline χ2 (2, N = 70) = 4.92, 
p = .085, Time 1 χ2 (2, N = 54) = 2.36, p = .307 and Time 2 χ2 (2, N = 56) =.89, p = .640 
(see Table 3.5).   
Table 3.5  
Means (SE) Withdrawal symptoms across time with all conditions collapsed  
Time Means SD Md N 
Baseline -.60 2.31 -1.0 70 
Time 1 .89 2.38 1 54 
Time 2 1.04 2.69 0.0 56 
 
Changes in Cigarette dependence at all time points per condition 
Mauchly’s test indicated that the assumption of sphericity had been violated, 
therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of 
sphericity (ɛ = .85 for the main effect of time).  A mixed between-within analysis of 
variance revealed a main effect of Time, F(1.71, 83.71) = 13.72, p = .0001, ƞ2 =  .219, 
suggesting that cigarette dependence decreased over time.  Means (SD) decreased from 
Baseline M = 4.11, SE = .35, 95% CI [3.41, 4.80] to Time 1 M = 3.26, SE = .35, 95% CI 
[2.56, 3.96] (p < .0001) and Time 1 to Time 2 M = 2.83, SE = .34, 95% CI [2.16, 3.51] 
(p < .0001).  The decrease between Time 1 and 2 was not statistically significant (p = 
.089). 
There was no main effect of condition F(2, 49) = .66, p = .52, , ƞ2 = .026 or 
interaction between time and condition (p > .05).  
Effects on ‘time to first cigarette’  
Levene’s test revealed that the variance across groups were unequal at Time 2, 
therefore non-parametric Friedman test was conducted and revealed a statistically 
significant effect of Time χ2 (2, n = 52) = 21.432, p < .0001.   Means (SD) decreased 
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from Baseline M = 1.65, SD = .95, Md = 2.00 to Time 1 M = 1.33, SD = 1.06, Md = 
2.00 and Time 2 M = 1.17, SD = .99, Md = 1.00, suggesting that the latency of the first 
cigarette of the day delayed to a later time in the day.   
 
Subjective effects 
Positive effects following e-cigarette use in the lab  
Means (SD) for all positive effects are tabulated individually (Table 3.6, 
appendix 23).  Mixed ANOVAs were conducted for the overall mean scores on Hit and 
Satisfaction as per commonly reported in the literature (Cox et al., 2016; Dawkins et al., 
2016, 2015; Rose, Behm, et al., 1999; Yingst et al., 2015).   
For the overall scores on all positive effects collectively, there was a main effect 
of Time F(2, 94) = 10.159, p < .0001, ƞ2 =  .178.  Following e-cigarette use across all 3 
sessions, overall scores (all conditions collapsed) on positive effects reduced from M = 
47.27, SE = 2.28, 95% CI [42.69, 51.85] at Baseline to M = 42.01, SE = 2.12, 95% CI 
[37.75, 46.27] at Time 1 then to M = 38.20, SD = 2.55, 95% CI [33.08, 43.32] at Time 
2.  Post Hoc tests using Pairwise comparisons Least Significant Difference revealed a 
statistically significant difference between Baseline and Time 1 (p = .015), Baseline and 
Time 2 (p < .0001) and Time 1 and 2 (p = .043).  This suggests that overall scores on all 
positive effects altogether worsened across the 2 weeks post initiation of e-cigarette use.   
There was no main effect of Condition F(2, 47) = .981, p = .383, ƞ2 =  .040 but there 
was a significant interaction between Time and Condition F(4, 94) = 2.623, p = .040, ƞ2 
=  .100 which demonstrated that the decrease in positive effects was largely driven by 
the cigalike condition (illustrated in Figure 3.6).   There was no statistically significant 
main effect of Time or Conditions for each of the positive effects singly (all means are 
reported in Table 3.6; appendix 23).   
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Hit 
There was a main effect of time F(2, 94) = 4.134, p = .019, ƞ2 =  .081.  
Following e-cigarette use across all 3 sessions, overall Hit scores (all conditions 
collapsed) reduced from M = 58.11, SE = 3.65, 95% CI [50.76, 65.45] at Baseline to M 
= 50.53, SE = 3.01, 95% CI [44.47, 56.58] at Time 1 then to M = 49.18, SE = 3.50, 95% 
CI [42.15, 56.21] at Time 2.  Post Hoc tests revealed a statistically significant difference 
between Baseline and Time 1 (p = .048) and Baseline and Time 2 (p = .013).  There was 
no statistically significant difference between Time 1 and Time 2 (p = .630).  
There was no main effect of condition F(2, 47) = 1.938, p = .155, ƞ2 =  .076.  
There was no significant interaction between time and condition for the overall mean 
scores of positive effects F(2, 47) = 2.749, p = .074, ƞ2 =  .105.  This suggests that 
overall scores in Hit declined over time regardless of the device type used. 
Satisfaction 
Mauchly’s test indicated that the assumption of sphericity had been violated, 
therefore degrees of freedom were corrected using Greenhouse-Geisser estimates of 
sphericity (ɛ = .82 for the main effect of time).  There was a main effect of time F(1.64, 
77.25) = 6.24, p = .005, ƞ2 =  .117.  Following e-cigarette use across all 3 sessions, 
overall scores on Satisfaction (all conditions collapsed) reduced from M = 61.73, SD 
=17.38, 95% CI [55.42, 65.49] at Baseline to M = 56.29, SD = 18.58, 95% CI [49.23, 
59.60] at Time 1 then to M = 51.90, SD = 23.82, 95% CI [42.64, 55.22] at Time 2.  Post 
Hoc tests using multiple comparisons Least Significant Difference revealed a 
statistically significant difference between Baseline and Time 2 (p = .004) and Time 1 
and Time 2 (p = .033).  There was no statistically significant difference between 
Baseline and Time 1 (p = .074).  This suggests that satisfaction worsened overall across 
the 2 weeks post initiation of e-cigarette use. 
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There was a main effect of condition F(2,47) = 7.42, p = .002, ƞ2 = .240.  
Following e-cigarette use across all 3 sessions, overall scores on Satisfaction were 
greater in the Tank 18, M = 61.75, SE =3.06, 95% CI [55.60, 67.90] in comparison to 
Cigalikes M = 42.77, SE = 4.12, 95% CI [34.47, 51.06] and Tank 6, M = 59.29, SE = 
3.14, 95% CI [52.98, 65.60].  Post Hoc tests using multiple comparisons Least 
Significant Difference revealed that the differences were statistically significant 
between Tank 18 and Cigalikes (p < .001) and Cigalikes and Tank 6 (p = .003).  The 
difference between Tank 18 and Tank 6 was not statistically significant (p = .577).  
Together, the results suggest that satisfaction was greater following the use of the tank 
models compared to Cigalikes.  There was no significant interaction between time and 
condition for the overall mean scores of positive effects F(2, 47) = 1.60, p = .193, ƞ2 =  
.064. 
Figure 3.6. Means (SE) for overall scores on Positive effects per condition and 
Time  
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Self-report adverse effects 
All means (SD) are reported for overall adverse effects in the appendices (Table 
3.7, appendix 23).  Mauchly’s test indicated that the assumption of sphericity had been 
violated, therefore degrees of freedom were corrected using Greenhouse-Geisser 
estimates of sphericity (ɛ = .754 for the main effect of time).  A mixed ANOVA 
revealed no main effect of Time for the overall adverse effects, F(1.51, 70.92) = .875, p 
= .394, ƞ2 =  .018.  There was no main effect of condition F(2, 47) = .864, p = .428, ƞ2 =  
.035 and no significant interaction between Time and Condition F(3.02, 70.92) = .636, p 
= .595, ƞ2 =  .026. 
For each of the individual adverse effects, Mixed ANOVAs were also conducted 
and revealed no main effect of Time or Condition and no significant interaction (all ps 
>.05).   
 
Changes in subjective effects from Week 1 to Week 2 based on the diary data 
Weekly averages of daily subjective effects were computed for week 1 (from 
baseline to day 7) and week 2 (day 7 to day 14) by averaging daily scores in a weekly 
total for Week 1 then this was repeated for Week 2. 
Daily ratings of satisfaction 
Mixed between-within ANOVA was conducted to measure changes in 
subjective effects from Week 1 to Week 2 for satisfaction.  There was no main effect of 
Time F(1, 34) = .249, p = .621, ƞ2 =  .007.  There was a near significant effect of 
Condition F(2, 34) = 3.242, p = .051, ƞ2 =  .160.  Following e-cigarette use after a week, 
self-rated scores on satisfaction differed but failed to reach statistical significance 
between conditions.  Means were higher in Tank 18 M = 51.65, SE = 5.44, 95% CI 
[40.60, 62.70] compared to the Cigalikes M = 33.15, SE = 6.01, 95% CI [20.93, 45.37] 
(p = .029).  Equally, participants in the Tank 6 condition rated the device as more 
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satisfying M = 50.05, SE = 4.38, 95% CI [41.16, 58.94] compared to the Cigalikes (p = 
.029).   The difference between Tank 18 and Tank 6 was not statistically significant (p = 
.829) (see Figure 3.7).   There was no significant Time X Conditions interaction F(2, 
34) = 2.373, p = .108, ƞ2 = .122.   
 
Figure 3.7. Means (SE) in Daily ratings of Satisfaction per condition at Week 1 and 
2 
 
Daily ratings of hit 
A Mixed ANOVA on ‘hit’ ratings, indicated no main effect of Time F(1, 33) 
=.058, p = .812, ƞ2 =  .002,  no main effect of Condition F(2, 33) = 1.574, p = .222, ƞ2 =  
.087, nor  interaction F(2, 33) = 1.333, p = .277, ƞ2 =  .075.   
Daily ratings of ‘Reduced craving’  
A Mixed ANOVA revealed no main effect of Time F(1, 33) = .075, p = .786, ƞ2 
= .002.  There was no significant Time X Condition interaction F(2, 33) = .246, p = 
.783, ƞ2 = .015.  There was a main effect of Condition F(2, 33) = 3.369, p = .047, ƞ2 =  
.170.  Post Hoc Tests Multiple Comparisons revealed that following e-cigarette use after 
a week, self-rated scores on ‘reduced craving’ differed between conditions.  Scores in 
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Tank 18 were greater M = 49.19, SE = 6.04, 95% CI [36.91, 61.47] compared to the 
Cigalikes M = 27.30, SE = 6.36, 95% CI [14.36, 40.25] (p = .018).  Equally, participants 
in the Tank 6 condition rated the Tank device higher M = 43.36, SE = 4.63, 95% CI 
[33.94, 52.78] compared to the Cigalikes (p = .049).   The difference between Tank 18 
and Tank 6 was not statistically significant (p = .449).   Means (SE) are represented in 
Figure 3.8. 
 
Figure 3.8. Means (SE) daily ratings of ‘Reduced craving’ for cigarettes per 
condition at Week 1 and 2 
 
Daily ratings of pleasant 
Mixed ANOVA revealed no main effect of Time F(1, 34) =.037, p = .849, ƞ2 =  
.001, no main effect of Condition F(2, 34) = .833, p = .444, ƞ2 =  .047, nor interaction 
F(2, 34) = .809, p = .454, ƞ2 =  .045.   
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Discussion 
 
Summary of findings  
The aims of Study 2 were threefold to explore:  i) how e-cigarette naïve 
smokers’ puffing behaviours differ a) between device types (cigalike vs. tank), b) 
according to nicotine concentration (18 mg/mL vs. 6 mg/mL) and c) evolve over time; 
ii) the effects of device types and nicotine concentrations on a) smoking reduction and 
cigarette dependence, b) craving and withdrawal symptoms alleviation, and d) 
satisfaction and other subjective effects. 
Effects on Puffing topography  
As hypothesised, participants increased their puff duration one week after e-
cigarette initiation (Time 1); there was no further increase at Time 2.  Conversely, they 
decreased the number of puffs after a week of initial use.  As for puff duration, there 
was no further change at Time 2.  A greater number of puffs were observed in the 
Cigalike condition compared to both Tank 18 and Tank 6 which did not differ from 
each other.  Similarly puff duration was greater in the Cigalike condition compared to 
both the Tank 18 and Tank 6.  Thus, it could be argued that there was no effect of 
nicotine concentrations per se but an effect of device type since statistically significant 
differences emerged between the Cigalike and the Tank 18 and the Cigalike and the 
Tank 6 but not between Tank 6 and Tank 18.  That shorter IPI were observed in the 
cigalikes compared to both the Tank 18 and the Tank 6 reiterates the effect of device 
type and suggests that cigalikes are associated with a harder mechanism suction 
compared to the tank systems.  
Effects on smoking reduction 
 Cigarettes smoked per day (CPD) decreased over time regardless of the device 
type.  This was echoed in the CO results suggesting that regardless of the device type or 
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nicotine concentration, initiation of e-cigarette use contributed to a reduction in 
smoking.  
Effect on Cigarette dependence 
 Cigarette dependence decreased over time from Baseline to Time 1.  There was 
no further decrease at Time 2 and no differences between conditions.  Similarly to 
smoking reduction, regardless of the device type or nicotine concentration, the e-
cigarette contributed to a reduction in cigarette dependence.  Likewise, participants 
reported a longer time to their first cigarette of the day at Week 1 compared to baseline, 
this did not differ between conditions and there was no difference at Week 2.   
Effects on craving reduction and withdrawal symptoms 
 Craving reduction (i.e. pre minus post e-cig use) scores remained the same at 
Baseline, Time 1 and 2.  Participants in the Tank 18 reported greater levels of reduction 
compared to those in the Tank 6.  Interestingly, there was no difference between the 
Tank 18 and the Cigalike.  Given the Cigalike helped reduce craving equally, to the 
same magnitude than the Tank 18 and that the Tank 6 performed the poorest, it could be 
argued that there was an effect of nicotine concentration rather than an effect of device 
type.  Thus, for craving, higher nicotine concentrations seemed to be more effective 
although this assertion cannot be corroborated given that actual nicotine delivery was 
not measured.  Besides, daily self-report data are slightly divergent and seem to also 
suggest a device type effect.  Participants in the Tank 6 reported greater craving 
reduction compared to those in the Cigalikes who reported the lowest craving reduction.  
Consistent with the lab-based data, participants using the Tank 18 reported greater 
craving reduction, which reiterates the superiority of the tank systems.   In relation to 
withdrawal symptoms, although the magnitude of the reduction improved over time, 
this did not depend on device type.   
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Effect on subjective effects  
Overall subjective effect scores decreased from Baseline to Time 1 and Baseline 
to Time 2 with no significant changes between Time 1 and 2, which indicates a short 
term effect following a week of e-cigarette use.  There was a significant interaction 
between time and conditions, whilst overall scores on positive effects remained fairly 
constant for the Tank 18, showing a marginal decrease at Time 1 then an increase at 
Time 2, scores for the Tank 6 and Cigalikes decreased considerably from Baseline to 
Time 2, this was more pronounced in the Cigalike condition. 
Contrary to expectation, ratings of hit and satisfaction decreased over time but 
this seemed to be largely due to the cigalike condition and, to a lesser extent the Tanks.  
In relation to Hit, scores were greater at Baseline compared to Time 1 but no further 
significant reduction at Time 2.  There were no differences between conditions.  
Similarly, for Satisfaction, following the ad lib vaping session in the lab, participants 
rated the e-cigarette higher at Baseline than they did at Time 2, there was no significant 
changes between Baseline and Time 1.   Tank 18 and Tank 6 were associated with 
greater scores on Satisfaction compared to Cigalikes, suggesting that tank systems are 
preferred in terms of satisfaction.  Consistent with the acute condition in the ad libitum 
lab session, data from diaries indicated that Tank 18 and Tank 6 were associated with 
greater scores on Satisfaction compared to the Cigalikes.   
For the overall adverse effects, there was no changes over time or differences 
between conditions.  Amongst all adverse effects, throat irritation was the most 
exacerbated symptom in each condition.  This is consistent with other reports that throat 
and mouth irritation are the most commonly reported adverse effects associated with e-
cigarette use (Dawkins & Corcoran, 2014; Dawkins et al., 2013).  
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E-cigarette type, Nicotine Concentrations and Practise Effects on Puffing Topography 
Puff duration 
Mean puff duration at initial use (M = 2.52 s, SD = 1.09) are in good agreement 
with previous findings (Behar et al., 2015; Farsalinos, Spyrou, et al., 2014; Lee et al., 
2015; Talih et al., 2014).   
Herein, participants in the Cigalike condition took longer puffs compared to 
both those using the Tank 6 and Tank 18, which is suggestive of a device type effect as 
opposed to a nicotine concentration effect.  Against expectations and in contrast to the 
findings in study 1, there was no significant difference between Tank 18 and Tank 6 
suggesting some degree of homogeneity in the puffing topography of participants in the 
two Tank conditions compared with the cigalike.  Nevertheless, that mean puff numbers 
and puff duration were higher in the Tank 6 in comparison with the Tank 18, but failed 
to reach statistical significance, suggest that the findings do not depart significantly 
from that of previous studies.  In previous research lower nicotine concentrations 
(Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013a) and shorter puff 
duration were found to be associated with poorer nicotine delivery (Farsalinos, Spyrou, 
Tsimopoulou, et al., 2015; Hajek, Przulj, Phillips, Anderson, McRobbie, 2017; Hiler, 
2016b).   Furthermore evidence from the nicotine titration literature also suggests the 
importance of dosage in compensatory smoking and higher nicotine concentrations as 
exerting a stronger influence on puffing topography (McMorrow & Foxx, 1983).   
Akin to the large standard deviations found between conditions the current 
findings echo the inter-variations in e-cigarette puffing topography reminiscent of those 
seen in previous studies (Behar et al., 2015; Hajek et al., 2015) including in Study 1, but 
also in smoking behaviours (Hammond et al., 2005).   Importantly, these large 
individual variations may provide some explanation for the non-statistically significant 
differences between the Tank 6 and Tank 18. 
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The findings that cigalikes were associated with greater puff duration but lower 
satisfaction provide new evidence for the literature and align with previous findings that 
cigalikes tend to be associated with a less efficient nicotine delivery compared to tank 
systems (Farsalinos, Spyrou, Tsimopoulou, Stefopoulos, Romagna, & Voudris, 2014; 
Rüther et al., 2017).   Consistent with the current study, in Rüther et al. (2017)’s study, a 
tank model successfully reduced craving to the same magnitude, as did the smoking of 
the combustible cigarette which reiterates tank models’ efficiency compared to 
cigalikes.  The fact that participants in the cigalike condition displayed greater puff 
duration may possibly be due to their stronger suction mechanism and differing airflow-
activated system compared to tanks (Williams, Ghai, & Talbot, 2015) which 
unavoidably will constrain the nicotine e-liquid delivery and affect sensory factors.    
Consistent with previous studies, participants increased their puff duration after 
a week following initial use from 2.52 s to 2.82 s then plateaued at Time 2 to an average 
of 2.88 s.  This increase in puff duration is suggestive of an adjustment in puffing 
topography by naïve users over time which corroborates the self-titration theory at least 
in the short term, in so far as the shorter puffs exerted at initial use may not have yielded 
satisfactory blood levels.  This increase in puff duration is a key finding specifically as 
puff duration along with IPI have been reported as the most influential drivers of 
aerosol yield (Kośmider, Madej, Gawron, & Sobczak, 2016).   Indeed, a week seems to 
be sufficient to observe an evolution in puffing topography and for e-cigarette naïve 
smokers to develop an awareness for the need to adjust their puffing from smoking to e-
cigarette use.   This is consistent with previous findings in which a sample of 20 
smokers who were introduced to a 18 mg/mL cigalike increased their puff duration from 
2.2 s (0.1) to 3.1 s (0.3) after a week of initial use (Lee et al., 2015).   
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Although puff duration increased at Time 1, this increase remained unchanged at 
Time 2 to an average of 2.88 s.  This mean puff duration is comparable to means reported 
in experiments which employed directed puffing protocols using naïve users and 18 
mg/mL nicotine concentrations (M = 2.85, SD = 1.49) though negligible compared to the 
commonly reported 4s puff duration seen in experienced users (Spindle et al., 2015) 
outside of the laboratory (Hua et al., 2011).   It would be reasonable to posit that should 
the current study extend to a longer period, more practise could have resulted in longer 
puff duration to match the puffing seen in real world behaviours by experienced users.  
Indeed, it has been reported that 4 weeks of practise using a 24 mg/mL cigalike resulted 
in significant blood nicotine increase which is a good indication that this period is amply 
sufficient for a successful adjustment in puffing topography (Hajek, et al., 2015).  The 
increase in puff duration over one week period found here is echoed in previous studies 
(Lee et al., 2015).   
The increase in puff duration herein is in line with the early suggestion that there 
is a learning process required for an effective use of e-cigarettes (McQueen, Tower & 
Summer, 2011).   Similarly, others have found that the efficiency of obtaining 
satisfactory blood nicotine levels depends upon the way the e-cigarette is used and is 
likely to improve with practise (Hajek et al., 2015).   Studies suggest that e-cigarette 
naïve smokers are less able to obtain systemic raised blood nicotine levels, unlike 
experienced users (Farsalinos, Spyrou, Stefopoulos, et al., 2015; Fearon et al., 2017).  
This is largely due to their typical shorter puff duration compared to experienced users 
at initial use (Farsalinos, Romagna, Tsiapras, Kyrzopoulos & Voudris, 2013).  That  
shorter puff duration tend to be associated with poorer nicotine delivery profile is 
evidenced in previous studies (Talih et al., 2015) in which lower plasma nicotine 
concentrations were found in e-cigarette naïve smokers who displayed lower puff 
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duration of 2.3 s compared to experienced users who displayed a mean puff duration of 
3.5 s (Farsalinos, Spyrou, Tsimopoulou, et al., 2015).    
IPI 
Other changes in puffing behaviour over time were the increase in IPI from 
Baseline to Time 1 and plateaued at Time 2.  In line with the longer puff duration in the 
Cigalike, IPI were greater in the Tank 18 compared to the latter; and although this was 
not statistically significant, mean scores were greater in Tank 18 compared to the Tank 
6.   This suggests that the participants in the higher nicotine concentrations condition in 
the tank exerted a longer pause between puffs, which coincides with the literature 
suggesting that nicotine concentrations relate directly to nicotine delivery (Lopez et al., 
2016) and to a great extent dictate puffing topography.  Likewise, the puffing 
topography derived from the cigalikes reiterates the proposition of a more erratic or 
intense puffing profile associated in the cigalikes compared to the tank systems and 
supports the aforementioned proposition of the interwoven relationship between 
nicotine delivery and puffing topography.   
Puff number 
Of particular interest, in the current study, was a significant decrease in the 
number of puffs over the two-week period which, combined with a significant increase 
in puff duration, strongly suggest a dramatic change in puffing behaviour characterised 
by a shift to slower, longer more paced puffs from a more erratic puffing style at initial 
use.  Like in the case of puff duration, there was no difference between Time 1 and 2 
suggesting a plateau effect after a week following initial use.  There was no difference 
between conditions, the importance of this finding may however be less relevant since 
some reports suggest that puff numbers have no or little effect on nicotine delivery 
(Kośmider et al., 2016; Spindle, 2015).   
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In the current study, participants took an average of 39.51 puffs in the cigalike 
condition across the 3 sessions together.  This is in good agreement with a previous 
study in which 20 experienced e-cigarette users took an average of more than 20 puffs 
in a 10-minute ad lib session (Behar et al., 2015) which, compares well with the mean 
of 39.51 in the 20-minute session in the current study.  Indeed, the likening of this 
observed adjustment in puffing topography to an attempt to compensate for the less 
efficient nicotine delivery compared to tobacco cigarettes is further evidenced in a 
previous study in which 50 puffs from a 24 mg/mL containing cigalike were required to 
raise blood nicotine to levels analogous of those obtained after the smoking of one 
combustible cigarette (which consisted of approximately 10 puffs) (Yan & D’Ruiz, 
2015).   That cigalikes are associated with poorer nicotine delivery is also documented 
in pharmacokinetic studies in which modest increases in plasma nicotine were obtained 
in naïve users’ and experienced users in relation to combustibles (Fearon et al., 2017).  
It can be posited that the greater number of puffs exerted in e-cigarettes compared to 
when smoking a single cigarette may be caused by a stronger suction mechanism and/or 
the need to generate sufficient heat to the heating element of the atomiser.   Further 
differences can also be seen in puffing topography between e-cigarette naïve smokers 
and the smoking of a cigarette (M = 2.3, SD = 0.5 s Vs M = 2.1, SD = 0.4 s) versus e-
cigarette users’ puffing topography (M = 4.2, SD = 0.7 s) (Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos & Voudris, 2013).    
Effects on Smoking Reduction and Cigarette Dependence  
Effects on smoking behaviour  
Self-reported CPD significantly reduced over time from Baseline to week 2.  
Similarly, there was a significant reduction in measured CO one week after initial use 
and a further decrease 2 weeks later, albeit to a lesser extent,  
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The current findings add to the literature which suggests that e-cigarettes can be 
an effective aid to support reducing smoking for those who do not intend to quit or are 
unable to do so.  .  The question addressed herein of whether e-cigarettes promote 
smoking reduction is pertinent and as such has been extensively researched in the past 
(Glasser et al., 2016).    
In the current study, both e-cigarette types, the 6 and 18 mg/mL nicotine 
concentrations led to a reduction in smoking.  Although it is worth noting that there was 
differential drop out across conditions with 20.8% drop out rate in the cigalike 
compared to 13% respectively in both the Tank 6 and 18.  The greater drop-out rate in 
the cigalike compared to the tanks conditions may suggest that those in the Cigalikes 
who successfully maintained use of the device and reduced their CPD may have had 
greater motivation to do so compared to those who dropped out.   
The reduction in smoking found overall, is consistent with previous findings.  In 
a 2 part 8-month RCT, 48 smokers unwilling to quit who received a 2nd generation e-
cigarette achieved a reduction in CO and CPD from the baseline to 4 weeks whilst an 
increase was observed in the control group. Salivary cotinine levels in e-cigarette users 
showed an initial decrease but then increased by 32 weeks.  Similarly, in an 8-month 
pilot study, 34 smokers unwilling to quit received medical assistance training on correct 
use of a cigalike e-cigarette.  At each follow-up session (1, 4 and 8-month) cotinine 
levels remained unchanged whilst CO and CPD reduced significantly.  Although these 
two studies have no account of puffing topography, one of the mechanisms by which 
cotinine levels remained stable despite the drop in CO, may have been through an 
adjustment in puffing.  This provides further evidence for the titration theory and 
accords with empirical evidence that more intensive use typically achieve greater 
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smoking reduction (Biener & Hargraves, 2015; Biener, Hargraves, & Hargraves, 2015; 
Brose et al., 2015; Hitchman et al., 2015; Manzoli et al., 2015). 
Effects on Cigarette dependence 
By virtue of its reinforcing properties from which dosage, mode (i.e. inhalation) 
and speed of delivery are key determinants of its dependence liability (Benowitz, 
1990b; Benowitz, 2010), it is anticipated that nicotine delivered via e-cigarettes will 
have the potential to reduce cigarette dependence by acting as substitutes to combustible 
cigarettes.   
In a similar fashion to smoking, in the current study, cigarette dependence 
reduced (as measured by the FTCD) from baseline to after a week after e-cigarette use 
initiation; a further, although less pronounced decrease was observed from week 1 to 
week 2.  Surprisingly, the decrease did not differ between conditions. Similarly, 
regardless of the device type or nicotine concentration, at the second session, 
participants’ habitual first cigarette of the day was reported to be smoked at a later time 
compared to the time reported in the baseline session.  
The reduction in cigarette dependence corroborates with the reduction in 
smoking and suggest that e-cigarettes were well accepted and offered an effective 
coping mechanism at least at the initiation stage; whether participants were able to 
maintain this reduction in cigarette dependence will be explored in the following 
chapter.  These findings align well with previous findings.  In a 26-day mixed study, 
dual users and smokers were instructed to reduce their smoking by 75% before 
instructions to abstain completely from smoking for 3 days with 2 ad libitum vaping 
weeks in between each condition (Jorenby, Smith, Fiore, & Baker, 2017).  In the 
smoking restriction period, dual users were more likely to sustain abstinence compared 
to smokers and did so by increasing their e-cigarette use 4-fold; this suggests that e-
cigarettes were used as a coping mechanism and avoid nicotine deprivation.  
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Interestingly, cigarette dependence was rated lower by dual users in comparison to 
smokers.  This concurs with the view that e-cigarettes may help reduce cigarette 
dependence.    
The lack of difference between device types in the current study is in sharp 
contrast with the existing literature suggesting the difference in nicotine delivery 
between device types.  Indeed, given the relationship between optimal nicotine delivery 
and dependence potential, one would expect a greater reduction in cigarette dependence 
in the Tank 18 group over the Tank 6 and Cigalikes groups.  Many studies have 
associated cigalikes with modest nicotine delivery (Bullen et al., 2010; Farsalinos, 
Spyrou, et al., 2014; Rüther et al., 2017; Vansickel et al., 2010) and significantly lower 
dependence potential in comparison to tank systems, even when used with nicotine 
concentrations deemed sufficient to raise blood nicotine levels and induce satisfaction 
(Foulds et al., 2015).  In one study, mean nicotine plasma concentration of 20 
participants using 3 different cigalike models and a tank model on 4 separate occasions 
were compared against those of tobacco smokers (Rüther et al., 2017).  Mean plasma 
nicotine concentrations within the first five minutes increased significantly following 
use of the tank compared to the cigalikes which led to modest increases; suggesting the 
ability of tanks to induce dependence certainly over cigalikes.   
Although e-cigarette users’ vaping patterns are as frequent as their cigarette 
consumption (Foulds et al., 2015), e-cigarette users are less dependent on their devices 
in comparison to their tobacco cigarettes as smokers (Etter & Eissenberg, 2015; 
Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013b; Foulds et al., 2015; 
Liu, Wasserman, Kong, & Foulds, 2017).  Given that e-cigarettes are associated with 
considerable reduced harm compared to smoking, it is reasonable to posit that the 
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benefits far outweigh existing concerns that e-cigarettes serve to maintain dependence 
and encourage continued use of an addictive substance (Rüther et al., 2017).   
Notwithstanding the importance of nicotine, the current findings suggest that 
other non-nicotine factors may also be important in cigarette dependence (e.g. the look, 
tactile components, taste, feeling of smoke in the throat), secondary factors which have 
become closely associated with the primary reinforcer, nicotine.  That use of a cigalike 
was associated with a comparable reduction in CPD compared with the tank devices 
suggests that some of these non-nicotine aspects of dependence may have been 
transferred to the e-cigarette (this is also supported by the lab-based data on craving 
discussed thereafter).  These factors however, may become less important over a more 
protracted period of abstinence wherein nicotine delivery becomes more important.  
This will be explored further in the next chapter.   
Effects on Craving reduction, withdrawal symptoms alleviation  
The inability of the e-cigarette to deal with craving was given as the one of the 
chief reasons for discontinued use, therefore greater emphasis must be put on educating 
smokers how to use their devices to obtain craving relief for tobacco.  That nicotine 
intake has a direct and linear effect on craving reduction has been suggested in previous 
clinical studies which found IPI to be inversely related to serum nicotine and cotinine 
levels as well as craving scores (Williams et al., 2011); this is suggestive of the 
influence of puffing topography and nicotine delivery over craving reduction.  
Following the ad lib vaping baseline session, craving reduction scores were greater in 
the Tank 18 compared to the Tank 6, differences between the Cigalikes did not differ 
from Tank 18 or Tank 6.  Across all 3 sessions and consistent with the baseline session, 
participants in the Tank 18 tended to report greater craving reduction than those in the 
Tank 6 but Cigalikes did not differ from Tank 18 or Tank 6, which is suggestive of a 
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nicotine concentration rather than a device type effect and that higher nicotine 
concentrations were more effective at reducing craving.   
Many studies have suggested that e-cigarettes can be effective at alleviating 
craving and withdrawal symptoms related to smoking (Bullen et al., 2010; Dawkins & 
Corcoran, 2014; Dawkins et al., 2015; Dawkins, Turner, & Crowe, 2013; Dawkins et 
al., 2012; Etter, 2015; Foulds et al., 2015; Lechner, Meier, et al., 2015; Spindle et al., 
2015; Vansickel, Weaver, & Eissenberg, 2012; Vansickel et al., 2010).  The nicotine 
concentration effect in craving scores is in line with previous studies which suggest that 
greater craving reduction is associated with higher nicotine concentrations (Etter, 2015).   
In an early study, a first generation cigalike model filled with 16 mg/mL was compared 
to a combustible cigarette, an inhalator and a placebo cigalike, the 16 mg/mL cigalike 
was found to be the second most effective at reducing craving after the combustible 
cigarette (Bullen et al., 2010) suggesting nicotine as more rewarding compared to 
placebo.  That said, because a delayed effect on craving reduction was observed (only 
10 mins following the last puff), the authors conjectured that changes in craving were 
not contingent upon nicotine absorption, rather sensory and tactile cues or an 
anticipation of the nicotine delivery may be have contributed to the decrease (Bullen et 
al., 2010).  Conversely, the remarkable findings that Cigalikes did not differ from Tank 
18 are inconsistent with previous studies which found that newer devices (K E 
Farsalinos, Spyrou, et al., 2014) and higher nicotine concentrations are more effective at 
reducing craving than cigalikes, and are capable of inducing greater satisfaction and 
nicotine dependence (Foulds et al., 2015).   However, others found that cigalikes 
equally reduced craving in e-cigarette naïve smokers to the same magnitude as did a 
second penlike generation over the short term and concluded that the visual similarities 
to a cigarette may have been partly responsible (Dawkins, Kimber, Puwanesarasa, & 
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Soar, 2015).  The latter results may have differed should the cigalike been compared to 
a third, as opposed to a second generation device, since these models use less powerful 
and smaller batteries.  However, it is unclear if, and to what extent, frequency of use had 
an impact on craving reduction.   That the lower nicotine concentration condition was 
associated with lower scores on craving agrees well with previous studies, which found 
that nicotine-containing e-cigarettes elicit greater levels of craving reduction compared 
to placebo e-cigarettes (Dawkins, Turner, Hasna, & Soar, 2012), although placebo e-
cigarettes have shown to reduce craving in smokers who were told they contained 
nicotine (Copp, Collins, Dar, & Barrett, 2015); thus since the experiment was not blind, 
whether knowledge of the nicotine concentrations administered influenced responses is 
unclear.    
Furthermore, although unexpected, that different device types did not give rise 
to varying craving reduction scores ought not to be so surprising.  In fact, 
pharmacokinetic studies suggest that nicotine delivery does not always dictate craving 
scores (D’Ruiz et al., 2015).  In 2 sessions, 24 participants were randomised to 5 e-
cigarettes with varying e-liquid formulation (16 and 24 mg/mL and differing PG/VG 
ratio) and a combustible cigarette; plasma nicotine levels and craving (urge to smoke) 
were measured during a 30-min standardised protocol (50 puffs, 30 s IPI) followed by a 
1 h ad lib use of the e-cigarettes.  Strikingly, following completion of both sessions, the 
differences in nicotine exposure (23 to 53% greater from the tobacco cigarette compared 
to the e-cigarettes) and means nicotine plasma concentrations were not reflective of the 
homogeneity observed in craving reduction scores (10% greater in the tobacco cigarette 
in relation to the e-cigarettes following the ad lib period) (D’Ruiz et al., 2015).  Given 
the differences in nicotine exposure, one would expect the differences in craving to be 
of magnitude greater than the values observed.   Thus, although nicotine concentrations 
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influenced plasma nicotine concentrations, craving did not seem to be impacted to the 
same extent.  Thus, it is reasonable to conclude that although an important determinant 
of smoking behaviours, craving does not always correlate with nicotine delivery and 
sensorimotor factors may also be important at least in the early stages of a quit or 
smoking reduction attempt.   
 Following use of the e-cigarette in the current study, withdrawal symptoms 
ameliorated across the 2 weeks post initiation of use, there was an increase in alleviation 
at week 1 and further increase at week 2.  Unlike craving, withdrawal symptoms scores 
did not differ across conditions.  This is divergent from the suggestion that e-cigarette 
types vary in their ability to attenuate withdrawal symptoms.  For example, a cross-over 
study of 22 smokers who were instructed to use a 16 mg/mL nicotine containing 
cigalike and second generation e-cigarette (with the same nicotine concentrations) on 
separate days, found that the latter was more effective at reducing withdrawal symptoms 
compared to the former (Lechner, Meier, et al., 2015).  Based on the diary data, 
following use of the e-cigarette, withdrawal symptoms ameliorated across the 2 weeks 
post initiation of use, there was an increase in alleviation at week 1 and further increase 
at week 2.  Unlike craving, withdrawal symptoms scores did not differ across 
conditions. 
 The steady increase in withdrawal relief reflects the changes in puffing 
topography, and may be synonymous of an increment in learning to use the e-cigarette 
more effectively.  These findings add to the current literature which suggests that e-
cigarettes are capable of alleviating withdrawal symptoms not only in acute conditions 
in clinical lab-based studies (Dawkins & Corcoran, 2014; Farsalinos, Spyrou, 
Tsimopoulou, et al., 2015; Nides et al., 2014) but also in real word conditions following 
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a period in which users have had the opportunity to accustom themselves with the 
device.   
Additionally, the importance of withdrawal symptoms for these findings is also 
implied in previous studies which have found that withdrawal symptoms can be a strong 
predictor of a quit attempt (West, Hajek, & Belcher, 1989).  Furthermore, although the 
presence of nicotine dictates greater craving reduction, there is substantial empirical 
evidence to suggest that similarly to smoking, conditional cues such as ‘throat hit’ 
(Dautzenberg, Scheck, Garelik, Kayal, & Dominique, 2016), handling, olfactory and 
visual cues may hold some key role in alleviating craving and withdrawal symptoms 
(Van Heel, Van Gucht, Vanbrabant, & Baeyens, 2017). 
Effects on Subjective effects 
As suggested in Chapter 1, the dosage and rapidity of nicotine are highly 
important for smokers’ satisfaction and craving reduction.  Sensory effects are also an 
important aspect of smoking behaviours (Carpenter et al., 2007; Rose et al., 2000, 2010) 
thus are likely to influence e-cigarette product acceptability.  
Surprisingly, scores on Hit reduced from baseline to week 1 and was followed 
by a plateau at week 2 and there was no significant difference between conditions.   
Similarly, participants rated the e-cigarette as more satisfying following the baseline ad 
lib vaping session than they did a week and 2 weeks later after initiation of use.  Tank 
18 and Tank 6 were rated as more satisfying compared to cigalikes, suggesting that tank 
systems are preferred in terms of satisfaction.  Scores on the overall scale of all positive 
effects together decreased from Baseline to week 1, and Baseline to week 2.  The lack 
of significant changes between the first and the second week indicates a short-term 
effect at Time 1.  Whilst overall scores on positive effects remained fairly constant for 
the Tank 18, showing a marginal decrease at week 1 then an increase at week 2, scores 
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for the Tank 6 and Cigalikes decreased considerably from Baseline to Time 2, this was 
more pronounced in the Cigalike condition.  There were no changes over time in the 
overall adverse effect scores and no significant differences between conditions.  
Amongst all adverse effects, throat irritation was the most exacerbated symptom in each 
condition.   
Several studies have documented the ability of e-cigarettes to elicit positive 
subjective effects (Bullen et al., 2010; Spindle et al., 2015; Vansickel et al., 2012; 
Vansickel et al., 2010; Vansickel & Eissenberg, 2013), however not to the same extent 
than tobacco cigarettes (Martínez-Sánchez et al., 2014; Norton, June, & O’Connor, 
2014); whilst others report differences in their ability to induce satisfaction and other 
positive effects between device types (Dawkins et al., 2015; Farsalinos, Spyrou, et al., 
2014).   For example, Farsalinos’ group employed a VAS questionnaire to compared 
subjective effects elicited following the use of a cigalike versus a tank system e-
cigarette and found the latter to be more satisfying than the former (Farsalinos, Spyrou, 
et al., 2014) which corroborates the current findings.  Of particular interest to this thesis, 
means in nicotine plasma levels mirrored findings of satisfaction.  That greater 
satisfaction and higher nicotine plasma levels were both linked to the tank device, evoke 
a strong correlation between nicotine delivery and satisfaction whilst supporting the 
titration theory.  Likewise, use of the tank induced greater ‘throat hit’ compared to the 
cigalikes.  In the same light, previous findings identified an individualistic and optimal 
throat hit (which differs from the rewarding nicotine bolus referred to previously) that is 
contingent upon e-liquid nicotine concentrations as well as the power applied to the 
coil, which in turn, all influence the desire to switch to e-cigarettes in smokers 
(Dautzenberg et al., 2016).  This confirms that nicotine concentration is an important 
determinant and reinforces previous recommendations that higher nicotine 
 
 
193 
 
concentrations may be more advisable (Dawkins et al., 2016) at least during initiation of 
use (Farsalinos, Romagna, & Voudris, 2015).   
Limitations  
The current study must be considered in the light of the following limitations. 
Unlike pharmacokinetic studies which by design, use standardised puffing protocol, the 
current study employed an ad libitum puffing paradigm in order to capture adjustments 
in puffing during initiation of use.  Indeed, such a paradigm is likely to reflect real 
world puffing behaviours whilst avoiding any satiation effect which could have 
influenced puffing topography.  That said, the instructed one-hour abstinence may have 
been counterintuitive in this regard, specifically for the low dependent (light) smokers 
for whom their normal routines may have been to smoke very few cigarettes in the day.   
Primary aims of the study were to observe evolution of puffing topography over 
a period of two weeks and differences in device types based on the rationale that 
cigalikes would be associated with poorer delivery.  To this effect, 24 participants were 
randomly allocated to the aforementioned condition compared to 23 in each of the 2-
separate conditions.  This group was associated with a large drop-out rate in subsequent 
sessions (20.8% vs 13 and 13% in the Tank 18 and 6 respectively) which affected the 
sample size and resulted in most of the analyses to be run with unequal group sizes. 
This differential drop-out may therefore explain some of the non-significant findings in 
relation to CPD, craving and withdrawal symptoms – that is, cigalikes were only helpful 
for those participants who were sufficiently motivated to continue to use or for whom 
positive subjective effects were experienced.   
Equally, other primary aims were to gain further understanding of the impact of 
a 6 and 18 mg/mL nicotine concentrations on puffing topography of naïve e-cigarette 
smokers.  However, the accuracy of nicotine exposure could not be established given 
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that nicotine concentrations contained in the e-liquid were not chemically measured.   
That said, contrary to early manufactured products (Cameron et al., 2014; Trehy et al., 
2011), in recent years, studies report little variability in the accuracy of the labelling of 
European and Western nicotine containing e-cigarettes and liquids (Etter et al., 2013; 
Farsalinos, Spyrou, et al., 2014; Goniewicz, Hajek, & McRobbie, 2014) suggesting 
some improvement in manufacturing practices.  One measure which could have 
counteracted the latter limitation would have been through collecting plasma nicotine 
concentrations, a rather onerous and invasive procedure.   
  Furthermore, three sessions were scheduled one week apart during which 
participants reduced their smoking and mean puff duration increased in the first week.  
This is reflective of an effective and rapid adaptation in puffing regimen.  However, the 
time at which this adjustment occurred is unclear.  It could have been within the first 10 
minutes into the baseline session or hours following the end of the session.  Future 
studies should consider incorporating a 24 hr follow-up session.    
It is possible that aside from taking longer puffs, the changes in puffing 
topography occurred through deeper inhalation also.  A further limitation may be that 
no apparatus was used to measure puff velocity and puff volume.  Nonetheless, studies 
suggest that such apparatus, although useful may influence the user’s experience 
thereby hindering the capture of naturalistic behaviours (Ross & Juliano, 2016).  In 
addition, that puff volume (Kósmider, Madej, Garwon, Sobczak, 2016) or velocity do 
not influence liquid evaporation (Talih et al., 2014) and that puff duration is the most 
common currency used in this area of research strengthens the validity of the current 
findings. 
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Moreover, the current study was conducted in a controlled laboratory 
environment which may not be a true reflection of real puffing behaviour (Robinson, 
Hensel, Morabito, & Roundtree, 2015) since previous studies suggest that smokers and 
e-cigarette users have a tendency to display more intensive puffing patterns in 
laboratory settings compared to when in their natural environment (June et al., 2012; 
Robinson et al., 2015).  Nevertheless, given that the means puffing duration and number 
of puffs are in line with those reported in the literature, the behaviours displayed in the 
lab were likely to be reflective of real world puffing behaviours.   
There are instances wherein e-cigarette users press the activation button before 
or whilst bringing the device to the mouth in order to warm the atomiser and allow a 
stronger throat hit, which is known as the pre-puff phenomenon (Behar et al., 2015), in 
contrast, others may do the opposite (Farsalinos et al., 2013b).  In such instances, the 
time frame was captured only when the device was clearly seen in the mouth with both 
lips closed.  Extra care was taken to ensure clear visibility of the start and end of puff 
and increase accuracy.  In terms of the evolution of puffing, the within-participants 
design would have helped mitigate this limitation since previous studies suggest intra-
consistency in puffing behaviours (Behar et al., 2015), any occurrences of such 
behaviours would have been likely to have been replicated in subsequent sessions.   
Furthermore, given the wide variations in device models and brands’ ability to 
deliver nicotine, the heterogeneity in e-liquid formulation, the current findings cannot 
be generalised to other e-cigarette device types and e-liquids. 
Finally, the current study relies heavily on self-reported data specifically for the 
measure of CPD, which may have rendered these results biased.  However, the strong 
similarity of the biochemical measure of CO levels in relation to CPD means has 
provided more credibility to these findings. 
 
 
196 
 
Summary of Chapter III 
The current study was not designed to allow for any direct conclusions on 
compensatory puffing, since the smokers do not switch between nicotine 
concentrations; rather it provides evidence on whether e-liquid with different nicotine 
concentrations and different e-cigarette types are puffed on differently and require 
different puffing patterns in order to optimise nicotine delivery and increase product 
acceptability.  Indeed, substantial research has demonstrated the importance of and 
interweaved relationship between puffing topography and nicotine delivery in their 
ability to elicit reward and maintain smoking behaviours; herein an attempt has been 
made to shed further light on how these factors interplay in e-cigarette naïve smokers.    
Consistent with previous studies, participants increased their puff duration after 
a week following initial use.  This increase in puff duration is suggestive of an 
adjustment in puffing topography by naïve users over time, which corroborates the self-
titration theory at least in the short term, in so far as initial puffs taken at baseline were 
evidently too short to yield satisfactory blood levels.  Indeed, a week seems to be 
sufficient to observe an evolution in puffing topography and for e-cigarette naïve 
smokers to develop an awareness for the need to adjust their puffing from smoking to e-
cigarette use.   Interestingly and consistent with the idea that the vacuum mechanism of 
cigalikes may be harder and require a stronger draw than tanks, the cigalike was 
associated with longer puff duration.  This reiterates the proposition of a more erratic or 
intense puffing profile associated in the cigalikes compared to the tank systems.   That 
they require stronger suction may have contributed to their inability to elicit satisfaction 
to the same magnitude than did the tanks.   The significant decrease in the number of 
puffs over the two-week period which, combined with a significant increase in puff 
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duration strongly suggest a dramatic change in puffing behaviour characterised by a 
shift to slower, longer more paced puffs from a more erratic puffing style at initial use.   
Of key interest to this thesis, in the lab, cigalikes and 18 mg/mL containing 
tanks were equally associated with craving reduction, whilst the 6 mg/mL nicotine 
containing tank performed the poorest.  In addition, the 18 mg/mL containing tank 
elicited greater levels of satisfaction whilst cigalikes were associated with a greater 
drop-out rates, which may indicate that cigalikes are less satisfying.  Given the 
predictive value of craving and satisfaction on smoking cessation attempts, and as 
discussed throughout, the influence of nicotine concentrations on puffing topography, in 
line with the existing literature suggests that higher nicotine concentrations may be 
more effective in the relief of craving at least during initiation of e-cigarette use.   
Taken together, these findings confirm previous observations that puffing 
patterns differ across device types and change over a one week period as the user learns 
to use the device.  Across all subjective variables, the Tank 18 performed the strongest 
and, although the cigalike was associated with some promising results, these need to be 
considered in the context of the high drop-out rate in this condition.  To conclude, these 
findings suggest higher nicotine concentrations and tanks appear the most suited tool to 
support the early stage of a smoking cessation attempt.   
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CHAPTER IV 
“PREDICTORS OF SMOKING CESSATION USING E-
CIGARETTES: DEVICE TYPES, NICOTINE DELIVERY, 
CRAVING AND CIGARETTE DEPENDENCE” 
 
 
Abstract 
 
Background: Although factors associated with smoking cessation success have been 
widely studied, very little is known about the factors that may promote cessation where 
e-cigarettes are used as aids.  This study aimed to identify the possible predictors of 
smoking cessation in smokers attempting to quit using an e-cigarette.   
Methods: 70 e-cigarette naïve smokers (N = 70; 62.9% female) were followed up at 1, 3 
and 6 months after a 2-week lab experiment (consisting of 3 separate sessions) in which 
they received either i) a cigalike e-cigarette model containing 18 mg/mL nicotine 
concentrations, ii) a tank e-cigarette device (containing 18 mg/mL), iii) a tank 
(containing 6 mg/mL).  Logistic regression analyses were conducted to assess whether 
device type (initial allocation and device type used at follow up), nicotine 
concentrations, craving reduction following e-cigarette use in the lab, mean puff 
duration, cigarette dependence and motivation to quit could predict cessation.  
Results: Cigarette dependence, Craving reduction with e-cigarette use and Device type 
at follow up were significant predictors of cessation at 1, 3 and 6 months respectively.  
Nicotine concentrations, mean puff duration and motivation to quit at baseline were not 
significant predictors.   
Conclusion:  In a sample of 70 e-cigarette-naïve smokers, less dependent smokers were 
more likely to quit at 1 month. Those who reported greater craving reduction following 
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e-cigarette use in the lab were more likely to have quit at 3 months; the predictive utility 
of measures of craving reduction at first use can be fostered to inform smoking 
cessation programmes.  The odds of quitting at 6 months were higher for those using a 
tank device at the time of follow-up compared to those using a cigalike, which is in line 
with previous studies suggesting that tank systems are associated with successful 
cessation.     
  
  
 
 
200 
 
Introduction 
 
In the previous chapter, the findings of Study 2 (Chapter III) suggest that higher 
nicotine concentrations and tanks seem more effective to support the early stage of a 
smoking cessation attempt.  Following their final ad libitum vaping session at week 2 
(Study 2; Chapter III), participants were followed at 1, 3 and 6 months via phone calls 
and/or emails to assess their current smoking status and e-cigarette use. 
Herein, Study 3 uses the cohort of participants in Study 2 to identify the possible 
predictors of successful cessation over a longer time period.  Based on the literature 
(Berry et al., 2018; Borland, Yong, O’Connor, Hyland, & Thompson, 2010; Hitchman 
et al., 2015; Rohsenow et al., 2018; Simonavicius et al., 2017; Vangeli et al., 2011) the 
following variables were selected as predictors: device types at baseline and follow-ups, 
nicotine concentrations used at baseline and follow-ups, cigarette dependence, 
motivation to quit, craving and satisfaction, and previous experience of e-cigarette 
before the start of the study (i.e. whether they have used an e-cigarette before).  
 
E-cigarettes and smoking cessation  
As described in Chapter I, there is some evidence that e-cigarettes are useful in 
promoting smoking cessation and reduction (Beard, West, Michie, & Brown, 2016; Bell 
& Keane, 2012; Glasser et al., 2016; Meier, Tackett, & Wagener, 2013; Weinberg & 
Segelnick, 2011), and help prevent relapse (Biener et al., 2015; Jamie Brown et al., 
2014; Giovenco & Delnevo, 2018; Hajek, Etter, Benowitz, Eissenberg, & McRobbie, 
2014).  However for many, e-cigarettes have not been sufficiently satisfying as 
substitutes to tobacco cigarettes (ASH, 2017).  There may be a number of factors that 
predict why e-cigarettes help some to quit and not others; the mechanisms by which e-
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cigarettes promote smoking reduction and cessation may be multiple. These include: 
helping to alleviate craving for tobacco smoking and other adverse abstinence related 
symptoms (Adriaens et al., 2014; Dawkins, Kimber, et al., 2015; Etter, 2015; Hajek, 
Przulj, Phillips-Waller, Anderson, & McRobbie, 2018; Rüther et al., 2017), delivering 
nicotine efficiently and in ways that approximate that of combustible cigarettes 
(Farsalinos, Spyrou, Tsimopoulou, et al., 2015; Hajek et al., 2015, 2017; Lechner, 
Meier, et al., 2015; Wagener et al., 2016), providing novel features such as device 
customisability (Vandrevala et al., 2017) or sensory such as olfactory factors (e.g. 
availability of wide range of flavours) (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, 
Spyrou, et al., 2013; Ward et al., 2018), and allowing lapses whilst minimising risks of 
complete relapse (Notley et al., 2017).  Given the difficulty of quitting and remaining 
abstinent the struggle for many to achieve a complete transition away from smoking 
remains.  Thus, further understanding of the factors that can predict successful cessation 
outcomes will be informative and can add to the support provided to smokers and dual 
users to facilitate complete cessation.   
Predictors of cessation  
Efficient Nicotine delivery:  Device types, Nicotine concentrations and Puffing duration 
Amongst the factors that are likely to determine product acceptance, nicotine 
delivery occupies a central role.  Although tank models tend to be favoured by 
experienced e-cigarette users, cigalikes have not completely lost their appeal and, 
though opinions are divergent (Dawkins et al., 2015; McKeganey & Dickson, 2017), 
many rate their cigarette-like appearance as very important (Dawkins, Kimber, et al., 
2015; Dawkins, Munafò, et al., 2015; McQueen et al., 2011).  This may partly explain 
why many choose a cigalike as their entry product during initiation of use (Wadsworth 
et al., 2016).  However, as discussed in previous chapters, cigalikes are associated with 
poorer nicotine delivery (Farsalinos, Spyrou, et al., 2014; Hajek et al., 2018, 2017; 
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Rüther et al., 2017) and reduced satisfaction (Dawkins, Kimber, et al., 2015; Rüther et 
al., 2017) compared with tank models and the latter may be more effective for smoking 
cessation (Hitchman et al., 2015; Rodu & Plurphanswat, 2017b).  However it has been 
suggested that for some, tank devices could constitute a barrier to e-cigarettes use.  The 
complexity of the technology of the tank systems (Wadsworth et al., 2016) combined 
with the intricacies of nicotine liquid composition further diminishes acceptability of the 
product (Mckeganey & Dickson, 2017).   Thus, this highlights the importance of device 
type as a key variable to predict cessation.   
Aside from device type, frequency and duration of use are critical in predicting 
complete transition to e-cigarette use.  In a longitudinal online survey of 1643 UK 
smokers followed up during a period of one year, those using a tank device on a daily 
basis were more likely to quit in comparison to those using cigalikes or any device type 
on a non-daily basis (Hitchman et al., 2015).  Consistent with this, in a US based study, 
of 695 (N = 1374 at baseline) users, daily use was 6 times at greater odds to be 
associated with cessation compared to non-daily use (Biener & Hargraves, 2015).  In a 
separate longitudinal study with 2028 US residents, long term e-cigarette use was 
associated with a greater cessation rate (Zhuang, Cummins, Y Sun, & Zhu, 2016).  The 
infrequent use of e-cigarettes as demonstrated by many smokers who discontinue e-
cigarette use may be driven by a high level of dissatisfaction which may dissuade from 
future use and promote smoking.   In the latest ASH survey, dissatisfaction was one of 
the main motivations for discontinuing use of e-cigarettes (ASH, 2017).   Reasons for 
discontinuation of use has also been associated with their reduced ability to alleviate 
craving for tobacco cigarettes (ASH, 2017).  Other studies suggest that greater craving 
and withdrawal relief are associated with high-powered tank systems, more intensive 
puffing patterns and higher nicotine concentration e-liquids (Etter, 2015), which 
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reiterates the importance of effective nicotine delivery and suggests nicotine 
concentrations as a key variable.  There is also evidence that higher nicotine 
concentration NRT products can increase smoking cessation (Tunnesen et al., 1999); 
and that in the early stages of a cessation attempt, smokers need to increase their 
nicotine concentration in order to achieve and sustain complete smoking abstinence 
(Farsalinos, Romagna, Tsiapras, Kyrzopoulos & Voudris, 2013).   
Another factor that may influence the likelihood of smoking reduction and 
cessation is puffing topography such as puff duration.  There are several indications that 
users acquire an optimum puffing technique over time to obtain satisfactory nicotine 
delivery, craving relief and satisfaction (Dawkins & Corcoran, 2014; Dawkins et al., 
2016; Farsalinos, Spyrou, et al., 2014; Farsalinos, Spyrou, Stefopoulos, et al., 2015; 
Hajek et al., 2015).  Further indication  pointing to the importance of puffing duration 
comes from empirical evidence suggesting that naïve users’ puffing duration increase 
over time in order to optimise nicotine delivery and increase satisfaction (Hajek et al., 
2017).  As reported in Chapter III and as documented previously (Hajek et al., 2015), 
naïve e-cigarette smokers rapidly learned to increase their puffing duration after a week 
of initiation of e-cigarette use, arguably to optimise nicotine delivery and obtain 
satisfactory blood levels.      
Craving and Satisfaction  
The interrelated association between craving, effective nicotine delivery and 
satisfaction in e-cigarette use is clear.  Previous research suggests that higher nicotine 
concentrations and better nicotine delivery devices relate to greater craving relief (Etter, 
2015).  This concords with other research suggesting that nicotine containing e-
cigarettes compared to placebo are more effective at promoting cessation (Hartmann-
Boyce et al., 2016).  That discontinuation of use of the device is commonly attributed to 
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dissatisfaction and the inability of the e-cigarette to alleviate craving for tobacco 
cigarettes (ASH, 2017; Simonavicius, McNeill, Arnott, & Brose, 2017) suggest craving 
as an important variable for predicting cessation.  
Cigarette dependence  
Historically, theoretical models of smoking have put a great emphasis on 
cigarette and nicotine dependence.  The widespread use of cigarette dependence as a 
key measure to understand smoking behaviours (Baker et al., 2010; Billieux et al., 2010; 
Borland et al., 2010; Fagerström, 2012; Foulds et al., 2015; Lechner, Meier, et al., 2015; 
Lee et al., 2015; Muhammad-Kah, Hayden, Liang, Frost-Pineda, & Sarkar, 2011; 
Parzynski, Jaszyna-Gasior, Franken, & Moolchan, 2008; Pechacek et al., 2017; Schnoll, 
Goren, Annunziata, & Suaya, 2013; Ucar et al., 2014; Van Overmeire et al., 2016; 
Zhang et al., 2012) is testament of its strong predictability value of future quit attempts 
and likely success.  Cigarette dependence therein encompasses two interrelated 
concepts, motivational factors and a degree of loss of control over tobacco use (West, 
2006).  Two key items i) Time to the first tobacco cigarette (hereafter TFTC) after 
waking and ii) the number of cigarettes per day (hereafter CPD) have high theoretical 
relevance due to the short half-life of nicotine which evokes a need to raise depleted 
blood nicotine up to habitual ‘awaken’ levels (Kozlowski et al., 1981).  This is 
corroborated by studies which have found CPD and TFTC to be strong correlates of 
biomarkers of exposure such as urine nicotine, serum cotinine and blood 
carboxyhaemoglobin (Muhammad-Kah et al., 2011).  Similarly, studies have found that 
the shortest latency to the first cigarette of the day to be the strongest predictor of lapses 
and relapse compared to other measures of cigarette dependence (Baker et al., 2010).  
The Fagerström Test for Cigarette Dependence (FTCD) (also referred to as Fagerström 
Test of Nicotine Dependence or FTND) (Fagerström, 2012), employed in this thesis, 
 
 
205 
 
comprises a total of 6 items including TFTC and CPD and has been widely used due to 
its predictive validity.  Although some studies have found mixed results (Etter, 2005; 
Ferguson et al., 2003; Kozlowski, Porter, Orleans, Pope, & Heatherton, 1994; Piper, 
McCarthy, & Baker, 2006), a substantial number of studies, and others pointing to its 
consistency in predicting cessation outcomes (Vangeli, Stapleton, Smit, Borland, & 
West, 2011), makes the FTCD a valid measure in predicting quit outcomes.   
The potential of e-cigarettes to deliver nicotine as efficiently as tobacco 
cigarettes under certain conditions (Dawkins et al., 2016; Ramôa et al., 2015; Wagener 
et al., 2016) may be attributed to e-cigarettes ‘puff-by-puff’ mode and route of delivery 
(inhalation route) which closely mimic the delivery afforded by tobacco cigarettes and 
allow a fast delivery to the brain (Russell & Feyerabend, 1978).  Since the ability of a 
drug to induce addiction is largely determined by the rapidity at which the drug reaches 
the brain (Le Houezec, 2003), understanding the predictive validity of cigarette 
dependence on cessation outcomes would be of great value.  As echoed in previous 
studies (Buu, Hu, Piper, & Lin, 2018; Rohsenow, Tidey, Martin, Colby, & Eissenberg, 
2018a) and reported in Chapter III, e-cigarette use can reduce cigarette dependence.  
Online longitudinal surveys (using retrospective data) have found that e-cigarettes tend 
to be less addictive than cigarettes (Etter & Eissenberg, 2015; Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos, & Voudris, 2013a; Foulds et al., 2015).  For example, in the 
PATH Study (Population Assessment of Tobacco and Health), in which 2727 exclusive 
smokers were followed from Wave 1 (2013–2014) to Wave 2 (2014–2015), the data 
suggested that e-cigarette use was associated with a reduction in cigarette dependence 
(Buu et al., 2018).  Another group of researchers, using the PATH data reported a 
reduction in CPD at Wave 2  following initiation of e-cigarettes use at Wave 1 (Berry et 
al., 2018).  Taken conjointly, these findings suggest that e-cigarettes have the potential 
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to lessen dependence and dependence levels of smokers (including dual users for whom 
a complete switch to e-cigarettes remains challenging) are greater than that of exclusive 
e-cigarette users (Dawkins, Turner, Roberts, et al., 2013; Etter & Eissenberg, 2015; 
Foulds et al., 2015; Goniewicz et al., 2013; Liu et al., 2017).  Based on the 
aforementioned evidence and that greater dependence is associated with reduced odds 
of quitting (Heatherton et al., 1989; Kozlowski et al., 1981), cigarette dependence a 
likely candidate for the prediction of smoking cessation outcomes following e-cigarette 
use initiation.   
Motivation to stop smoking  
Another likely factor to affect e-cigarette use and a cessation attempt is 
motivation.  Both public preconceptions and the existing literature suggest that 
motivation could be a key factor to determine the likelihood of successful smoking 
cessation outcomes.  Similarly smokers crucially perceive motivation as essential and 
also sufficient to successfully quit smoking (Balmford & Borland, 2008).  However, 
despite a strong motivation to quit, many smokers are unable to do so resulting in  high 
relapse rates (Etter & Stapleton, 2006). One of the core theoretical assumptions that is 
relevant to smoking behaviours posit that a strong intent (motivation) to engage in a 
given behaviour and the perceived control upon that behaviour are likely to determine 
future outcomes of this given behaviour (West, 2007).   
A robust measure of motivation,  Kotz et al’s (2013) Motivation to Stop Scale 
(MTSS), has been widely used in the tobacco and e-cigarette literature.  Motivation, 
herein as measured in the MTSS questionnaire, refers to intentions and desire to 
perform the behaviour (i.e. initiating a quit attempt).  The literature which supports 
motivation to quit as a central role in predicting smoking cessation is somewhat 
conflicting.  Whilst some studies found an association between motivation and cessation 
 
 
207 
 
(Hagimoto, Nakamura, Morita, Masui, & Oshima, 2010; R West, McEwen, Bolling, & 
Owen, 2001; Zhou et al., 2009), others found no such association (Hellman, Cummings, 
Haughey, Zielezny, & O’Shea, 1991), and many found that its predictive ability is 
constrained to predicting future cessation attempts as opposed to predicting successful 
outcomes or sustained abstinence (Borland, Yong, Balmford, et al., 2010; Vangeli et al., 
2011).  A recent systematic review of 8 studies from both the UK, US, Canada, 
Australia (plus the ITC-four countries data), France, Spain, Japan, China, Malaysia and 
Thailand, and samples varying from n = 267 to 16 469 of smokers trying to quit, 
examined the best predictors of smoking cessation and found that of all the variables 
(including demographics), cigarette dependence was the only variable to systematically 
predict success in quitting whilst desire to quit tended to predict future attempts 
(Vangeli et al., 2011).     
As for the impact of e-cigarettes on motivation to quit, the evidence suggesting a 
positive effect of e-cigarette use on motivation to quit is predominant but not unanimous 
(Kalkhoran & Glantz, 2016; Pokhrel, Herzog, Muranaka, Regmi, & Fagan, 2015).  In 
one study, a week of e-cigarette use was sufficient to increase ‘readiness’ and 
confidence to quit  (Wagener et al., 2014).  Consistent with this, in a pilot study, 17 
smokers reported an increase in ‘contemplating’ the idea to quit from baseline towards 
week 6 and 10 weeks ; this was in line with the observed reduction in CPD, CO and 
cigarette dependence (Rohsenow et al., 2018a).  Although some could argue that 
financial incentives including the provision of free e-cigarettes may have influenced the 
results, the fact that smoking and a reduction in cigarette dependence, as well as 
motivation to quit, were all maintained even after provision of the free e-cigarettes had 
ceased, suggest a real effect of e-cigarette use initiation (Rohsenow et al., 2018a).  
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Aims and hypotheses 
The current study uses the cohort of participants in Study 2 to identify possible 
predictors of successful cessation.  Based on the most recent and appropriate literature 
(Berry et al., 2018; Borland, Yong, O’Connor, Hyland, & Thompson, 2010; Hitchman 
et al., 2015; Rohsenow et al., 2018; Simonavicius et al., 2017; Vangeli et al., 2011) the 
following variables were selected: device types used at baseline and follow-ups, 
nicotine concentrations used at baseline and follow-ups, cigarette dependence, 
motivation to quit, craving and satisfaction, and previous experience of e-cigarette use 
before the start of the study . Following their final ad libitum vaping session (Study 2; 
Chapter III), participants were followed at 1, 3 and 6 months via phone calls and/or 
emails to assess their current smoking status (biochemical verification via CO readings 
where ≥ 7 days abstinence was self-reported) and e-cigarette use.  Participants’ device 
types were recorded at each follow-ups, thus in addition to baseline allocation of the 
device type, device type at each follow-ups will be entered in the regression model.   
It is hypothesised that a greater likelihood of quitting would be associated with 
participants using a Tank, those using higher nicotine concentrations, those with lower 
cigarette dependence, higher motivation to quit and those who experienced greater 
craving reduction during e-cigarette use at initiation.  
 
Methods 
 
Design and ethical approval 
The study received full ethical approval from the University of East London’s 
ethics committee (UREC_1516_04; approved on the 15th September 2015, see appendix 
16).  All participants provided written informed consent to be followed up to 6 months 
after the start of the study.   
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The cohort of smokers (from Study 2, see Chapter 3) were contacted via 
telephone and email between January 2016 and June 2017.  At the end of Study 2, 
participants were instructed that they can change devices and e-liquid nicotine 
concentrations as they wished.  As a result, device type and nicotine concentrations as 
per self-report at each follow-up point were entered as predictor variables, in addition to 
the baseline conditions (see predictor variables).     
Outcome measures:   Smoking cessation at 1, 3 and 6 months (binary coded, 
‘quit’ or ‘did not quit’).  
 Predictor variables:  i) The primary predictor device types combined with 
nicotine concentrations as per the baseline allocation Cigalikes (18 mg/mL), Tank 18 
and Tank 6;  ii) Device types reported at follow-ups (1, 3 and 6 months) coded as 
Cigalikes and Tanks. Those reporting using Sub-ohming systems (using atomisers with 
> 1 ohm resistance) were classified as using tanks (as only 5 did so);  iii) Nicotine 
concentration at follow-up, although participants reported a wide variation in nicotine 
concentrations, to avoid violating the assumption of case numbers per cell, nicotine 
concentrations were initially grouped into 3 categories a) ≤ 6 mg/mL, b) ≥ 8 but ≤ 16 
mg/mL and c) ≥ 18 mg/mL, however, this was still problematic resulting in more than 
20% of the expected counts to be less than 5.  To address this issue and avoid the loss of 
statistical power, nicotine concentration categories were revised and grouped into High 
(≥ 8 mg/mL) versus Low (≤ 6 mg/mL)h categories; iv) Baseline cigarette dependence 
(FTCD), (Fagerström, 2012); vii) Daily consumption of e-liquid (in mL) (at each 
                                                 
h Note that at the time of data collection, nicotine concentrations equal to or exceeding 18 mg/mL were 
considered as high and were commonly used.  Advanced technology with devices compatible to atomisers 
which allow greater wattage to flow to the coil and generate more power, has led to a shift towards an 
increase in use of lower nicotine concentrations (< 6 mg/mL) with recent reports of 4-8 mg/mL amongst 
dual and exclusive users (Adriaens et al., 2017), hence the categorization of nicotine concentrations in the 
present analysis.  
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respective time-point) and Mean puff duration (in seconds; at the last experimental 
session); viii) Baseline measures of motivation to quit (MTSS); ix)  Baseline 
satisfaction and craving reduction (measured in the first experimental session); x) past 
e-cigarette use (binary coded: Yes or No). 
Participants 
From the cohort of Study 2 (Chapter III), participants were followed up at 3 
time-points; 1-, 3- and 6-months.  As per West al. (2015), an intention to treat analysis 
was used wherein lost to follow-up participants were treated as maintaining smoking. 
To that effect, the initial sample of 70 smokers at Day 1 was included in all subsequent 
analyses. 
 
Measures  
Baseline measures 
Baseline data (including demographics, smoking history, motivation to stop 
smoking, confidence to quit, past e-cigarette use and cigarette dependence were 
collected as described in Study 2, Chapter III).  See Table 3.1 in Results section in 
Chapter III/Study 2 for baseline participants’ characteristics. 
Follow up measures at 1, 3 and 6 months  
Follow-up CPD by asking number of cigarettes smoked per day in the last 7 
days and number of cigarettes smoked per day on average.  Follow-up Cigarette 
dependence was measured using the FTCD (as described in Study 2 Chapter III). 
E-cigarette dependence and patterns of use at follow up assessed by employing 
an adapted version of the FTCD and included items questionnaire such as time of first 
puffs and so on (as described in Study 1, Chapter II and in appendix 20) (Dawkins & 
Corcoran; Dawkins et al., 2016).  Patterns of use were assessed by asking participants 
about current device type used and if applicable, date they stopped/resumed use of the 
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device, nicotine concentrations, flavours and estimate of liquid and cartridges used.  
Please note that volume consumed is not analysed but only reported due to the 
inconsistency between units of measurements for tank (mL) and cigalike (cartridges). 
The outcome variable, cessation at each follow up point, was measured with 
self-report CPD (abstinence was denoted by 0 cigarettes in the last 7 days.  Participants 
were then invited to the lab for a CO breath test. 
Mixed ANOVA was used to measure changes in cotinine levels at follow-ups 
from baseline by collecting saliva samples at baseline and upon self-report of quit only.   
Procedure 
 During the final ad lib vaping session in Study 2 (Chapter 3), participants were 
debriefed (see appendix 16 for debrief letter) and informed about what the 3 follow-ups 
time points would involve.  They also received some guidance on how to maintain their 
devices (replacing the atomisers, and so on).  At 1, 3 and 6 months after their baseline 
session, each participant was contacted via a 10 minute phone call to collect information 
on their smoking status, CPD and e-cigarette dependence (outlined above),  patterns of 
e-cigarette use, device type and nicotine concentrations.  
Data and statistical analysis 
IBM SPSS version 23 was used for all analyses.  Frequencies of device types 
and nicotine concentrations reported at follow ups were examined as well as descriptive 
statistics (means and SD) for all predictors.  Chi square analyses were conducted to 
examine quit rates per condition and at each time point.  A parsimony heuristic 
approach was adopted for the logistic regression to explore factors predicting cessation.  
As such the model was built entering predictor variables that are in line with the 
theoretical basis of this thesis and most prominent in the e-cigarette literature.   Binary 
logistic regression analyses were conducted with the main outcome variables cessation 
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at 1, 3 then 6 months (Yes or No) and the main predictor variables in the following 
respective order:  i) Device types combined with nicotine concentrations at baseline;  ii) 
Device types at follow-ups (3 categories, see design section);  iii) Nicotine 
concentrations at follow-ups (2 categories, see design section), iv) Baseline cigarette 
dependence (continuous variable) ; v) Mean puff duration (continuous variable) at 2-
week follow up (see Study 2, Chapter III); vi) Baseline measures of motivation to quit 
(continuous variable); ; vii) Baseline satisfaction and craving reduction following e-
cigarette use (continuous variables); viii) past e-cigarette use (‘yes’ or ‘no’); ix) The 
interaction Device type X Nicotine concentrations.  Based on model improvement, 
predictors were retained and further logistic regression analyses were conducted.  
 
 
Results 
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Participation flow chart - Quit and lost to follow-up frequencies  
 
Baseline 
N = 70
Cigalikes
N = 24
Tank 18
N = 23
1-month FU
N = 52 
Lost to FU
N = 18
Quit
N = 11
3-month FU
N = 49
Lost to FU
N = 21
Quit
N = 15
6-month FU
N = 43
Lost to FU
N = 27
Quit
N = 18
Cigalikes
N = 1
Tanks
N = 24
Cigalikes
N = 5
Tanks
N = 26
Cigalikes
N = 11
Tanks 
N = 34
Tank 6
N = 23
2-week Lab 
sessions 
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Figure 4.1. Flow diagram of study participation from 1- to 6-month FU (follow-
up).  Following a 2-week period of 3 lab-based ad lib vaping sessions, in which 70 e-
cigarette (EC) naïve smokers were randomly allocated to either i) a cigalike (18mg/mL 
nicotine concentrations), ii) a tank (18 mg/mL) iii) a tank (6 mg/mL) and encouraged to 
substitute as many tobacco cigarettes (TC) as they can.  Participants were at liberty to 
upgrade e-cigarette model and change nicotine concentrations, to this effect, tank 18 and 
6 were merged into ‘Tanks’ in subsequent regression models.  Participants were 
followed up at 1, 3 and 6 months to assess smoking status, EC use and levels of 
dependency.  At the end of the 2-week lab-based sessions, smokers were given 
minimum advice on EC use and product maintenance, and were given permission to 
upgrade devices and nicotine concentrations (at their own cost and volition).  This 
explains the merging of both tank conditions and the increase in self-report of tanks use 
and decrease in cigalikes from the 1-month FU upwards. Quit rates encompass self-
report dual users, exclusive EC use and quitters (former smokers no longer using an 
EC). 
 
Predictors: Device type and nicotine concentrations at baseline and at follow-ups  
Table 4.2 presents frequencies (number of participants in each condition) for 
device type and nicotine concentration at baseline and at follow-ups (1, 3 and 6 
months).  Note that device type at follow up has been reclassified to denote those using 
a cigalike versus a tank.  Table 4.2 highlights the contrast between cigalikes and tanks 
with a decrease in frequency in cigalike use and an increase in tank use.  Changes in 
nicotine concentrations over time is less clear due to a large amount of missing data at 
follow-ups. 
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Table 4.2  
Frequencies of Device Type and nicotine concentrations (Nic Concent.) at Baseline, 1, 3 and 6 months follow-up (FU) and Past e-cigarette (EC) 
use.  
Device Type   Baseline 
 
1-month FU 3-month FU 6-month FU 
 N % N % N       % N % 
Cigalikes 24 34.29 22 31.4 21 30 19 27.1 
Tanks* 46 65.71 48 68.6 49 70 51 72.9 
Total 70 100 70 70 70 70 70 70 
     
Nic concent. 
(mg/mL)   
 Baseline  
 
1-month FU 3-month FU 6-month FU 
 N % N % N % N % 
  ≤ 6  23 32.86 11 15.7 13 18.6 14 20 
  ≥ 8 (incl. ≥ 18) 47 67.1 33 47.1 19 27.1 12 17.1 
Total 70 100 44 62.9 32 45.7 26 37.1 
Missing 0 0 26 37.1 38 54.3 44 62.9 
Total 70 100 70 100 70 100 70 100 
         
Note   *Tanks represent Tank 6 and Tank 18 collapsed   
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Changes in Cotinine levels at follow-ups in self-report quit 
Of the 70 baseline samples collected, 11 saliva samples were collected at follow-
ups for the self-report quit.  Thus mixed ANOVA analyses included only the 11 samples 
that were returned and compared against their respective baseline levels.  Mauchly’s test 
indicated that the assumption of sphericity had been violated.   Therefore, Greenhouse-
Geisser corrected values are reported and revealed no main effect of time F(1, 8) = .358, 
p =.358, ƞ2 = .043.  (Estimated Marginal Means, Time 1: M = 137.38, SD = 97.65, Time 
2: M =167.65, SD = 161.96).  There was no main effect of condition F(2,8) = .255, p = 
.781, ƞ2 = .06 (Estimated Marginal Means, Cigalike: M = 107.76, SD = 172.29; Tank 
18: M = 172.65, SD = 135.50; Tank 6: M = 159.25, SD =  61.79).  There was no 
significant interaction effect between time and condition F(2,8) = .039, p = .952, ƞ2 = 
.01. 
 
Quit frequencies per conditions and time points 
 
As can be seen in Table 4.3, at 1 month, 11 participants (15.71%) reported that they had 
quit smoking and 59 (84.29%) continued to smoke.  Although more participants 
reported having quit in the tank versus the cigalike condition, there was not a 
statistically significant association between Device type and Quit at 1-month follow up, 
χ2 (1, n = 70) = 1.917, p = .154, phi = .208. 
Table 4.3 
Crosstabulations of frequencies and percentages for quit rates at 1 month (1-M) and 
Device type reported at 1 month follow up (FU).  
 1-M Quit   Device Type at 1-M FU   
   Cigalikes Tanks Total 
 No Count 21 38 59 
 Yes Count 1 10 11 
Total  Count 22 48 70 
  
 
 
217 
 
There was no statistically significant association between Device type and Quit at 3-
month follow up, χ2 (1, n = 70) = 1.616, p = .202, phi = .190.  As displayed in Table 4.4, 
similar to the one month follow up, there was a greater number of quit reports in those 
using a tank.  
Table 4.4 
Crosstabulations of frequencies and percentages for quit rates at 3-month (3-M) and 
Device type reported at 1 month follow up (FU).  
3-M Quit   Device Type at 3-M FU   
   Cigalikes Tanks Total 
 No Count 19 36 55 
 Yes Count 2 13 15 
Total  Count 21 49 70 
 
 
There was a statistically significant association between Device type and Quit at 6-
month, χ2 (1, n = 70) = 4.335, p = .016, phi = .286.  Those who reported using a tank 
device were more likely to report cessation at 6-month follow up (as can be seen in 
Table 4.5). 
Table 4.5 
Crosstabulations of frequencies and percentages for quit rates at 6-month (6-M) and 
Device type reported at 1 month follow up (FU).  
6-M Quit   Device Type at 6-M FU   
   Cigalikes Tanks Total 
 No Count 18 34 52 
 Yes Count 1 17 18 
Total   Count 19 51 70 
 
 
 
There were no significant association between Nicotine concentrations and Quitting at 
either the 1, [χ2 (2, n = 44) = 1.011, p = .603, phi = .152], 3 [χ2 (2, n = 32) = 2.245, p = 
.367, phi = .265], or 6 month follow ups [χ2 (2, n = 26) = 1.489, p = .552, phi = .234] 
(see Tables 4.6 – 4.8for counts).  However, note that the assumptions of Chi square 
were violated due to small expected cell counts. 
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Table 4.6 
Crosstabulations of frequencies and percentages for quit rates at 1 month (1-M) and 
Nicotine concentrations reported at 1 month follow up (FU).  
1-M Quit   Nicotine concentrations (mg/mL) at 1-M FU 
   ≤ 6 ≥ 8  Total 
 No Count 9 27 36 
 Yes Count 2 6 8 
Total  Count 11 33 44 
 
 
Table 4.7 
Crosstabulations of frequencies and percentages for quit rates at 3-month (3-M) and 
Nicotine concentrations reported at 1 month follow up (FU).  
3-M 
Quit 
  Nicotine concentrations (mg/mL) at 3-M 
FU 
   ≤ 6 ≥ 8  Total 
 No Count 8 13 21 
 Yes Count 5 6 11 
Total  Count 13 19 32 
 
Table 4.8 
Crosstabulations of frequencies and percentages for quit rates at 6-month (6-M) and 
Nicotine concentrations reported at 6 month follow up (FU).  
6-M 
Quit 
  Nicotine concentrations (mg/mL) at 6-M 
FU 
   ≤ 6 ≥ 8   Total 
 No Count 7 8 15 
 Yes Count 7 4 11 
Total  Count 14 12 26 
 
 
Table 4.9 displays inter-correlations between variables.  To avoid issues of 
multicollinearity, Cigarette dependence (FTCD scores) was selected instead of CPD 
since past studies suggest Cigarette dependence as a key predictor of cessation.  
Likewise, Confidence in quitting was removed as it correlated highly with motivation to 
quit, another variable of key interest in the literature.  Finally, craving reduction and 
satisfaction correlated, given the critical role of craving in reinforcing of smoking and in 
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e-cigarette use (ASH, 2017; Etter, 2015; Simonavicius et al., 2017), craving was 
favoured to be retained in the model instead of satisfaction.   
Table 4.9   Correlational analyses between continuous variables targeted as predictors 
for the initial model  
Predictor 
Variables 
CPD FTCD MTSS Conf. Craving Satis. 
CPD1 1 .741** .091 -.302* .111 .059 
FTCD2 - 1 -.120 -.216 .082 -.018 
MTSS3 - - 1 .547* .057 .081 
Conf.4 - - - 1 .224 .061 
Craving5 - - - - 1 .298* 
Satis. 6 - - - - - 1 
Note ** Correlation is significant at p = .001 (2-tailed) 
* Correlation is significant at p = .005 (2-tailed). 
1 CPD corresponds to Cigarette smoked per day 
2  FTCD corresponds to Cigarette dependence 
3  MTSS corresponds to Motivation to quit 
4 Conf. corresponds to Self-reported confidence in quitting at baseline  
5 Craving reduction measured in the last experimental ad lib session  
6 Satis. corresponds to satisfaction 
 
 
Logistic Regression analyses  
Three logistic regressions were run with the primary outcomes Quit at 1 month, 
Quit at 3, then Quit at 6 months; the results for each of these outcomes will be presented 
separately.  Note that initial analyses were conducted with all the aforementioned 
predictors (see statistical analysis section), however at each time point, models (at 1, 3 
and 6 months) contained issues regarding  ratio of cases to variables (too few data in 
some cases) which gave rise to very large standard errors rendering the outputs 
uninterpretable (Field, 2013) for the variable nicotine concentrations at follow-up.  In 
order to rectify issues of complete separation (one predictor variable predicting the 
outcome variable perfectly based on inspection of Chi square results), nicotine 
concentrations at follow-ups were re-coded as binary (High versus Low; ≤ 6 vs. ≥ 8 
mg/mL, see method section for rationale of categorisation) to counteract the issues of 
few cases in the mid-nicotine concentrations and to align the follow-ups with the initial 
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allocated condition.   In addition, the predictor variable consumption of e-liquid in mL 
was removed due to a large proportion of missing data at all time points.  Furthermore, 
contrary to expectation, one of the key predictors of interest, the Nicotine concentration 
at follow-ups X Device type interaction was not significant and did not improve the 
model.  Consequently, models were revised to include baseline condition, baseline 
measures of motivation to quit and Cigarette dependence, Device types (Tanks vs 
Cigalikes) and Nicotine concentrations (High vs Low) at follow ups, and Baseline 
Craving reduction scores collected in the initial ad lib vaping experimental session. 
Other changes to the analysis for each follow up time point are described below.  For all 
regression analyses, Cigalikes were entered as the reference category. 
 
Predictors of Quit at 1-month follow-up 
The initial model was run to include the predictors as described above however, 
due to issues of complete separation (unusually large standard errors), problematic 
variables were identified and removed (device type at 1 month follow-up), thus the final 
model was re-run to include the following: i) Baseline conditions, ii) Nicotine 
concentrations, iii) Puff duration, iv) Craving reduction, v) Motivation to quit and vi) 
Cigarette dependence.  The overall model was statistically significant (p = .012).  
Cigarette dependence was found to be a significant predictor; participants who scored 
the lowest on the FTCD scale were at greater odds of quitting (95% CI = .294 to .992, p 
= .047). More specifically, for every one point decrease on the FTCD, odds of quitting 
increased by 0.54.  None of the remaining variables predicted quit at 1 month (see Table 
4.10). 
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Table 4.10    
Coefficients of the model with Odds Ratio of predictors of cessation at 1 Month 
 b  95% CI for Odds Ratio 
   SE Lower  Odds  Upper p 
Included          
Constant  5.172 3.942 -  176.199  - .190 
Tank 18 (vs 
Cigalikes) 
 2.398 1.579 .498  11.00  243.074 .129 
Tank 6 (vs 
Cigalikes) 
 -.970 1.868 .010  .379  14.748 .604 
Nicotine concent.  -1.787 1.591 .007  .168  3.791 .262 
Puff duration  -.013 .434 .421  .987  2.311 .976 
Craving reduction  .888 .614 .729  2.430  8.09 .148 
MTSS  -.718 .469 .195  .488  1.223 .126 
FTCD  -.616 .311 .294  .540*  .992 .047 
 Note  R2 =  23.430 (Hosmer & Lemeshow) .340 (Cox & Snell) .551 (Nagelkerke).  Model χ2(7, n = 43) 
= 17.89, p = .012. 
Bold indicates significant at p < .05 
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Predictors of Quit at 3 months follow-up 
The initial model was run to include all predictors as described above 
previously.  Due to issues of complete separation (unusually large standard errors) 
including the addition of the key predictor variable - baseline device type, problematic 
variables were identified and removed, thus the final model was re-run to include the 
following: i) Device used at 3 months follow up, ii) Puff duration, iii) Craving 
reduction, iv) Motivation to quit, v) Cigarette dependence.  The overall model was 
statistically significant (p = 0.031).  Craving reduction with e-cigarette use at baseline 
was found to be the only significant predictor, participants who reported greater craving 
relief in the baseline ad lib vaping session were more likely to quit at 3 months (95% CI 
= 1.118 to 2.913, p = .016). For every one point increase in craving reduction with e-
cigarette use at baseline, odds of quitting increased by 1.142.  None of the remaining 
variables predicted quitting at 1 month (see Table 4.11). 
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Table 4.11    
Coefficients of the model with Odds Ratio of predictors of cessation at 3 Months 
   95% CI for Odds Ratio 
  b SE Lower  Odds  Upper p 
Included          
Constant  -3.126 1.728 -  .044  - .070 
Device at FU (Tanks 
vs Cigalikes) 
 1.729 1.164 .576  5.638  55.212 .137 
Puff duration  .009 .255 .613  1.009  1.662 .971 
Craving reduction  .133 .233 1.118  1.142  2.913 .016 
MTSS  .133 .223 .738  1.142  1.768 .551 
FTCD  -.101 .144 .682  .904  1.198 .482 
Note.  R2 = 50.086 (Hosmer & Lemeshow) .201 (Cox & Snell) .296 (Nagelkerke).  Model χ2(5, n = 55) = 
12.314, p = .031. 
Bold indicates significant at p < .050 
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Predictors of Quit at 6 months follow-up 
The initial model was run to include all predictors as previously described.  Due 
to issues of complete separation (unusually large standard errors), problematic variables 
were identified and removed (Baseline condition, Puff duration), thus the final model 
was re-run to include the following: i) Baseline condition, ii) Device type at follow up, 
iii) Craving reduction, iv) Motivation to quit and v) Cigarette dependence.  The overall 
model was statistically significant (p = .035).  Type of e-cigarette used at 6 months was 
statistically significant; participants reporting using a tank device at 6 months were 
17.14 times more likely to quit (95% CI = 1.2 to 244.59, p = .036) compared to those 
using a cigalike.   For craving reduction, for every one point increase in reduction with 
e-cigarette use at baseline, odds of quitting increased by 1.51 although this fell short of 
statistical significance (p = .053), (see Table 4.12).  None of the other variables 
predicted quitting at 6 months.    
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Table 4.12   
Coefficients of the model with Odds Ratio of predictors of cessation at 6 Months 
   95% CI for Odds Ratio 
  b SE Lower  Odds  Upper p 
Included          
Constant  -4.443 1.696 -  .012  - .009 
Tank 18 vs 
Cigalikes 
 -.813 .988 .064  .444  3.074 .411 
Tank 6 vs 
Cigalikes 
 -901 .975 .060  .406  2.744 .355 
Device at FU 
(Tanks vs. 
Cigalikes) 
 2.841 1.356 1.20  17.135  244.59 .035 
Craving red  .409 .211 .995  1.506  2.279 .053 
MTSS  .107 .211 .736  1.113  1.684 .611 
FTCD  -.050 .127 .741  .951  1.221 .695 
Note.  R2 =  66.261 (Hosmer & Lemeshow) .176 (Cox & Snell) .259 (Nagelkerke).  Model 
χ2 (6, n = 70) = 13.545, p = .035. 
Bold indicates significant at p < .05 
 
 
226 
 
 
Discussion 
Summary of findings  
The aim of the current study was to investigate the variables that best predict 
smoking cessation at 1, 3 and 6 months in a sample of 70 e-cigarette-naïve smokers.  At 
1-month follow-up, 11 out of 70 smokers reported quitting, 15 did at 3 months and 18 
did at 6-months.  The 11 participants who self-reported quit (CO verified) and returned 
their saliva samples, maintained their cotinine levels after quit.  At 1-month follow-up, 
only cigarette dependence significantly predicted smoking cessation; those with lower 
scores at baseline were more likely to quit compared to participants with higher baseline 
dependence scores.  Baseline condition (cigalike, Tank 6, Tank 18), nicotine 
concentrations, craving and motivation to quit did not predict cessation.  At the 3-month 
follow-up, only craving reduction predicted cessation at 3 months.  Participants 
reporting a higher reduction in craving following use of the e-cigarette device at 
baseline had greater odds of a successful cessation outcome at 3 months.  At 6 months, 
only the type of e-cigarette device at follow-up was a significant predictor of cessation.  
Thus, regardless of the nicotine concentration, participants using a tank device were at 
greater odds of quitting smoking compared to those using a cigalike device.   
Nicotine delivery a critical factor in the transition to exclusive e-cigarette use: Device 
types, Nicotine concentrations and puffing behaviours 
In a sample of 70 e-cigarette-naïve smokers, the odds of quitting at 6 months 
were 17.135 times higher for those using a tank device compared to a cigalike at the 
time of follow up.  These findings are in line with previous studies concluding that 
device characteristics play an important role in promoting sustained use of the device 
and smoking cessation.  In a US based study (N = 923), successful quitters were more 
likely to be exclusive tank users and report greater craving reduction compared to 
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current smokers (Chen, Zhuang, & Zhu, 2016).  Although, the nature of this study limits 
any inferences of causation, such associations have been reported elsewhere in larger 
samples.  An online longitudinal survey which followed 1643 smokers over  1 year, 
found that those using a tank daily were more likely to have quit at 1 year compared to 
non-daily users of both cigalikes and tanks, whilst non-daily users of cigalikes and tanks 
were no more or less likely to have quit (Hitchman et al., 2015).  This accords with 
more recent findings which suggest that tank users were more likely to have 
successfully quit and be heavier users compared to those using cigalikes (Shiffman et 
al., 2018).  Although in agreement with the current findings, both studies point to one 
aspect that has hitherto received less attention in this field, frequency of use, which is 
not reported in the current study and may constitute a limitation.  Although estimate of 
volume consumed was collected, it could not be used as a predictor variable as the unit 
of measurement differed across the groups (mL for tank users and units of cartridges for 
cigalike users).  Other reports of the association between tank users and achievement of 
complete cessation provide further support for tanks as more efficient devices over 
cigalikes (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, Voudris, 2014).  A large EU 
cross-sectional survey of 19000 respondents, suggested that cigalike users were less 
likely to have quit (Farsalinos, Romagna, et al., 2014).  Moreover, a relatively small 
Catalonian sample of smokers (N = 71) reported a remarkably high reduction and 
cessation rate at 12 months follow-up (25.4 and 40.8% respectively), in smokers 
purchasing their first tanks; the increase in product transition from standard basic tanks 
to more sophisticated modifiable tanks (8.5 to 18.4% from baseline to 12 months 
follow-up) (Polosa et al., 2015)  could be attributed to a need for better nicotine delivery 
products and a more fulfilling vaping experience.  
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Further cues to the importance of the differences between cigalikes and tanks 
originate from a number of studies suggesting a transition from cigalikes to more 
advanced tank models (Tacket et al, 2015) arguably for a more enhanced experience 
notably ‘a more satisfying hit’ (Yingst et al., 2015); but also to address the 
dissatisfaction with starter kits such as cigalikes (McQueen et al., 2011).  Here, the 
movement over time was also away from cigalikes towards tanks.  That the design and 
greater customisability afforded by tanks are amongst the most valued qualities sought 
after by experienced users (Baweja et al., 2016) may also help to explain this organic 
transition to tank systems.  In the current study, many reported stopping using the 
device due to a lack of satisfaction.  On the other hand, the ease of use, simplicity of 
cigalikes (Baweja et al., 2016; Wadsworth et al., 2016) and close resemblance to 
tobacco cigarettes (Dawkins, Kimber, et al., 2015; Dawkins, Munafò, et al., 2015; 
Hoek, Thrul, & Ling, 2017) are equally valued qualities that appeal to smokers trying to 
transition.  In fact, some cigalike users have experimented with several tanks only to 
return to cigalikes in need for a closer enactment of the rituals of smoking (Hoek et al., 
2017).  For others, it is the complex technology combined with the knowledge required 
to deal with the intricacies of nicotine liquid composition that are discouraging factors 
against sustaining e-cigarette use (Mckeganey & Dickson, 2017), which reiterates the 
heterogeneity of e-cigarette use and users.  Whilst much evidence suggests nicotine as 
central in facilitating the transition to exclusive e-cigarette use, it appears that some 
smokers/users are able to concede and favour a design that is closer to the rituals of 
smoking over the importance of effective nicotine delivery.  In fact, that nicotine 
delivery may not be a determinant factor for all is not so surprising given that placebo e-
cigarettes have been shown to reduce craving for cigarettes albeit in the short term only 
(Dawkins et al., 2012).  Thus, whilst non-pharmacological cues play an important role, 
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nicotine delivery remains a central factor in promoting complete substitution.  Besides, 
the sudden surge in popularity of the new e-cigarette device ‘JUUL’ (developed in the 
US) suggests a continued demand for improved nicotine delivery products, given that it 
can be mounted with pods containing nicotine concentrations that largely exceed the 20 
mg/mL cap (Willett et al., 2018). 
The predicting model at 6 months included device type at follow up as opposed 
to device type at baseline.  The issues with device type at baseline may have emerged 
due to a lack of statistical power.  The differences in categorisation with three 
conditions at baseline (to include nicotine concentrations, high vs. low) whilst at follow 
up there were two clear categories (tanks vs. cigalikes).  A likely factor to explain why 
the tanks were more able to promote cessation could have been that they provided 
greater levels of satisfaction compared to the cigalikes.  It is possible that the cigalikes 
did not provide comparable levels of satisfaction perhaps due to technical issues (e.g. 
leakages), less pleasant taste or more resistant mechanism suction.  This is reflective in 
the decrease from baseline to 6 months in participants using a cigalike compared to the 
increase in the number of participants using a tank at 6 months.  Other possible 
explanation could be that tanks were more able to relieve craving for tobacco cigarettes.  
The greater capability of the tank models to alleviate craving compared to cigalikes may 
lie in their nicotine delivery efficiency.  Several experimental lab-based studies 
assessing the nicotine delivery of e-cigarette models have found that tanks 
systematically deliver higher nicotine levels to the user compared to cigalikes 
(Farsalinos et al., 2014; Hajek et al., 2018; Rüther et al., 2017), even at levels that 
equate those reached after the smoking of a cigarette (Dawkins et al., 2016; Ramôa et 
al., 2015; Rüther et al., 2017; Wagener et al., 2016).  The reinforcing value of nicotine 
in smoking (Benowitz, 2010; Henningfield & Keenan, 1993), to alleviate craving, 
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provide satisfaction (Etter, 2015; Dawkins, Kimber et al., 2015), may be the route by 
which tanks are better able to facilitate sustained use of the product and provide an 
effective replacement to smoking (Hitchman et al., 2015; Yingst et al., 2015). 
Unexpectedly, nicotine concentrations was not found to significantly predict 
cessation at 1month and was subsequently removed from the model at 3 and 6 months 
due its poor predictive ability.  This is at odds with the findings reported in Chapter III; 
where ad libitum use of the 18 mg/mL nicotine concentration containing tank led to 
greater craving relief compared to use of the 6 mg/mL.  Given the predictive ability of 
craving on relapse to smoking (Zhou et al., 2009), and that higher nicotine 
concentration is a negative correlate of craving relief for cigarettes (Etter, 2015), one 
would have expected nicotine concentrations to be a critical in predicting cessation.  It 
is likely that the increase in puff duration over time seen in Study 2 (Chapter III) may 
have been accompanied by stable nicotine delivery even following a reduction in 
nicotine concentrations (as found in previous studies see Soar, Kimber, McRobbie, & 
Dawkins, 2018), and possible moves to more sophisticated devices; together these 
factors would militate against finding an effect of nicotine concentrations over the 
longer term.   Counterintuitively, the reduction in nicotine concentrations is not 
accompanied by a reduction in nicotine exposure.  Recent studies found that whilst 
experienced users reduce their nicotine concentrations over time, they increase their 
consumption of nicotine liquid while maintaining constant cotinine levels (Soar et al., 
2018).  One likely mechanism that could explain this phenomenon may be that users 
self-titrate by adjusting their puffing patterns in order to obtain (or maintain) 
satisfactory nicotine levels in their blood.  This accords with the increase in puffing 
duration seen in Study 2 over time and the findings that those who completely switched 
from smoking to e-cigarette use maintained their cotinine levels (Study 3, although this 
 
 
231 
 
is based on a small subset of the sample).  This makes it difficult to consider nicotine 
concentrations as an isolated variable given its interweaved relationship with device and 
user characteristics under the umbrella of nicotine delivery.    
Puff duration (measured at 2 weeks) was not a significant predictor of cessation 
at 3-month follow-up and was removed from the model at 1 and 6 months.  Given 
numerous studies have highlighted the importance of puffing duration to optimise 
nicotine delivery (Dawkins & Corcoran, 2014; Dawkins et al., 2016; Farsalinos, 
Spyrou, et al., 2014; Farsalinos, Spyrou, Stefopoulos, et al., 2015; Hajek et al., 2015), 
increase satisfaction (Hajek et al., 2017) and promote sustained use of the e-cigarette in 
replacement of smoking, the current findings are at odds with the literature.  That said, 
to date, few studies refer to puff duration as a single predictor of cessation.  This may be 
due to the difficulty in detangling puffing duration from other factors (i.e. nicotine 
concentrations, device characteristics, satisfaction and liking) which when combined 
exert a great influence over nicotine delivery as discussed in previous chapters. 
Craving  
The predictive ability of Baseline craving reduction associated with e-cigarette 
use fell short of significance at 6-months and was not significant at 1 month.  
Conversely, at 3 months follow-up, craving was found a significant predictor of 
cessation.  Those who experienced greater craving reduction after using the e-cigarette 
at baseline were more likely to quit at 3 months.  Although it’s unclear why this effect 
was found at 3 months but not earlier, it aligns well with the findings of Study 3.  That 
higher nicotine concentrations and the use of tanks elicit greater craving reduction 
compared to lower nicotine concentrations and cigalikes respectively, provide a good 
explanation for the greater probability of success in quitting using tanks over cigalikes, 
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and reiterate the critical role of nicotine delivery in promoting sustained use (of e-
cigarettes) and smoking reduction.   
That craving reduction associated with e-cigarette use at baseline is a predictor 
of cessation at 3 months suggests that the initial encounter of e-cigarette use can provide 
some indication of the ability of the e-cigarette to satisfy craving; thereby facilitate 
sustained use and promote smoking reduction.  Likewise, this also suggests craving 
reduction as a possible precipitator of relapse.   In a Spanish sample of 775 continuing 
smokers, whilst positive and negative affect were found the predominant factors in 
predicting relapse, craving was also identified as a significant contributing factor 
(Piñeiro et al., 2017).   
An increasing number of studies suggest that e-cigarettes are capable of 
alleviating craving (Bullen et al., 2010; Dawkins et al., 2018; Dawkins & Corcoran, 
2014; Dawkins et al., 2012; Etter, 2015; Farsalinos, Spyrou, Tsimopoulou, et al., 2015) 
and more recent studies suggest that tanks are more efficient in doing so compared to 
cigalikes (Chen et al., 2016; Hajek et al., 2018; Rüther et al., 2017).  In a small sample 
of 20 young New Zealand residents, those using tanks were more likely to report that 
the e-cigarette satisfied their craving for tobacco cigarettes compared to those using 
cigalikes (Chen et al., 2016).   Others found that e-cigarettes help reduce their craving 
for cigarettes but lack in authenticity (Robertson et al., 2018).   This perceived lack of 
authenticity is echoed in other studies (Hoek et al., 2017; Mckeganey & Dickson, 2017).  
It is suggested that the e-cigarette only partly mimics smoking sensory cues but does not 
compare to the throat hit associated with smoking.  Given the central role and hedonic 
properties of the latter (Dautzenberg et al., 2016) and that for many that e-cigarettes can 
deliver this throat hit, constitutes as one of the primary motives for initiation of use 
(Yingst et al., 2015).  However, no studies have explored the ability of craving to 
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predict cessation in a sample of smokers who have been newly introduced to e-cigarette; 
thus, in this sense the current findings are novel.    
Motivation and Cigarette dependence as related predictors 
Motivation did not predict cessation at 1, 3 or 6 months follow-up.  Whilst 
previous studies suggest that motivation is predictive of a cessation attempt, this 
predictive ability seldom translates into predicting success outcomes or sustained 
abstinence (Borland, Yong, Balmford, et al., 2010; Vangeli et al., 2011).  Thus, 
motivation appears to be insufficient to achieve and maintain cessation.  Based on the 
preconceptions held by smokers that the mere presence of motivation is sufficient to 
quit, a likely explanation may be that an overreliance on their motivation and/or self-
confidence to quit may be an impediment to seeking support and using other  effective 
coping mechanisms (Balmford & Borland, 2008).  This evidence provides some 
explanation for the lack of predictive ability of motivation predicting cessation in this 
study.  
Though motivation to quit measured at baseline has proven a robust measure to 
predict quit attempts (Borland, Yong, Balmford, et al., 2010b; Hummel, Brown, 
Willemsen, West, & Kotz, 2016; Kotz, Brown, & West, 2013; Vangeli, Stapleton, Smit, 
Borland, & West, 2011), it conveys a flawed idea that motivation or intention to quit is 
static (Hughes et al., 2014).  In a sample of 16,657 smokers intending to quit, who 
responded to questions about their past quit attempt, current motivation to quit and 
consistency of their motivation in cross-sectional surveys, it was found that the 
incorporation of measures of the consistency of motivation to quit strengthened the 
prediction model of cessation above and beyond motivation alone (Perski, Herd, Brown, 
& West, 2018).  Thus, it seems that motivation is fluid and the extent, and the continued 
presence, of motivation may be better predictors of cessation.   
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Although cigarette dependence has consistently emerged as a predictor in 
standard smoking cessation studies, no studies have looked at cigarette dependence as a 
predictor of quit success using e-cigarettes.  Cigarette dependence was a significant 
predictor at 1 month only.  That dependence could predict cessation accords well with 
the literature, although, that dependence did not successfully predict cessation at 6 
months was unexpected.  Several studies suggest dependence levels as a predictor of 
cessation in smokers followed up over a period exceeding 6 months (Hagimoto et al., 
2010; Hughes et al., 2014; Rohsenow, Tidey, Martin, Colby, & Eissenberg, 2018b; 
Vangeli et al., 2011).  In a Japanese population sample of smokers (N = 1358) who were 
followed-up a year later, higher nicotine dependent smokers were less likely to quit 
smoking (Hagimoto et al., 2010), this is not surprising given that light smokers (based 
on CPD and first time of TC) have stronger motivation to stop than moderate to heavy 
smokers (Kotz, Fidler, & West, 2012).  That the overall sample in the current study had 
relatively low to moderate cigarette dependence scores may explain the predictive 
ability of cigarette dependence in this model; although the quit rate at 1 month was 
relatively modest (15.71 %).   
Cigarette dependence predicted cessation at 1 month but not at 6 months.  Like 
motivation to quit, this is indicative that cigarette dependence is not a static process.  
Thus not surprisingly, it predicted early success but as the smoker navigates through 
his/her slow transition towards a vaper’s identity, s/he may become less dependent on 
cigarettes as dependence is transferred over to e-cigs.  This is reflected in reports of 
several studies suggesting reduced and lower cigarette dependence in experienced e-
cigarette users in comparison to smokers (Etter & Eissenberg, 2015; Farsalinos, 
Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013a; Foulds et al., 2015).  At this point, 
the effectiveness of the device for delivering nicotine and alleviating craving becomes 
 
 
235 
 
more important for maintaining cessation.   Thus, because e-cigarettes differ from other 
cessation aids and quitting cold turkey (with very low or no abuse liability), the 
usefulness of cigarette dependence as a predictor of cessation is unclear.  
 
Limitations 
Due to several limitations, the current findings must be interpreted with caution.  
The cigalike group suffered a large drop-out rate which affected the sample size and 
gave rise to issues in the statistical analyses. Variables such as nicotine concentrations 
had to be re-categorized to account for the missing data.  The small sample size along 
with the gender imbalance at baseline (62.9% female) may constitute a further sampling 
bias since gender differences are well documented in the tobacco (Perkins et al., 1999) 
as well as in the e-cigarette literature (Jorenby et al., 2017). 
In addition, the data relies on self-report and due to limited resources, cessation 
was not always biologically verified, (as it was not always possible to collect CO).  
More frequent face-to-face follow-ups would have allowed better monitoring of daily e-
cigarette use behaviours including greater understanding of the interactions between 
device characteristics and users’ responses, which would have allowed for a better 
understanding of how e-cigarettes promote smoking reduction and cessation.  Instead, 
participants were contacted every 2 months over the 6 month period which could have 
caused recall bias.  That said, such approach (telephone contacts) is and continues to be 
standard practise in many large-scale surveys and has contributed greatly to the 
literature on predictors of cessation (Bauld et al., 2017; Maddison et al., 2010).  
Likewise, salivary cotinine was collected at baseline but could not always be collected 
at self-reported quit to assess nicotine exposure following smoking cessation.  A further 
limitation may come from the lack of representation of lower education smokers, 
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however it must be noted that the university campus wherein the study took place 
strives as an inclusive institution made up of a large black and ethnic minority groups 
from varied socio-economic status, and this is reflected in the current sample.  Lastly, 
given the lengthy process in the running of studies involving human participants (ethical 
approval, completion of data collection and so on) combined with the rapid evolving 
nature of this field of research (i.e. technological advancement), the current findings 
must be limited to the e-cigarette models assessed herein. 
 
Summary of Chapter IV 
Despite the above limitations, the current study is informative.  In a sample of 
70 e-cigarette naïve smokers willing to quit, predictors of smoking cessation were 
assessed at 1, 3 and 6 months after e-cigarette initiation.  From the predictors i) device 
type and nicotine concentrations combined (as per baseline allocation), ii) nicotine 
concentrations at follow-up, iii) device type at follow up, iv) baseline craving reduction 
(measured during e-cigarette initiation), v) baseline motivation to quit and vi) cigarette 
dependence and vii) puff duration post 2 weeks of initiation, only cigarette dependence 
was a significant predictor of cessation at 1 month, followed by baseline craving 
reduction at 3 months and e-cigarette device used at 6 months follow-up.  These 
findings suggest that lower cigarette dependent smokers were more likely to quit at 1 
month, whilst those with higher craving reduction at baseline had greater odds of 
successfully quitting at 3 months. Participants using tanks at follow up were at greater 
odds of quitting smoking at 6 months compared to those using cigalikes.  This is 
consistent with the literature and aligns well with the findings of Study 3.  That higher 
nicotine concentrations and the use of tanks elicit greater craving reduction compared to 
lower nicotine concentrations and cigalikes respectively, provide a good explanation for 
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the greater probability of success in quitting using tanks over cigalikes, and reiterate the 
critical role of nicotine delivery in promoting sustained use (of e-cigarettes) and 
smoking reduction.
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CHAPTER V 
OVERVIEW OF RESEARCH FINDINGS: GENERAL 
DISCUSSION 
 
 
Introduction: Summary of key findings 
 
The current thesis aimed to shed light on the inter-relationships between e-
cigarette puffing topography, nicotine concentrations and e-cigarette characteristics.    
Specific objectives were to: i) determine the effects of varying nicotine concentrations 
(high vs. low) in e-cigarettes on users’ puffing topography, ii) explore the effects of 
device types (tanks vs. cigalikes) on users’ puffing topography and smoking related 
effects and behaviours, iii) document how e-cigarette puffing topography evolves over 
time and differs in response to device types and nicotine concentrations and, iv) further 
the understanding of the complementary roles of subjective effects namely satisfaction, 
the alleviation of craving and withdrawal symptoms.  Additional objectives were to 
explore v) the factors (including puffing topography) that best predict smoking 
cessation at 1, 3 and 6 months in a sample of 70 e-cigarette-naïve smokers using 
different device types and varied nicotine concentrations.   
In the first main and pilot study (described in Chapter II), findings suggested 
that like smokers, experienced e-cigarette users will self-titrate, that is, respond to 
nicotine concentrations by changing their puffing patterns in order to regulate their 
blood nicotine to satisfactory/habitual levels, sufficient to alleviate craving and 
withdrawal symptoms.  E-cigarette users in this study drew longer puffs and increased 
their puffing frequency when administered the low, compared to the high, nicotine 
concentrations.  Following a 60 min ad lib use of 6 mg/mL nicotine concentration e-
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liquid, titration was only partial, evidenced by marked differential plasma nicotine 
levels yet no differences in craving and withdrawal symptom alleviations between the 
low and high nicotine concentrations.   
In Study 2, (Chapter III), 70 e-cigarette-naïve smokers increased their puff 
duration one week following initial use, seemingly to compensate for the less effective 
nicotine delivery of e-cigarettes relative to their tobacco cigarettes.  Those using the 
cigalikes drew more frequent and longer puffs compared to those using tank devices.  
Furthermore, cigalikes and tanks both containing 18 mg/mL nicotine concentration did 
not differ in their ability to alleviate craving, whilst the 6 mg/mL tank performed the 
poorest.  In contrast, regardless of the nicotine concentrations the tank model elicited 
greater levels of satisfaction compared to the cigalike.  Encouragingly, regardless of the 
device type and nicotine concentrations, e-cigarettes helped reduce smoking and 
cigarette dependence in the first two weeks following initiation.  However, smoking 
reduction plateaued between the first and second week.   
Study 3 (Chapter IV) revealed cigarette dependence as the best predictor for 
smoking cessation at 1 month, the less dependent smokers were more likely to quit at 1 
month.  Those who reported greater craving relief at baseline following the 20-minute 
ad libitum vaping session were at greater odds to have quit at 3 months, whilst those 
reporting using a tank device at 6-month follow-up were more likely to have succeeded 
in their quit attempt.   
Self-titration and nicotine delivery: Effects of e-liquid nicotine 
concentrations, device types and practise  
The addictiveness of a drug directly relates to the time at which it is 
administered and the time for the reward to manifest in the brain; this may explain the 
direct relationship between nicotine dependence and the speed of nicotine delivery (de 
Wit et al., 1992; Henningfield and Keenan, 1993).  Thus, nicotine delivery is a key 
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determinant in the appeal and effectiveness of e-cigarettes which in turn will influence 
their potential to be accepted and replace smoking.    
A likely mechanism by which users exert control over this delivery is through 
altering their puffing patterns in order to obtain desired and maintain steady levels of 
nicotine.  Although well documented in the tobacco literature, Study 1 is the first to 
provide direct evidence of self-titration in experienced e-cigarette users (Dawkins et al., 
2016).  Like smokers, e-cigarette users will alter their puffing frequency and duration in 
response to the nicotine exposure in an attempt to match habitual levels.  Thus, 
compensatory puffing behaviours observed in Study 1 suggest that nicotine 
concentrations play a key role in influencing puffing topography, which in turn affects 
blood nicotine delivery, satisfaction and craving alleviation.  The recent national survey 
citing the inability of e-cigarettes to reduce craving for tobacco cigarettes as one of the 
chief reasons for discontinuing use of the device (ASH, 2017), highlights the relevance 
of the findings of Study 2.  In e-cigarette naïve smokers, higher nicotine concentrations 
(18 mg/mL) were more effective in relieving craving compared to lower ones (6 
mg/mL) (see Chapter III).   
The efficacy of obtaining satisfactory blood nicotine levels depends upon the 
way the e-cigarette is used and studies have shown that both are likely to improve with 
practise (Hajek et al., 2015).  Although the nicotine delivery from e-cigarettes appears 
less effective in e-cigarette-naïve smokers, Study 2 suggests that this could be reversed 
with a week of practice.  By learning to adjust their puffing patterns (increasing the 
duration of each puff), e-cigarette users can obtain satisfactory blood nicotine levels, 
withdrawal and craving alleviation (Dawkins & Corcoran, 2014; Dawkins, Turner, 
Hasna, & Soar, 2012; Etter & Bullen, 2011) and eventually succeed in substituting their 
tobacco smoking to e-cigarette use.  Although nicotine exposure was not measured in 
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study 2, reflecting on their smoking reduction and craving alleviation, it is reasonable to 
argue that overall, participants were able to obtain satisfactory blood levels. 
Another likely factor to influence nicotine delivery is the proficiency of the 
device used.  As highlighted in chapter I, early studies reported that e-cigarettes could 
not deliver nicotine efficiently (Bullen et al., 2010; Eissenberg, 2010; Vansickel et al., 
2010).  In contrast, later studies in long term users (Dawkins & Corcoran, 2014) found 
that later tank models can be effective in increasing blood nicotine levels and alleviating 
craving to a greater extent than do cigalikes (Farsalinos et al., 2014a; Nides, Leischow, 
Bhatter, & Simmons, 2014; Vansickel & Eissenberg, 2013).   In Study 2 although 
cigalikes reduced smoking, cigarette dependence and craving to the same extent than 
did the tanks, cigalikes were associated with reduced satisfaction at all time points.  
Given that dissatisfaction with e-cigarettes has been cited as one of the main reasons for 
discontinuing use (ASH, 2017; Simonavicious, 2017), these findings are important.  
Consistent with the literature, the findings here help explain the trend for users to 
transition to tank models.  Additionally, Study 3 found that those using tanks at follow-
up, were more likely to have succeeding in their quit attempts at 6 months compared to 
those using cigalikes, which reflects the larger drop-out rate in those using cigalikes, in 
study 3.  
The effects of nicotine concentrations on puffing topography and nicotine delivery  
Findings of Study 1 lend support to the proposition that puffing topography is a 
key determinant of nicotine delivery (Williams et al., 2011) with longer puff duration 
and shorter IPIs yielding more efficient nicotine delivery (Hajek et al., 2015).  There 
was a near two-fold increase in the e-liquid consumption in the low compared with the 
high nicotine concentration (see Figure 2.6, Chapter II).  This was coupled with a 
significant increase in puff duration and puff number in the 6 mg/mL compared to the 
24 mg/mL nicotine concentrations condition.  Nevertheless plasma nicotine levels 
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reached a much greater level under the 24 mg/mL compared to the 6 mg/mL (See Table 
2.2 and Figures 2.2 and 2.3, Chapter II).  The near doubling of liquid consumption 
combined with a more intensive puffing regimen suggest that participants may have felt 
the need to invest substantial effort in an attempt to raise their blood nicotine to 
satisfactory levels, although whether this behavioural mechanism is conscious is 
unclear; this could be a focus for future research.  The time constraint (one hour) 
combined with the four-fold drop in nicotine availability may have caused a saturation 
effect and impeded their attempt to self-titrate successfully.  This could be attributed to 
the fact that any constrained time period restricts the quantity of nicotine liquid that an 
individual is able to consume comfortably.  A more prolonged ad lib session could have 
raised plasma nicotine to the same levels as those achieved in the high nicotine 
concentrations although whether this is achievable and the time course required remain 
unknown.  
The one hour ad libitum use of the low nicotine concentrations (6 mg/mL) in 
Study 1, led to longer mean puff durations and markedly higher plasma nicotine levels 
compared to levels observed in naive users in other studies (Farsalinos et al., 2015).   
However, although slightly longer, the average puff duration in the high condition (24 
mg/mL) observed is in good agreement with those previously reported in experienced 
users (Hua et al., 2011) using newer generation devices (Farsalinos et al., 2014).  The 
differences in puff duration between naïve and experienced users have been previously 
reported (Farsalinos, Spyrou, Stefopoulos, et al., 2015; Farsalinos, Romagna, Tsiapras, 
Kyrzopoulos, & Voudris, 2013b; Fearon et al., 2017; Hiler, 2016a; Talih et al., 2014), 
and are a good reflection of the increased puff duration observed in e-cigarette-naïve 
smokers a week following e-cigarette initiation (as seen in Study 2, Chapter III).  This 
adjustment in puffing characteristics may be attributed to a lower nicotine flux (that is 
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the pace to dosage ratio of the aerosol delivered) (Shihadeh & Eissenberg, 2015; Talih 
et al., 2015) in relation to tobacco cigarettes requiring an increase in puff duration.  
Thus, altogether, the adjustment seen in the sample of e-cigarette naïve users within this 
thesis (Study 2, Chapter III) strongly suggests an attempt to compensate for a slower 
and less efficient nicotine delivery.   The significant decrease in the number of puffs 
over the two-week period seen in Study 2, which combined with a significant increase 
in puff duration, suggests a dramatic change in puffing behaviour.  This appears to be 
characterised by a shift from a more erratic puffing regimen at initial use to longer and 
more paced puffs in subsequent sessions which may form part of the learning process 
required when transitioning from smoking to exclusive e-cigarette use.   
In Study 2, mean puff duration at initial use are consistent with previous 
findings using e-cigarette naïve smokers (Behar et al., 2015; Farsalinos, Spyrou, et al., 
2014; Lee et al., 2015; Talih et al., 2014) which suggests some degree of homogeneity 
in the puffing topography of smokers, but contrasts with the typical topography of 
experienced users (Farsalinos et al., 2013; 2014; 2015; Talih et al., 2015).   Indeed, 
mean scores in puff duration (both conditions collapsed) found in Study 1 in 
experienced users were higher than those observed in the e-cigarette-naïve smokers in 
Study 2.   These differences in puffing topography mirror the reduced ability of e-
cigarette naïve users to obtain systemic raised blood nicotine levels, satisfaction and 
craving relief (Farsalinos, Spyrou, Stefopoulos, et al., 2015; Fearon et al., 2017); which 
affect nicotine delivery (Foulds et al., 2015).  That shorter puff duration tend to be 
associated with poorer nicotine delivery profile is evidenced in previous studies in 
which lower plasma nicotine concentrations were found in e-cigarette naïve smokers 
who displayed lower puff duration of 2.3s compared to experienced users who 
displayed a mean puff duration of 3.5s (Farsalinos, Spyrou, Tsimopoulou, et al., 2015).   
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In another study comparing e-cigarette naïve smokers’ puffing profiles to those of 
experienced users, Talih and colleagues (2015), found the 2-second duration profile to 
be associated with much lower nicotine delivery compared to longer puffing duration of 
4s commonly exerted by experienced users.  Similarly, following a 65 min ad lib vaping 
session, Farsalinos’ group reported significantly greater levels of plasma nicotine levels 
in experienced users versus e-cigarette naïve smokers; this was mirrored by the 
difference in puff duration with a mean puff duration of 2.3 s in naïve e-cigarette 
smokers and 3.5 s in experienced users (Farsalinos, et al., 2015).    
Consistent with previous studies, participants increased their puff duration after 
a week following initial use which subsequently plateaued at the final follow-up session 
2 weeks post e-cigarette initiation (Study 2, Chapter III).  This increase in puff duration 
is suggestive of an adjustment in puffing topography by naïve users over time which 
corroborates the self-titration theory at least in the short term insofar as the shorter puffs 
exerted at initial use may not have yielded satisfactory blood levels.  This increase in 
puff duration is a key finding specifically as puff duration along with IPI have been 
reported as the most influential drivers of aerosol yield (Kośmider et al., 2016).   
Indeed, a week seems to be sufficient to observe an evolution in puffing topography and 
for e-cigarette naïve smokers to develop an awareness for the need to adjust their 
puffing from smoking to e-cigarette use.  This is consistent with previous findings in 
which a sample of 20 smokers who were introduced to a 18 mg/mL cigalike increased 
their puff duration from 2.2 s to 3.1 s after a week of initial use (Lee et al., 2015).  The 
increase in puff duration herein is in line with the early suggestion that there is a 
learning process required for an effective use of e-cigarettes (McQueen, Tower & 
Summer, 2011).   Similarly, others have found that the efficiency of obtaining 
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satisfactory blood nicotine levels depends upon the way the e-cigarette is used and is 
likely to improve with practise (Hajek et al., 2015).    
In Study 2, there was a significant decrease in the number of puffs over the two-
week period which, combined with a significant increase in puff duration strongly suggest 
a dramatic change in puffing behaviour characterised by a shift to slower, longer more 
paced puffs from a more erratic puffing style at initial use.  Like in the case of puff 
duration, there was no difference between time points 1 and 2 suggesting a plateau effect 
after a week of use.  There was no significant difference between the 6 and 18  mg/mL 
nicotine concentrations tanks or the cigalike, although previous studies suggest that puff 
numbers have no or little effect on nicotine delivery (Kośmider et al., 2016; Spindle, 
2015).  The present findings are in line with the findings relating to puff duration thus are 
informative.  Altogether, Studies 1 and 2 provide evidence which lends support to the 
notion that like smokers, e-cigarette users self-titrate to regulate their nicotine intake to 
desired levels. 
Conversely, puff duration an important factor in nicotine delivery as suggested 
in Study 1 and 2, was not a significant predictor at 3-month follow-up and was removed 
from the model at 1 and 6 months, in study 3.  Findings of Study 2 suggested adjusting 
puff duration over time as part of the learning process to help in reducing smoking and 
for a successful transition to e-cigarettes use.   Study 1 found that puffing duration to be 
a key differential factor that partly contributed to plasma nicotine levels.  Thus, given 
that numerous studies have highlighted the importance of puff duration to optimise 
nicotine delivery (Dawkins & Corcoran, 2014; Dawkins et al., 2016; Farsalinos, 
Spyrou, et al., 2014; Farsalinos, Spyrou, Stefopoulos, et al., 2015; Hajek et al., 2015),  
and increase satisfaction (Hajek et al., 2017), which may help promote sustained use of 
the e-cigarette in replacement of smoking, the poor predictive ability of puff duration in 
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study 3 was unexpected.  This may be due to the difficulty in distinguishing puff 
duration from other variables (i.e. nicotine concentrations, device characteristics) which 
when combined, exert a greater influence on nicotine delivery as discussed in previous 
chapters. 
Plasma nicotine levels  
A number of studies have found that smokers are usually successful in 
regulating their blood nicotine to satisfactory levels in response to higher nicotine 
content cigarettes (that is they are able to down-regulate and lower their blood nicotine 
to habitual non-aversive levels) (Russell, 1980; Russell, Sutton, Iyer, Feyerabend, & 
Vesey, 1982; Sutton et al., 1982).  However, when presented with lower nicotine 
content cigarettes, raising blood nicotine to habitual levels is more challenging and 
rarely achieved (Ashton et al., 1979; Russell et al., 1975).  This was also the case in 
experienced e-cigarette users in Study 1.  Despite the more intensive puffing regimen 
exerted in the low nicotine concentrations condition, plasma nicotine levels did not 
reach levels achieved in the high nicotine concentrations; though an alternative and 
plausible explanation may be that levels achieved in the high nicotine concentrations 
were unusually high in respect to participants’ habitual levels and they were 
unsuccessful in their attempts to achieve downward titration.  However, both 
conditions, the 6 and 24 mg/mL nicotine concentrations, helped alleviate craving and 
withdrawal symptoms to the same extent which suggests that the partial titration 
achieved was sufficient from a subjective perspective.  Thus, although it could be 
tempting to argue that these findings undermine the primacy role played by nicotine 
delivery in the reinforcement of smoking, the explicit increase in puffing intensity 
certainly suggests otherwise.  Besides, a more plausible explanation would be that the 
lower plasma nicotine levels are the result of a ceiling effect and that the four-fold drop 
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in nicotine concentrations was too great to yield equal levels in plasma nicotine.  It is 
unclear whether a more mid-range nicotine concentration (e.g. 12 mg/mL as opposed to 
6) would lessen the gap in plasma nicotine levels and result in complete titration; this 
could be a focus for future research. 
Thanks to the rapid advancement in technology, recent findings suggest that the 
shape of the pharmacokinetic curve of the nicotine delivery of e-cigarettes is 
increasingly approaching that of combustible cigarettes (St Helen et al., 2015); findings 
of the present study certainly seem to support this trend.  Plasma nicotine levels 
achieved in the sample of experienced users in Study 1 were remarkably high compared 
to those in previous reports and exceed levels observed in tobacco smoking (Russell et 
al., 1980; Russell, Wilson, Patel, Feyerabend, & Cole, 1975) and in previous e-cigarette 
studies in which similar (Farsalinos et al., 2014; Farsalinos et al., 2015; Yan & D’Ruiz, 
2015) and higher nicotine concentrations (Hajek et al., 2017; Lopez et al., 2016; Ramôa 
et al., 2015) were employed.  In a relatively recent study the smoking of a tobacco 
cigarette in a five-minute puffing period (10 puffs, 30 seconds apart) resulted in Cmax 
of 13.4 ng/mL (Fearon et al., 2017), which seems negligeable compared to levels 
achieved by some individuals in study 1 (means ranged from 5 to 110.12 ng/mL); 
although it is worth noting that earlier titration studies in smokers demonstrated much 
higher Cmax compared to more recent studies (Russell et al., 1975).  Such discrepancies 
may be attributed to the differences in puffing protocols between studies.  In particular, 
in order to control for baseline nicotine delivery, previous studies imposed a 
standardised puffing regimen prior to the ad libitum session (Lopez et al., 2016; Ramôa 
et al., 2015).  Although such approach allows for greater control and internal validity on 
one hand, on the other, it may affect participants’ responses and bias the results by 
imposing unrealistic puffing patterns.  Alternatively, in study 1, such high plasma 
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nicotine levels may be due to the one-hour ad libitum vaping design combined with the 
requirement to abstain for 10 to 12 hours and a self-selected sample of experienced 
users with high baseline salivary cotinine levels equal or exceeding 100 ng/mL nicotine 
concentration.  Such prolonged periods of abstinence could have evoked or exacerbated 
the increased puffing exertion to counter depleted blood nicotine levels and produce 
rapid elevation (Sutton et al., 1982).   
Further evidence of compensation could be found in the per interval puffing 
topography data in Study 1.  In the high condition, the increase in plasma nicotine boost 
was accompanied by analogous decrease in puffing.  The number of puffs taken from 
baseline to 30 minutes was significantly lower than the number of puffs taken during 
the remaining 30 minutes, and in some cases, the trajectory of the nicotine boost went 
downwards after the 30 minutes, suggesting an attempt to down-regulate to habitual 
comfortable plasma nicotine levels.  Already the first 10 minutes were marked by a 
significant difference in puff duration, with a higher overall mean in the low compared 
to the high condition.  Given the rapid 10 to 20 seconds period in which nicotine 
typically reaches the brain (Henningfield et al., 1993) and that the greatest amount of 
nicotine is transported in the first two minutes of e-cigarettes use (Rüther et al., 2017), 
this first 10 minutes would have been amply sufficient to allow for possible aversive 
effects to be experienced, triggering a need to reduce the nicotine intake and down-
titrate.  This puffing behaviour is reminiscent of cigarette smoking.  Smokers are able to 
regulate their smoke and nicotine intake on a puff-by-puff basis by exerting a more 
intensive puffing regimen on the first puffs of a single cigarette subsequently decreasing 
the intensity of their puffing as the cigarette is smoked (Collins et al., 2010).  Similarly, 
the results of Study 1 suggest that e-cigarette users will adjust and decrease their puffing 
in response to nicotine overload or saturation.  In fact, although, this did not differ 
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statistically, mean scores on ‘vomiting’ were greater in the high nicotine condition 
compared to the low condition, suggesting that aversive effects may have occurred in 
the high condition more so than in the low nicotine concentration condition.   
Individual differences 
Puffing topography and plasma nicotine levels varied widely amongst 
participants (in Study 1, Chapter II) however, like in the smoking population (Gust et 
al., 1983) and as seen in previous studies (Behar et al., 2015), puffing patterns were 
consistent across both conditions (6 and 24 mg/mL nicotine concentrations) within 
participants.  As indicated by the standard deviations (study 1), individual variabilities 
were more pronounced in the low nicotine concentration condition with the lowest 
individual mean puff number of 14 and the highest 131.  Mean volume consumed 
ranged from .45 to 2.38 mL and mean puff duration ranged from 3.20 to 7.31 s, in some 
cases exceeding 10 s.  Such extreme long puffs are not uncommon in e-cigarette use, 
Hua and colleagues observed puff duration of 8 s in experienced e-cigarette users (Hua 
et al., 2013).  As was the case for most of the sample, participant 6 increased his puffing 
frequency by almost double from 63 to 131 puffs and his puff duration from 3.94 to 
5.17 s and his liquid consumption from .88 to 2.38 mL.  The lack of statistical 
significance in correlational analysis between puffing topography and plasma cotinine 
levels suggests that inhalation depth may have differed widely between participants and 
influenced nicotine absorption.  The individual variations are likely to be due to the 
small size of the sample and may also be a reflection of the variations in nicotine 
dependence within the sample with baseline cotinine levels varying from 134.2 to 890.6 
ng/mL.  Nonetheless, these wide individual differences seen here are consistent with 
variations observed in tobacco smoking  (Hammond et al., 2005) with plasma nicotine 
levels varying from 5 to 70 ng/mL (Russell, 1980), but also in previous studies in e-
cigarette use (Farsalinos et al., 2015; Yan & D’Ruiz, 2015).   
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Participants’ puffing patterns seemed to fluctuate in the same fashion across 
vaping sequence and conditions.  In the low condition, mean puff number and duration 
accompanied an increase in nicotine boost in most cases whereas in the high condition, 
increases in nicotine boost were generally followed by downward trends in puffing 
patterns. .  Two participants (P 6 and P 10) seemed to achieve complete self-titration 
raising their plasma nicotine in the low condition to similar levels achieved in the high 
condition, which suggests that it is possible for some e-cigarette users to self-titrate by 
adjusting their puffing patterns in order to obtain desired and satisfactory plasma 
nicotine levels.  Nonetheless this was only achieved by almost a two-fold increase in 
puff numbers, a significant increase in puff duration and more than two-fold increase in 
e-liquid consumption, which altogether may be associated with long term adverse health 
consequences (Dawkins et al., 2018; Kośmider, Kimber, Kurek, Corcoran, & Dawkins, 
2017).   
Likewise, individual differences were observed in Study 2.  Akin to the large 
standard deviations found between conditions, the findings of Study 2 echo the inter-
variations in e-cigarette puffing topography reminiscent of those seen in previous 
studies (Behar et al., 2015; Hajek et al., 2015) but also in smoking behaviours 
(Hammond et al., 2005).   Importantly, these large individual variations may provide 
some explanation for the non-statistically significant differences in puffing topography 
between the Tank 6 and Tank 18 (refer to the section on E-cigarette type, nicotine 
concentrations in the discussion in Chapter III). 
Relationships between nicotine metabolism, nicotine intake and puffing topography 
In Study 1, baseline cotinine levels and trans-3-hydroxy-cotinine to cotinine 
ratio (OH-cot/cotinine) were measured to confirm that any changes in puffing 
topography were not due to nicotine metabolism alone but largely to the availibility of 
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nicotine.  In the sample of experienced e-cigarette users means in OH-cot/cotinine ratio 
were within the common range seen amongst smokers (Dempsey et al., 2004), with 
wide inter-individual variation, thus would have little influence on puffing patterns.  
Puff number and duration were not associated with baseline cotinine levels, 3-hydroxy 
cotinine or OH-cot/cotinine ratio.  Neither did baseline cotinine, OH-cot or OH-
cot/cotinine correlate with plasma nicotine boost under high or low conditions at any 
time point.  This suggests that phenotypic status did not affect puffing behaviours.  
Besides, whilst nicotine metabolism has been shown to influence smoking and nicotine 
intake (Scherer & Lee, 2014), the one hour ad libitum vaping session probably did not 
allow sufficient time for the metabolism of nicotine to exert any effect on puffing 
behaviours.  
The effects of device types on puffing topography and nicotine delivery  
The average puff duration using the 6 mg/mL by experienced users in Study 1 
were longer than those reported for cigalikes in other studies (Behar et al., 2015) and 
combustible cigarettes (Hua et al., 2013); whilst puff duration associated with the 
cigalikes in Study 2 exceeded that associated with the tanks.  That previous studies 
found longer puff duration in cigalikes to be associated with greater discomfort 
compared to slightly later tank models (eGo e-cigarette) (Dawkins, Kimber, 
Puwanesarasa, & Soar, 2015) reinforces the notion that rather than a nicotine 
concentrations effect, here the longer puff duration seen in cigalikes may have been 
driven by  device characteristics namely, a more resistant draw mechanism.  However, 
of worthy mention, aside from nicotine concentration and device types, other factors 
such as the e-liquid ingredients and parameters applied during use have been found to 
influence puffing patterns and nicotine yield.   For instance, liquids containing a 
combination of propylene glycol (PG) and vegetable glycerine (VG) elicit lower and 
shallower puffing frequency but higher plasma nicotine levels compared to VG-based e-
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liquid due to their chemical properties (Yan & D’Ruiz, 2015).  In the same light, 
flavours have also been found to affect puffing topography (Litt, Duffy, & Oncken, 
2016) and nicotine delivery (St.Helen, Shahid, Chu, & Benowitz, 2018).  In this 
experimental work, this was controlled for by ensuring in each study, all products 
(including atomisers) were purchased in batches, labelled with the same PG/VG ratio, 
and same flavours within and across conditions and participants, with the exception of 
the use of two cigalikes brands due to leakage issues (see methods section in Study 2, 
Chapter III).  Nonetheless, variance in device parameters could not be fully controlled 
as participants were instructed to use the tank within the recommended range of 3.3 to 4 
volts; such variances may have affected nicotine delivery. 
In Study 2, participants in the Cigalike condition took longer puffs compared to 
both those using the Tank 6 and Tank 18, which is suggestive of a device type, rather 
than a nicotine concentration effect.   Against expectations and in contrast with the 
findings in Study 1, there was no significant difference between Tank 18 and Tank 6 at 
any time point suggesting some degree of homogeneity in the puffing topography of 
participants in both tank conditions compared with the cigalike, which may be driven by 
the fact that both are the same model with the same mechanism suction, thus same 
aerosol density emission; although such comparison between Study 1 and 2 is 
problematic since participants in Study 1 were experienced users whilst those in Study 2 
were naïve users.   Given the three-fold drop in concentrations (18 to 6 mg/mL) that 
Tank 6 did not differ from Tank 18 is surprising; one might have expected significantly 
longer puff duration in the Tank 6.  Nevertheless, although failing to reach statistical 
significance, mean scores in puff numbers and duration were higher in the Tank 6 in 
comparison with the Tank 18 across all sessions.  This concurs with previous studies in 
which lower nicotine concentrations (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & 
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Voudris, 2013a; Hajek et al., 2017) and shorter puff duration were found to be 
associated with poorer nicotine delivery (Farsalinos, Spyrou, Tsimopoulou, et al., 2015; 
Hiler, 2016b).    
In Study 2, the inter-puff intervals (IPI) increased from Baseline to Time 1 and 
plateaued at Time 2.  In line with the longer puff duration in the Cigalike, IPI were 
greater in the Tank 18 in comparison; and although this was not statistically significant, 
mean scores were greater in Tank 18 compared to the Tank 6.   This suggests that the 
participants in the higher nicotine concentration tank condition exerted a longer pause 
between puffs, consistent with the literature suggesting that nicotine concentrations 
relate directly to nicotine delivery (Lopez et al., 2016) and dictate puffing topography.  
Likewise, the puffing topography derived from the cigalikes reiterates the proposition of 
a more erratic or intense puffing profile associated with cigalikes compared to the tank 
systems and are suggestive of an interweaved relationship between nicotine delivery 
and puffing topography.   
In Study 2, participants took an average of 39.51 puffs in the cigalike condition 
across the 3 sessions together.  This is in good agreement with a previous study in 
which 20 experienced e-cigarette users took an average of more than 20 puffs in a 10-
minute ad lib session (Behar et al., 2015) which, compares well with the mean of 39.51 
in the 20-minute session.  Indeed, the likening of this observed adjustment in puffing 
topography in an attempt to compensate for the less efficient nicotine delivery compared 
to tobacco cigarettes is further evidenced in a previous study in which 50 puffs from a 
24mg/mL containing cigalike were required to raise blood nicotine to levels analogous 
of those obtained after the smoking of one combustible cigarette (which consisted of 
approximately 10 puffs) (Yan & D’Ruiz, 2015).   That cigalikes are associated with 
poorer nicotine delivery is also documented in pharmacokinetic studies in which modest 
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increases in plasma nicotine were obtained in naïve and  experienced users compared to 
combustibles (Fearon et al., 2017).   
An increasing number of studies suggest the superiority of tanks over cigalikes 
in alleviating craving (Chen et al., 2016; Hajek et al., 2018; Rüther et al., 2017).  The 
results of Study 2 suggesting no differences between tanks and cigalikes in craving 
alleviation contradict previous findings.  An online cross-sectional survey of 374 
respondents, found that tanks systems and higher nicotine concentrations were found to 
be associated with greater craving relief (Etter, 2015) which suggests that the greater 
capability of the tank models to alleviate craving compared to cigalikes could be 
attributed to their nicotine delivery efficiency.  Several experimental lab-based studies 
assessing the nicotine delivery of e-cigarette models have found that tanks 
systematically deliver higher nicotine levels compared to cigalikes (Farsalinos et al., 
2014; Hajek et al., 2018; Rüther et al., 2017), even at levels that equate to those reached 
after the smoking of a cigarette (Dawkins et al., 2016; Ramôa et al., 2015; Rüther et al., 
2017; Wagener et al., 2016).  The reinforcing value of nicotine in smoking (Benowitz, 
2010; Henningfield & Keenan, 1993), to alleviate craving and provide satisfaction 
(Etter, 2015; Dawkins, Kimber et al., 2015), may be the route by which tanks are better 
able to facilitate sustained use of the product and provide an effective replacement to 
smoking (Hitchman et al., 2015; Yingst et al., 2015).   
In Study 2, the unexpected lack of differences between Tank 18 and cigalikes in 
craving reduction scores despite the arguably different nicotine delivery systems may 
suggest a reduced role for craving in dictating puffing topography.  This has been 
suggested in previous studies.  In 2 separate sessions, 24 participants were randomised 
to 5 e-cigarettes with varying e-liquid formulation (16 and 24 mg/mL and differing 
PG/VG ratio) and a combustible cigarette; plasma nicotine levels and craving (urge to 
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smoke) were measured during a 30-min standardised protocol (50 puffs, 30 s IPI) 
followed by a 1 h ad lib use.  Strikingly, following completion of both sessions, the 
differences in nicotine exposure (23% to 53% greater from the tobacco cigarette 
compared to the e-cigarettes) and mean scores in nicotine plasma concentrations were 
not reflective of the homogeneity observed in craving reduction scores (10% greater in 
the tobacco cigarette in relation to the e-cigarettes following the ad lib period).  Given 
the differences in nicotine exposure, one would expect the differences in craving to be 
of magnitude greater than the values observed.   Thus, as per the authors’ comments, 
although higher nicotine concentrations and the presence of PG influenced means 
plasma nicotine concentrations, craving did not seem to be impacted.  Therefore, it is 
reasonable to conclude that although an important determinant of smoking behaviours, 
the alleviation of craving is not always proportional with nicotine delivery.  This is in 
line with the findings of Study 1.  Compensatory puffing failed to raise plasma nicotine 
levels but was sufficient to yield craving alleviation in the 6 mg/mL nicotine 
concentrations condition; this further suggests that craving would make a poor indicator 
of efficient or poor nicotine delivery.  Alternatively, the aforementioned findings 
reiterate that non-pharmacological factors such as visual stimuli (e.g. aerosol visibility) 
play a significant role in the alleviation of craving as suggested in previous studies 
(Dawkins, Munafò, et al., 2015; Dawkins et al., 2012), and may partly contribute to the 
appeal for e-cigarettes.    
The findings of  Study 2 that cigalikes were associated with greater puff duration 
but lower satisfaction provide novel evidence for the literature and align with previous 
findings that cigalikes tend to be associated with a less efficient nicotine delivery 
compared to tank systems (Farsalinos, Spyrou, Tsimopoulou, Stefopoulos, Romagna, & 
Voudris, 2014).   This is consistent with a previous study which compared plasma 
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nicotine concentrations between device types and a combustible cigarette.  In the first 
five minutes, whilst cigalikes failed to yield comparable increase in nicotine in relation 
to the tank and the combustible cigarette, the tank model successfully reduced craving 
to the same magnitude as did the smoking of the combustible cigarette (Rüther et al., 
2017).  This reiterates tank models’ superiority in providing satisfactory nicotine levels 
to its user compared to cigalikes.  The inability of cigalikes to provide satisfaction levels 
that equal those obtained with tanks may be due to differences in device components’ 
design (Gillman et al., 2016), which may be responsible for the stronger vacuum 
mechanism of cigalikes compared to tanks.  Altogether, these findings highlight the 
importance of nicotine delivery and align well with the notion that more intensive 
puffing intensity exerted in cigalikes compared to tanks may be attributed to a more 
resistant airflow-activated system (Williams, Ghai, & Talbot, 2015) which constrains 
the nicotine e-liquid delivery and affect sensory factors.    
In Study 2 although cigalikes reduced smoking, cigarette dependence and 
craving to the same extent as tanks, cigalikes were associated with reduced satisfaction 
at all time points.  The latter could have contributed to the larger drop-out rate in those 
using cigalikes compared to other conditions.  This in concordance with the findings of 
Study 3 indicating that those using tanks at follow-up, were more likely to have 
succeeded in their quit attempts at 6 months compared to those using cigalikes.  Given 
that dissatisfaction with e-cigarettes has been cited as one of the main reason for 
discontinuing use (ASH, 2017; Simonavicious, 2017), these findings are important and 
reiterate the need for better nicotine delivery devices that provide satisfaction.  Whilst 
nicotine remains central in facilitating the transition to exclusive e-cigarette use, it 
appears that for some, the rituals of smoking are of equal, or even greater importance 
compared to nicotine delivery.  This reiterates the heterogeneity of e-cigarette use, and 
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users, and the need to maintain a market that offers a wide range of products for those 
seeking an experience that closely approximates smoking and for those requiring 
effective nicotine delivery.  In line with this proposition, recently, there has been a 
dramatic surge of a novel vaporiser ‘JUUL’ (developed in the US); its characteristics, a 
relatively slim shape, small size and non-rechargeable pod (Willett et al., 2018) do not 
depart from that of a cigalike.  Importantly it can be mounted with pods containing 
nicotine concentrations that largely exceed the 20 mg/mL cap (Willett et al., 2018).  The 
sudden increase in popularity of this novel device in the US is indicative of a continued 
need for improved nicotine delivery products which do not diverge greatly from the 
resemblance of tobacco cigarettes.  
Predictors of smoking cessation: the interweaved relationship between 
device type, nicotine concentration, puffing behaviour and subjective effects 
Studies suggest multiple mechanisms by which e-cigarettes help promote 
smoking reduction and cessation.  These may be by i) helping to alleviate craving for 
tobacco cigarettes and other adverse abstinence related symptoms (Adriaens et al., 
2014; Dawkins, Kimber, et al., 2015; Etter, 2015; Hajek, Przulj, Phillips-Waller, 
Anderson, & McRobbie, 2018; Rüther et al., 2017), ii) delivering nicotine efficiently 
and in ways that approximate that of combustible cigarettes (Farsalinos, Spyrou, 
Tsimopoulou, et al., 2015; Hajek et al., 2015, 2017; Lechner, Meier, et al., 2015; 
Wagener et al., 2016), iii) providing novel features such as device customisability 
(Vandrevala et al., 2017) or enhanced sensory factors (Farsalinos, Romagna, Tsiapras, 
Kyrzopoulos, Spyrou, et al., 2013; Ward et al., 2018), and iv) by allowing lapses whilst 
minimising risks of complete relapse (Notley et al., 2017).   
In Study 3, in a sample of 70 naïve e-cigarette smokers, those reporting using a 
tank device at the time of follow-up were more likely to have quit at 6 months 
compared to those using a cigalike, regardless of the nicotine concentrations.  As 
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described in Chapter IV, these findings are consistent with previous studies suggesting 
that tank users are more likely to report craving reduction and complete cessation (Chen 
et al., 2016; Hitchman et al., 2015; Shiffman et al., 2018).  Past studies point to an 
important factor which has often been neglected in many past correlational studies 
exploring the relationship between e-cigarettes and subsequent smoking: frequency or 
heaviness of e-cigarette use (Leventhal et al., 2015).  In Study 2, self-reported puffing 
patterns did not significantly differ between conditions (cigalikes, tank 18 and tank 6), 
nor were there any significant differences over time.  These findings contradict those 
obtained during the ad libitum lab-based sessions (Study 1), although participants’ 
puffing patterns changed over time and differed between conditions, these did not 
extend outside of the lab.   In Study 3, participants were asked to recall the volume of e-
liquid they consume in mL per day for those using tanks and cartridges per week in the 
cigalike group.  However, many had difficulties making such recalls (in addition there 
were some reports of spillages and refilling with third parties’ liquid at times) which 
lessened the reliability of the variable volume consumed.  Such challenges in the 
reporting of quantity consumed is echoed in the literature (Cooper, Harrell, & Perry, 
2016) and suggests that the lack of changes over time or differences in self-report 
puffing patterns in Study 2 outlined previously may lack accuracy and reliability.   
The findings that tanks were associated with complete cessation in relation to 
cigalikes in Study 3, are consistent with cross-sectional surveys which suggest that 
cigalike users are less likely to have quit (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, 
Voudris, 2014).  This is echoed in longitudinal studies in which the first purchase of 
tanks led to just over 40% of cessation rate, whilst transition from standard basic tanks 
to more sophisticated modifiable tanks increased from 8.5% to 18.4% at 12 months 
follow-up (Polosa et al., 2015), suggesting a need for better nicotine delivery products.  
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Unexpectedly, nicotine concentration did not predict cessation.  This is at odds 
with the findings reported in Study 2 where craving relief was greater with a higher 
nicotine concentration e-liquid, suggesting an important role for nicotine concentrations.  
Given the predictive ability of craving on relapse to smoking (Zhou et al., 2009), and 
that higher nicotine concentration is a positive correlate of craving relief for cigarettes 
(Etter, 2015), one would have expected nicotine concentration  to  predict cessation.  On 
the other hand, although studies suggest that higher nicotine concentrations better 
facilitate the complete switch to e-cigarettes, the gradual decrease in nicotine 
concentrations seen in experienced e-cigarette users over time (Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos, & Voudris, 2013a; Lechner, Tackett, et al., 2015b; Polosa et al., 
2015) is suggestive of a lesser important role of nicotine concentrations as a unique 
variable at least over time.  Counterintuitively, reducing nicotine concentrations in e-
liquid do not necessarily lead to a reduction in nicotine exposure.  In fact, whilst 
experienced users gradually reduce their nicotine concentrations in liquid over time, 
they do by increasing their nicotine liquid consumption, which may form part of the 
mechanism by which they maintain their cotinine to steady levels (Etter, 2016; Soar, 
Kimber, McRobbie, & Dawkins, 2018).  The increase in nicotine liquid consumption 
and constant cotinine levels suggest that users self-titrate and adjust their puffing 
patterns in response to changes in nicotine exposure; and they do so to maintain 
satisfactory nicotine levels in their blood.  Thus, although nicotine concentrations is 
critical to nicotine delivery, its interweaved relationship with device characteristics and 
puffing patterns makes it difficult to treat it in isolation.    
Effects of e-cigarettes use on craving, withdrawal and subjective effects  
Many studies have suggested that e-cigarettes can be effective at alleviating 
craving and withdrawal symptoms related to smoking (Bullen et al., 2010; Dawkins & 
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Corcoran, 2014; Dawkins et al., 2015; Dawkins, Turner, & Crowe, 2013; Dawkins et 
al., 2012; Etter, 2015; Foulds et al., 2015; Lechner, Meier, et al., 2015; Spindle et al., 
2015; Vansickel, Weaver, & Eissenberg, 2012; Vansickel et al., 2010).  That nicotine 
intake has a direct and linear effect on craving reduction has been suggested in previous 
clinical studies which found IPI to be inversely related to serum nicotine and cotinine 
levels as well as craving reduction scores (Williams et al., 2011).  This suggests that 
puffing topography and nicotine delivery influence craving reduction, and highlights the 
importance of efficient nicotine delivery given the strong negative reinforcement 
potential of craving on smoking and vulnerability to relapse (Adriaens, Van Gucht, & 
Baeyens, 2018; Pokhrel et al., 2015).  Crucially, research suggests that the inability of e-
cigarettes to deal with craving is one of the chief reasons for discontinued use (ASH, 
2017). It is important therefore to further the understanding of the influence of nicotine 
concentration and puffing patterns on craving alleviation in order to increase the product 
acceptability to smokers and capitalise on the potential of e-cigarettes.   
In Study 1, although plasma nicotine levels in the low nicotine concentration 
condition failed to equate those in the high nicotine concentration, such attempts to self-
titrate appeared to be effective in alleviating subjective urge to vape and withdrawal 
discomfort.  The e-cigarette with both high and low nicotine concentrations were able to 
raise plasma nicotine to satisfactory levels, and were sufficient to satisfy craving and 
alleviate withdrawal symptoms.  These findings are inconsistent with previous studies 
suggesting that higher plasma nicotine levels are associated with greater craving 
reduction and higher ‘satisfaction’ (Farsalinos, Spyrou, Tsimopoulou et al., 2014).  That 
craving was reduced to the same magnitude in the low compared to the high condition 
may be largely due to the more intensive puffing regimen exerted in the low nicotine 
concentrations.  Thus, the use of a standard puffing regimen by Farsalinos et al’ study 
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(2014) unlike Study 1 may explain these conflicting results.  Moreover, it is worth 
noting that the small sample size could be a contributing factor for the lack of 
statistically significant differences between conditions since the study was powered to 
detect an effect of puffing topography not subjective effects.  Nonetheless, that e-
cigarettes can reduce craving to the same extent than tobacco cigarettes has been 
observed in previous studies also, in which five minutes of ad libitum e-cigarette use 
was sufficient to alleviate craving symptoms to the same levels obtained after the 
smoking of a tobacco cigarette (Adriaens et al., 2014).  In a more recent experiment, ad 
libitum use of 36mg/mL nicotine containing e-cigarettes led to greater craving reduction 
compared to no nicotine e-cigarettes which strongly suggests a nicotine concentrations 
effect (Van Heel et al., 2017).  Interestingly, in the same study, conditioning cues, such 
as hand to mouth gestures, elicited a significant craving reduction regardless of the 
presence of nicotine.  This suggests that whilst nicotine has reinforcement value, 
conditioning cues that form part of the rituals of smoking, can also be reinforcing; this 
may explain the appeal of e-cigarettes, particularly tanks, which are associated with 
effective nicotine delivery.   
In Study 2, following the ad libitum vaping baseline session, craving reduction 
scores were greater in the Tank 18 compared to the Tank 6.  Craving reduction scores in 
the cigalike condition fell mid-way between Tank 18 and 6 but did not differ 
statistically from either.  Across all 3 sessions (baseline, 1 week, 2 weeks) and 
consistent with the baseline session, participants in the Tank 18 tended to report greater 
craving reduction than those in the Tank 6; which suggests a nicotine concentration 
rather than a device type effect and that higher nicotine concentrations were more 
effective at reducing craving.  The nicotine concentration effect in craving scores is in 
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line with previous studies which suggests that greater craving reduction is associated 
with higher nicotine concentrations (Etter, 2015).    
Conversely, in the same study, that cigalikes did not differ from Tank 18 conflict 
with previous studies which found that newer devices (Farsalinos, Spyrou, et al., 2014) 
and higher nicotine concentrations are more effective at reducing craving than cigalikes, 
and are capable of inducing greater satisfaction and nicotine dependence (Foulds et al., 
2015).   Given that nicotine exposure was not measured in Study 2, such discrepancies 
between findings may be attributed to the variance in nicotine delivery of cigalikes, 
since chemical analyses have demonstrated that this may vary widely within e-cigarette 
categories (Goniewicz, Kuma, Gawron, Knysak, & Kosmider, 2013).  Furthermore, 
others found that cigalikes equally reduced craving in e-cigarette naïve smokers to the 
same magnitude as did a second penlike generation over the short term and concluded 
that the visual similarities to a cigarette may have been partly responsible (Dawkins, 
Kimber, Puwanesarasa, & Soar, 2015).  In Study 1, that the lower nicotine 
concentration condition was associated with lower scores on craving agrees well with 
previous studies which found that nicotine-containing e-cigarettes elicit greater levels of 
craving reduction compared to placebo e-cigarettes (Dawkins, Turner, Hasna, & Soar, 
2012), although placebo e-cigarettes have shown to reduce craving in smokers who 
were told they contained nicotine (Copp et al., 2015); thus since the experiment was not 
blinded whether knowledge of the nicotine concentrations administered influenced 
responses is unclear.    
An alternative explanation may be that craving alleviation may also be influenced by 
non-pharmacological cues such as the visual similarity with a tobacco cigarette.  In a lab 
experiment, a white cigalike (visually similar to a cigarette) elicited greater craving 
reduction in naïve e-cigarette smokers compared to those using the same cigalike in a 
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red colour (visually dissimilar to a cigarette) (Dawkins, Munafò, Christoforou, 
Olumegbon, & Soar, 2015); this is in good agreement with earlier e-cigarette studies 
which found non-nicotine e-cigarettes to be associated with craving alleviation 
(Dawkins et al., 2012) as well as tobacco studies which found that nicotine’s influence 
on negative and positive affect is negligible (Perkins, Karelitz, Conklin, et al., 2010).  
This evidence suggests that these sensorimotor cues may be important and have 
reinforcing properties, at least in naive e-cigarette smokers.  However, findings from the 
diary data in study 2, are inconsistent with the lab-based findings and suggest that both 
Tank 18 and Tank 6 were associated with greater scores on craving reduction compared 
to the cigalike.  The fact that these self-recorded data were noted at the end of each day 
across 7 days in settings where the experimenter had no control over accuracy, may 
explain the conflicting findings, but also draws attention to the fluctuating nature of e-
cigarettes impact on smoking related symptoms such as craving.   On the other hand, 
that the data were obtained outside of the contrived lab environment, in the ‘real world’ 
lends more credibility to the findings based on the diary.  The real-world data better 
reflects the chronic aspect (seven time points over a week) rather than acute aspect of 
the experience with the device.  The fact that the cigalikes were just as effective for 
craving reduction in the lab may represent non-pharmacological, short-term cue effects 
which over time may dissipate whilst other factors (such as the ease of drawing the 
aerosol, smoothness and tastes of the aerosol) become more important.   
The findings of Study 3 are novel; to date, no studies have explored the ability 
of craving reduction to predict cessation in a sample of smokers who have been newly 
introduced to e-cigarette.  Findings of Study 3 suggest that the first encounter with e-
cigarettes may have some predictive value for smoking cessation. Whilst, the predictive 
ability of craving reduction fell short of significance at 6-months and was not significant 
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at 1 month, craving reduction experienced at baseline was found to be a significant 
predictor of cessation at 3 months follow-up.  Those who experienced greater craving 
reduction following e-cigarette use at baseline were more likely to quit at 3 months.  
That higher nicotine concentrations and the use of tanks elicit greater craving reduction 
compared to lower nicotine concentrations and cigalikes respectively (see Study 2, 
Chapter III), provides a good explanation for the greater probability of success in 
quitting using tanks over cigalikes in Study 3.  These findings are important and suggest 
that measures of craving reduction at e-cigarettes initiation have some predictive utility 
that can be fostered to inform smoking cessation programmes and vape shops (for 
example, initial craving reduction can be monitored in order to tailor devices to 
smokers).  Future research could focus on disentangling the effects of craving reduction, 
the factors and mechanisms that mediate smoking cessation, and to what extent initial 
craving reduction can predict cessation.   
In Study 1, in relation to withdrawal symptoms, there were no statistically 
significant difference between High (24 mg/mL) and Low (6 mg/mL) nicotine 
concentrations; ‘depressed mood’, ‘irritability’, ‘anxiety’, ‘drowsiness’, ‘restlessness’, 
‘hunger’ and ‘inability to concentrate’.  There were no statistically significant 
differences in subjective effects also, although means in hit and satisfaction were 
numerically higher in the high compared with the low condition. These results reiterate 
that although self-titration was incomplete with significantly lower plasma levels in the 
low condition, compensatory puffing was sufficient to achieve subjective satisfaction at 
least in the short term.  It is unclear whether a longer ad libitum session or a larger 
sample could have yielded differences between conditions.  Likewise, there were no 
statistically significant differences in adverse effects.  
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 In  study 2, based on both in lab reporting and diary data, withdrawal symptoms 
ameliorated across the 2 weeks post initiation of use, there was an increase in alleviation 
at week 1 and further increase at week 2.  Unlike craving, withdrawal symptoms scores 
did not differ across conditions.  This is inconsistent with a previous study which 
demonstrated that a second generation e-cigarette (with the same nicotine concentration) 
was more effective than a cigalike for attenuating withdrawal symptoms (Lechner, 
Meier, et al., 2015).   
 The steady increase in withdrawal relief reflects the changes in puffing 
topography, and may be synonymous of an increment in learning to use the e-cigarette 
more effectively.  These findings add to the current literature which suggests that e-
cigarettes are capable of alleviating withdrawal symptoms not only in acute (Dawkins & 
Corcoran, 2014; Farsalinos, Spyrou, Tsimopoulou, et al., 2015; Nides et al., 2014) but 
also in real word conditions following a period in which users have had the opportunity 
to accustom themselves with the device.   
Subjective effects 
As suggested in Chapter 1, the dosage and rapidity of nicotine are highly 
important for smokers’ satisfaction, craving reduction and other subjective effects. 
These subjective effects (Carpenter et al., 2007; Rose et al., 2000, 2010) are likely to 
influence e-cigarette product acceptability and promote sustained use.  Several studies 
have documented the ability of e-cigarettes to elicit positive subjective effects (such as 
satisfaction, ‘pleasant’ and ‘taste good’) (Bullen et al., 2010; Spindle et al., 2015; 
Vansickel et al., 2012; Vansickel et al., 2010; Vansickel & Eissenberg, 2013), however 
not always to the same extent as tobacco cigarettes (Martínez-Sánchez et al., 2014; 
Norton et al., 2014); whilst others report varying abilities between device types to 
induce these positive effects (Dawkins et al., 2015; Farsalinos, Spyrou, et al., 2014).   In 
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line with the latter, Tank 18 and Tank 6 were rated as more satisfying compared to 
cigalikes, suggesting that tank systems are preferred in terms of satisfaction.  This is 
consistent with previous studies comparing tanks and cigalikes.  For example, among 
experienced e-cigarette users, Farsalinos’ group reported that use of a tank versus a 
cigalike was more satisfying (Farsalinos, Spyrou, et al., 2014).   
Interestingly and against expectations, in Study 2, when asked about the device 
similarities with that of tobacco cigarettes (“Does it feel like…”) the cigalike did not 
differ from the tank.  Thus, the close visual resemblance of cigalikes to tobacco 
cigarettes does not necessarily translate into a closer approximation of tobacco 
cigarettes in respect of tanks.  The weight of the cigalike in relation to a tobacco 
cigarette is likely to have played a part as anecdotally noted by some participants in 
study 2 and in previous studies (Van Heel et al., 2017).  In Study 2, other anecdotal 
reports by those using the cigalike comprised mentions of the unpleasant sensation and 
taste of the aerosol, which may have also contributed to these findings. 
In Study 2, scores on the overall scale of all positive effects decreased from 
Baseline to week 2.  Whilst overall scores on positive effects remained fairly constant 
for the Tank 18, scores for the Cigalikes decreased considerably from Baseline to week 
2, suggesting a marked decline in satisfaction levels, which is reflective in the higher 
drop-out rate in the Cigalike condition.   
In Study 2, there were no changes over time in the overall adverse effect scores 
and no differences between Cigalikes, Tank 18 and 6.  Amongst all adverse effects, 
throat irritation was the most exacerbated symptom in each condition for the cohort of 
e-cigarette-naïve smokers as well as in the sample of experienced users.  Farsalinos et al 
(2014) found that the use of the tank induced greater ‘throat hit’ compared to the 
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cigalikes, which corroborates the findings of Study 2.  However, documenting throat-
related sensory effects present its challenges.  Whilst throat hit can be a desired effect 
sought after by smokers (Dawkins, Turner, Roberts, et al., 2013; Farsalinos, Romagna, 
Tsiapras, Kyrzopoulos, Spyrou, et al., 2013), it can equally be synonymous of adverse 
effects; thus, it seems that an optimal and individualistic throat hit is required, that is 
sufficiently strong to be discernible and satisfying to the user but at an optimal level not 
to induce harsh and unpleasant effects (Dautzenberg et al., 2016).   Here, in this thesis, 
throat irritation was measured as opposed to throat hit, although this makes direct 
comparisons with previous studies challenging, that both concepts capture similar 
sensory effects are of worthy mention given the dependent relationship with nicotine 
concentrations and device characteristics.    Interestingly, previous studies found that for 
an optimum throat hit, a specific nicotine concentration and voltage combination is 
required to better support the switch to e-cigarettes in smokers (Dautzenberg et al., 
2016), which, given that cigalike devices do not allow voltage adjustment, renders tanks 
more compatible in providing an optimal throat hit.   Given the link between satisfaction 
and the latter, the findings of Study 2 suggesting a reduced satisfaction in the cigalike 
condition aligns well with this.   
Smoking Reduction and Cigarette Dependence  
Smoking behaviour  
The findings of this thesis add to the literature which suggests that e-cigarettes 
can be an effective aid to support smoking reduction for those who do not intend to quit 
or are unable to do so.  In study 2, a two-week experimentation period led to a reduction 
in smoking and cigarette dependence in e-cigarette-naïve smokers.   However, complete 
cessation was modest at 1 and, 3 months but encouraging at 6 months.   Studies have 
demonstrated little health benefits of smoking reduction using e-cigarettes as indicated 
by biomarkers in dual users (Shahab et al., 2018), thus the quit rate obtained in the 
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current study may be too negligible to translate into real public health benefit.  
Nonetheless, consistent with the findings of Study 2, a number of studies suggest an 
increased likelihood of reducing cigarette dependence over time (Etter & Eissenberg, 
2015; Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 2013a; Foulds et al., 
2015) thereby increasing their e-cigarette use to daily use and eventually achieving 
complete cessation (Biener & Hargraves, 2015).   
In Study 2, both e-cigarette types, the tank and the cigalike as well as the 6 and 
18 mg/mL nicotine concentrations led to a reduction in smoking.  Although it is worth 
noting that there was differential drop-out rates across conditions with 20.8% in the 
cigalike compared to 13% in both the Tank 6 and 18.  The greater drop-out rate in the 
cigalike compared to the tank conditions may suggest that those who used the Cigalikes 
and successfully maintained use of the device and reduced their smoking may have had 
greater motivation to do so compared to those who dropped out.  This corroborates the 
prediction model also, suggesting that participants in the cigalikes condition were less 
likely to have quit at 6 months.  That both tanks 18 and 6 were more likely to induce 
satisfaction compared to cigalikes during the early stage of the cessation attempt (see 
Study 2, chapter III) fits with the increased likelihood of quitting using a tank.   
The reduction in smoking found over the two-week period in Study 2 (Chapter 
III), is consistent with previous findings (Adriaens et al., 2014).  In an 8-month RCT, in 
48 smokers who successfully reduced their smoking over time, the initial decrease in 
salivary cotinine during the early stage post e-cigarette use initiation was soon followed 
by an increase in later months (Adriaens et al., 2014).  This reflects the learning period 
process characterised by an adjustment in puffing practices to equate the blood nicotine 
levels that they are accustomed to as smokers.  This shares similarity with the increase 
in puffing duration seen in Study 2.   The stability in cotinine levels over time in the 
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transitional phase from smoker to dual user to exclusive e-cigarette user has been 
reported by others.  In an 8-month pilot study, 34 smokers unwilling to quit received 
medical assistance training as a way to enhance learning.  At each follow-up session (1, 
4 and 8-month) cotinine levels remained unchanged whilst CO and CPD reduced 
significantly.  Although these two aforementioned studies do not report puffing 
topography, a successful adjustment in puffing regimen combined with the use of 
effective nicotine delivery e-cigarettes are likely to have facilitated the stability in 
cotinine levels despite the reduction in smoking.  This further supports the titration 
theory of e-cigarette use and accords with empirical evidence that more intensive users 
typically achieve greater smoking reduction (Biener & Hargraves, 2015; Biener, 
Hargraves, & Hargraves, 2015; Brose et al., 2015; Hitchman et al., 2015; Manzoli et al., 
2015). 
Cigarette dependence 
By virtue of its reinforcing properties from which dosage, mode (i.e. inhalation) 
and speed of delivery are key determinants of its dependence liability (Benowitz, 
1990b; Benowitz, 2010), it is anticipated that nicotine delivered via e-cigarettes will 
have the potential to reduce cigarette dependence by acting as substitutes to combustible 
cigarettes.   
Consistent with previous studies (Baldassarri et al., 2018; Rohsenow et al., 
2018a), cigarette dependence reduced significantly over the two-week period of the 
early cessation attempt in Study 2, and surprisingly, the decrease did not differ between 
conditions.  Similarly, regardless of the device type or nicotine concentration, at the 
second session, participants’ habitual first cigarette of the day was reported to be 
smoked at a later time compared to the time reported in the baseline session.  The 
reduction in cigarette dependence concurs with the reduction in smoking and suggests 
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that e-cigarettes offered an effective coping mechanism in the absence (or reduction) of 
smoking at least at the initiation stage.   
Given the influence of nicotine delivery on dependence potential, the lack of 
difference in cigarette dependence scores between those in the tank 18, tank 6 and 
cigalikes conditions was unexpected.  Many studies have associated cigalikes with 
modest nicotine delivery (Bullen et al., 2010; Farsalinos, Spyrou, et al., 2014; Rüther et 
al., 2017; Vansickel et al., 2010) and significantly lower dependence potential in 
comparison to tank systems specifically when used with nicotine concentrations deemed 
sufficient to raise blood nicotine levels and induce satisfaction (Foulds et al., 2015).  
The short duration of the e-cigarette experimentation (two-week period) may have been 
insufficient to allow for differences to arise between conditions given the chronic and 
fluctuating nature of cigarette dependence within which lapses are likely to occur even 
after cessation (Baldassarri et al., 2018; Notley et al., 2017).   
The link between cigarette dependence and cessation is well founded, several 
studies suggest dependence levels as a predictor of cessation (Hagimoto et al., 2010; 
Hughes et al., 2014; Rohsenow et al., 2018b; Vangeli et al., 2011).  However, findings 
are contradictory, and although this may be due to the use of varying methods and 
indexes (e.g. Cigarette Dependence Scale, Heaviness of Smoking Index) (Zawertailo, 
Voci, & Selby, 2018), it remains the case that cigarette dependence has its limitations in 
predicting cessation certainly where e-cigarettes are involved.  In study 3, whilst 
cigarette dependence predicted cessation at 1 month, it did not at subsequent follow-ups 
3 and 6 months.  A reasonable hypothesis may be that as the smoker transitions from 
smoking to e-cigarette use, reducing smoking whilst increasing e-cigarette use, his/her 
dependence on cigarettes slowly transfers onto the e-cigarette, thereby becoming less 
dependent on cigarettes.  This proposition is consistent with previous reports 
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documenting lower cigarette dependence in experienced e-cigarette users in comparison 
to smokers (Etter & Eissenberg, 2015; Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & 
Voudris, 2013a; Foulds et al., 2015).  Thus, it appears that quitting smoking with the aid 
of e-cigarettes differs from quitting via other means (e.g. cold turkey or with NRT), and 
that cigarette dependence is not as important when transitioning to e-cigarettes use as 
the dependence can be transferred, which is not the case when quitting cold turkey for 
example.  This might explain why cigarette dependence only predicted cessation at 1 
month; whether the dependence transference is an important mechanism which 
facilitates complete cessation would merit further exploration.   
The role of motivation  
Motivation did not predict cessation at any of the follow-up points despite a 
moderately motivated sample at baseline; this may suggest that motivation alone is not 
sufficient to achieve complete cessation.  Although motivation to quit measured at 
baseline has proven a robust measure to predict quit (Borland, Yong, Balmford, et al., 
2010b; Hummel, Brown, Willemsen, West, & Kotz, 2016; Kotz, Brown, & West, 2013; 
Vangeli, Stapleton, Smit, Borland, & West, 2011), it falsely suggests motivation as a 
static process (Hughes et al., 2014).  Rather, past studies suggest like cigarette 
dependence, since motivation fluctuates over time, it is not sufficient to measure 
motivation at one time, rather its consistency over time should be taken into account in 
any predictive model (Perski et al., 2018).  Further considerations are that unlike 
quitting with more conventional cessation aids (i.e. NRT) or cold turkey, when quitting 
with e-cigarettes motivation may be a less salient factor.  For instance, previous studies 
have consistently demonstrated high levels of successful cessation outcomes even in 
smokers unmotivated to quit (Caponnetto et al., 2014; Polosa et al., 2015); such success 
may have been ‘accidental’ indeed facilitated by the use of e-cigarettes (Notley, Ward, 
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Dawkins, & Holland, 2018).  This certainly highlights the differences between quitting 
with e-cigarettes versus quitting with other methods.   
Limitations and strengths: E-cigarette technology a changing landscape   
In addition to the aforementioned limitations specific to each study, there are 
several more general issues and limitations to consider.  Firstly, one of the primary aims 
of this thesis was to gain further understanding of the impact of high versus low nicotine 
concentrations on puffing topography.  However, the accuracy of nicotine exposure 
could not be determined given that nicotine concentrations contained in the e-liquid 
were not chemically measured.   That said, newer chemical studies suggest little 
discrepancy between labels and content (Etter et al., 2013; Farsalinos, Spyrou, et al., 
2014; Goniewicz, Hajek, & McRobbie, 2014) compared to earlier manufactured 
products (Cameron et al., 2014; Trehy et al., 2011); suggesting some improvement in 
manufacturing practices.   
Another possible limitation is the possible lack of statistical power to detect 
differences between conditions.  Study 2 and 3 suffered a large drop-out rate in follow-
up sessions which considerably affected the sample size.  Likewise Study 1 also used a 
very modest sample size, powered on puffing topography but which may have led to 
some non-significant findings on other measures.   
The overreliance on self-reported data may also be considered a limitation, 
specifically in Study 2, for the measure of CPD.  In Study 3, cessation was not 
biologically verified as it was not always possible to collect CO, and salivary cotinine 
was collected at baseline but could not always be collected at self-reported quit to assess 
nicotine exposure after quitting.  More frequent face-to-face follow-ups would have 
allowed better monitoring of daily e-cigarette use behaviours, including greater 
understanding of the interactions between device characteristics and users’ responses 
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which would have allowed for a better understanding of how e-cigarettes promote 
smoking reduction and cessation.  Instead, participants were contacted every 2 months 
for 6 months which could have resulted in recall bias.  That said, such an approach 
(telephone contacts) continues to be standard practise in many large scale surveys and 
has contributed greatly to the literature on predictors of cessation (Bauld et al., 2017; 
Maddison et al., 2010).  Additionally, that previous studies found self-report measures 
of puffing patterns to have good reliability (Shahab et al., 2008), combined with the 
strong correlation found between the biochemical measure of CO levels and self-report 
CPD in Study 2, provides a great deal of confidence in these findings.   
Furthermore, given the apparent differences in gender and between ethnic 
groups (Benowitz, Hukkanen, & Jacob III, 2009) in the tobacco (Perkins et al., 1999) 
and the e-cigarette literature (Dawkins et al., 2012; Jorenby et al., 2017), another 
limitation is the sample constitution of each study within this thesis; all suffering a 
gender imbalance, more so study 1 with 100% Caucasian and 92% male, whilst study 2 
included a sample consisting of 63% females at baseline, which is not a true reflection 
of the smoking population.  Unlike study 1, studies 2 and 3 suffer a lack of 
representation of lower education smokers, however it is worth noting that the 
university campus (UEL) wherein all studies took place as an inclusive institution made 
up of a large black and ethnic minority groups from varied socio-economic status, and 
this was reflected in the samples.   
Finally, the lengthy process of the running of studies involving human 
participants (ethical approval, completion of data collection and so on) combined with 
the rapid evolving nature of this field of research in terms of technological 
advancement, reinforce the point that any findings in this area of studies are often 
already outdated at point of publication, and thus must be interpreted cautiously.   At the 
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time study 2 and 3 were designed, the prevalence of cigalikes was greater and little data 
had been published in relation to the factors influencing puffing topography.  Since data 
collection for this thesis, due to significant technology advancement, the e-cigarettes 
landscape has evolved rapidly shaping users’ behaviours and preferences.  The 
emergence of subohming has led to in an increase in the use of lower nicotine 
concentrations perhaps by users who would have otherwise opted for higher 
concentrations or by high nicotine dependent smokers with needs for higher 
concentrations.  Thus, cigalikes have slowly fallen in disfavour for better nicotine and 
aerosols delivery tank systems that are associated with more enhanced experience 
(Tackett et al., 2015).  Further changes in the e-cigarettes landscape has been the recent 
introduction of JUUL devices in the UK and growing prevalence in the US.  Its visual 
similarity with cigalikes in size and purported effective nicotine delivery combined with 
its appeal in the US, suggest that the findings of the current study continue to be 
relevant.   Given their close similarity to cigalikes, the high popularity of the JUUL 
devices suggests the need for effective nicotine delivery products and for a ‘vaping’ 
experience that closely approximates smoking still remain.   
One of the strengths of this work was contrasting two valid methods (video 
recordings and the use of the eVic™) to measure puffing topography, both of which 
have been previously used and proven to yield reliable results (e.g. Farsalinos et al., 
2013, 2014, 2015).  The use of video recordings allowed to counteract the issues of pre-
puff phenomenon which refers to pressing the activation button prior to the start of a 
puff, whilst bringing the device to the lips, or once in the mouth (Farsalinos et al., 
2013b), in order to warm the atomiser and allow a stronger throat hit (Behar et al., 
2015).  In such instances, the time frame was captured only when the device was clearly 
seen in the mouth with both lips closed.   A further strength of the ad libitum paradigm, 
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is its pragmatic design which allowed to capture e-cigarette-naïve smokers’ puffing 
adjustments as they learned to use the e-cigarette over time.  That said, the instructions 
of a modest one-hour abstinence in Study 2 may have been insufficient for the low 
dependent (light) smokers for whom their habitual routines may have been to smoke 
very few cigarettes in the day and felt satiated at the start of the session.   
Implications  
The findings of this thesis carry several implications.  The first implication to 
consider is compensatory puffing behaviours which carry greater financial expense 
(consuming a greater quantity of e-liquid) and potential health risks.  Whilst studies 
suggest that e-cigarette emissions carry only five percent of the health risks of tobacco 
cigarettes (McNeill et al., 2015), more intensive puffing regimens as documented with 
the use of low nicotine concentrations in this thesis, may lead to increased toxicant 
exposure and adverse long term health effects (Dawkins et al., 2018; Kośmider, 
Kimber, Kurek, Corcoran, & Dawkins, 2017).  Secondly, whilst most experienced e-
cigarettes users gradually reduce their nicotine concentration over time (as a result of 
either more advanced products with greater nicotine delivery or regulatory restrictions) 
(Farsalinos, et al, 2013a; Soar et al., 2018); on the other hand, e-cigarette naïve smokers 
are likely to require an increase in their nicotine e-liquid concentration in order to 
achieve complete smoking abstinence in the early stages of a cessation attempt 
(Farsalinos et al., 2013a; Polosa, Caponnetto, Cibella, & Le-Houezec, 2015).  This is in 
line with the observed increase in puffing intensity found here.  Thus, a sensible 
strategy would be to recommend higher nicotine concentrations to smokers that closely 
approximate that of their tobacco cigarettes to optimise acceptability, promote sustained 
use and eventually smoking cessation.  Thirdly, in line with the literature, Study 2 and 
Study 3 findings from both suggest the use of tanks or products that deliver a more 
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enhanced experienced and are associated with better nicotine delivery may be more 
advisable for cessation.  A fourth implication is the craving reduction findings in Study 
3.  As noted earlier, if craving reduction associated with early e-cigarettes use can 
predict cessation, this could be harnessed for advice given in vape shops and smoking 
cessation programmes, but also this can be used in a cost and time effective approach to 
assess likely effectiveness of devices without the need for lengthy studies; although 
these findings are in need of replication.   
 
Future Directions for Research 
Using a low and a high nicotine concentration (6 and 24 mg/mL) in a double-
blind within-participants design, Study I provided direct evidence for compensatory 
puffing behaviours.  However, such dramatic drop in nicotine concentrations does not 
reflect the gradual reduction in nicotine concentrations use seen in most experienced 
users overtime (Soar et al., 2018).  As highlighted in the limitations of Study 1, it is 
unclear whether the use of a closer range of concentrations for example 18 and 24 
mg/mL (or 6 and 12 mg/mL) would have allowed participants to self-titrate fully and 
achieve matching plasma nicotine levels.  Likewise, despite significantly lower puff 
number and duration as found in Study 1, plasma nicotine levels were significantly 
higher in the high nicotine concentration condition.  It is unclear whether the use of a 
more prolonged ad libitum session would have led to further increase in plasma nicotine 
levels in the lower nicotine concentration.  Future work may focus on more naturalistic 
settings to obtain more realistic puffing topography data and biomarkers whilst 
including a greater range of nicotine concentrations and more intermediary ones. 
In the same light, in the smoking literature, great attention has been given to 
exploring whether, aside nicotine, other chemicals are responsible for self-titration.  
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Since in Study 1 all variables were held constant, and that fewer chemicals are present 
in e-liquid compared to in tobacco cigarettes, there is a great deal of certainty that 
nicotine played the key role in driving compensatory behaviours.  However, given the 
continued rise in the use of low nicotine concentrations and emerging research on the 
influence of flavours on puffing topography (St Helen et al., 2018), future compensatory 
work can focus on exploring the possible role of other agents aside nicotine on driving 
titration. 
In Study 2, cigalikes and 18 mg/mL containing tanks did not differ and led to 
similar levels in craving reduction, whilst the 6 mg/mL nicotine containing tank 
performed the poorest.  That the 18 mg/mL containing tank did not differ from the 
cigalike in reducing craving, points to the important role of high nicotine concentrations 
to reduce craving.  Future research could focus in exploring whether there is a nicotine 
concentration threshold to help dealing with cigarette craving and explore its 
underpinning mechanisms and associated users’ characteristics (e.g. nicotine/cigarette 
dependence).   
Furthermore, Study 3 found craving reduction experienced by e-cigarette naïve 
smokers at first use a significant predictor at 3 months follow-up.  It could be useful to 
investigate the predictive value of craving reduction further, so this could be applied in 
e-cigarettes smoking cessation programmes.  Future research could focus on 
disentangling the effects of craving reduction, the factors and mechanisms that mediate 
smoking cessation, and to what extent initial craving reduction can predict cessation.  
In addition, the 18 and 6 mg/mL containing tanks elicited greater levels of 
satisfaction whilst cigalikes were associated with poor satisfaction rates; this reduced 
satisfaction was echoed in a greater drop-out rates in the cigalike condition.   That the 
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low nicotine concentrations tank did not reduce craving to the same extent, whilst 
providing equal levels of satisfaction compared to Tank 18 is suggestive of different 
pathways by which e-cigarette users experience craving and satisfaction.   These 
differences could be due to greater levels of pleasantness and more favourable taste 
and/or higher aerosol visibility associated with tank systems compared to cigalikes 
(Vena, Howe, Cao & King, 2019), and this may account for the greater satisfaction 
levels in tanks.   Equally important, this thesis draws attention to the differences 
between satisfaction and craving and suggests a lesser important role for nicotine 
concentrations for providing satisfaction.  Future work should turn their focus towards 
delineating the subtlety between satisfaction and craving, and furthering the 
understanding of the various facets of satisfaction.   
  
 
Summary and conclusion  
 
The aims of this thesis were primarily to explore the inter-relationships between 
e-cigarette puffing topography, nicotine concentrations and e-cigarette characteristics.    
Specific objectives were to: i) determine the effects of varying nicotine concentrations 
(high vs. low) in e-cigarettes on users’ puffing topography, ii) explore the effects of 
device types (tanks vs. cigalikes) on users’ puffing topography and smoking related 
effects and behaviours, iii) document how e-cigarette puffing topography evolves over 
time and differs in response to device types and nicotine concentrations and, iv) further 
the understanding of the complementary roles of subjective effects namely satisfaction, 
the alleviation of craving and withdrawal symptoms.  Additional objectives were to 
explore v) the factors (including puffing topography) that best predict smoking 
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cessation at 1, 3 and 6 months in a sample of 70 e-cigarette-naïve smokers using 
different device types and varied nicotine concentrations.   
Study 1 was the first to directly explore self-titration by allowing experienced e-
cigarette users, customarily using high nicotine concentration e-liquid, to use an e-
cigarette device ad libitum in the lab.  In fact, the findings provide direct empirical 
evidence of a clear attempt to self-titrate; when given a lower nicotine concentration e-
liquid, users increased their puff frequency and duration and consumed more e-liquid.  
The findings herein suggest that, similar to smokers, experienced e-cigarette users have 
a tendency to attempt to self-titrate by altering their puffing patterns when switching to 
lower nicotine concentrations.  Similar to previous tobacco cigarette studies which 
suggest that upregulation is more commonly achieved compared to downregulation 
REF, titration was only partial; despite significantly lower puff number and duration, 
plasma nicotine levels were significantly higher in the high nicotine concentration 
condition.  However, that users reported equivalent reduction in craving and withdrawal 
symptoms between conditions, suggests that very high nicotine content liquids may not 
be an absolute necessity for alleviation of craving or withdrawal, at least for 
experienced vapers in acute laboratory conditions.  Study 1 has demonstrated that 
experienced users using a tank system e-cigarette filled with 24 mg/mL nicotine 
concentrations e-liquid can achieve high blood nicotine levels very quickly, matching 
and even exceeding those reported in tobacco smokers; this is indicative of a remarkable 
improvement in e-cigarette nicotine delivery.  Such patterns of nicotine delivery, may 
bolster cessation rates but may raise concerns over nicotine dependence.  Whilst 
previous studies have used standardised puffing protocols either exclusively or 
preceding an ad lib session, here it is argued that the use of prescribed puffing regimes 
do not reflect real-life device use and will affect nicotine delivery and absorption.  Thus, 
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although they are suggestive of compensatory puffing behaviours, they do not provide 
clear evidence of titration.   
Although Study 2 was not designed to allow for any direct conclusions on 
compensatory puffing, it did provide useful data in support of the titration theory.  
Indeed, the increase in puffing duration a week post e-cigarette initiation suggests a 
need to optimise nicotine delivery and bring nicotine blood to habitual levels.  Study 2 
adds to the literature by suggesting that a week seems to be sufficient for e-cigarette 
naïve smokers to develop an awareness for the need to adjust their puffing from 
smoking to e-cigarette use.   Likewise, differences in puffing intensity between smokers 
using cigalikes versus those using tanks concur with the observed adjustment in puffing 
topography, and reiterate the proposition of a more erratic or intense puffing profile 
associated in the cigalikes compared to the tank systems.  Consistent with the idea that 
the vacuum mechanism of cigalikes may be harder and require a stronger draw than 
tanks, the cigalike was associated with longer puff duration and more frequent puffs.  
That they require stronger suction may have contributed to their inability to elicit 
satisfaction to the same magnitude than did the tanks.   The significant decrease in the 
number of puffs over the two-week period which, combined with a significant increase 
in puff duration strongly suggest a dramatic change in puffing behaviour characterised 
by a shift to slower, longer more paced puffs from a more erratic puffing style at initial 
use, again this is in good agreement with the differences between smokers’ and 
experienced users’ puffing profiles.   
Cigalikes and 18 mg/mL nicotine concentrations containing tanks did not differ 
in the ability to reduce craving, whilst the 6 mg/mL nicotine containing tank performed 
the poorest.  In addition, the 18 mg/mL containing tank elicited greater levels of 
satisfaction.  Given that craving and satisfaction are chief motives for e-cigarette use 
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discontinuation, these findings suggest that higher nicotine concentrations may be more 
effective in the relief of craving at least during initiation of e-cigarette use.   
Taken together, these findings confirm previous observations that puffing 
patterns differ across device types and change over a one-week period as the user learns 
to use the device.  Across all subjective variables, the 18 mg/mL nicotine concentrations 
containing tank performed the strongest and, although the cigalike was associated with 
some promising results, these need to be considered in the context of the high drop-out 
rate in this condition.   
In a sample of 70 e-cigarette naïve smokers willing to quit (Study 3), predictors 
of smoking cessation were assessed at 1, 3 and 6 months after e-cigarette initiation.  
These findings suggest that lower cigarette dependent smokers were more likely to quit 
at 1 month, whilst those with higher craving reduction associated with e-cigarette use at 
baseline had greater odds of successfully quitting at 3 months.  At 6 months, only 
device type at follow-up and craving reduction following e-cigarette use at baseline 
were significant predictors.  Thus, participants using a tank device were at greater odds 
of quitting smoking compared to those using a cigalike.  The evidence presented herein 
add to the literature and suggest i) the superiority of tanks over cigalikes in nicotine 
delivery (e.g Farsalinos et al., 2014; Lechner et al., 2015) and ii) the importance to 
consider nicotine concentrations certainly during the initiating phase of e-cigarette use.  
Thus, in order to maintain the appeal of e-cigarettes in allowing them to rival with, and 
act as an effective substitution to tobacco cigarettes, the findings of this thesis support 
previous recommendations that adopting higher nicotine concentrations may be more 
sensible (Dawkins et al., 2016). 
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APPENDICES 
APPENDIX 1 – IMAGES OF VARIOUS E-CIGARETTE MODELS AND 
THEIR COMPONENTS 
Figure 1.1 Typical components of an e-cigarette  
Figure 1.2. Main components of a typical cigalike model 
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Figure 1.3. Typical penlike e-cigarette (2nd 
generation e-cigarette)  
Figure 1.4. Typical clearomiser (2nd 
generation e-cigarette) 
Figure 1.5. Examples of third generation tank system e-cigarettes 
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Figure 1.6. Sub-ohm tank, side and top view of the atomiser (Talih et al., 2017) 
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APPENDIX 2 – IMAGES OF E-CIGARETTE EQUIPMENT USED IN 
STUDY 1 AND PILOT STUDY (CHAPTER II) 
Figure 2.1 The ‘Joyetech eVic™ Supreme’ e-cigarette and its components 
Figure 2.2 The ‘Aspire Nautilus’ tank 
and its components  
Figure 2.3 The ‘bottom vertical coil (BVC) 
Aspire’ atomiser (1.8 ohm resistance) 
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APPENDIX 3 - PILOT STUDY ETHICS APPLICATION (INCLUDE 
AMENDMENTS, RISK ASSESSMENT) AND APPROVAL LETTER 
Application for ethical review of research involving human participants, human data or 
human material 
This application should be completed by members of staff and postgraduate research degree 
students (i.e. MRes, MPhil, PhD and Professional Doctorate) undertaking research which 
involves human participants, sensitive human data (personal or otherwise) and human material 
(including human tissue, embryos, foetuses and bodily fluids, from living or deceased 
participants). 
No form of contact with potential participants for the proposed research should occur until written 
approval has been received from University Research Ethics Committee (UREC). Where a 
member of staff or student is found to have breached this expectation, they may be subject to 
disciplinary action. 
This application should be submitted alongside copies of any supporting documentation 
which will be handed to participants, including a participant information sheet, consent 
form, self-completion survey or questionnaire. 
For further guidance please contact researchethics@uel.ac.uk or refer to the guidance at 
http://www.uel.ac.uk/qa/research/index.htm. Only those applications received by the submission 
deadline date shown on the University’s Research Ethics web page will be considered at the next 
meeting. Where a form is submitted and sections are incomplete, the form will not be considered 
by UREC and will be returned to the applicant for completion.  
PROJECT DETAILS 
Current project title E-cigarette puffing behaviour with different nicotine strength e-
liquids 
Is this project 
externally funded? 
YES NO ☒  NOT APPLICABLE
Does the project 
require UREC 
approval before 
consideration by the 
funding body? 
YES   NO NOT APPLICABLE ☒ 
If YES, please indicate funding body deadline below: 
If externally funded, 
please provide details 
of funding body. 
N/A 
How will participants be informed of the source of funding? N/A 
PARTICIPANT INFORMATION SHEET   CONSENT FORM    OTHER 
If OTHER, please specify further below: 
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Proposed project 
start date 
22/9/14 Anticipated project 
end date 
December 2014 
 
 
 
 
APPLICANT DETAILS 
 
Name of Principal 
Investigator (PI) 
(For research degree 
students, the Director 
of Studies) 
 
Catherine Kimber 
School Psychology 
Status (please tick 
relevant box) 
UEL STAFF  ☒  RESEARCH DEGREE STUDENT  
Email address l.e.dawkins@uel.ac.uk 
Contact telephone 
number 
020 8223 4421 
Name of co-
researchers  
Catherine Kimber (PhD UEL) 
Olivia Corcoran (HS&B, UEL) 
 
Will parts of the 
proposed research or 
research 
administration be 
carried out by 
independent 
contractors or partner 
institutions, domestic 
or international? 
YES      NO ☒   
 
If YES, please provide a brief explanation of who the contractor or partner is, 
what their role will be and how their contribution will be monitored. Please 
note, responsibility for proper conduct of all parties involved in the research 
resides with the Principal Investigator. 
 
 
CONFLICTS OF INTEREST 
 
Will any of the researchers or their institutions receive any other benefits or incentives for taking 
part in this research over and above their normal salary package or the costs of undertaking the 
research?  
YES      NO ☒ 
If YES, please detail below: 
 
Is there any further possibility for conflict of interest? YES      NO ☒  
If YES, please detail below: 
 
 
FOR ALL APPLICANTS 
 
Has external ethics approval been sought for this research?  
(i.e. submission via Integrated Research Application System (IRAS) 
to the Health Research Authority (HRA) or other external research 
ethics committee) 
YES      NO ☒   
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If YES, please supply details below: 
DEAN OF SCHOOL OR ASSOCIATE DEAN 
• Does the proposed research as detailed herein have your support and endorsement to proceed?
YES ☒     NO
Signed 
Date 
APPLICANT DECLARATION 
I confirm that: 
• The information contained in this application is, to the best of my knowledge, correct and up to
date.
• I have attempted to identify all risks related to the research.
• I acknowledge my obligations and commitment to upholding our University’s Code of Practice
for ethical research and observing the rights of the participants.
• I am aware that cases of proven misconduct, in line with our University’s policies, may result in
formal disciplinary proceedings and/or the cancellation of the proposed research.
Applicant Lynne Dawkins 
Signed L. Dawkins
Date 1/8/14 
FOR RESEARCH DEGREE STUDENT APPLICANTS ONLY 
Name and School of 
Director of Studies 
Qualification for which 
research is being 
undertaken 
Director of Studies (DoS) – 
• Does the student have the necessary skills to carry out the research?
YES      NO 
▪ Is the participant information sheet, consent form and any other documentation appropriate?
YES      NO 
▪ Are the procedures for recruitment of participants and obtaining informed consent suitable and
sufficient?
YES      NO
▪ Where required, do all members of the research team have current Criminal Records Bureau
(CRB) clearance?
YES      NO
Signed 
Date 
DETAILS OF THE PROPOSED RESEARCH 
1. Provide a brief description of the proposed research, including the requirements
of participants. This must be in lay terms and free from technical or discipline
specific terminology or jargon. If such terms are required, please ensure they are
adequately explained (Do not exceed 500 words)
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This pilot study aims to explore the puffing patterns (puff frequency, puff duration, 
puff strength) of 5-10 regular e-cigarette users under two conditions:  a ‘usual 
strength’ condition and ‘2 strengths lower’ condition (e.g. 24mg/ml nicotine and 
12mg/ml nicotine e-liquids).  Evidence from cigarette smokers indicates that when 
regular smokers switch to ‘light’ (i.e. lower nicotine content) cigarettes, they alter 
their puffing patterns (i.e. take more, longer & harder puffs) in order to maintain a 
fairly constant blood nicotine level (self-titration).  It is likely that the same happens 
with e-cigarette users although this has not yet been explored empirically.  If e-
cigarette users do take more intensive puffs when switching to a lower strength e-
liquid, this is likely to lead to higher atomiser temperature, evaporation and increased 
exposure to toxins and carcinogens (see plans for full grant application to MRC under 
section 2 below).    
In this proposed pilot study, regular e-cigarette users using second or third generation 
devices and e-liquid of 18mg/ml or higher will be recruited.  They will be asked to 
refrain from all nicotine use overnight (10-12 hours) before visiting our lab in the 
School of Psychology, Stratford Campus, UEL (or another pre-arranged location) on 
2 consecutive mornings.   Participants will use the eVik e-cigarette from Joyetech with 
a Nautilus Tank System (which collects information on puff frequency; see further 
details in section 3 below) and will be asked to use the device for 45 minutes whilst 
the researcher video-records their puffing behaviour.  On one occasion, participants 
will use their own e-liquid and on the other occasion, a liquid (matched for flavour) 
two strengths lower will be used (order counterbalanced).  Data on puff frequency, 
puff duration and inhalation time will be gathered from video recordings and from 
eVik software.   
2. Provide a statement on the aims and significance of the proposed research,
including potential impact to knowledge and understanding in the field (where
appropriate, indicate the associated hypothesis which will be tested). This should
be a clear justification of the proposed research, why it should proceed and a
statement on any anticipated benefits to the community. (Do not exceed 700 words)
Electronic cigarettes are becoming increasingly popular and are currently used by 
approximately 2 million smokers in the UK.  The recent EU Tobacco Products 
Directive (TPD) stipulates that all nicotine containing fluids above a 20mg/ml will be 
banned from 2017 unless they are licensed as medicines (UK only).  Since an 
estimated 1/3 of e-cigarette users use strengths higher than this, they will be forced to 
switch to a lower strength fluid.  We plan to submit an application to the MRC to 
assess the behavioural and health outcomes associated with the use of different 
strength nicotine containing e-liquid and in order to do so, we require pilot data from 
5-10 participants.  Evidence from the tobacco smoking literature demonstrates that 
regular smokers compensate (by taking larger puff volumes, more frequent puffs and 
holding the puff for longer) when they switch to lower strength cigarettes to gain 
similar levels of nicotine and it is likely that the same happens with e-cigarette users 
although this has not yet been explored.  Although studies of e-cigarette vapour have 
reported very low levels of toxicants and carcinogens, given that a more intensive 
puffing pattern is associated with a higher atomiser temperature, a high amount of 
inhaled vapour, and potentially greater exposure to toxins and carcinogens, any 
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compensatory puffing behaviour might subject the user to increased health risks 
(albeit, still far lower than from conventional tobacco cigarettes).   This pilot study 
will provide essential information on whether, and how, puffing patterns change when 
a higher strength nicotine containing e-liquid is replaced with a lower one.  This will 
then help to inform the design and sample size for the larger scale application to the 
MRC.  If e-cigarette users do adapt the way they puff when switching to a lower 
strength nicotine e-liquid, and this increases exposure to toxins, although the risks are 
likely to be low compared to smoking, e-cigarette users might be inadvertently 
increasing their risks of cancer and respiratory disease.  The results of the larger scale 
study will have implications for those making decisions about the strength of nicotine 
e-liquid including smokers, stop smoking service advisors and policy makers. 
3. Provide an outline of the methodology for the proposed research, including
proposed method of data collection, tasks assigned to participants of the research
and the proposed method and duration of data analysis. If the proposed research
makes use of pre-established and generally accepted techniques, please make this
clear. (Do not exceed 500 words)
Design: 
Within-subjects design with two conditions:  ‘usual strength’ and ‘low strength’ e-
liquid.  
Equipment: 
Carbon Monoxide (CO) Breatherlyser (Bedfont Smokerlyser) to measure exhaled 
CO levels 
eVic™ electronic cigarette from Joyetech.  Joyetech is the world’s leading electronic 
cigarette manufacturer and the company has been at the forefront of the industry 
with top quality products and excellent reviews.  We are using this product because 
it has downloadable software allowing us to collect data on puff duration and 
frequency from the product itself.  See:  http://www.joyetech.co.uk/electronic-
cigarettes/eVic™-supreme#.U9uFRKNeLpd 
Nautilus Tank System.  This top of the range tank system is large enough to hold 
5ml of fluid which means we will not have to re-fill it during the 45 minute ad lib 
vaping period.  It also comes with a measuring gauge and airflow control system 
which makes it ideal for our purposes.  See:    http://www.ukecigstore.com/nautilus-
tank-system-by-aspire.html 
Nicotine e-liquid:  participants usual e-liquid will be used as well as a lower strength 
e-liquid purchased from the same provider. 
Video recorder 
Precision scales 
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Procedure: 
Potential volunteers will be given an invitation letter and consent form (see 
appendices) and if agreeable to participate, a date for testing will be set.  Participants 
will be asked to remain abstinent from e-cigarette use, smoking and any other 
nicotine products overnight (10-12 hours).  All testing will take place in the morning 
to avoid discomfort associated with not using nicotine.    
 
On the morning of testing, after going through the information sheet and ensuring 
that the participant understands what is required of him/her, the researcher will ask 
the participant to sign the consent form.  Participants will then be asked to breath 
into the smokerlyser to verify their abstinence from smoking. 
 
Participants will then complete a demographic and smoking/e-cigarette related 
questionnaire and a craving and mood scale.  S/he will then be invited to use the e-
cigarette ad lib for 45 minutes whilst being video-recorded and finally will complete 
a subjective effects scale and the craving/mood scale for the second time (see 
appendices for all questionnaires).  The whole procedure will last approximately one 
hour and will be repeated the following day with the other strength nicotine e-liquid 
(order counterbalanced).  
 
Participants will be informed at the beginning of the session that they are free to 
leave at any point either for a comfort break or permanently should they wish to do 
so.  After 20 minutes, participants will be reminded that they can take a break at any 
point.  
 
On each occasion the researcher will weigh the e-cigarette tank before and after use 
in order to more accurately calculate the amount of fluid used and cross reference 
this will the measuring gauge on the side of the tank.  
 
 
 
PARTICIPANT DETAILS  
 
4. Provide an explanation detailing how you will identify, approach and recruit the 
participants for the proposed research, including clarification on sample size and 
location. Please provide justification for the exclusion/inclusion criteria for this 
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study (i.e. who will be allowed to / not allowed to participate) and explain briefly, in 
lay terms, why this criteria is in place. (Do not exceed 500 words) 
 
This study aims to test 5 – 10 non-smoking, regular e-cigarette users (vapers). This 
sample size is sufficient for this proof of principle pilot study and will help to inform 
sample size, design and procedural aspects of the larger scale study.   We will directly 
approach e-cigarette users known to us via e-mail, twitter or facebook.   Testing will 
take place in the School of Psychology, Stratford Campus wherever possible, but if 
participants are unable to travel to UEL, we will consider travelling to participants’ 
homes (where participants are known to us and after informing a third party).  
 
Inclusion Criteria: Ex-smoker, Daily e-cigarette user, using a second or third 
generation device and at least 18mg/ml nicotine e-liquid.  Aged 18 or over.  Fluent 
English speakers. 
 
Exclusion Criteria: Smokers, non-daily vapers, pregnancy, breast-feeding, 
neurological or heart condition, under 18 years.    
 
 
 
 
5. Will the participants be from any of the following groups?(Tick as appropriate) 
 
☒  Students or staff of this University (i.e. recruitment on-site at University of East London). 
☒Adults (over the age of 18 years with mental capacity to give consent to participate in the 
research). 
   Young people between 16 and 18 years (please note parental consent may still be 
required for s006Fme research).   Children or legal minors (anyone under the age of 16 
years)1 
  Adults who are unconscious, severely ill or have a terminal illness. 
  Adults who may lose mental capacity to consent during the course of the research.                                                           
  Adults in emergency situations. 
  Adults2 with mental illness - particularly those detained under the Mental Health Act (1983 
& 2007). 
  Participants who may lack capacity to consent to participate in the research under the 
research requirements of the Mental Capacity Act (2005). 
  Prisoners, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Young Offenders, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Healthy volunteers (in high risk intervention studies). 
  Participants who may be considered to have a pre-existing and potentially dependent3 
relationship with the investigator (e.g. those in care homes, students, colleagues, service-
users, patients). 
  Other vulnerable groups (see Question 6). 
  Adults who are in custody, custodial care, or for whom a court has assumed 
responsibility. 
  Participants who are members of the Armed Forces. 
 
 
1If the proposed research involves children or adults who meet the Police Act (1997) definition of 
vulnerability3, any researchers who will have contact with participants must have current  enhanced 
Disclosure and Barring Service check (was previously called Criminal Records Bureau, or CRB, 
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clearance). 2 ‘Adults with a learning or physical disability, a physical or mental illness, or a reduction in 
physical or mental capacity, and living in a care home or home for people with learning difficulties or 
receiving care in their own home, or receiving hospital or social care services.’ (Police Act, 1997) 
3 Proposed research involving participants with whom the investigator or researcher(s) shares a 
dependent or unequal relationships (e.g. teacher/student, clinical therapist/service-user) may 
compromise the ability to give informed consent which is free from any form of pressure (real or implied) 
arising from this relationship. UREC recommends that, wherever practicable, investigators choose 
participants with whom they have no dependent relationship. Following due scrutiny, if the investigator is 
confident that the research involving participants in dependent relationships is vital and defensible, UREC 
will require additional information setting out the case and detailing how risks inherent in the dependent 
relationship will be managed. UREC will also need to be reassured that refusal to participate will not result 
in any discrimination or penalty.   
 
6. Will the study involve participants who are vulnerable?  YES      NO ☒   
 
For the purposes of research, ‘vulnerable’ participants may be adults whose ability to protect 
their own interests are impaired or reduced in comparison to that of the broader population.  
Vulnerability may arise from the participant’s personal characteristics (e.g. mental or physical 
impairment) or from their social environment, context and/or disadvantage (e.g. socio-
economic mobility, educational attainment, resources, substance dependence, displacement 
or homelessness).  Where prospective participants are at high risk of consenting under duress, 
or as a result of manipulation or coercion, they must also be considered as vulnerable. 
 
Adults lacking mental capacity to consent to participate in research and children are 
automatically presumed to be vulnerable. Studies involving adults (over the age of 16) who 
lack mental capacity to consent in research must be submitted to a REC approved for that 
purpose. 
 
6.1. If YES, a Disclosure and Barring Service (DBS) check within the last three years is 
required. 
 Please provide details of the “clear disclosure”: 
 Date of disclosure: 
 Type of disclosure: 
 Organisation that requested disclosure: 
 DBS certificate number: 
  
(NOTE: information concerning activities which require DBS checks can be found via  
https://www.gov.uk/government/publications/dbs-check-eligible-positions-guidance) 
 
 
6.2.If YES, what special arrangements are in place to protect vulnerable participants’ 
interests? 
 
 
7. Do you propose to make any form of payment or incentive available to participants 
of the research? YES     NO   ☒ 
 
If YES, please provide details taking into account that any payment or incentive should be 
representative of reasonable remuneration for participation and may not be of a value that 
could be coercive or exerting undue influence on potential participants’ decision to take 
part in the research. Wherever possible, remuneration in a monetary form should be 
avoided and substituted with vouchers, coupons or equivalent.  Any payment made to 
research participants may have benefit or HMRC implications and participants should be 
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RISK ASSESSMENT AND RISK MANAGEMENT 
 
alerted to this in the participant information sheet as they may wish to choose to decline 
payment. 
 
 
 
 
 
 
 
 
 
 
8. What special arrangements are in place for eliciting informed consent from 
participants who may not adequately understand verbal explanations or written 
information provided in English; where participants have special communication 
needs; where participants have limited literacy; or where children are involved in 
the research? (Do not exceed 200 words)  
 
For this pilot study, all participants will be known to the research team and will be 
native English speakers.  However, the researcher will go through the information 
sheet with every participant and check that they understand what is involved prior 
to their consent.  Information sheets will also be e-mailed to participants before the 
date of testing so that participants have time to process and digest the information.  
No children are involved in the research.  
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9. Does the proposed research involve any of the following? (Tick as appropriate)  
 
☒  use of a questionnaire, self-completion survey or data-collection instrument (attach 
copy) 
  use of emails or the internet as a means of data collection 
  use of written or computerised tests 
  interviews (attach interview questions) 
  diaries  (attach diary record form) 
☒ participant observation 
  participant observation (in a non-public place) without their knowledge / covert research 
  audio-recording interviewees or events 
☒  video-recording interviewees or events 
  access to personal and/or sensitive data (i.e. student, patient, client or service-user 
data) without the participant’s informed consent for use of these data for research purposes 
  administration of any questions, tasks, investigations, procedures or stimuli which may 
be experienced by participants as physically or mentally painful, stressful or unpleasant 
during or after the research process 
  performance of any acts which might diminish the self-esteem of participants or cause 
them to experience discomfiture, regret or any other adverse emotional or psychological 
reaction 
  investigation of participants involved in illegal or illicit activities (e.g. use of illegal drugs)  
  procedures that involve the deception of participants 
☒  administration of any substance or agent   (yes, but NOTE:  only what participants 
would use themselves anyway on a daily basis).  
  use of non-treatment of placebo control conditions 
  collection of body tissues or fluid samples 
  collection and/or testing of DNA samples 
  collection and/or testing of gametes or embryo tissue 
  participation in a clinical trial 
  administration of ionising radiation to participants 
☒research undertaken at an off-campus location (risk assessment attached) 
  research overseas (copy of VCG overseas travel approval attached) 
  
10. Does the proposed research involve any specific or anticipated risks (e.g. physical, 
psychological, social, legal or economic) to participants that are greater than those 
encountered in everyday life? YES      NO ☒   
If YES, please describe below including details of precautionary measures. 
 
Participants will all be regular e-cigarette users and will be using their own strength 
e-liquid as well as a lower strength e-liquid, both  ad libitum (i.e. as much or as little 
as they want)   Therefore the risks are no greater than those encountered in everyday 
life through participants’ usual vaping habits.   Adverse effects of nicotine include 
nausea and headache and e-cigarettes are sometime associated with a dry mouth 
although these effects are rarely experienced in regular e-cigarette users. Water or any 
drink will be available at all times and the participants will be reminded that they are 
free to leave at any time either for a comfort break or permanently.  The investigator 
and researcher are experienced in e-cigarette and smoking research and any 
participant experiencing adverse effects will be advised to stop using the device and 
allowed to rest in a quiet location with the researcher present should they wish to do 
so. Adverse effects usually subside within an hour. A taxi home will be also offered 
to anyone experiencing ill effects.  
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11. Where the procedures involve potential hazards and/or discomfort or distress for 
participants, please state what previous experience the investigator or researcher(s) 
have had in conducting this type of research. 
 
 
As mentioned above, it is unlikely that there are any hazards associated with taking 
part in this research although water will be available throughout the session and 
participants will be reminded that they are under no obligation to use the product 
and are free to leave at any time.  Participants may experience slight discomfort 
associated with not using nicotine for 10-12 hours although all testing sessions will 
be held in the morning in order to minimise any discomfort.  
 
The principle investigator (Lynne Dawkins) has had over 15 years of experience of 
working with smokers in a research capacity and 4 years experience of working with 
electronic cigarettes.  She is generally regarded as one of the UK’s leading 
authorities on e-cigarettes.  The researcher (Catherine Kimber) has recently 
conducted her undergraduate project on e-cigarette use and choice in smokers with 
Dr Dawkins so has on years experience of working with smokers and e-cigarettes. 
 
 
 
 
 
12. Provide an explanation of any potential benefits to participants. Please ensure this 
is framed within the overall contribution of the proposed research to knowledge or 
practice.  (Do not exceed 400 words) 
NOTE: Where the proposed research involves students of our University, they should be 
assured that accepting the offer to participate or choosing to decline will have no impact on 
their assessments or learning experience. Similarly, it should be made clear to participants 
who are patients, service-users and/or receiving any form of treatment or medication that 
they are not invited to participate in the belief that participation in the research will result in 
some relief or improvement in their condition.   
 
 
 
 
There are no direct benefits to the participants themselves although the findings of the 
study will help to inform a larger scale study that will benefit the wider clinical, 
academic and regulatory community by providing information about e-cigarette 
puffing behaviour and effects on toxin and carcinogen production.  Participants will 
be informed that whilst their involvement in the study will not benefit them directly, 
the findings will help to add to the knowledge base on e-cigarettes. 
 
No UEL students will take part.   
 
Although most of the participants taking part will be known to the researcher, none 
are in a dependent relationship with the researcher and all have previously expressed 
interest in taking part in research studies after hearing of her work.  
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13. Provide an outline of any measures you have in place in the event of adverse or 
unexpected outcomes and the potential impact this may have on participants 
involved in the proposed research. (Do not exceed 300 words) 
 
 
No adverse effects are expected as all participants will be regular e-cigarette users 
using their own e-liquid or a lower strength.   
 
Participants will however, be using a new device which they are not familiar with, 
and may experience difficulty with at first.  We have factored in sufficient time (45 
mins) in order to demonstrate use and for participants to become familiar with the 
device.  
 
In the unexpected event of the device malfunctioning, participants will be permitted 
to use their own device in order to avoid re-scheduling.    
 
In relation to the study findings, it is possible that we find no changes in puffing 
behaviours with the two strength e-liquids.  This will be informative in itself and 
will help to shape our future funding applications.   
 
 
 
14. Provide an outline of your debriefing, support and feedback protocol for 
participants involved in the proposed research. This should include, for example, 
where participants may feel the need to discuss thoughts or feelings brought about 
following their participation in the research. This may involve referral to an external 
support or counseling service, where participation in the research has caused 
specific issues for participants. Where medical aftercare may be necessary, this 
should include details of the treatment available to participants. Debriefing may 
involve the disclosure of further information on the aims of the research, the 
participant’s performance and/or the results of the research. (Do not exceed 500 
words) 
 
At the end of the study, the researcher will allow 5-10 minutes in order to answer 
any questions that the participant may have about their participation and e-cigarette 
use.   Participants will be verbally informed of the aim of the study – i.e. to look at 
any changes in puffing patterns that occur when users switch to a lower strength e-
liquid.  They will also be told that the findings will help to inform a larger scale 
study looking at effects of different puffing techniques on toxicants in the vapour.  
Participants will also be given the principle investigator’s e-mail address and 
telephone number should they feel the need to discuss any aspect of their 
participation at a later date.   
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15. Have you attached a copy of your participant information sheet (this should be in
plain English)? Where the research involves non-English speaking participants,
please include translated materials. YES☒     NO
If NO, please indicate what alternative arrangements are in place below:
16. Have you attached a copy of your participant consent form (this should be in
plain English)? Where the research involves non-English speaking participants,
please include translated materials.
YES ☒     NO
If NO, please indicate what alternative arrangements are in place below:
17. The following is a participant information sheet checklist covering the various
points that should be included in this document.
☒ Clear identification of UEL as the sponsor for the research, the schools(s) involved, the
project title, the Principal Investigator and other researchers along with relevant contact
details.
☒Details of what involvement in the proposed research will require (e.g., participation in
interviews, completion of questionnaire, audio/video-recording of events), estimated time
commitment and any risks involved.
☒A statement confirming that the research has received formal approval from UREC.
☒ If the sample size is small, advice to participants that this may have implications for
confidentiality / anonymity.
N/A A clear statement that where participants are in a dependent relationship with any of
the researchers that participation in the research will have no impact on assessment /
treatment / service-use or support.
☒ Assurance that involvement in the project is voluntary and that participants are free to
withdraw consent at any time, and to withdraw any unprocessed data previously supplied.
☒Advice as to arrangements to be made to protect confidentiality of data, including that
confidentiality of information provided is subject to legal limitations.
☒A statement that the data generated in the course of the research will be retained in
accordance with the University’s Data Protection Policy.
☒Advice that if participants have any concerns about the conduct of the investigator,
researcher(s) or any other aspect of this research project, they should contact
researchethics@uel.ac.uk.
☒Confirmation on any limitations in confidentiality where disclosure of imminent harm to
self and/or others may occur.
N/A. For research involving under 16 s or vulnerable groups, where true, a statement has
been included on all information sheets that the investigators have passed appropriate
Disclosure and Barring Service checks.
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18. The following is a consent form checklist covering the various points that should 
be included in this document.  
 
☒University of East London letterhead or logo. 
☒Title of the project (with research degree projects this need not necessarily be the title of 
the thesis) and names of investigators. 
☒Confirmation that the project is research.  
☒Confirmation that involvement in the project is voluntary and that participants are free to 
withdraw at any time, or to withdraw any unprocessed data previously supplied. 
☒Confirmation of particular requirements of participants, including for example whether 
interviews are to be audio-/video-recorded, whether anonymised quotes will be used in 
publications advice of legal limitations to data confidentiality. 
☒ If the sample size is small, confirmation that this may have implications for anonymity any 
other relevant information. 
☒The proposed method of publication or dissemination of the research findings. 
N/A. Details of any external contractors or partner institutions involved in the research. 
N/A. Details of any funding bodies or research councils supporting the research. 
N/A Confirmation on any limitations in confidentiality where disclosure of imminent harm to 
self and/or others may occur. 
N/A. Separate forms and information sheets requesting parental/guardian consent for 
research involving under age children have been included / attached. 
N/A. Letters requesting consent for the research to be conducted at external sites (e.g.  
Managers/ owners/ head teachers /etc.) where the research will be carried out have been 
included / attached. 
☒Where research is to be published (it is envisaged that this is true in most cases) it has 
been made clear in the information sheet and, or form (preferably both)  that both consent to 
take part and to publication is being obtained.  
 
 
 
 
 
CONFIDENTIALITY AND ANONYMITY 
 
19. Below is a checklist covering key points relating to the confidentiality and 
anonymity of participants. Please indicate where relevant to the proposed 
research. 
 
 Participants will be completely anonymised and their identity will not be known by the 
investigator or researcher(s) (i.e. the participants are part of an anonymous randomised 
sample and return responses with no form of personal identification)? 
 The responses are anonymised or are an anonymised sample (i.e. a permanent process 
of coding has been carried out whereby direct and indirect identifiers have been removed 
from data and replaced by a code, with no record retained of how the code relates to the 
identifiers). 
☒The samples and data are de-indentified (i.e. direct and indirect identifiers have been 
removed and replaced by a code. The investigator or researchers are able to link the code to 
the original identifiers and isolate the participant to whom the sample or data relates). 
 Participants have the option of being identified in a publication that will arise from the 
research. 
 Participants will be pseudo-anonymised in a publication that will arise from the research. 
 The proposed research will make use of personal sensitive data. 
 Participants consent to be identified in the study and subsequent dissemination of 
research findings and/or publication. 
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20. Participants must be made aware that the confidentiality of the information they 
provide is subject to legal limitations in data confidentiality (i.e. the data may be 
subject to a subpoena, a freedom of information request or mandated reporting by 
some professions).  This only applies to named or de-identified data.  If your 
participants are named or de-identified, please confirm that you will specifically 
state these limitations.   
 
YES ☒    NO    
 
If NO, please indicate why this is the case below: 
 
 
NOTE: WHERE THE PROPOSED RESEARCH INVOLVES A SMALL SAMPLE OR FOCUS 
GROUP, PARTICIPANTS SHOULD BE ADVISED THAT THERE WILL BE DISTINCT 
LIMITATIONS IN THE LEVEL OF ANONYMITY THEY CAN BE AFFORDED.  
 
DATA ACCESS, SECURITY AND MANAGEMENT 
 
21. Will the Principal Investigator be responsible for the security of all data collected 
in connection with the proposed research? YES ☒     NO    
If NO, please indicate what alternative arrangements are in place below: 
 
 
22. In line with the 5th principle of the Data Protection Act (1998), which states that 
personal data shall not be kept for longer than is necessary for that purpose or 
those purposes for which it was collected; please state how long data will be 
retained for. 
 
     ☒  1-2 years   3-5 years   6-10 years  10> years  
 
NOTE: Research Councils UK (RCUK) guidance currently states that data should 
normally be preserved and accessible for 10 years, but for projects of clinical or major 
social, environmental or heritage importance, for 20 years or longer. 
(http://www.rcuk.ac.uk/documents/reviews/grc/grcpoldraft.pdf) 
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23. Below is a checklist which relates to the management, storage and secure 
destruction of data for the purposes of the proposed research. Please indicate 
where relevant to your proposed arrangements. 
 
☒Research data, codes and all identifying information to be kept in separate locked filing 
cabinets. 
☒Access to computer files to be available to research team by password only. 
 Access to computer files to be available to individuals outside the research team by 
password only (See 23.1). 
 Research data will be encrypted and transferred electronically within the European 
Economic Area (EEA). 
 Research data will be encrypted and transferred electronically outside of the European 
Economic Area (EEA). (See 23.2). 
NOTE: Transfer of research data via third party commercial file sharing services, such as 
Google Docs and YouSendIt are not necessarily secure or permanent. These systems may 
also be located overseas and not covered by UK law. If the system is located outside the 
European Economic Area (EEA) or territories deemed to have sufficient standards of data 
protection, transfer may also breach the Data Protection Act (1998). 
☒Use of personal addresses, postcodes, faxes, e-mails or telephone numbers. 
☒Use of personal data in the form of audio or video recordings. 
 Primary data gathered on encrypted mobile devices (i.e. laptops). NOTE: This should be 
transferred to secure UEL servers at the first opportunity. 
☒All electronic data will undergo secure disposal.  
NOTE: For hard drives and magnetic storage devices (HDD or SSD), deleting files does not 
permanently erase the data on most systems, but only deletes the reference to the file. Files 
can be restored when deleted in this way. Research files must be overwritten to ensure they 
are completely irretrievable. Software is available for the secure erasing of files from hard 
drives which meet recognised standards to securely scramble sensitive data. Examples of 
this software are BC Wipe, Wipe File, DeleteOnClick and Eraser for Windows platforms. Mac 
users can use the standard ‘secure empty trash’ option; an alternative is Permanent eraser 
software. 
☒All hardcopy data will undergo secure disposal. 
NOTE: For shredding research data stored in hardcopy (i.e. paper), adopting DIN 3 ensures 
files are cut into 2mm strips or confetti like cross-cut particles of 4x40mm. The UK government 
requires a minimum standard of DIN 4 for its material, which ensures cross cut particles of at 
least 2x15mm. 
 
23.1. Please provide details of individuals outside the research team who will 
be given password protected access to encrypted data for the proposed 
research. 
 
N/A 
23.2. Please provide details on the regions and territories where research 
data will be electronically transferred that are external to the European 
Economic Area (EEA). 
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N/A 
 
 
 
 
 
 
 
 
OVERSEAS TRAVEL FOR RESEARCH 
 
24. Does the proposed research involve travel outside of the UK? YES      NO ☒ 
 
24.1. Have you consulted the Foreign and Commonwealth Office website for 
guidance/travel advice? http://www.fco.gov.uk/en/travel-and-living-abroad/       YES 
     NO    
 
24.2. If you are a non-UK national, have you sought travel advice/guidance from 
the Foreign Office (or equivalent body) of your country? YES      NO     NOT 
APPLICABLE     
    
24.3. Have you completed the overseas travel approval process and enclosed a 
copy of the document with this application?                                                  YES      
NO    
              Details on this process are available here 
http://www.uel.ac.uk/qa/research/fieldwork.htm  
 
24.4. Is the research covered by our University’s insurance and indemnity 
provision? 
                                                                                                     YES      NO    
       (Please seek confirmation via researchethics@uel.ac.uk) 
 
NOTE: Where research is undertaken at an off-campus location within the UK or overseas, 
the Risk Assessment policy must be consulted:  
http://dl-cfs-01.uel.ac.uk/hrservices/documents/hshandbook/risk_assess_policy.pdf.  
The Dean of School or Director of Service has overall responsibility for risk assessment 
regarding the health and safety of staff or students conducting research where UEL is the 
sponsor. 
 
 
24.5. Please evidence how compliance with all local research ethics and research 
governance requirements have been assessed for the country(ies) in which the 
research is taking place. 
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24.6. Will this research be financially supported by the United States Department 
of Health and Human Services or any of its divisions, agencies or programs? YES 
     NO    
 
 
PUBLICATION AND DISSEMINATION OF RESEARCH FINDINGS 
 
25. How will the results of the research be reported and disseminated? (Select all that 
apply) 
 
☒  Peer reviewed journal 
☒  Conference presentation 
  Internal report 
☒  Dissertation/Thesis 
  Other publication 
  Written feedback to research participants 
☒  Presentation to participants or relevant community groups 
  Other (Please specify below) 
 
 
 
 
 
 
 
 
 
OTHER ETHICAL ISSUES 
 
26. Are there any other ethical issues that have not been addressed which you would 
wish to bring to the attention of University Research Ethics Committee (UREC)? 
 
No 
 
CHECKLIST FOR ATTACHED DOCUMENTS 
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27. Please check that the following documents are attached to your application. 
 
    Recruitment advertisement 
☒Participant information sheets (including easy-read where relevant) 
☒Consent forms (including easy-read where relevant) 
 Assent form for children (where relevant) 
  Evidence of any external approvals needed 
☒  Questionnaire 
  Interview Schedule or topic guide 
☒  Risk assessment (where applicable) 
  Overseas travel approval (where applicable) 
 
27.1. Where it is not possible to attach the above materials, please provide 
an explanation below. 
 
Recruitment will be via direct e-mail invitation to e-cigarette users known to us, or 
twitter/facebook if insufficient numbers are recruited via personal e-mail contacts.  
 
E-mail example:  Dear X, we are conducting a pilot study of e-cigarette users to explore 
patterns of puffing behaviour with different strength e-liquids and we wondered whether you 
would be able to take part?  It would involve 2 visits to UEL (or we could come to your home 
if that’s easier) on 2 consecutive days and you would complete one questionnaire and then 
be video-recorded using an e-cigarette for about 45 minutes.  I have attached an information 
sheet which provides further information.  I look forward to hearing from you... Best 
wishes.... 
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RISK ASSESSMENT FOR THE PILOT STUDY 
 
University of East London 
School of Psychology 
 
Risk assessment for testing participants away from UEL. 
E-cigarette puffing behaviour with different strength e-liquids 
 Testing 
Location(s)  
Possible 
Risk 
Severit
y of 
hazard 
(H, M, 
L) 
Likelihoo
d of 
hazard 
(H, M, L) 
Ris
k 
(H, 
M, 
L) 
Mitigating Activity 
1
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most testing 
will take place 
at UEL 
(Stratford 
campus) 
although at 
times it may be 
necessary to 
test participants 
in their own 
homes or at 
their place of 
work in order to 
maximise 
recruitment.  
 
 
 
 
 
 
 
UEL/participan
ts home 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The 
researcher 
may be 
exposed to 
risk if she is 
alone with a 
participant 
in an 
unfamiliar 
environmen
t. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants 
experience 
adverse 
effect of 
nicotine  
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lo
w 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lo
w 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the participants 
will be known to 
the research team so 
we do not expect 
there to be any 
risks.  However, the 
researcher will 
always keep the PI 
or another 
colleague  informed 
of her whereabouts 
if testing 
participants in 
locations other than 
UEL.   
 
Very unlikely as 
participants will be 
given their OWN 
STRENGTH and a 
LOWER strength 
nicotine e-liquid 
and using ad 
libitum.  However, 
should a participant 
feel any adverse 
effects, s/he will be 
advised to stop 
using the e-cigarette 
immediately and 
the research will 
stay with the 
participant until 
s/he feels better.  
Effects usually 
wear off within an 
hour.  
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3
. 
 
 
 
 
 
 
 
UEL/participan
ts own home  
 
 
 
 
 
 
 
 
 
 
E-liquid 
spill 
 
 
 
Low 
 
 
 
Low 
 
 
 
 
 
Lo
w 
 
 
 
 
The device we have 
chosen is very easy 
to re-fill and the 
investigator and 
researcher have 
experience using e-
liquid refills.  We 
will only use 10ml 
of liquid at a time.  
In the case of 
accidental spillage 
or contact with the 
skin, the 
participant/research
er will use the sink 
in the laboratory to 
wash their hands 
immediately.  No 
reports of adverse 
effects relating to 
exposure of this 
concentration and 
amount of e-liquid 
to the skin have 
been reported.  
 
 
 
 
 
 
Principle Investigator:  L. Dawkins     
 
 
 
 
NOTE THAT TO AVOID REPETITIONS, QUESTIONNAIRES HAVE BEEN 
REMOVED FROM THE ETHICS APPLICATION AND CAN BE FOUND IN 
SUBSEQUENT APPENDICES   
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APPENDIX 4 - PARTICIPANT INVITATION LETTER (PILOT STUDY) 
 
UNIVERSITY OF EAST LONDON 
 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
 
The Principal Investigator(s) 
Dr. Lynne Dawkins; E-mail: l.e.dawkins@uel.ac.uk 
Catherine Kimber; E-mail:  C.Kimber@uel.ac.uk 
 
 
Consent to Participate in a Research Study 
The purpose of this letter is to provide you with the information that you need to 
consider in deciding whether to participate in a research study being conducted at the 
University of East London. 
 
 
Project Title 
E-cigarette puffing behaviour with different strength nicotine e-liquids 
 
 
Project Description 
This study aims to compare e-cigarette puffing behaviour with two different strength e-
liquids – your own, and another lower strength liquid matched to your preferred flavour 
and from the same supplier.   If you decide to take part, we would like to see you on two 
consecutive days for about 1 hour each time.  You will be asked to refrain from e-
cigarette and nicotine use overnight (for 10-12 hours) prior to each session.  Testing 
sessions will take place in the mornings in order to minimize any discomfort associated 
with not using nicotine.  We will provide the e-cigarette (an eVic™ third generation 
device) for you to use.   
 
During the study, you will first be asked to use a smokerlyser to check your carbon 
monoxide levels to show that you have not smoked.  This is a simple, non-invasive 
breath test which simply requires you to hold your breath and then breath slowly into a 
tube.  You will then be asked to provide some background information about yourself 
and your e-cigarette use via a questionnaire and complete a craving and mood scale.  
We would then like to video-record you using the e-cigarette for about 45 minutes, after 
which, you will complete another questionnaire about your mood and vaping 
experience.  Please note, you are free to take comfort breaks during this time and you 
will be reminded after 20 minutes that you are free to take a break. 
 
 
Confidentiality of the Data 
All data generated in the course of the research will be treated confidentially and will be 
retained in accordance with the University’s Data Protection Policy.   All data will be 
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numerically coded although we plan to collect data from only 5-10 people so it is 
possible that complete anonymity may not be achievable.    Nevertheless, consent forms 
will be detached and separated from the numerically-coded data and your questionnaire 
data and video recordings will be stored in a locked filing cabinet at UEL.  Your video 
recordings will be analysed by two independent researchers at UEL who will look at the 
number and length of puffs you took. The e-Vic e-cigarette also records puff number 
and length and we will compare this information with our video recordings.  Once this 
information is entered into a computerised dataset, we will reset the eVic™ to delete 
this information and will dispose of the original video recordings securely.  The 
anonymised data will be used for the current study and it is expected that the findings 
will be written up for publication in a peer reviewed journal.  Should any data be used 
in subsequent studies or for further analysis, the data will still be kept anonymous and 
confidential.  Nevertheless, please be aware that the confidentiality of the information 
provided is subject to legal limitations in data confidentiality (i.e. the data may be 
subject to a subpoena, a freedom of information request or mandated reporting by some 
professions). 
 
 
Location 
The study is likely to be carried out at the University East London, Stratford Campus.   
However, should it be required, the study may be carried out at a place more convenient 
to you such as your own home. 
 
 
Remuneration 
There is no payment for taking part in this study, nor will your involvement in this study 
benefit you directly although the findings will help to add to the scientific knowledge 
base on e-cigarettes. 
 
 
 
Disclaimer 
You are not obliged to take part in this study and should not feel coerced. You are free 
to withdraw at any time. Should you choose to withdraw from the study you may do so 
without disadvantage to yourself and without any obligation to give a reason. Your right 
to withdraw from the study includes the right to request the destruction of any of your 
data obtained from the study though you must memorise your personal participant 
number in order for the experimenter to delete your data.  You can email us at any point 
prior stating your participation number, and we will remove your data for you.  
Following completion of the study, none of your contact information will be retained 
without your specific permission. 
 
Please feel free to ask any questions. If you are happy to continue you will be asked to 
sign a consent form prior to your participation. Please retain this invitation letter for 
reference.  
 
This study has received full approval from the University of East London’s Ethical 
Committee.  If you have any questions or concerns about how the study has been 
conducted, please contact the study’s Principle Investigator: 
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Dr. Lynne Dawkins, School of Psychology, University of East London, Water Lane, 
London E15 4LZ. +44 (0)20 8223 4421. E-mail:  l.e.dawkins@uel.ac.uk 
 
Or  
 
Catherine Fieulleteau, Ethics Integrity Manager, Graduate School, EB 1.43 
University of East London, Docklands Campus, London E16 2RD  
(Telephone: 020 8223 6683, Email: researchethics@uel.ac.uk). 
 
 
 
 
347 
 
APPENDIX 5 - CONSENT FORM (PILOT STUDY) 
 
UNIVERSITY OF EAST LONDON 
 
Consent to participate in a research study 
 
 
Title 
 
E-cigarette puffing behaviour with different strength nicotine e-liquids 
 
 
I have the read the information sheet relating to the above research study and have been 
given a copy to keep. The nature and purpose of the research has been explained to me, 
and I have had the opportunity to discuss the details and ask questions about this 
information. I understand what is being proposed and the procedures in which I will be 
involved have been explained to me.  I understand that I am able to take breaks 
whenever I want and that I am free to leave at any time.  
 
I understand that my involvement in this study, and particular data from this research, 
will remain strictly confidential.   Only the researcher(s) involved in the study will have 
access to identifying data.  I understand that the findings from this research project may 
be written up, submitted for publication and presented at conferences. I understand that 
all collected data will remain confidential during this process. It has been explained to 
me what will happen once the research study has been completed. 
 
I hereby freely and fully consent to participate in the study which has been fully 
explained to me. Having given this consent I understand that I have the right to 
withdraw from the study at any time without disadvantage to myself and without being 
obliged to give any reason. 
 
 
Participant’s Name (BLOCK CAPITALS)  
 
………………………………………………………………………………………. 
 
Participant’s Signature  
 
……………………………………………………………………………………….. 
 
Researcher’s Name (BLOCK CAPITALS)  
 
……………………………………………………………………………………….. 
 
Researcher’s Signature  
 
………………………………………………………………………………………… 
 
Date: ……………………..……. 
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APPENDIX 6 - PILOT STUDY BASELINE DEMOGRAPHIC DATA 
QUESTIONNAIRE 
 
 
  
1. Which type of device do you currently use most (please circle one): 
 
a. A disposable e-cigarette (non-rechargeable) 
b. A rechargeable e-cigarette (sometimes called ‘stick-like’,  
‘cigarette-like’ or ‘cartomizers’ without fluid)  
c. A rechargeable e-cigarette (‘stick-like/cigarette-
like/cartomizer’ without fluid) starter kit 
d. A rechargeable e-cigarette (non cigarette-like with fluid) 
e. A rechargeable e-cigarette (non cigarette-like with fluid) starter 
kit 
f. A modular system (your own combination of separate parts: 
battery, atomizer, fluid etc). 
g. E-cigar 
 
 
2. Which brand and model of e-cigarette are you currently using most:? 
 
Brand  (please state) _________________ 
Model (please state)_________________ 
 
 
3. Which strength(s) of nicotine fluid/cartridge are you currently using? 
(circle all that apply). 
a. 0mg 
b. 4 mg  
c. 6mg 
d. 8mg 
e. 10 mg 
f. 11mg 
g. 15 mg 
h. 16mg 
i. 18mg 
j. 24mg 
k. 36mg  
l. Higher than 36mg 
m. I don’t know 
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4. If you have circled more than one strength, please state which 
strength you use most:  _______________________________ 
 
 
 
5. Please try to estimate the amount you use per day: 
a. In puffs ____________ 
b. In cartridges ___________ 
c. In ml _______________ 
 
 
6. Which is your preferred flavour? (please circle one) 
a. Tobacco 
b. Mint/menthol 
c. Fruit (various) 
d. Coffee 
e. Vanilla 
f. RY4 
g. Chocolate 
h. Cinnamon 
i. Tea 
j. Alcohol-related 
k. Other (please state) 
 
 
 
7. How soon after you wake up do you use your electronic cigarette? 
(circle one answer) 
a. Within 5 minutes 
b. 6 – 30 minutes 
c. 31 – 60 minutes 
d. After 60 minutes 
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APPENDIX 7 – MPSS (MOOD AND PHYSICAL SYMPTOMS SCALE) 
 
How strong is your urge to vape right now? (Circle one number) 
 
 
Not at all 
strong 
 
   
Moderately 
strong 
   
Extremely 
strong 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
Please indicate how you feel right now by placing a tick in the appropriate box for each 
of the descriptions below 
 
 
 
 Not at all Slightly  Somewhat Very  Extremely 
Depressed      
Irritable      
Anxious      
Drowsy      
Restless      
Hungry       
Unable to 
concentrate 
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APPENDIX 8 – SUBJECTIVE EFFECTS (POSITIVE AND ADVERSE) 
 
Subjective Effects: 
 
Please indicate, by marking the line, the extent to which you agree with each of the 
following statements based on how you feel right now 
 
 
 
 
 I feel a definite hit from the e-cigarette 
 
 
Not at all  
 
The e-cigarette is satisfying 
 
Extremely 
 
 
Not at all  
 
The e-cigarette is pleasant 
 
Extremely 
 
 
Not at all  
 
The e-cigarette tastes good 
 
Extremely 
Not at all  
 
The e-cigarette has reduced my craving for nicotine 
 
Extremely 
Not at all  
 
The e-cigarette has helped my concentration 
 
Extremely 
Not at all  
 
The e-cigarette has made me feel calmer 
 
Extremely 
Not at all  
 
The e-cigarette has made me feel more awake 
 
Extremely 
Not at all  
 
The e-cigarette has reduced my hunger 
 
Extremely 
Not at all  
 
The e-cigarette tastes like my usual brand/model 
 
Extremely 
Not at all  
 
The e-cigarette feels like using my usual brand/model  
 
Extremely 
Not at all  
 
 
Extremely 
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Subjective Effects  
 
Please indicate, by marking the line, the extent to which you feel each of the following 
based on how you feel right now 
 
 Confused 
 
 
Not at all  
 
Dizzy 
 
Extremely 
 
 
Not at all  
 
Headache 
 
Extremely 
 
 
Not at all  
 
Pounding Heart 
 
Extremely 
Not at all  
 
Light-headed 
 
Extremely 
Not at all  
 
Nausea/Feeling sick 
 
Extremely 
Not at all  
 
Nervous 
 
Extremely 
Not at all  
 
Salivation 
 
Extremely 
Not at all  
 
Sweaty 
 
Extremely 
Not at all  
 
Weak 
 
Extremely 
Not at all  
 
Mouth irritation 
 
Extremely 
Not at all  
 
Throat irritation 
 
Extremely 
Not at all  
 
Aching jaws 
 
Extremely 
Not at all  
 
 
 
Extremely 
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Vomiting 
 
Not at all  
 
Flatulence/Bloating 
 
Extremely 
Not at all  
 
Stomach ache 
 
Extremely 
Not at all  
 
Heartburn 
 
Extremely 
Not at all  
 
Diarrhoea 
 
Extremely 
Not at all  
 
Hiccups 
 
Extremely 
Not at all  
 
Cold hands/feet 
 
Extremely 
Not at all  
 
Palpitations 
 
Extremely 
Not at all  
 
 
 
 
 
 
 
 
 
 
 
Extremely 
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APPENDIX 9 – ETHICS APPLICATION AND APPROVAL FOR STUDY 
1 (INCLUDE AMENDMENTS AND RISK ASSESSMENT)  
 
APPLICATION FOR ETHICAL REVIEW OF RESEARCH INVOLVING 
HUMAN PARTICIPANTS, HUMAN DATA OR HUMAN MATERIAL 
 
This application should be completed by members of staff and postgraduate research degree 
students (i.e. MRes, MPhil, PhD and Professional Doctorate) undertaking research which 
involves human participants, sensitive human data (personal or otherwise) and human material 
(including human tissue, embryos, foetuses and bodily fluids, from living or deceased 
participants). 
 
No form of contact with potential participants for the proposed research should occur until written 
approval has been received from University Research Ethics Committee (UREC). Where a 
member of staff or student is found to have breached this expectation, they may be subject to 
disciplinary action. 
 
This application should be submitted alongside copies of any supporting documentation 
which will be handed to participants, including a participant information sheet, consent 
form, self-completion survey or questionnaire. 
 
For further guidance please contact researchethics@uel.ac.uk or refer to the guidance at 
http://www.uel.ac.uk/qa/research/index.htm. Only those applications received by the submission 
deadline date shown on the University’s Research Ethics web page will be considered at the next 
meeting. Where a form is submitted and sections are incomplete, the form will not be considered 
by UREC and will be returned to the applicant for completion.  
 
PROJECT DETAILS 
 
Current project title Puffing Patterns in Electronic Cigarettes: Self-titration of 
Nicotine   
Is this project 
externally funded? 
YES      NO ☒  NOT APPLICABLE  
Does the project 
require UREC 
approval before 
consideration by the 
funding body? 
YES   NO   NOT APPLICABLE ☒ 
 
If YES, please indicate funding body deadline below: 
If externally funded, 
please provide details 
of funding body. 
N/A 
How will participants be informed of the source of funding? N/A 
 
PARTICIPANT INFORMATION SHEET   CONSENT FORM    OTHER  
 
If OTHER, please specify further below: 
 
 
Proposed project 
start date 
22/03/15 Anticipated project 
end date 
December 
2015 
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APPLICANT DETAILS 
 
Name of Principal 
Investigator (PI) 
(For research degree 
students, the Director 
of Studies) 
 
Dr Lynne Dawkins (DoS, School of Psychology) on behalf of 
Catherine Kimber (PhD student) 
School Psychology 
Status (please tick 
relevant box) 
UEL STAFF  ☒ RESEARCH DEGREE STUDENT    
Email address L.e.dawkins@uel.ac.uk 
Contact telephone 
number 
0208 223 2241 
Name of co-
researchers  
Catherine Kimber (PhD student) 
Prof. Olivia Corcoran (Second supervisor from HSB school) 
 
Will parts of the 
proposed research or 
research 
administration be 
carried out by 
independent 
contractors or partner 
institutions, domestic 
or international? 
YES      NO ☒   
 
If YES, please provide a brief explanation of who the contractor or 
partner is, what their role will be and how their contribution will be 
monitored. Please note, responsibility for proper conduct of all parties 
involved in the research resides with the Principal Investigator. 
 
 
CONFLICTS OF INTEREST 
 
Will any of the researchers or their institutions receive any other benefits or incentives for 
taking part in this research over and above their normal salary package or the costs of 
undertaking the research?  
YES      NO ☒ 
If YES, please detail below: 
 
Is there any further possibility for conflict of interest? YES      NO ☒  
If YES, please detail below: 
 
 
FOR ALL APPLICANTS 
 
Has external ethics approval been sought for this research?  
(i.e. submission via Integrated Research Application System (IRAS) 
to the Health Research Authority (HRA) or other external research 
ethics committee) 
YES      NO ☒   
If YES, please supply details below: 
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DEAN OF SCHOOL OR ASSOCIATE DEAN 
• Does the proposed research as detailed herein have your support and endorsement to 
proceed?  
YES ☒     NO    
 
Signed  
 
Date  
 
 
APPLICANT DECLARATION 
 
I confirm that: 
• The information contained in this application is, to the best of my knowledge, correct and 
up to date. 
• I have attempted to identify all risks related to the research.  
• I acknowledge my obligations and commitment to upholding our University’s Code of 
Practice for ethical research and observing the rights of the participants. 
• I am aware that cases of proven misconduct, in line with our University’s policies, may 
result in formal disciplinary proceedings and/or the cancellation of the proposed research. 
Applicant Lynne Dawkins (for Catherine Kimber) 
Signed L.Dawkins  
Date 15/12/14 
 
FOR RESEARCH DEGREE STUDENT APPLICANTS ONLY 
 
Name and School of 
Director of Studies 
Dr Lynne Dawkins, School of Psychology 
Qualification for which 
research is being 
undertaken 
PhD via MPhil  
 
Director of Studies (DoS) – 
• Does the student have the necessary skills to carry out the research?  
YES ☒     NO    
▪ Is the participant information sheet, consent form and any other documentation appropriate?  
YES ☒    NO    
▪ Are the procedures for recruitment of participants and obtaining informed consent suitable 
and sufficient? 
YES ☒    NO    
▪ Where required, do all members of the research team have current Criminal Records Bureau 
(CRB) clearance? 
YES      NO   N/A 
 
Signed  
Date  
 
DETAILS OF THE PROPOSED RESEARCH 
 
28. Provide a brief description of the proposed research, including the requirements 
of participants. This must be in lay terms and free from technical or discipline 
specific terminology or jargon. If such terms are required, please ensure they are 
adequately explained (Do not exceed 500 words) 
 
 
358 
 
This application is essentially combining two previous studies conducted at UEL by 
exploring effects of e-cigarette puffing patterns on blood nicotine delivery. A 
previously published study by Dawkins and Corcoran (‘An evaluation of the SKYCIG 
electronic cigarette; UREC approval gained 7/11/12 and amendment approved 
14/1/13 by Merlin Harries) which explored nicotine delivery in e-cigarette users and 
a pilot study entitled “E-cigarette puffing behaviour with different nicotine strength e-
liquids” (ethic approval UREC_1415_02, 8/10/14).  
The proposed study aims to explore puffing patterns (puff frequency, duration and 
interval between puffs) and blood nicotine delivery in experienced electronic cigarette 
(hereafter referred to as e-cigarettes) users under two conditions:  a ‘high nicotine 
strength’ and a ‘low nicotine strength’ condition (i.e.: 24mg/ml nicotine and 6mg/ml 
nicotine e-liquids). Evidence from tobacco cigarette smokers suggests that when given 
lower nicotine content cigarettes, smokers tend to alter their puffing patterns by 
increasing the duration, numbers and intensity of their puffs in order to maintain a 
constant blood nicotine level. This phenomenon referred to as self-titration has been 
extensively explored in tobacco smoking. Although findings from studies on nicotine 
delivery from e-cigarettes seem to indicate that self-titration might occur, this is yet 
to be properly explored in the laboratory.  The eventuality that e-cigarette users take 
more intensive puffs when switching to a lower nicotine concentration, presents the 
risk of increasing temperature of the heating element of the device, the atomiser and 
eventually formation and exposure to toxins and carcinogens.    
 
The study will be carried at the UEL clinical education building at the Stratford 
campus. In this proposed study, recruited participants will be experienced e-cigarette 
users with a history of at least 3 months use, currently using the newest re-fillable 
(second or third generation) e-cigarette devices and nicotine concentration of 24mg/ml 
or higher will be recruited. Following an initial saliva screening session, participants 
will attend two sessions a week apart to allow for a sufficient rest period, where they 
will be given a third generation device with a high nicotine concentration on one day 
and a lower nicotine concentration on the other (the order of presentation will be 
counterbalanced).  Third generation devices are latest models customisable and more 
sophisticated than earlier models, they have a rechargeable battery and adjustable 
power and can be mounted with a refillable tank system. E-liquid flavours will be 
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selected based on participants’ preferences as this worked well in our pilot study. 
Participants will be asked to refrain from all nicotine use overnight (10-12 hours) prior 
to each session.  
 
Demographic and vaping/smoking history will be collected using questionnaires. 
Blood samples will be collected from participants at a maximum of six time-points 
(baseline, five, ten, twenty, thirty and sixty minutes) and a questionnaire measuring 
‘urge to vape’ and ‘withdrawal symptoms’ will be administered at each point. 
Participants will be presented with the e-Vic e-cigarette from ‘Joyetech’ with a 
Nautilus Tank System (which collects data on puff frequency; see further details in 
section 3 below) and asked to use the device for 60 minutes whilst the puffing 
behaviour is being video-recorded.  Data on puff frequency, puff duration and 
inhalation time will be gathered from video recordings as well as from e-Vic Joyetech 
software for back up purposes.   
 
 
29. Provide a statement on the aims and significance of the proposed research, 
including potential impact to knowledge and understanding in the field (where 
appropriate, indicate the associated hypothesis which will be tested). This should 
be a clear justification of the proposed research, why it should proceed and a 
statement on any anticipated benefits to the community. (Do not exceed 700 words) 
 
 
Smoking is the most preventable cause of premature mortality. Each year, in the UK 
alone, approximately 100 000 of premature death is attributed to smoking. Although, 
the ultimate goal remains that smokers should cease any use of tobacco and nicotine 
products totally and permanently, there is a consensus which support regulated harm 
reduction approaches to help smokers unable or unwilling to quit. While some studies 
indicate that nicotine replacement therapies (hereafter referred to as NRTs) help in 
achieving abstinence (Ucar et al., 2014), fewer than 20% of users remain abstinent 
after 12 months (Stead et al., 2012). It could be because NRTs fall short of providing 
the psycho-behavioural cues associated with the rituals of smoking or because of the 
slow nicotine delivery pace. 
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E-cigarettes (also known as electronic nicotine delivery systems or personal 
vaporisers) are battery-operated devices which deliver nicotine via a mist-produced 
mechanism. Given there is no tar and combustion they provide a safer alternative to 
traditional smoking. Since their introduction, e-cigarettes are becoming increasingly 
popular, with the latest figures suggesting 2.1 million users in the UK.  Because they 
closely mimic the appearance and use of traditional tobacco smoking, e-cigarettes 
hold the promise to significantly reduce the prevalence of smoking compared to 
NRTs. Studies show they can be more effective than NRTs (Brown, Beard, Kotz, 
Michie, & West, 2014) and effective at helping smokers to achieve abstinence and 
quit tobacco smoking (Etter and Bullen, 2014). 
 
E-cigarettes are currently regulated as consumer products and there is no mandatory 
quality standard control in place to ensure a standard of quality across manufacturers. 
That said, in May 2016, once the European Commission Tobacco Product Directive 
comes into effect, all e-cigarette products which contain a nicotine concentration of 
20 mg/ml or above will require authorisation by the Medicines and Healthcare 
Products and Regulatory Agency (MHRA) thus be classified as medicinal products. 
The implications are that for users who requires nicotine concentration of 20mg/ml or 
above, access and availability will be severely restricted, thus these users will be 
forced to switching to lower nicotine concentration. If e-cigarettes are to be successful 
in reducing tobacco cigarette consumption, it is crucial that smokers are given the 
nicotine concentration that they need. Indeed, evidence in the literature found that 
some users had to increase their nicotine concentration in order to sustain tobacco 
smoking abstinence (Farsalinos, Romagna, Tsiapras, Kyrzopoulos, & Voudris, 
2013a). 
Moreover, empirical evidence from tobacco studies show that smokers will 
compensate to achieve a desired (habitual) blood nicotine level, when given lighter 
cigarettes (lower nicotine concentration) by increasing the puff frequency, taking 
longer and more intensive puffs (Strasser et al., 2006), thereby increasing their 
exposure to toxicants and carcinogens and risk of cancer. Although, toxic substances 
and carcinogens reported in e-cigarettes vapour are at only at trace levels (Hajek et 
al., 2014), a harsher puffing pattern can lead to an increase to over-heating the 
atomiser and results in greater amount of e-liquid mass per unit of air volume and 
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lead to an alteration of particle sizes (Tucker & Jordan, 2013); thereby increasing the 
risk of production and exposure to toxins and carcinogens. Self-titration has been 
extensively investigated in tobacco smokers, however has not been explored 
empirically in e-cigarette use, despite findings on pharmacokinetics effects of 
nicotine via e-cigarettes indicating that users might self-titrate. Besides, data 
gathered from our recent pilot study (previously approved by UREC; reference 
1415_02, 8th October 2014) conducted in five e-cigarette users, indicates that users 
do change their puffing patterns when given a lower nicotine concentration e-liquid. 
However, this pilot study did not measure blood nicotine levels, thus it is unknown 
whether altered puffing patterns were effective for increasing blood nicotine delivery 
in the lower condition. 
 
This study aims are to explore puffing topography in e-cigarette users and evaluate 
whether users self-titrate (compensate) to maintain their plasma nicotine levels when 
given an acute administration of a lower nicotine concentration than their habitual 
strength by increasing their puff number and duration. Additional aims are to 
explore whether altered puffing patterns lead to increases in blood nicotine levels. 
Findings of this study will be informative to regulatory bodies and those making 
decisions vis-à-vis nicotine concentration of e-liquids but also to smokers, e-
cigarette users and smoking cessation service advisors. 
 
 
30. Provide an outline of the methodology for the proposed research, including 
proposed method of data collection, tasks assigned to participants of the research 
and the proposed method and duration of data analysis. If the proposed research 
makes use of pre-established and generally accepted techniques, please make this 
clear. (Do not exceed 500 words) 
 
 
Design: 
 
Double-blind within-participants design with two conditions:  ‘high strength’ and 
‘low strength’ e-liquid.  
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The order of presentation will be counterbalanced. 
 
Equipment: 
 
• For blood collection: 
• Pre-filled pharmaceutical grade saline syringes for flushing 
• 22 gauge needles and peripheral IV cannula with injection port 
• BDQ Stand Alone 385100 
• BD Veca-C IV dressings 
• Lithium Heparin vacutainers  
• Personal protective equipment (surgical gloves, lab coat, laboratory safety 
spectacles) 
• (All purchased from AB Medicals; http://www.bd.com/uk/) 
 
To render blood samples acellular for storage: 
• Centrifuge 
• Gas chromatography – mass spectrometer (Agilent technologies, 5975a 
series, GC/MSD with triple-axis detector; Agilent, Atlanta, GA) in UH006/7 
chemistry laboratory UEL.  
• Freezer designated for storage of biological samples (Norhof biological 
storage freezer, model DPF30, Norhof, Holland) in UH006/7 chemistry 
laboratory UEL. 
 
For the vaping session: 
• Carbon Monoxide (CO) Breatherlyser (Bedfont Smokerlyser) to measure 
exhaled CO levels. 
• ‘Salivette’ to measure saliva cotinine concentration at the screening phase 
(provided by ABS labs) 
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• eVic™ e-cigarette from ‘Joyetech’ (as used in our pilot study; 
UREC_1415_02, 8th October 2014) has a downloadable software which 
collects data such as puff duration and frequency.  See:  
http://www.joyetech.co.uk/electronic-cigarettes/eVic™-
supreme#.U9uFRKNeLpd 
• Nautilus Tank System (as used in our pilot study; UREC_1415_02, 8th 
October 2014) which has a large capacity of 5ml of fluid which is beneficial 
for research purposes  we will not have to re-fill it during the 45 minute ad 
lib vaping period.  It also comes with a measuring gauge and airflow control 
system which makes it ideal for our purposes.  See:    
http://www.ukecigstore.com/nautilus-tank-system-by-aspire.html 
• Nicotine e-liquid: a 6mg/ml and 24mg/ml nicotine concentration. Sampling 
will be based on the most popular brands available in the market. This 
information will be accessed via market research databases (eg. MINTEL). 
To avoid biases, the manufacturer or provider will be chosen using a blinding 
process, where several of the most popular providers will be selected in the 
first instance by one researcher, then one provider will be selected at random 
by a colleague researcher. The research team intends to seek advice with 
regard to manufacturer liability through the UEL legal advisor. In addition, 
prior to the current study and as part of a PhD research project, a study will 
be conducted to confirm that the nicotine concentration present in each e-
liquid bottles is accurate. These concentrations have been selected in the 
context of the proposed regulations in the European Tobacco Product 
Directive (hereafter referred to as TPD) which will come into effect in May 
2016 stipulating that all e-cigarette products containing nicotine e-liquid 
above 20mg/mL will require to undergo an application process through the 
Medicines and Healthcare Products Regulatory Agency (MHRA) (Action on 
Smoking and Health, 2014) and be classified as medicines.  
• Video recorder 
• Precision scales for weighing tank before and after use. 
 
Questionnaires / Measures: 
The questionnaires used will be the same as in our pilot study and will comprise: 
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• Baseline demographics questionnaire (Appendix C) 
• The Fagerström Test of Nicotine Dependence (Fagerström, 2012) will be 
modified to measure nicotine dependence, vaping history and e-cigarette use 
(Appendix D). Examples of items include “How soon after you wake up, you 
use your e-cigarette?”. The available option ‘within 5 minutes’ corresponds 
to the highest score, whilst the option ‘after 60 minutes’ scores the lowest. 
High scores signify high dependence. 
• A modified version of the multidimensional Mood and Physical Symptoms 
Scale (MPSS) questionnaire (West & Hajek, 2004) to measure ‘Urge to 
vape’ and withdrawal symptoms (Appendix E). The former is measured on a 
seven-point rating scale (scores range from 1 to 7, “Not at all strong” to 
“Extremely strong”); the latter is divided as follow ‘depressed mood’, 
‘irritability’, ‘anxiety’, ‘restlessness’, ‘hunger’ and ‘inability to concentrate’, 
each measured using a five-point rating scale (scores range from 1 to 5 “Not 
at all” to “Extremely”).  
• Subjective effects to nicotine: ‘Positive’ effects will be measured using an 
11-item visual analogue scale derived from Blank et al., (2008) (Appendix 
F). Participants are required to rate each statement by drawing a cross or a 
small line adjacent to the 20cm-line with the far left representing ‘not at all’ 
and the opposite right end ‘extremely’. Examples include ‘I feel a definite hit 
from the e-cigarette’, ‘The e-cigarette is satisfying?’, ‘The e-cigarette is 
pleasant’. Scoring is obtained by measuring from the far left corner to the 
drawn cross or line in millimetres then this is halved to translate the score in 
percentage. A higher score is indicative of more positive effect.  
• Subjective effects: Adverse effects will be measured with a 21-item visual 
analogue scale. This has been used in previous work (Vansickel & 
Eissenberg, 2013) (Appendix G). Examples of items include ‘confused’, 
‘dizzy’, ‘nausea’, ‘headache’, ‘salivation’, ‘sweaty’. Participants are required 
to place a cross through a 20cm-line.  
 
Procedure: 
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Participants will be screened via phone interviews to ensure all inclusion criteria are 
met and an information sheet will be provided via emails or post. Thereafter, pre-
screening analysis will be conducted by sending via post a ‘Salivette’ kit measuring 
salivary cotinine in order to ensure that participants are daily users and accustomed 
to the nicotine concentration specified in the inclusion criteria (cut-off point for 
cotinine ≤ 100mg/mL). Participants will be informed that cotinine analysis will only 
be used for the purposes of screening for this study then destroyed. 
 
If participants are eligible to take part, they will be asked to abstain from any 
tobacco and nicotine products including e-cigarette use for a period of 12 hours prior 
to the testing sessions. Smoking abstinence will be verified by measuring carbon 
monoxide in exhaled breath levels and nicotine abstinence from a baseline blood 
sample. 
 
Upon arrival, the researcher will go through the information sheet with the 
participants and check that they understand all aspects of the procedure.  Participants 
will be asked to provide written informed consent (Appendices A and B) where they 
will be invited to ask further questions. The researcher will ensure that they fully 
understand the nature and purpose of their participation. Participants will be invited 
to have a break and reminded of their right to withdraw at the beginning and during 
sessions. 
 
Baseline questionnaires (Appendix C) will be administered before a qualified 
phlebotomist nurse inserts a venous cannula into the participant’s forearm and 
collects a baseline blood sample. The cannula will be secured and remain in place 
for the duration of the study (maximum 1.5 hr) as in our previous pharmacokinetic 
study of nicotine delivery via e-cigarettes (UREC approval gained on 7/11/12 and 
amendment on 14/1/13 from Merlin Harries. Participants’ blood samples will be 
taken (by the phlebotomy nurse only) and MPSS questionnaires (Appendix D) 
completed at baseline, at five, ten, twenty, thirty and sixty minutes. Similar protocols 
have been successfully used in previous studies (Dawkins & Corcoran, 2014; 
Farsalinos et al., 2014; Vansickel & Eissenberg, 2013). After baseline questionnaires 
have been completed and a blood sample has been taken, participants will be 
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presented with the e-Vic and ask to use it ad libitum for an hour (for hygiene 
purposes, a new dismountable drip-tip mouth-piece will be attached to the device for 
each participant). During this time, the whole session will be video-recorded to 
measure puffing patterns. The venous cannula will be removed following the last 
blood sample collection, before completion of the final subjective effects (positive 
and adverse) questionnaires. Finally, participant will be thanked, offered 
refreshments and reimbursed for their time. 
 
The next session will take place a week later using the other nicotine concentration. 
 
Blood Nicotine Analysis: 
 
Blood will be stored on ice then centrifuged within 4 hours of collection to render 
samples acellular before storage in the HSB forensic lab at minus 20 Degrees 
centigrade, awaiting transportation at an offsite laboratory, the Advanced 
Bioanalytical Service (ABS) Laboratories Ltd., Welwyn Garden City, UK. Blood 
samples will be transported in one full batch in designated and appropriate 
containers via taxi. All blood nicotine analysis will be conducted by ABS labs and 
disposed of in accordance with the MHRA, GLP (Good Laboratory Practise) and 
GCP (Good Clinical Practise) accreditation protocols. A certificate of destruction 
will be issued and provided by ABS laboratories Ltd.  
 
Data protection: 
 
All data will be coded and treated confidentially and will be retained in accordance 
with the University’s Data Protection Policy, stored for a limited period of time on 
password protected hard drives. Hard copies of questionnaires will be stored in a 
locked filing cabinet in a locked room then destroyed in accordance with the 
university’s data protection policies. Signed consent forms will be detached and 
stored separately from questionnaire and video data, accessible to only the principal 
investigator and the researchers. To facilitate any withdrawal, each participant will 
be given a participant number which they will need to memorise in order to later 
request that their data is withdrawn. 
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Video recordings will be analysed (by 2 members of the team) and then entered into 
a computerised dataset before being disposed of securely.  
 
 
 
 
PARTICIPANT DETAILS  
 
31. Provide an explanation detailing how you will identify, approach and recruit the 
participants for the proposed research, including clarification on sample size and 
location. Please provide justification for the exclusion/inclusion criteria for this 
study (i.e. who will be allowed to / not allowed to participate) and explain briefly, in 
lay terms, why this criteria is in place. (Do not exceed 500 words) 
 
 
Participants: 
 
All testing sessions will take place in a specialist laboratory, the UEL clinical 
education building at the Stratford campus with secure access to develop the study.  
 
Fifteen participants will be recruited.  A similar study by Dawkins and Corcoran 
(2014) demonstrated that this sample size is sufficient to generate enough statistical 
power and statistically significant results. Moreover, such sample size would allow 
for some degree of drop out (failure to attend second testing session). All will be e-
cigarette users (ex-smokers) with a history of 3 months use minimum. Empirical 
evidence shows that a three-month practise is sufficient for users to develop effective 
puffing techniques and achieve tobacco abstinence (Hajek et al., 2014). Given that 
Dawkins & Corcoran (2014) previously found it more challenging to collect blood 
samples from females, all participants will be male as to reduce the risk of 
unnecessary physical discomfort.  
Recruitment will be initiated via advertisements on social media (Twitter and 
Facebook), diverse e-cigarette forums, leaflet distribution on and outside UEL, 
posters display at UEL’s permitted points and at e-cigarette retail outlets and vaping 
cafes. Thus, participants may include UEL staff and students as well as members of 
the general public. However, students will be made aware that their learning, 
assessments or experience at UEL will not be impacted by their participation, 
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withdrawal or non-participation. This will be clearly outlined in the information sheet 
(see appendices).  
The inclusion criteria are as follow: 1) must be male, 2) must no longer be a smoker, 
3) regular / daily e-cigarette users, 4) currently using a second or third generation e-
cigarette 5) being accustomed to (using or having used in recent past) 24 mg/mL 
nicotine concentration, 6) aged 18 years or above, 7) fluent in English, 8) be willing 
to abstain from any nicotine including e-cigarette use for a period of at least 12 hours 
before testing session. Exclusion criteria are that participants must not be females, 
current smokers, non-daily e-cigarette users, under the age of 18, have 
neurobiological or heart conditions or previous history of fainting during blood 
collection procedures and have levels of cotinine under 100mg/mL during pre-
screening phase. 
 
 
 
32. Will the participants be from any of the following groups?(Tick as appropriate) 
 
☒ Students or staff of this University (i.e. recruitment on-site at University of East London). 
☒Adults (over the age of 18 years with mental capacity to give consent to participate in the 
research). 
   Young people between 16 and 18 years (please note parental consent may still be 
required for s006Fme research). 
  Children or legal minors (anyone under the age of 16 years)1 
  Adults who are unconscious, severely ill or have a terminal illness. 
  Adults who may lose mental capacity to consent during the course of the research.                                                           
  Adults in emergency situations. 
  Adults2 with mental illness - particularly those detained under the Mental Health Act (1983 
& 2007). 
  Participants who may lack capacity to consent to participate in the research under the 
research requirements of the Mental Capacity Act (2005). 
  Prisoners, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Young Offenders, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Healthy volunteers (in high risk intervention studies). 
  Participants who may be considered to have a pre-existing and potentially dependent3 
relationship with the investigator (e.g. those in care homes, students, colleagues, service-
users, patients). 
  Other vulnerable groups (see Question 6). 
  Adults who are in custody, custodial care, or for whom a court has assumed 
responsibility. 
  Participants who are members of the Armed Forces. 
 
 
1If the proposed research involves children or adults who meet the Police Act (1997) definition of 
vulnerability3, any researchers who will have contact with participants must have current  enhanced 
Disclosure and Barring Service check (was previously called Criminal Records Bureau, or CRB, 
clearance). 2 ‘Adults with a learning or physical disability, a physical or mental illness, or a reduction in 
physical or mental capacity, and living in a care home or home for people with learning difficulties or 
receiving care in their own home, or receiving hospital or social care services.’ (Police Act, 1997) 
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3 Proposed research involving participants with whom the investigator or researcher(s) shares a 
dependent or unequal relationships (e.g. teacher/student, clinical therapist/service-user) may 
compromise the ability to give informed consent which is free from any form of pressure (real or implied) 
arising from this relationship. UREC recommends that, wherever practicable, investigators choose 
participants with whom they have no dependent relationship. Following due scrutiny, if the investigator is 
confident that the research involving participants in dependent relationships is vital and defensible, UREC 
will require additional information setting out the case and detailing how risks inherent in the dependent 
relationship will be managed. UREC will also need to be reassured that refusal to participate will not result 
in any discrimination or penalty.   
 
33. Will the study involve participants who are vulnerable?  YES      NO ☒   
 
For the purposes of research, ‘vulnerable’ participants may be adults whose ability to protect 
their own interests are impaired or reduced in comparison to that of the broader population.  
Vulnerability may arise from the participant’s personal characteristics (e.g. mental or physical 
impairment) or from their social environment, context and/or disadvantage (e.g. socio-
economic mobility, educational attainment, resources, substance dependence, displacement 
or homelessness).  Where prospective participants are at high risk of consenting under duress, 
or as a result of manipulation or coercion, they must also be considered as vulnerable. 
 
Adults lacking mental capacity to consent to participate in research and children are 
automatically presumed to be vulnerable. Studies involving adults (over the age of 16) who 
lack mental capacity to consent in research must be submitted to a REC approved for that 
purpose. 
 
6.1. If YES, a Disclosure and Barring Service (DBS) check within the last three years is 
required. 
 Please provide details of the “clear disclosure”: 
 Date of disclosure: 
 Type of disclosure: 
 Organisation that requested disclosure: 
 DBS certificate number: 
  
(NOTE: information concerning activities which require DBS checks can be found via  
https://www.gov.uk/government/publications/dbs-check-eligible-positions-guidance) 
 
 
6.2.If YES, what special arrangements are in place to protect vulnerable participants’ 
interests? 
 
 
34. Do you propose to make any form of payment or incentive available to participants 
of the research? YES  ☒  NO    
 
If YES, please provide details taking into account that any payment or incentive should be 
representative of reasonable remuneration for participation and may not be of a value that 
could be coercive or exerting undue influence on potential participants’ decision to take 
part in the research. Wherever possible, remuneration in a monetary form should be 
avoided and substituted with vouchers, coupons or equivalent.  Any payment made to 
research participants may have benefit or HMRC implications and participants should be 
alerted to this in the participant information sheet as they may wish to choose to decline 
payment. 
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RISK ASSESSMENT AND RISK MANAGEMENT 
 
A remuneration of £50 will be offered to participants at the end of their second testing 
session: firstly, in compensation for their time (up to 4 hours in total), secondly to 
cover travel expenses and thirdly because the study involves an invasive procedure 
involving collection of blood samples. The remuneration will be offered at the end of 
the second testing session. 
 
The remuneration will be clearly outlined in the information sheet. However, to avoid 
coercion, this will not be advertised and will only be disclosed once potential 
participants have expressed their interest in taking part and have asked for further 
information. 
 
 
 
 
35. What special arrangements are in place for eliciting informed consent from 
participants who may not adequately understand verbal explanations or written 
information provided in English; where participants have special communication 
needs; where participants have limited literacy; or where children are involved in 
the research? (Do not exceed 200 words)  
 
Part of the inclusion criteria are to be fluent in English. Nonetheless, the researcher 
will ensure that participants are fully aware and understand what the study involves 
and what their participation entails. Each participant will be invited to ask questions 
before giving informed consent. Participants will be provided with a copy of the 
information sheet via e-mail or post, to allow time for participants to understand and 
absorb the content prior to testing sessions.  
There will be no children or under 18s involved in the research.  
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36. Does the proposed research involve any of the following? (Tick as appropriate)  
 
☒  use of a questionnaire, self-completion survey or data-collection instrument (attach 
copy) 
  use of emails or the internet as a means of data collection 
  use of written or computerised tests 
  interviews (attach interview questions) 
  diaries  (attach diary record form) 
☒ participant observation 
  participant observation (in a non-public place) without their knowledge / covert research 
  audio-recording interviewees or events 
☒  video-recording interviewees or events 
  access to personal and/or sensitive data (i.e. student, patient, client or service-user 
data) without the participant’s informed consent for use of these data for research purposes 
☒  administration of any questions, tasks, investigations, procedures or stimuli which may 
be experienced by participants as physically or mentally painful, stressful or unpleasant 
during or after the research process (initial insertion of the catherter might induce slight 
discomfort, however, note this will be done by a qualified and experienced 
phlebotomist nurse) 
  performance of any acts which might diminish the self-esteem of participants or cause 
them to experience discomfiture, regret or any other adverse emotional or psychological 
reaction 
  investigation of participants involved in illegal or illicit activities (e.g. use of illegal drugs)  
  procedures that involve the deception of participants 
☒ administration of any substance or agent   (yes, but NOTE:  all participants will 
control their own level of nicotine intake and will be regular nicotine products users 
who are therefore exposed to nicotine on a daily basis so are fully aware and tolerant 
of any potential adverse effects).  
  use of non-treatment of placebo control conditions 
☒  collection of body tissues or fluid samples 
  collection and/or testing of DNA samples 
  collection and/or testing of gametes or embryo tissue 
  participation in a clinical trial 
  administration of ionising radiation to participants 
 research undertaken at an off-campus location (risk assessment attached) 
  research overseas (copy of VCG overseas travel approval attached) 
  
37. Does the proposed research involve any specific or anticipated risks (e.g. physical, 
psychological, social, legal or economic) to participants that are greater than those 
encountered in everyday life? YES ☒     NO   
If YES, please describe below including details of precautionary measures. 
 
Potential risks and hazards: 
• The current study involves blood samples collection, so unavoidably 
participants will be exposed to invasive venal puncture equipment under 
controlled conditions. 
• Participants might feel slight discomfort during the insertion of the needle 
and cannula. 
• There is a minimal risk of infection and cross-infection associated with the 
use of needles in blood sampling. 
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• There is a minimal risk of syncope (fainting) during blood sampling
Precautions which will be taken: 
• All researchers handling blood samples will be fully trained and vaccinated
against Hepatitis B.
• An insured, qualified and experienced phlebotomist nurse will be employed
to collect all blood samples. Only she will be carrying out blood samples
collection.
• Blood sampling will be carried in a sterile and safe environment.
• Proper procedures will be adhered to, to minimise risks associated with
hazards of handling certain types of equipment and samples. All researchers
will be issued with and instructed on proper usage of personal protective
equipment including lab coat, surgical gloves and laboratory safety
spectacles. For transfer of the biological samples a surgical mask will be
worn where appropriate as in direct exposure to the blood samples.
• Prior to sessions (approximately two weeks), a full walk through of the
laboratory with all equipment in place will be carried out with the technical
lab manager.
• In the information letter and initial screening stage, participants will be
advised that if they have a history of fainting or feeling faint when providing
blood samples, they should not take part.
• To reduce the likelihood of fainting occurring, all participants will be
recommended to have a substantial breakfast before the commencement of
the study.
• Participants will be pre-screened (via cotinine analysis in a saliva sample) to
ensure they are daily users and accustomed to the nicotine concentration
specified in the inclusion criteria.
Given that vapers are characterised by their dependency on nicotine, participants 
may experience slight discomfort induced by the required 12 hours or overnight 
abstinence. To minimise discomfort, testing sessions will be held in the morning. 
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As with any nicotine product, there is a small risk of side effects associated with e-
cigarette use. This includes nausea, headache, dizziness, and mouth/throat irritation. 
Refreshment and a glass of water will be offered to participants upon arrival and 
throughout the entire duration of the experiment. However, given that all 
participants will be regular users and be given nicotine concentrations that are below 
or equal to their habitual ones, adverse effects are unlikely to occur. Note, as part of 
the study’s procedures, participants will be asked to use the device ad libitum (i.e. as 
much as they desire), thus potential risks associated with adverse effects are not 
greater than those encountered in their everyday lives. In the event that adverse 
effects do occur, it is likely that they will be short-lived. In the unlikely event that 
ill-effects are reported, participants will be strongly recommended to stop using the 
device, the cannula will be removed immediately, and they can rest in a calm and 
quiet location with the researcher and nurse by his side should they wish to do so.  If 
required, a taxi home will be offered when the participant has been assessed to be 
well enough to leave the premises. 
38. Where the procedures involve potential hazards and/or discomfort or distress for
participants, please state what previous experience the investigator or researcher(s)
have had in conducting this type of research.
As stated above, in the event of hazards and/or discomfort, participants will be 
advised to stop using the device and be reminded that they are not obliged to 
continue with the study. 
Professor Olivia Corcoran is experienced in biological fluids handling and plasma 
extraction. She has previously worked in partnership with Dr Lynne Dawkins on a 
similar project, the first study on the pharmacokinetics effects of nicotine via e-
cigarettes to be published in Europe. Participants were required to use an e-cigarette 
whilst providing blood samples (Dawkins & Corcoran, 2014). 
An insured, qualified phlebotomist nurse with extensive experience taking blood 
samples will be employed to collect all blood samples. 
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Dr Lynne Dawkins, the principle investigator and Director of Studies has over 
seventeen years of experience of working with smokers in a research capacity and 
six years of experience of working with electronic cigarettes.  She has published 
extensively in various peer-reviewed journals work on smoking addiction and 
electronic cigarettes, and is regarded as one of the UK’s leading authorities on e-
cigarettes. Dr Lynne Dawkins has been awarded the Good Clinical Practise 
certificate.  
The PhD student and researcher Catherine Kimber has recently completed and 
passed the UEL Ethic and Research Integrity course. She has conducted her 
undergraduate project on e-cigarette use and choice in smokers with Dr Dawkins, 
which has been recently published in a peer-reviewed journal article (Dawkins, 
Kimber, Puwanesarasa & Soar, in press). In addition, she has undertaken a research 
internship at UEL with Dr Lynne Dawkins, conducting a project on the effects of 
nicotine on smokers’ cognitive functioning, thus involving smokers recruitment. 
More recently, she has conducted a pilot study which received full ethics approval 
by UREC, involving the recruitment of e-cigarette users. Thus, she currently has 
more than a year experience of working with smokers, vapers and e-cigarettes.  
39. Provide an explanation of any potential benefits to participants. Please ensure this
is framed within the overall contribution of the proposed research to knowledge or
practice.  (Do not exceed 400 words)
NOTE: Where the proposed research involves students of our University, they should be
assured that accepting the offer to participate or choosing to decline will have no impact on
their assessments or learning experience. Similarly, it should be made clear to participants
who are patients, service-users and/or receiving any form of treatment or medication that
they are not invited to participate in the belief that participation in the research will result in
some relief or improvement in their condition.
Through the information sheet, participants will be made aware that there are no direct 
benefits, £50 will be given as compensation for their time, to cover their travel 
expenses and for the invasive procedure of blood sampling.   
Participants will be informed that findings of the study will be informative and 
beneficial to the wider clinical, academic and regulatory community. If findings 
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indicate that e-cigarette users self-titrate by taking longer, harder and more puffs when 
given a lower nicotine concentration, this will enable future studies to replicate these 
conditions and mimic these altered puffing behaviours to assess if toxicants and 
carcinogens exposure is increased. Likewise, if findings indicate that e-cigarette users 
do not seem to self-titrate, this will be as equally informative for regulatory bodies 
and future regulations.  
This study will add to the knowledge surrounding e-cigarette puffing behaviours and 
the pharmacokinetic effects of different nicotine concentration.  
Participants will be informed that whilst their involvement in the study will not benefit 
them directly, the findings will help to add to the knowledge base on e-cigarettes. It 
will be clearly stated on the information sheet that where participant is a student, 
participation, non-participation and withdrawal will not impact their learning 
experience or assessments at UEL. It will be clearly stated that participants will be not 
obliged to take part. If they decide to do so, they may wish and have the right to 
withdraw at any time.  
Although some of the participants taking part will be known to the researcher, most 
of these are external to UEL and none are in a dependent relationship with the 
researcher.  
40. Provide an outline of any measures you have in place in the event of adverse or
unexpected outcomes and the potential impact this may have on participants
involved in the proposed research. (Do not exceed 300 words)
During blood sampling there is a minimal risk that participant might feel faint or 
faint. Note, all participants will be screened for previous history of feeling faint or 
fainting during blood samples collection. Participants will be asked to eat a 
substantial breakfast on the morning prior to each testing session. A telephone 
emergency services will be accessible and a nominated and trained first aider will be 
informed of the timings of our scheduled sessions and will be on call throughout the 
duration of the experiment to intervene if need be. Note also that the nurse will be 
present throughout the entire session. 
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Participants might feel a slight discomfort or pain during the insertion of the needle 
or cannula. All blood samples collection will be carried out by a qualified 
phlebotomist nurse who has experience and expertise in handling risks and hazards 
associated with blood sampling.  
It is possible that blood samples could be spilt or dropped.  All care will be taken to 
avoid this by ensuring that all the correct equipment is in place and is easily 
accessible.  Only the qualified phlebotomy nurse and those with full Hepatitis B 
vaccination will handle blood samples.  
If ill-effects are reported as a result of using the device, participants will be strongly 
recommended to stop and have a rest in a calm and quiet location with the researcher 
and nurse by his side should they wish to do so, and a taxi home will be offered 
when the participant has been assessed to be well enough to leave the premises. 
Participants will be regular e-cigarette users with experience in using this type of 
tank system e-cigarettes, however, at first they might feel unfamiliarity with the 
device, sufficient time has been factored in to allow for familiarization. Also 
precautions will be taken to prepare and check the device is in working order prior 
to sessions. In the unforeseen event of malfunction, an alternative device will be 
available.  
41. Provide an outline of your debriefing, support and feedback protocol for
participants involved in the proposed research. This should include, for example,
where participants may feel the need to discuss thoughts or feelings brought about
following their participation in the research. This may involve referral to an external
support or counseling service, where participation in the research has caused
specific issues for participants. Where medical aftercare may be necessary, this
should include details of the treatment available to participants. Debriefing may
involve the disclosure of further information on the aims of the research, the
participant’s performance and/or the results of the research. (Do not exceed 500
words)
377 
At the end of the study, participants will be thanked and fully debriefed verbally vis-
à-vis the rationale, aims, hypotheses and the expected impacts of this research in the 
wider academic, clinical and regulatory communities.  Participants will be invited to 
ask questions about their participation and other questions they may have regarding 
e-cigarette use. Participants will be verbally informed of the aims of the study – i.e. 
to look at any changes in puffing patterns and blood nicotine levels that may occur 
when users switch to a lower strength e-liquid.  Participants will also be given the 
principle investigator’s e-mail address and telephone number should they have any 
further queries at a later date.   
PARTICIPANT CONSENT AND WITHDRAWAL 
42. Have you attached a copy of your participant information sheet (this should be in
plain English)? Where the research involves non-English speaking participants,
please include translated materials. YES☒     NO
If NO, please indicate what alternative arrangements are in place below:
43. Have you attached a copy of your participant consent form (this should be in
plain English)? Where the research involves non-English speaking participants,
please include translated materials.
YES ☒     NO
If NO, please indicate what alternative arrangements are in place below:
44. The following is a participant information sheet checklist covering the various
points that should be included in this document.
☒ Clear identification of UEL as the sponsor for the research, the schools(s) involved, the
project title, the Principal Investigator and other researchers along with relevant contact
details.
☒Details of what involvement in the proposed research will require (e.g., participation in
interviews, completion of questionnaire, audio/video-recording of events), estimated time
commitment and any risks involved.
☒A statement confirming that the research has received formal approval from UREC.
☒ If the sample size is small, advice to participants that this may have implications for
confidentiality / anonymity.
N/A A clear statement that where participants are in a dependent relationship with any of
the researchers that participation in the research will have no impact on assessment /
treatment / service-use or support.
☒ Assurance that involvement in the project is voluntary and that participants are free to
withdraw consent at any time, and to withdraw any unprocessed data previously supplied.
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☒Advice as to arrangements to be made to protect confidentiality of data, including that
confidentiality of information provided is subject to legal limitations.
☒A statement that the data generated in the course of the research will be retained in
accordance with the University’s Data Protection Policy.
☒Advice that if participants have any concerns about the conduct of the investigator,
researcher(s) or any other aspect of this research project, they should contact
researchethics@uel.ac.uk.
☒Confirmation on any limitations in confidentiality where disclosure of imminent harm to
self and/or others may occur.
N/A. For research involving under 16 s or vulnerable groups, where true, a statement has
been included on all information sheets that the investigators have passed appropriate
Disclosure and Barring Service checks.
45. The following is a consent form checklist covering the various points that should
be included in this document.
☒University of East London letterhead or logo.
☒Title of the project (with research degree projects this need not necessarily be the title of
the thesis) and names of investigators.
☒Confirmation that the project is research.
☒Confirmation that involvement in the project is voluntary and that participants are free to
withdraw at any time, or to withdraw any unprocessed data previously supplied.
☒Confirmation of particular requirements of participants, including for example whether
interviews are to be audio-/video-recorded, whether anonymised quotes will be used in
publications advice of legal limitations to data confidentiality.
☒ If the sample size is small, confirmation that this may have implications for anonymity any
other relevant information.
☒The proposed method of publication or dissemination of the research findings.
N/A. Details of any external contractors or partner institutions involved in the research.
N/A. Details of any funding bodies or research councils supporting the research.
N/A Confirmation on any limitations in confidentiality where disclosure of imminent harm to
self and/or others may occur.
N/A. Separate forms and information sheets requesting parental/guardian consent for
research involving under age children have been included / attached.
N/A. Letters requesting consent for the research to be conducted at external sites (e.g.
Managers/ owners/ head teachers /etc.) where the research will be carried out have been
included / attached.
☒Where research is to be published (it is envisaged that this is true in most cases) it has
been made clear in the information sheet and, or form (preferably both)  that both consent to
take part and to publication is being obtained.
CONFIDENTIALITY AND ANONYMITY 
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46. Below is a checklist covering key points relating to the confidentiality and
anonymity of participants. Please indicate where relevant to the proposed
research.
 Participants will be completely anonymised and their identity will not be known by the 
investigator or researcher(s) (i.e. the participants are part of an anonymous randomised 
sample and return responses with no form of personal identification)? 
 The responses are anonymised or are an anonymised sample (i.e. a permanent process 
of coding has been carried out whereby direct and indirect identifiers have been removed 
from data and replaced by a code, with no record retained of how the code relates to the 
identifiers). 
☒The samples and data are de-indentified (i.e. direct and indirect identifiers have been
removed and replaced by a code. The investigator or researchers are able to link the code to
the original identifiers and isolate the participant to whom the sample or data relates).
 Participants have the option of being identified in a publication that will arise from the 
research. 
 Participants will be pseudo-anonymised in a publication that will arise from the research. 
 The proposed research will make use of personal sensitive data. 
 Participants consent to be identified in the study and subsequent dissemination of 
research findings and/or publication. 
47. Participants must be made aware that the confidentiality of the information they
provide is subject to legal limitations in data confidentiality (i.e. the data may be
subject to a subpoena, a freedom of information request or mandated reporting by
some professions).  This only applies to named or de-identified data.  If your
participants are named or de-identified, please confirm that you will specifically
state these limitations.
YES ☒    NO
If NO, please indicate why this is the case below: 
NOTE: WHERE THE PROPOSED RESEARCH INVOLVES A SMALL SAMPLE OR FOCUS 
GROUP, PARTICIPANTS SHOULD BE ADVISED THAT THERE WILL BE DISTINCT 
LIMITATIONS IN THE LEVEL OF ANONYMITY THEY CAN BE AFFORDED. 
DATA ACCESS, SECURITY AND MANAGEMENT 
48. Will the Principal Investigator be responsible for the security of all data collected
in connection with the proposed research? YES ☒     NO
If NO, please indicate what alternative arrangements are in place below:
49. In line with the 5th principle of the Data Protection Act (1998), which states that
personal data shall not be kept for longer than is necessary for that purpose or
those purposes for which it was collected; please state how long data will be
retained for.
☒ 1-2 years 3-5 years 6-10 years 10> years
NOTE: Research Councils UK (RCUK) guidance currently states that data should 
normally be preserved and accessible for 10 years, but for projects of clinical or major 
social, environmental or heritage importance, for 20 years or longer. 
(http://www.rcuk.ac.uk/documents/reviews/grc/grcpoldraft.pdf) 
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50. Below is a checklist which relates to the management, storage and secure
destruction of data for the purposes of the proposed research. Please indicate
where relevant to your proposed arrangements.
☒Research data, codes and all identifying information to be kept in separate locked filing
cabinets.
☒Access to computer files to be available to research team by password only.
Access to computer files to be available to individuals outside the research team by
password only (See 23.1). 
 Research data will be encrypted and transferred electronically within the European 
Economic Area (EEA). 
 Research data will be encrypted and transferred electronically outside of the European 
Economic Area (EEA). (See 23.2). 
NOTE: Transfer of research data via third party commercial file sharing services, such as 
Google Docs and YouSendIt are not necessarily secure or permanent. These systems may 
also be located overseas and not covered by UK law. If the system is located outside the 
European Economic Area (EEA) or territories deemed to have sufficient standards of data 
protection, transfer may also breach the Data Protection Act (1998). 
☒Use of personal addresses, postcodes, faxes, e-mails or telephone numbers.
☒Use of personal data in the form of audio or video recordings.
Primary data gathered on encrypted mobile devices (i.e. laptops). NOTE: This should be
transferred to secure UEL servers at the first opportunity. 
☒All electronic data will undergo secure disposal.
NOTE: For hard drives and magnetic storage devices (HDD or SSD), deleting files does not
permanently erase the data on most systems, but only deletes the reference to the file. Files
can be restored when deleted in this way. Research files must be overwritten to ensure they
are completely irretrievable. Software is available for the secure erasing of files from hard
drives which meet recognised standards to securely scramble sensitive data. Examples of
this software are BC Wipe, Wipe File, DeleteOnClick and Eraser for Windows platforms. Mac
users can use the standard ‘secure empty trash’ option; an alternative is Permanent eraser
software.
☒All hardcopy data will undergo secure disposal.
NOTE: For shredding research data stored in hardcopy (i.e. paper), adopting DIN 3 ensures
files are cut into 2mm strips or confetti like cross-cut particles of 4x40mm. The UK government
requires a minimum standard of DIN 4 for its material, which ensures cross cut particles of at
least 2x15mm.
50.1. Please provide details of individuals outside the research team who will 
be given password protected access to encrypted data for the proposed 
research. 
N/A 
50.2. Please provide details on the regions and territories where research 
data will be electronically transferred that are external to the European 
Economic Area (EEA). 
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N/A 
OVERSEAS TRAVEL FOR RESEARCH 
51. Does the proposed research involve travel outside of the UK? YES NO ☒
51.1. Have you consulted the Foreign and Commonwealth Office website for 
guidance/travel advice? http://www.fco.gov.uk/en/travel-and-living-abroad/       YES 
     NO 
51.2. If you are a non-UK national, have you sought travel advice/guidance from 
the Foreign Office (or equivalent body) of your country? YES      NO     NOT 
APPLICABLE  
51.3. Have you completed the overseas travel approval process and enclosed a 
copy of the document with this application?    YES 
NO 
 Details on this process are available here 
http://www.uel.ac.uk/qa/research/fieldwork.htm  
51.4. Is the research covered by our University’s insurance and indemnity 
provision? 
     YES      NO 
       (Please seek confirmation via researchethics@uel.ac.uk) 
NOTE: Where research is undertaken at an off-campus location within the UK or overseas, 
the Risk Assessment policy must be consulted:  
http://dl-cfs-01.uel.ac.uk/hrservices/documents/hshandbook/risk_assess_policy.pdf.  
The Dean of School or Director of Service has overall responsibility for risk assessment 
regarding the health and safety of staff or students conducting research where UEL is the 
sponsor. 
51.5. Please evidence how compliance with all local research ethics and research 
governance requirements have been assessed for the country(ies) in which the 
research is taking place. 
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51.6. Will this research be financially supported by the United States Department 
of Health and Human Services or any of its divisions, agencies or programs? YES 
     NO 
PUBLICATION AND DISSEMINATION OF RESEARCH FINDINGS 
52. How will the results of the research be reported and disseminated? (Select all that
apply)
☒ Peer reviewed journal
☒ Conference presentation
Internal report
☒ Dissertation/Thesis
Other publication
Written feedback to research participants
☒ Presentation to participants or relevant community groups
Other (Please specify below)
OTHER ETHICAL ISSUES 
53. Are there any other ethical issues that have not been addressed which you would
wish to bring to the attention of University Research Ethics Committee (UREC)?
No 
CHECKLIST FOR ATTACHED DOCUMENTS 
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54. Please check that the following documents are attached to your application.
☒ Recruitment advertisement
☒ Participant information sheets (including easy-read where relevant)
☒ Consent forms (including easy-read where relevant)
Assent form for children (where relevant)
Evidence of any external approvals needed
☒ Questionnaire
Interview Schedule or topic guide
☒ Risk assessment (where applicable)
Overseas travel approval (where applicable)
54.1. Where it is not possible to attach the above materials, please provide 
an explanation below. 
Recruitment will be via e-mail invitations to e-cigarette users known to us, or 
twitter/facebook if insufficient numbers are recruited via personal e-mail contacts. In 
addition, flyers will be distributed at various e-cigarette retail outlets and vape café 
(e.g. Vape lab). 
E-mail example:  Dear X, We are conducting a study exploring e-cigarette users’ 
puffing patterns under two different nicotine concentrations and would like to ask if 
you would be interested in taking part.  
The study has received full ethical approval by the university’s research committee 
and involves 2 visits to the Strafford campus of UEL a week apart. It is expected that 
each session will take approximately 2 hours.  
You will be asked to provide a total of six blood samples via an intravenous cannula 
whilst you use an e-cigarette we provide for 45mins – 1 hour.  . The entire session 
will be video-recorded to capture your puffing patterns.  
All data generated in the course of the research will be treated confidentially and 
will be retained in accordance with the University’s Data Protection Policy. Your 
video recordings will be analysed and entered into a computerised dataset. Finally, 
the video recordings will be disposed of securely. Should you require further details, 
I will send you the participation information sheet.  
I look forward to hearing from you. 
The recruitment advertisement materials will be based on the following text: 
• Take part in a study exploring e-cigarette users’ puffing patterns.
• The study involves 2 visits (2 hours each approx.) to the UEL Strafford
campus one week apart.
• You will be asked to provide a total of six blood samples via an intravenous
cannula whilst you use a third generation e-cigarette we provide for 45mins –
1 hour.  Blood samples collection will be taken by a fully qualified and
experienced phlebotomist nurse. The entire session will be video-recorded.
• To take part you must be:
• 18 or over
• Male
• Non- or ex-smoker
• Be willing to provide screening saliva sample for nicotine analysis
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• Currently using a 2nd or 3rd generation e-cigarette
• Have used 24 mg/mL nicotine concentration e-liquid in recent past
• If interested contact the researcher:
• Catherine Kimber at u0951767@uel.ac.uk or C.kimber@uel.ac.uk;  020
8223 4592 and 078 9146 3562 leaving your name and contact details. Find
me on Twitter at @Cat_kimber
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22 July 2015 
 
Dear Catherine, 
 
 Project Title: 
  
 
 
Puffing Patterns in Electronic Cigarettes: Self-titration 
of Nicotine 
 
Principal 
Investigator:  
 
 
 
Lynne Dawkins 
 
Researcher: 
 
 
Catherine Kimber 
 
Amendment ref no: 
 
 
AMD 1415 23  
 
Original UREC 
reference: 
 
 
UREC 1415 40 
 
I am writing to confirm that the application for an amendment to the aforementioned 
research study has now received ethical approval on behalf of University Research 
Ethics Committee (UREC). 
 
Should any significant adverse events or considerable changes occur in connection with 
this research project that may consequently alter relevant ethical considerations, this 
must be reported immediately to UREC. Subsequent to such changes an Ethical 
Amendment Form should be completed and submitted to UREC.  
 
Approved Research Site 
 
I am pleased to confirm that the approval of the proposed research applies to the 
following research site. 
 
Research Site Principal Investigator / Local 
Collaborator 
University of East London, Stratford campus Lynne Dawkins 
 
Approved revised documents 
Document Version Date 
UREC application form 2.0 01 July 2015 
Information sheet 2.0 01 July 2015 
 
Summary of Amendments 
Study to include female participants, as well as the male participants originally 
proposed. 
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Ethical approval for the original study was granted on 04 January 2015. 
Approval is given on the understanding that the UEL Code of Good Practice in Research 
is adhered to. 
With the Committee’s best wishes for the success of this project. 
Please ensure you retain this letter, as in the future you may be asked to provide 
evidence of ethical approval for the changes made to your study. 
Yours sincerely, 
Rosalind Eccles 
University Research Ethics Committee (UREC) 
UREC Servicing Officer 
Email: researchethics@uel.ac.uk  
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University of East London 
School of Psychology 
Risk assessment for testing participants  
Puffing Patterns in Electronic Cigarettes: Self-titration of Nicotine 
Testing 
Location(s) 
Possible 
Risk 
Severity 
of hazard 
(H, M, L) 
Likelihood 
of hazard 
(H, M, L) 
Risk 
(H, M, 
L) 
Mitigating Activity 
1. 
2. 
UEL 
clinical 
education 
building, 
Stratford 
campus 
UEL 
clinical 
education 
building, 
Participants 
experience 
adverse 
effect of 
nicotine 
It is 
possible 
that blood 
Low 
Medium 
Low 
Low 
Low 
Low 
Very unlikely as 
participants will be 
given their 
PREFERED 
STRENGTH and a 
LOWER strength 
nicotine e-liquid and 
using ad libitum.  
However, should a 
participant feel any 
adverse effects, s/he 
will be advised to 
stop using the e-
cigarette 
immediately and the 
nurse and one of the 
researchers will stay 
with the participant 
until s/he feels 
better.  Effects 
usually wear off 
within an hour.  
If needed, participant 
will be offered a taxi 
home. 
As a further 
precautionary 
measure, participants 
will be screened to 
ensure that they are 
regular users and 
accustomed to 
24mg/mL, therefore 
risks are not greater 
than risks 
encountered in their 
everyday lives.   
 
 
388 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. 
Stratford 
campus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UEL 
clinical 
education 
building, 
Stratford 
campus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
samples 
could be 
spilt or 
dropped.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants 
might feel 
faint  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Medium 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
All care will be 
taken to avoid this 
by ensuring that all 
the correct 
equipment and is in 
place and is easily 
accessible.  A walk 
through of the 
protocol (without 
collection of blood 
samples) in the lab 
will be carried out 
with the technical 
lab manger prior to 
sessions. Only the 
qualified 
phlebotomy nurse 
and those with full 
Hepatitis B 
vaccination will 
handle blood 
samples. All 
researchers and the 
nurse will be issued 
with and instructed 
on proper usage of 
the personal 
protective 
equipment. 
 
All participants will 
be screened for 
previous history of 
feeling faint or 
fainting during blood 
samples collection. 
Participants will be 
asked to eat a 
substantial breakfast 
on the morning prior 
to each testing 
session. A telephone 
emergency services 
will be accessible 
and a qualified first 
aider will be on call 
throughout the 
duration of the 
experiment to 
intervene if need be. 
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UEL 
clinical 
education 
building, 
Stratford 
campus 
 
 
 
 
 
 
E-liquid 
spill 
 
 
 
The device we have 
chosen is very easy 
to re-fill and the 
investigator and 
researcher have 
extensive experience 
in using e-liquid 
refills.  We will only 
use 5ml of liquid at a 
time.  In the case of 
accidental spillage or 
contact with the 
skin, the 
participant/researche
r will use the sink in 
the laboratory to 
wash their hands 
immediately.  No 
reports of adverse 
effects relating to 
exposure of this 
concentration and 
amount of e-liquid to 
the skin have been 
reported.  
 
 
 
 
 
 
Principle Investigator:  L. Dawkins     
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APPENDIX 10 - STUDY 1 PARTICIPANT INVITATION LETTER 
 
UNIVERSITY OF EAST LONDON 
 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
 
The Principal Investigator(s) 
Dr. Lynne Dawkins; E-mail: l.e.dawkins@uel.ac.uk ; tel: 020 8223 4421 
Catherine Kimber; E-mail:  C.Kimber@uel.ac.uk or u0951767@uel.ac.uk; tel: 020 8223 
4592 
Professor Olivia Corcoran; E-mail:  o.corcoran@uel.ac.uk; tel: 020 8223 4034 
 
 
Consent to Participate in a Research Study 
The purpose of this letter is to provide you with the information that you need to 
consider in deciding whether to participate in a research study being conducted at the 
University of East London. 
 
 
Project Title 
Puffing Patterns in Electronic Cigarettes: Self-titration of Nicotine   
 
 
Project Description 
 
This study aims to compare e-cigarette puffing behaviour and blood nicotine levels 
under two different strength e-liquids – a strength that is similar to the one you are 
currently using, and another lower strength e-liquid from the same supplier.   If you 
decide to take part, we would like to see you on two occasions a week apart for 
approximately 2 hours each time.  You will be asked to refrain from e-cigarette and 
nicotine use overnight (for 10-12 hours) prior to each session.  Since the study involves 
blood sampling, we strongly recommend that you have a large breakfast in the morning 
before attending the session. 
Testing sessions will take place in the mornings in order to minimize any discomfort 
associated with not using nicotine.  We will provide the e-cigarette (an e-Vic third 
generation device) for you to use. For hygiene purposes, a new removable drip-tip will 
be provided at each session although you are welcome to bring your own.  
 
During the study, you will first be asked to use a smokerlyser which measures your 
carbon monoxide levels thus indicates whether you have smoked.  This is a simple, non-
invasive breath test which simply requires you to hold your breath and then breathe 
slowly into a tube.  You will then be asked to provide some background information 
about yourself and your e-cigarette history of use then complete a brief questionnaire 
measuring craving, mood and physical symptoms.  Thereafter, a fully qualified 
phlebotomist nurse will insert an intravenous catheter into your forearm before taking a 
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baseline blood sample. A total of six blood samples will be collected at 5, 10, 20, 30 and 
60 minutes where you will be asked to complete the brief craving, mood and physical 
symptoms questionnaire. The entire session will be video-recorded to capture your 
puffing patterns (i.e. puff frequency and duration), after which, you will complete 2 
questionnaires about your mood state and vaping experience. Please note, you are free 
to take comfort breaks during this time (although you will not be permitted to leave the 
building with an indwelling catheter) and you will be reminded after 20 minutes that 
you are free to take a break. 
 
 
 
Study Eligibility and exclusion criteria 
 
To take part you must be: 
 
• male  
• a regular e-cigarette user – that is you have been using the product for at least 3 
months  
• be a non- or ex-smoker 
• accustomed to 24mg/ml nicotine concentration – that is you have used 24mg/ml 
nicotine concentration in the last 3 months. 
• be willing to provide a saliva sample by post to check your nicotine levels. 
• aged 18 or over 
• physically fit and willing to provide blood samples 
• available and willing to participate in two sessions at UEL, Stratford, each takes 
approximately two hours.   
• willing to abstain from vaping and use of all nicotine-containing products for 12 
hours prior to testing.   
 
You cannot participate, if you: 
 
• are female 
• are under 18 years of age 
• are a smoker or a dual user – that is you are still smoking whilst using an e-
cigarette 
• do not use your e-cigarette on a daily basis 
• have previous history of fainting whilst providing blood samples 
• have neurobiological or heart conditions 
 
 
 
Confidentiality of the Data 
All data generated in the course of the research will be treated confidentially and will be 
retained in accordance with the University’s Data Protection Policy. All data will be 
numerically coded although we plan to collect data from only 15 people so it is possible 
that complete anonymity may not be achievable.    Nevertheless, consent forms will be 
detached and separated from the numerically-coded data and your questionnaire data 
and video recordings will be stored in a locked filing cabinet at UEL, analysed by three 
independent researchers at UEL, entered into a dataset then discarded securely. Data 
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captured by the video-recording will be cross-referenced with data collected by the e-
Vic e-cigarette which also records puff number and duration. The anonymised data will 
be used for the current study only. It is aimed that the findings will be written up for 
publication in a peer reviewed journal and might be presented at conferences.  Should 
any data be used in subsequent studies or for further analysis, the data will still be kept 
anonymous and confidential. Nevertheless, please be aware that the confidentiality of 
the information provided is subject to legal limitations in data confidentiality (i.e. the 
data may be subject to a subpoena, a freedom of information request or mandated 
reporting by some professions). 
 
 
 
Blood Samples 
 
Providing blood can sometimes lead to feeling dizzy, nauseous or faint. If you have any 
history of this, please do not volunteer to participate in the study. To reduce the 
likelihood of this occurring, you should ensure you have a substantial breakfast before 
the start of the study.  
You might feel slight discomfort during the insertion of the catheter in your forearm. 
However, all blood samples will be collected by an experience and qualified 
phlebotomist nurse. Blood samples will be stored at the University of East London 
before being transported to the Advanced Bioanalysis Service Laboratories Ltd., 
Welwyn Garden City, UK, for analysis of the nicotine content. Sampled blood will not 
be used for any other purposes or studies.  Once blood nicotine levels from all samples 
have been determined and recorded electronically, all samples will be disposed of in 
accordance with the Human Tissue Authority’s Code of Practice. 
 
 
Location 
The study will be conducted at the University East London, Stratford Campus in a 
clinical laboratory which offers safe and adequate facilities for blood samples 
collection.   
 
 
Remuneration 
Given the study involves an intrusive procedure blood samples collection, a 
remuneration of £50 will be offered as compensation and to cover your travel costs. 
However, there is no further direct benefit for taking part in the study, although the 
findings, thus your participation will help to add to the scientific knowledge base on e-
cigarettes. Note, if you are a student, your participation, non-participation or later 
withdrawal will have no impact on your assessments (i.e.: no module credits involved) 
and learning experience at UEL. 
 
 
 
Disclaimer 
You are not obliged to take part in this study and should not feel coerced. You are free 
to withdraw at any time. Should you choose to withdraw from the study you may do so 
without disadvantage to yourself and without any obligation to give a reason. Your right 
to withdraw from the study includes the right to request the destruction of any of your 
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data obtained from the study though you must memorise your personal participant 
number in order for the experimenter to delete your data.  You can email us at any point 
prior stating your participation number, and we will remove your data for you.  
Following completion of the study, none of your contact information will be retained 
without your specific permission. 
 
Please feel free to ask any questions. If you are happy to continue you will be asked to 
sign a consent form prior to your participation. Please retain this invitation letter for 
reference.  
 
This study has received full approval from the University of East London’s Ethical 
Committee.  If you have any questions or concerns about how the study has been 
conducted, please contact the study’s Principle Investigator: 
 
Dr. Lynne Dawkins, School of Psychology, University of East London, Water Lane, 
London E15 4LZ. +44 (0)20 8223 4421. E-mail:  l.e.dawkins@uel.ac.uk 
 
Or  
 
Catherine Fieulleteau, Ethics Integrity Manager, Graduate School, EB 1.43 
University of East London, Docklands Campus, London E16 2RD  
(Telephone: 020 8223 6683, Email: researchethics@uel.ac.uk). 
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APPENDIX 11- CONSENT FORM 
 
UNIVERSITY OF EAST LONDON 
 
Consent to participate in a research study 
 
 
Title 
 
Puffing Patterns in Electronic Cigarettes: Self-titration of Nicotine 
 
I have the read the information sheet relating to the above research study and have been 
given a copy to retain. The nature and purpose of the research has been explained to me, 
and I have had the opportunity to discuss the details and ask questions about this 
information. I understand what is being proposed and the procedures in which I will be 
involved have been explained to me.  I understand that I am able to take breaks 
whenever I want and that I am free to leave at any time.  
 
I understand that my involvement in this study, and particular data from this research, 
will remain strictly confidential. Only the researcher(s) involved in the study will have 
access to identifying data. I understand that the findings from this research project may 
be written up, submitted for publication and presented at conferences. I understand that 
all collected data will remain confidential during this process. It has been explained to 
me what will happen once the research study has been completed. 
 
I hereby freely and fully consent to participate in the study which has been fully 
explained to me. Having given this consent, I understand that I have the right to 
withdraw from the study at any time without disadvantage to myself and without being 
obliged to give any reason. 
 
 
Participant’s Name (BLOCK CAPITALS)  
 
………………………………………………………………………………………. 
 
Participant’s Signature  
 
……………………………………………………………………………………….. 
 
Researcher’s Name (BLOCK CAPITALS)  
 
……………………………………………………………………………………….. 
 
Researcher’s Signature  
 
………………………………………………………………………………………… 
 
 
Date: ……………………..……. 
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APPENDIX 12 – MATERIALS AND APPARATUS FOR STUDY 1 
 
For the blood collection, handling and storage, the materials used was as follows: 
• Pre-filled pharmaceutical grade saline syringes for flushing 
• 22 gauge needles and peripheral IV cannula with injection port 
• BDQ Stand Alone 385100 
• A non-latex tourniquet 
• BD Veca-C IV dressings 
• 4mL BD K2EDTA Lithium Heparin vacutainers (pre-labelled with participant 
number, times and dates) 
• Personal protective equipment (surgical gloves, lab coat, laboratory safety 
spectacles) 
• A disposable box (Designated yellow sharps needle bucket with cover firmly 
secured) 
• A trolley at the foot of the bed to contain the blood collection equipment 
For the plasma extraction: 
• MSE Falcon 6/300R Centrifuge  
• Pipette  
• Pipette heads 
• Blue roll Clinell to disinfect surfaces and to wipe spillages  
• Soft tissue (to wipe vacutainer tubes to ensure accuracy during balancing  
• Weighing scales to balance samples before centrifugation 
• 10ml glass beaker to weigh vacutainer tubes 
• 1.5ml Micro-vials to contain plasma after extraction 
• Biohazard waste bags 
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• Freezer designated for storage of biological samples at minus 20 degrees Celsius 
(Norhof biological storage freezer, model DPF30, Norhof, Holland). 
• Gas chromatography – mass spectrometer (Agilent technologies, 5975a series, 
GC/MSD with triple-axis detector; Agilent, Atlanta, GA) as in Dawkins and 
Corcoran’s (2014) paper.  
For the pre-screening of participants: 
• ‘Salivette’ kits to measure saliva cotinine concentration and ensure that 
participants are regular users and habituated to 24mg/ml (cut-off point ≤ 100 
ng/mL). 
 
The equipment used for the vaping session was as follows: 
• The Bedfont piCO Smokerlyzer® as used in the pilot study  
•  The ‘e-Vic’ e-cigarette was shown to be reliable and well tolerated in the pilot 
study. Findings from the pilot study, showed a strong correlation with the video 
recordings data also. 
• Nicotine liquid bottles all, tobacco flavour, 6 and 24mg/mL nicotine 
concentration.  
Other equipment included: 
• Precision scales (Microbalance, readability .00001g) 
• A ‘Toshiba Camileo X400’ video recorder.  All sessions were video recorded for 
cross-referencing purposes and also as a backup in case ‘e-Vic’ data would 
undergo loss, be distorted or corrupted.   
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APPENDIX 13 - STUDY 1 - BASELINE CHARACTERISTICS 
QUESTIONNAIRE 
 
The information provided will be treated as strictly confidential and anonymous, and will 
only be used in the interest of this study. Please complete or tick the most appropriate 
option.  
 
Participant’s unique number: …….. 
 
Age (please state):  …….. 
 
Gender:  ☐ Male ☐ Female 
 
Ethnicity: 
☐White ☐ Black Afro-Caribbean ☐ Mixed raced  
☐ Asian (Indian/ Pakistani/Bangadleshi)     ☐ North/South East Asian (Chinese)  
☐Other 
 
Occupational status: 
☐ employed     ☐ non-employed 
☐ self-employed ☐ studying  
 
What is your highest qualification to date?  
 ☐ GCSEs or equivalent  ☐ A-levels or equivalent ☐ Undergraduate study 
(level 5 to 6)      
 ☐ Postgraduate study (level 7 and above) 
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APPENDIX 14 - STUDY 1 VAPING HISTORY AND 
CHARACTERISTICS (NAMED eFTND) 
 
1. Which type of device do you currently use most (please circle one): 
 
e. A disposable e-cigarette (non-rechargeable) 
f. A rechargeable e-cigarette (sometimes called ‘stick-like’,  ‘cigarette-like’ 
or ‘cartomizers’ without fluid)  
g. A rechargeable e-cigarette (‘stick-like/cigarette-like/cartomizer’ without 
fluid) starter kit 
h. A rechargeable e-cigarette (non-cigarette-like with fluid) 
i. A rechargeable e-cigarette (non-cigarette-like with fluid) starter kit 
j. A modular system (your own combination of separate parts: battery, 
atomizer, fluid etc). 
k. E-cigar 
 
 
2. Which brand and model of e-cigarette are you currently using the most? 
 
Brand (please state) _________________ 
Model (please state)_________________ 
 
 
3. Which strength(s) of nicotine fluid/cartridge are you currently using? (circle all 
that apply). 
a. 0mg 
b. 4 mg  
c. 6mg 
d. 8mg 
e. 10 mg 
f. 11mg 
g. 15 mg 
h. 16mg 
i. 18mg 
j. 24mg 
k. 36mg  
l. Higher than 36mg 
m. I don’t know 
 
 
4. If you have circled more than one strength, please state which strength you use 
most:  _______________________________ 
 
 
 
5. Please try to estimate the amount you use per day: 
a. In puffs ____________ 
b. In cartridges ___________ 
c. In ml _______________ 
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6. Which is your preferred flavour? (please circle one) 
a. Tobacco 
b. Mint/menthol 
c. Fruit (various) 
d. Coffee 
e. Vanilla 
f. RY4 
g. Chocolate 
h. Cinnamon 
i. Tea 
j. Alcohol-related 
k. Other (please state) 
 
7. How soon after you wake up do you use your electronic cigarette? 
 
a. Within 5 minutes 
b. 6 – 30 minutes 
c. 31 – 60 minutes 
d. After 60 minutes 
 
8. Do you find it difficult to refrain from using your electronic cigarette in places 
where it is forbidden (e.g. on the train, in a business meeting) 
 
a. Yes 
b. No 
 
9. Which puffs on your e-cigarette would you hate most to give up? 
 
a. The first ones in the morning 
b. Any other one 
 
10. Do you puff more frequently on your e-cigarette during the first hours after 
waking than during the rest of the day? 
 
a. Yes 
b. No 
 
11. Do you use your e-cigarette if you are so ill that you are in bed most of the day? 
 
a. Yes 
b. No 
 
12.    Please rate your addiction to e-cigarettes on a scale of 0 to 
100:______________ 
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I am NOT addicted to cigarettes at all = 0 
I am extremely addicted to cigarettes = 100 
 
 
13. For you, stopping using the e-cigarette for good would be: 
 
a. Impossible 
b. Very difficult 
c. Fairly difficult 
d. Fairly easy 
e. Very easy 
 
 
 
14. How much of the time have you felt the urge to vape (i.e. use your e-cigarette) in 
the past week? (Circle one number) 
 
All the time Almost all 
the time 
A lot of the 
time 
Some of the 
time 
A little of the 
time 
Not at all 
5 4 3 2 1 0 
 
 
15. How strong have the urges been? (Circle one number) 
 
 
Extremely 
strong 
Very strong Strong Moderate Slight No urges 
5 4 3 2 1 0 
 
 
 
 
16. Since you started using the electronic cigarette, have you attempted to cut down 
the amount that you use it? 
 
a. Yes  
b. No  
 
If YES:  In your attempt to cut down your use of the electronic cigarette, how successful 
have you been? 
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a. Extremely successful: I have stopped using it completely now  
b. Very successful: I only use it occasionally now    
c. Quite successful: I use it much less that I did initially   
d. Not very successful: I have only cut down slightly    
e. Unsuccessful: My use has not changed      
f. Very unsuccessful: I use it more than I did initially  
   
 
17. Is it likely that in one month from now, you will have stopped using the electronic 
cigarette? 
 
a. Very likely 
b. Rather likely 
c. Rather unlikely 
d. Very unlikely 
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APPENDIX 15 – INDIVIDUAL PUFFING TOPOGRAPHY DATA (STUDY 1) 
 
 
Figure 2.14 Participant 1 Puff number and duration 
against changes in plasma nicotine in the high condition  
 
Figure 2.15 Participant 1 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.16 Participant 2 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.17 Participant 2 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.18 Participant 3 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
 
Figure 2.19 Participant 3 Puff number and duration 
against plasma nicotine in the low condition 
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Figure 2.20 Participant 4 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.21 Participant 4 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.22 Participant 5 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.23 Participant 5 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.24 Participant 6 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
 
Figure 2.25 Participant 6 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.26 Participant 7 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
 
Figure 2.27 Participant 7 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.28 Participant 8 Puff number and duration in 
the high condition (plasma nicotine scores unavailable) 
 
 
Figure 2.29 Participant 8 Puff number and duration in 
the low condition (plasma nicotine scores unavailable) 
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Figure 2.30 Participant 9 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.31 Participant 9 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.32 Participant 10 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
 
Figure 2.33 Participant 10 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.34 Participant 11 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.35 Participant 11 Puff number and duration 
against changes in plasma nicotine in the low condition 
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Figure 2.36 Participant 12 Puff number and duration 
against changes in plasma nicotine in the high condition 
 
Figure 2.37 Participant 12 Puff number and duration 
against changes in plasma nicotine in the low condition 
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APPENDIX 16 – ETHICS APPLICATION AND APPROVAL LETTER 
FOR STUDY 2 (INCLUDE RISK ASSESSMENT) 
 
 
 
 
 
APPLICATION FOR ETHICAL REVIEW OF RESEARCH INVOLVING HUMAN 
PARTICIPANTS, HUMAN DATA OR HUMAN MATERIAL 
 
This application should be completed by members of staff and postgraduate research degree 
students (i.e. MRes, MPhil, PhD and Professional Doctorate) undertaking research which 
involves human participants, sensitive human data (personal or otherwise) and human material 
(including human tissue, embryos, foetuses and bodily fluids, from living or deceased 
participants). 
 
No form of contact with potential participants for the proposed research should occur until written 
approval has been received from University Research Ethics Committee (UREC). Where a 
member of staff or student is found to have breached this expectation, they may be subject to 
disciplinary action. 
 
This application should be submitted alongside copies of any supporting documentation 
which will be handed to participants, including a participant information sheet, consent 
form, self-completion survey or questionnaire. 
 
For further guidance please contact researchethics@uel.ac.uk or refer to the guidance at 
http://www.uel.ac.uk/qa/research/index.htm. Only those applications received by the submission 
deadline date shown on the University’s Research Ethics web page will be considered at the next 
meeting. Where a form is submitted and sections are incomplete, the form will not be considered 
by UREC and will be returned to the applicant for completion.  
 
PROJECT DETAILS 
 
Current project title Cigalikes Versus Tank systems: Effects of Users’ experience, 
Device Characteristics and Nicotine Concentration During a 
Quit Attempt 
 
Is this project 
externally funded? 
YES      NO ☒  NOT APPLICABLE  
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Does the project 
require UREC 
approval before 
consideration by the 
funding body? 
YES   NO   NOT APPLICABLE ☒ 
 
If YES, please indicate funding body deadline below: 
If externally funded, 
please provide details 
of funding body. 
N/A 
How will participants be informed of the source of funding? N/A 
 
PARTICIPANT INFORMATION SHEET   CONSENT FORM    OTHER  
 
If OTHER, please specify further below: 
 
 
Proposed project 
start date 
28/09/15 Anticipated project 
end date 
September 
2017 
 
 
 
 
 
 
 
 
 
 
 
 
APPLICANT DETAILS 
 
Name of Principal 
Investigator (PI) 
(For research degree 
students, the Director 
of Studies) 
 
Dr Lynne Dawkins (DoS, School of Psychology) on behalf of 
Catherine Kimber (PhD student) 
School Psychology 
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Status (please tick 
relevant box) 
UEL STAFF    RESEARCH DEGREE STUDENT ☒  
Email address L.e.dawkins@uel.ac.uk 
Contact telephone 
number 
0208 223 2241 
Name of co-
researchers  
Catherine Kimber (PhD student) 
Prof. Olivia Corcoran (Second supervisor from HSB school) 
 
Will parts of the 
proposed research or 
research 
administration be 
carried out by 
independent 
contractors or partner 
institutions, domestic 
or international? 
YES      NO ☒   
 
If YES, please provide a brief explanation of who the contractor or 
partner is, what their role will be and how their contribution will be 
monitored. Please note, responsibility for proper conduct of all parties 
involved in the research resides with the Principal Investigator. 
 
 
CONFLICTS OF INTEREST 
 
Will any of the researchers or their institutions receive any other benefits or incentives for 
taking part in this research over and above their normal salary package or the costs of 
undertaking the research?  
YES      NO ☒ 
If YES, please detail below: 
 
Is there any further possibility for conflict of interest? YES      NO ☒  
If YES, please detail below: 
 
 
FOR ALL APPLICANTS 
 
Has external ethics approval been sought for this research?  YES      NO ☒   
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(i.e. submission via Integrated Research Application System (IRAS) 
to the Health Research Authority (HRA) or other external research 
ethics committee) 
If YES, please supply details below: 
 
 
DEAN OF SCHOOL OR ASSOCIATE DEAN 
• Does the proposed research as detailed herein have your support and endorsement to 
proceed?  
YES ☒     NO    
 
Signed  
 
Date  
 
 
APPLICANT DECLARATION 
 
I confirm that: 
• The information contained in this application is, to the best of my knowledge, correct and 
up to date. 
• I have attempted to identify all risks related to the research.  
• I acknowledge my obligations and commitment to upholding our University’s Code of 
Practice for ethical research and observing the rights of the participants. 
• I am aware that cases of proven misconduct, in line with our University’s policies, may 
result in formal disciplinary proceedings and/or the cancellation of the proposed research. 
Applicant Lynne Dawkins (for Catherine Kimber) 
Signed  
 
Date  
 
FOR RESEARCH DEGREE STUDENT APPLICANTS ONLY 
 
Name and School of 
Director of Studies 
Dr Lynne Dawkins, School of Psychology 
Qualification for which 
research is being 
undertaken 
PhD via MPhil  
 
 
 
418 
 
Director of Studies (DoS) – 
• Does the student have the necessary skills to carry out the research?  
YES ☒     NO    
▪ Is the participant information sheet, consent form and any other documentation appropriate?  
YES ☒    NO    
▪ Are the procedures for recruitment of participants and obtaining informed consent suitable 
and sufficient? 
YES ☒    NO    
▪ Where required, do all members of the research team have current Criminal Records Bureau 
(CRB) clearance? 
YES      NO   N/A 
 
Signed  
Date  
 
DETAILS OF THE PROPOSED RESEARCH 
 
55. Provide a brief description of the proposed research, including the requirements 
of participants. This must be in lay terms and free from technical or discipline 
specific terminology or jargon. If such terms are required, please ensure they are 
adequately explained (Do not exceed 500 words) 
 
This application is part of a PhD research project and a continuity of a precedent study 
which investigated compensatory behaviours for lower nicotine concentration e-liquid 
in regular electronic cigarette (hereafter referred to as e-cigarette) users over a one 
hour period. The proposed study will explore compensatory behaviours over a longer 
period of time alongside other factors which may also affect puffing topography and 
nicotine delivery. Puffing topography refers to number of puffs taken, duration of each 
puff and intervals between each puff (Inter-Puff Intervals hereafter referred to as IPI). 
 
E-cigarettes are battery-operated devices which deliver nicotine via a mist-produced 
mechanism. They  have now been endorsed as part of the tobacco harm reduction 
strategy by Public Health England (hereafter referred to as PHE) stating “The option 
of switching to electronic cigarettes as an alternative and much safer source of 
nicotine, as a personal lifestyle choice rather than medical service has enormous 
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potential to reach smokers currently refractory to existing approaches” (Britton & 
Bogdanovica, 2014).  
When first introduced, e-cigarettes were designed to strongly resemble combustible 
cigarettes, hence their names ‘cigalike’. Today, more sophisticated devices known as 
tank systems have been introduced. Studies suggest they are more popular with 
experienced users (Dawkins, Turner, Roberts, & Soar, 2013) and are thought to 
enhance users’ experience.  
Differences between cigalikes and tank systems initially emerged with the failure of 
the former to deliver nicotine with no to little increase in blood nicotine (Bullen et 
al., 2010; Eissenberg, 2010). However, later clinical studies using experienced e-
cigarette users (Dawkins & Corcoran, 2014; Vansickel & Eissenberg, 2013) and 
tanks (Farsalinos et al., 2014) found significant increases in plasma nicotine levels. 
Additionally, studies found that practise could lead to significant increase in blood 
nicotine (Hajek et al., 2014); and the use of tanks to be associated with greater 
success quit rates in comparison to cigalikes (Hitchman, Brose, Brown, Robson, & 
McNeill, 2015; Polosa, Caponnetto, Maglia, Morjaria, & Russo, 2014).  
Altogether, much evidence suggests users’ experience, device characteristics and 
nicotine concentrations as likely factors influencing nicotine delivery and the way a 
device is used or puffed on (e.g. puff duration and frequency) (Talih et al., 2014). 
Given that nicotine is the primary reinforcer of smoking behaviour (Harvey et al., 
2004), the implications are that models with poor nicotine delivery will preclude 
product acceptability, influence puffing behaviour and possibly put users at risk of 
relapsing to tobacco smoking.  
Thus, this study will explore how puffing behaviours and nicotine delivery in naïve 
e-cigarette users (smokers) change over time (as a user becomes more experienced 
in vaping) and vary according to device type and nicotine concentration.  It will also 
explore satisfaction, craving alleviation and product acceptability, and predictors of 
quitting behaviour.   
 
A sample of 60 current smokers, willing to initiate a quit attempt, will be recruited 
(≥ 5 cigarettes daily for > 1 year). Participants will be randomly (with the roll of a 
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dice) allocated to either condition:  1) given a cigalike, 2) given a tank with low 
nicotine concentration (6mg/ml), 3) given a tank with high nicotine concentration 
(18mg/ml). Participants will be invited to attend three sessions: at baseline, week-1 
and week-2. They will be provided with an e-cigarette and refill cartridges/bottles 
(1-2 weeks supply depending on budgetary restraints) at baseline and told to 
substitute as many cigarettes as possible with the e-cigarette with the aim of quitting 
smoking completely. Each participant will be given a diary to record their daily e-
cigarette and cigarette use and subjective effects associated with e-cigarettes use. 
Socio-demographic data, urge to smoke/vape and information on nicotine/smoking 
dependence will be collected.  
After the 2-week session participants will be invited to keep the device and 
encouraged to continue use and stop smoking, however, there will be no reward or 
motivational incentives.  
Follow-up interviews will be conducted at 4 weeks, 3 and 12 months to assess 
smoking status and e-cigarette use.  
 
 
56. Provide a statement on the aims and significance of the proposed research, 
including potential impact to knowledge and understanding in the field (where 
appropriate, indicate the associated hypothesis which will be tested). This should 
be a clear justification of the proposed research, why it should proceed and a 
statement on any anticipated benefits to the community. (Do not exceed 700 words) 
 
 
Each year, in the UK alone, approximately 100 000 of premature death is attributed 
to smoking (Peto et al, n.d.). Smoking still remains the most preventable cause of 
premature mortality. Although some commentators argue that the ultimate goal for 
smokers is to cease any use of tobacco and nicotine products, there is a consensus 
which support harm reduction approaches to help smokers unable or unwilling to quit. 
While some studies indicate that nicotine replacement therapies (hereafter referred to 
as NRTs) help in achieving abstinence (Ucar et al., 2014), fewer than 20% of users 
remain abstinent after 12 months (Stead et al., 2012). It could be because NRTs fall 
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short of providing the psycho-behavioural cues associated with the rituals of smoking 
or because the user has no control over the nicotine delivery pace. 
 
Studies suggest that they are more effective than NRTs (Brown, Beard, Kotz, Michie, 
& West, 2014) and have helped smokers achieving abstinence and quit smoking (Etter 
& Bullen, 2014) even in smokers who were not interested to quit (Polosa et al., 2014). 
If e-cigarettes are to remain and help in alleviating the huge burden of smoking 
prevalence, it is important to further explore their potential as smoking cessation aids. 
 
Although e-cigarettes research is in its infancy, in the past year there has been a surge 
in new studies depicting e-cigarettes as a potential smoking cessation aid (Caponnetto 
et al., 2013; Hajek et al., 2014; Polosa et al., 2014; Polosa et al., 2011). However, to 
date there is little evidence which help understand the dynamic interplay of the factors 
and mechanisms (e.g. puffing behaviour, nicotine concentration, device type) which 
influence nicotine delivery positively or negatively and  result in success at quitting 
smoking. Previous studies, including some work from our group at UEL (Farsalinos’ 
study, Dawkins & Corcoran, 2014 & the Dawkins, Kimber study 2015) suggest that 
different puffing behaviours may be associated with different blood nicotine delivery 
and that puffing behaviour may change over time and with different devices and 
nicotine strengths. Nevertheless how puffing behaviour and device characteristics 
influence smoking cessation success has not been explored.  
Taking a more naturalistic approach, the aims of this study are threefold:  1) to explore 
how naïve users’ puffing behaviours differ or change a) over time, b) between devices 
(cigalike vs. tank) and c) according to nicotine concentration (high vs. low);  2) to 
explore a) satisfaction, craving alleviation and product acceptability and b) nicotine 
delivery (via cotinine, a nicotine metabolite measured in saliva) between devices and 
according to nicotine concentration; and 3) to explore quit rates between groups and 
predictors of successful cessation. 
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The study is both novel and broad in its scope, generating a wealth of information on 
puffing topography and user behaviour with different e-cigarette devices/nicotine 
concentrations as well as information of successful predictors of smoking cessation.  
As such it will likely lead to a high impact publication (or two publications) and will 
be well cited in the academic literature. Outside of academia, the findings will be 
useful for policy makers, e-cigarette companies and health professionals, potentially 
enhancing smoking cessation programmes thus helping current smokers and 
ultimately alleviating the burden of smoking on the wider society.   
 
 
Study 2 
Main aims: 
1- To explore how naïve users’ puffing behaviours differ or change  
i. over time  
ii. between devices (cigalike vs. tank)  
iii. according to nicotine concentration (high vs. low)  
2- To explore  
i. satisfaction, craving alleviation and product acceptability  
ii. nicotine delivery (via cotinine, a nicotine metabolite measured in 
saliva) between devices and according to nicotine concentration 
 
Study 3 
In a 4-week, 3 month  and 12-month follow-up (Study 3), participants from the current 
study will be interviewed (via phone calls) to collect information vis-à-vis their 
smoking status (self-reported continuous abstinence, 7 day point prevalence 
abstinence and reduction in cigarette smoked), motivation to quit and e-cigarette use, 
to assess the efficacy of these devices as smoking cessation aids.  
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Primary aims: 
1- To explore 
i. Quit rates (cigarette consumption reduction) between groups  
ii. Predictors of successful cessation  
57. Provide an outline of the methodology for the proposed research, including 
proposed method of data collection, tasks assigned to participants of the research 
and the proposed method and duration of data analysis. If the proposed research 
makes use of pre-established and generally accepted techniques, please make this 
clear. (Do not exceed 500 words) 
 
 
Design: 
A mixed-participants design will be used, comprising 3 within-subjects factors for 
‘time’:  
                  Study 2                 Study 3 
➢ Baseline  
➢ One-week  
➢ Two-week  
➢ 4 weeks 
➢ 3 months  
➢ 12 months  
 
Participants will be randomly allocated to one of the following (between-subject 
factor): 
1- cigalike - high nicotine concentration (18mg/ml)  
2- tank - high nicotine concentration (18mg/ml) 
3- tank -  low nicotine concentration (6mg/ml) (Figure 1) 
 
Outcome measures: 
1- Puffing topography (‘numbers of puffs’, ‘puff duration’, ‘IPI’) and ‘volume 
consumed’ 
2- Salivary cotinine at baseline and at complete cessation  
3- Self-reported cigarette consumption/reduction  
4- Subjective effects (e.g. ‘urge to smoke’ and ‘withdrawal’) and others (e.g. 
satisfaction, hit) 
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5- eCO (Exhaled Carbon Monoxide) levels at baseline, 1 and 2 weeks and at 
cessation 
 
 
Figure 1. Diagram outline of study 2/3 
 
Equipment: 
 
• Carbon Monoxide (CO) Bedfont Smokerlyzer 
• ‘Salivette’ to measure salivary cotinine  
• Video recorder 
• ‘Go e-cig’ Cigalike including a user manual, battery and charger  
o Tobacco flavour ‘Go e-cig’ Refill cartridges 1.8% nicotine 
concentration 
• ‘Curve Mini’ Electronic cigarette by Totally Wicked with a tank and manual 
instructions 
o Refill bottles Tobacco flavour ‘Totally Wicked’s Red Label’ 1.8% 
and 0.6% nicotine concentration 
Note, the choice to purchase these products was based on price competitiveness and 
appropriateness in terms of design and features. All e-cigarette purchases were 
funded by ReDS (funds were allocated to the applicant’s studentship). The e-
N=60
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1-wk 2-wk
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cigarette and nicotine e-liquid provider has no connection with this project or the 
applicant. 
  
Questionnaires/Measures: 
• Baseline socio-demographic questionnaire (Appendix C). 
• Smoking history questionnaire (appendix D).  
• The Fagerström Test of Nicotine Dependence (Fagerström, 2012) (Appendix 
E). 
• The Mood and Physical Symptoms Scale (MPSS) questionnaire (West & 
Hajek, 2004) (Appendix F).  
• A diary to record daily e-cigarette use, number of cigarettes smoked, 
etcetera. (Appendix G). 
• Follow-up Interview questions for Study 3 (Appendix H)  
• Subjective effects to nicotine (Appendix I and J)  
 
Procedure: 
The study will be advertised internally and externally, using social media (Twitter 
and Facebook), leaflets and posters. Respondents to the advert via emails or phone 
calls will be screened via phone interviews to ensure all inclusion criteria are met, 
and an information sheet provided. Participants will be invited to attend a baseline, 1 
and 2-week individual sessions after a one-hour smoking abstinence.   
Upon arrival, the researcher will go through the information sheet with participants 
and ensure all aspects of the procedure are understood. Participants will be asked to 
provide written informed consent (Appendices A and B), informed of their right to 
withdraw from the study and invited to ask further questions.  
Salivary cotinine and Carbon monoxide breath tests will be administered before 
collecting baseline, socio-demographic data and information about their 
nicotine/cigarette dependence. Participants will be asked to place the test swab in 
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their mouth for 5 minutes until completely saturated, then place in a capped 
centrifugation tube on ice.  
MPSS questionnaires will be completed at the start and end of each session. 
Participants will be allocated a condition, given the e-cigarette with instructions on 
how to use it and instructed to vape ad libitum for 30 minutes. Puffing topography 
will be measured by video-recording each session then using a frame by frame 
analysis of 29.97 fps (frame per second) to analyse timing measurements (using the 
‘Adobe Premiere Pro CS5’ software).  
At the end of the first session, participants will be told to keep a record of their e-
cigarette use and number of cigarettes smoked in the diary and return all used and 
unused refills.  
At week-2 post intervention initiation, supply of e-liquid/cartridges will cease. 
Participants will be invited to keep the device and encouraged to continue use, 
however, there will be no reward incentives.  
Participants will be asked for consent to be contacted via phone calls for further 
follow-up phone interviews at 4 weeks, 3 and 12 months to provide information 
regarding their smoking status at these time points.  
 
Salivary cotinine analysis: 
Samples will be frozen (-20oC) and stored in UH006/7 at UEL. Once collection of 
all samples is complete, they will be transported on dry ice in an appropriate 
container to the Advanced Bioanalytical Service (ABS) Laboratories Ltd., Welwyn 
Garden City, UK. All analysis will be conducted by ABS labs and disposed of in 
accordance with the MHRA, GLP (Good Laboratory Practise) and GCP (Good 
Clinical Practise) accreditation protocols. A certificate of destruction will be issued 
and provided by ABS laboratories Ltd.  
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PARTICIPANT DETAILS  
 
58. Provide an explanation detailing how you will identify, approach and recruit the 
participants for the proposed research, including clarification on sample size and 
location. Please provide justification for the exclusion/inclusion criteria for this 
study (i.e. who will be allowed to / not allowed to participate) and explain briefly, in 
lay terms, why this criteria is in place. (Do not exceed 500 words) 
 
 
Participants: 
 
All 60 participants will be current smokers (smoking 5 cigarettes or more per day for 
at least the preceding year), willing to make a quit attempt and not a current e-
cigarette user (i.e. have not used an e-cigarette more than 5 times in the past and for 
no more than a week continuously). A sample size calculation was conducted based 
on data obtained from our pilot study (using ‘G Power’): 
Puff duration variable: Effect size = 0.448, p ≤ 0.05, CI = 0.95, N = 57 (sample size 
of 57) 
Puff number variable: Effect size = 2.97, p ≤ 0.05, CI = 0.95, N = 6 (sample size of 6) 
Other inclusion criteria include aged 18 or over, fluent in English. Exclusion criteria 
are pregnant or lactating females, any known neurobiological or heart conditions. 
Participants will be included regardless of their gender, ethnicities and SES (collected 
via questionnaires). This information will be used in subsequent analysis. 
 
Recruitment will be initiated via advertisements on social media (Twitter and 
Facebook), leaflet distribution on and outside UEL, posters display at UEL’s 
permitted points and at various supermarkets. Thus, participants are likely to include 
UEL staff and students as well as members of the general public. However, students 
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will be made aware that their learning, assessments or experience at UEL will not be 
impacted by their participation, withdrawal or non-participation. This will be clearly 
outlined in the information sheet (Appendix A).  
 
59. Will the participants be from any of the following groups?(Tick as appropriate) 
 
☒ Students or staff of this University (i.e. recruitment on-site at University of East London). 
☒Adults (over the age of 18 years with mental capacity to give consent to participate in the 
research). 
   Young people between 16 and 18 years (please note parental consent may still be 
required for s006Fme research). 
  Children or legal minors (anyone under the age of 16 years)1 
  Adults who are unconscious, severely ill or have a terminal illness. 
  Adults who may lose mental capacity to consent during the course of the research.                                                           
  Adults in emergency situations. 
  Adults2 with mental illness - particularly those detained under the Mental Health Act (1983 
& 2007). 
  Participants who may lack capacity to consent to participate in the research under the 
research requirements of the Mental Capacity Act (2005). 
  Prisoners, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Young Offenders, where ethical approval may be required from the National Offender 
Management Service (NOMS). 
  Healthy volunteers (in high risk intervention studies). 
  Participants who may be considered to have a pre-existing and potentially dependent3 
relationship with the investigator (e.g. those in care homes, students, colleagues, service-
users, patients). 
  Other vulnerable groups (see Question 6). 
  Adults who are in custody, custodial care, or for whom a court has assumed 
responsibility. 
  Participants who are members of the Armed Forces. 
 
 
1If the proposed research involves children or adults who meet the Police Act (1997) definition of 
vulnerability3, any researchers who will have contact with participants must have current  enhanced 
Disclosure and Barring Service check (was previously called Criminal Records Bureau, or CRB, 
clearance). 2 ‘Adults with a learning or physical disability, a physical or mental illness, or a reduction in 
physical or mental capacity, and living in a care home or home for people with learning difficulties or 
receiving care in their own home, or receiving hospital or social care services.’ (Police Act, 1997) 
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3 Proposed research involving participants with whom the investigator or researcher(s) shares a 
dependent or unequal relationships (e.g. teacher/student, clinical therapist/service-user) may 
compromise the ability to give informed consent which is free from any form of pressure (real or implied) 
arising from this relationship. UREC recommends that, wherever practicable, investigators choose 
participants with whom they have no dependent relationship. Following due scrutiny, if the investigator is 
confident that the research involving participants in dependent relationships is vital and defensible, UREC 
will require additional information setting out the case and detailing how risks inherent in the dependent 
relationship will be managed. UREC will also need to be reassured that refusal to participate will not result 
in any discrimination or penalty.   
 
60. Will the study involve participants who are vulnerable?  YES      NO ☒   
 
For the purposes of research, ‘vulnerable’ participants may be adults whose ability to protect 
their own interests are impaired or reduced in comparison to that of the broader population.  
Vulnerability may arise from the participant’s personal characteristics (e.g. mental or physical 
impairment) or from their social environment, context and/or disadvantage (e.g. socio-
economic mobility, educational attainment, resources, substance dependence, displacement 
or homelessness).  Where prospective participants are at high risk of consenting under duress, 
or as a result of manipulation or coercion, they must also be considered as vulnerable. 
 
Adults lacking mental capacity to consent to participate in research and children are 
automatically presumed to be vulnerable. Studies involving adults (over the age of 16) who 
lack mental capacity to consent in research must be submitted to a REC approved for that 
purpose. 
 
6.1. If YES, a Disclosure and Barring Service (DBS) check within the last three years is 
required. 
 Please provide details of the “clear disclosure”: 
 Date of disclosure: 
 Type of disclosure: 
 Organisation that requested disclosure: 
 DBS certificate number: 
  
(NOTE: information concerning activities which require DBS checks can be found via  
https://www.gov.uk/government/publications/dbs-check-eligible-positions-guidance) 
 
 
6.2.If YES, what special arrangements are in place to protect vulnerable participants’ 
interests? 
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RISK ASSESSMENT AND RISK MANAGEMENT 
61. Do you propose to make any form of payment or incentive available to participants 
of the research? YES  ☒  NO    
 
If YES, please provide details taking into account that any payment or incentive should be 
representative of reasonable remuneration for participation and may not be of a value that 
could be coercive or exerting undue influence on potential participants’ decision to take 
part in the research. Wherever possible, remuneration in a monetary form should be 
avoided and substituted with vouchers, coupons or equivalent.  Any payment made to 
research participants may have benefit or HMRC implications and participants should be 
alerted to this in the participant information sheet as they may wish to choose to decline 
payment. 
 
There will be no monetary compensation for taking part in the study. However, all 
participants will be given an e-cigarette device accompanied with nicotine e-liquid 
refills (1-2 weeks supply) at the start of the study. Given the study’s design, 
participants will be permitted to keep the device so their use and the effects on 
tobacco smoking can be followed over a period of time.  
This will be clearly outlined in the information sheet but will not be used explicitly to 
coerce individuals into taking part. 
 
 
62. What special arrangements are in place for eliciting informed consent from 
participants who may not adequately understand verbal explanations or written 
information provided in English; where participants have special communication 
needs; where participants have limited literacy; or where children are involved in 
the research? (Do not exceed 200 words)  
 
Part of the inclusion criteria are to be fluent in English. Nonetheless, the researcher 
will ensure that participants are fully aware and understand what the study involves 
and what their participation entails. Each participant will be invited to ask questions 
before giving informed consent. Participants will be provided with a copy of the 
information sheet via e-mail or post, to allow time for participants to understand and 
absorb the content prior to testing sessions.  
There will be no children or under 18s involved in the research.  
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63. Does the proposed research involve any of the following? (Tick as appropriate)  
 
☒  use of a questionnaire, self-completion survey or data-collection instrument (attach 
copy) 
  use of emails or the internet as a means of data collection 
  use of written or computerised tests 
☒  interviews (attach interview questions) 
☒  diaries  (attach diary record form) 
☒ participant observation 
  participant observation (in a non-public place) without their knowledge / covert research 
  audio-recording interviewees or events 
☒  video-recording interviewees or events 
  access to personal and/or sensitive data (i.e. student, patient, client or service-user 
data) without the participant’s informed consent for use of these data for research purposes 
  administration of any questions, tasks, investigations, procedures or stimuli which may 
be experienced by participants as physically or mentally painful, stressful or unpleasant 
during or after the research process  
  performance of any acts which might diminish the self-esteem of participants or cause 
them to experience discomfiture, regret or any other adverse emotional or psychological 
reaction 
  investigation of participants involved in illegal or illicit activities (e.g. use of illegal drugs)  
  procedures that involve the deception of participants 
☒ administration of any substance or agent   (yes, but NOTE:  all participants will 
control their own level of nicotine intake and will be regular smokers  who are 
therefore exposed to nicotine on a daily basis so are fully aware and tolerant of 
any potential adverse effects).  
  use of non-treatment of placebo control conditions 
☒  collection of body tissues or fluid samples (Non-invasive, non-painful salivary 
cotinine test to measure participants’ cotinine (a by-product of nicotine) levels 
  collection and/or testing of DNA samples 
  collection and/or testing of gametes or embryo tissue 
  participation in a clinical trial 
  administration of ionising radiation to participants 
☒ research undertaken at an off-campus location (risk assessment attached) 
  research overseas (copy of VCG overseas travel approval attached) 
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64. Does the proposed research involve any specific or anticipated risks (e.g. physical, 
psychological, social, legal or economic) to participants that are greater than those 
encountered in everyday life? YES  ☒   NO   
If YES, please describe below including details of precautionary measures. 
 
Potential risks and hazards: 
• Given that saliva is a potentially hazardous source of infective hepatitis, 
there is a minimal risk that the researcher might get in contact with saliva 
samples.  
• It is unlikely that participants experience any discomfort from the required 
period of abstinence, given it is only one hour. 
• Small risk of side effects associated with nicotine delivery via e-cigarette use 
including, nausea, headache, dizziness, and mouth/throat irritation. 
 
Precautions which will be taken: 
 
• Gloves will be worn during handling of saliva samples. All saliva samples 
will be taken by participants themselves, these will be sealed then placed 
straight in a centrifugation tube then in a bag before being handed to the 
researcher. 
• Refreshment and a glass of water will be offered to participants upon arrival 
and throughout the entire duration of the experiment. However, given that all 
participants will be smokers thus accustomed to the use of nicotine and be 
given nicotine concentrations that are below or equal to their habitual ones, 
adverse effects are unlikely to occur. Note, as part of the study’s procedures, 
participants will be asked to use the device ad libitum (i.e. as much as they 
desire), thus potential risks associated with adverse effects are not greater 
than those encountered in their everyday lives. In the event that adverse 
effects do occur, it is likely that they will be short-lived. In the unlikely event 
that ill-effects are reported, participants will be strongly recommended to 
stop using the device, and they can rest in a calm and quiet location with the 
researcher by his/her side should they wish to do so.  If required, a taxi home 
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will be offered when the participant has been assessed to be well enough to 
leave the premises. 
 
65. Where the procedures involve potential hazards and/or discomfort or distress for 
participants, please state what previous experience the investigator or researcher(s) 
have had in conducting this type of research. 
 
 
 
As stated above, in the event of hazards and/or discomfort, participants will be 
advised to stop using the device and be reminded that they are not obliged to 
continue with the study. 
Dr Lynne Dawkins, the principle investigator and Director of Studies has over 
seventeen years of experience of working with smokers in a research capacity and 
six years of experience of working with electronic cigarettes.  She has published 
extensively in various peer-reviewed journals work on smoking addiction and 
electronic cigarettes, and is regarded as one of the UK’s leading authorities on e-
cigarettes. Dr Lynne Dawkins has been awarded the Good Clinical Practise 
certificate.  
 
The PhD student and researcher Catherine Kimber has recently passed the UEL 
Ethic and Research Integrity course and attended the Risk assessment and 
Laboratory Safety training session provided by the HSB school on 1st July 2015. She 
has conducted her undergraduate project on e-cigarette use and choice in smokers 
with Dr Dawkins, which was published in a peer-reviewed journal article (Dawkins, 
Kimber, Puwanesarasa & Soar, 2015). In addition, she completed a research 
internship at UEL with Dr Lynne Dawkins, conducting a project on the effects of 
nicotine on smokers’ cognitive functioning, thus involving smokers recruitment. She 
conducted a pilot study which received full ethics approval by UREC, involving the 
recruitment of e-cigarette users. She also directed the recruitment of e-cigarette users 
and was involved in a study involving blood samples collection from e-cigarette 
users. Thus, she currently has 2 years of experience working with smokers and e-
cigarette users.  
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The PhD student Catherine Kimber will be conducting the individual testing 
sessions with participants, thus will be at risk of exposure to the biohazardous fluids 
saliva samples. The researcher has received Hepatitis B vaccinations and will ensure 
to wear gloves at all times when handling samples. 
 
66. Provide an explanation of any potential benefits to participants. Please ensure this 
is framed within the overall contribution of the proposed research to knowledge or 
practice.  (Do not exceed 400 words) 
NOTE: Where the proposed research involves students of our University, they should be 
assured that accepting the offer to participate or choosing to decline will have no impact on 
their assessments or learning experience. Similarly, it should be made clear to participants 
who are patients, service-users and/or receiving any form of treatment or medication that 
they are not invited to participate in the belief that participation in the research will result in 
some relief or improvement in their condition.   
 
 
 
Taking part in this study could be greatly beneficial to participants. Indeed, evidence 
from observational studies and randomised control trials (Bullen et al., 2014; Bullen 
et al., 2013; Caponnetto et al., 2013; McRobbie et al., 2014) suggests that for many 
unable to quit with the use of NRTs, e-cigarettes have significantly helped reduce their 
cigarette consumption and achieve complete cessation (Brown et al., 2014; Bullen, 
Howe, & Laugesen, 2014; Caponnetto et al., 2015; McRobbie, Bullen, Hartmann-
Boyce, & Hajek, 2014; Polosa et al., 2011). One study found that 22% of a sample of 
smokers (N = 477) using e-cigarettes had stopped smoking after one month and 46% 
(N = 367) following a year (Etter & Bullen, 2014). Others report significant 
improvement in asthmatic smokers’ respiratory systems following a switch from 
cigarettes to e-cigarettes (Polosa et al., 2014). Moreover, a recent report by PHE 
suggests a) the decline in smoking prevalence to be attributed to the increase in e-
cigarettes use and b) smokers unable to stop smoking should be encouraged to use e-
cigarette (McNeill et al, 2015).   
Altogether, the outcomes for each participant (cigarette reduction and/or stop 
smoking) could be greatly beneficial to their health. Indeed, as a consequence of 
taking part, it is likely that 20 to 40% of this sample will have quit smoking or at least 
halved their cigarette consumption thereby improving their overall health and 
potentially save lives. However, the information sheet states that if participants are 
patients, service-users and/or receiving any form of treatment or medication, they are 
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advised that although e-cigarette use may increase the likelihood of a positive outcome 
in terms of cigarette consumption reduction, they are not invited to hold the belief that 
participation in the research guarantees such an outcome. Equally, where participant 
is a student, participation, non-participation and withdrawal will not impact their 
learning experience or assessments at UEL.  
The information sheet states participants are not obliged to take part. If they decide to 
do so, they have the right to withdraw at any time with no need to provide an 
explanation.  
Although some of the participants taking part may be known to the researcher, most 
of these are external to UEL and none are in a dependent relationship with the 
researcher.  
 
 
67. Provide an outline of any measures you have in place in the event of adverse or 
unexpected outcomes and the potential impact this may have on participants 
involved in the proposed research. (Do not exceed 300 words) 
 
 
Participants will be submitted to salivary cotinine testing which involves a non-
invasive procedure whereby the subject is instructed to gently place a swab in the 
mouth for a few minutes until saturated to take a saliva sample. Since there are 
potential risks of hepatitis associated with being in contact with infectious human 
tissue, gloves will be worn during the handling of the sample. Moreover, to further 
minimize risks, samples will be placed in a small bag before being handed to the 
researcher. 
 
Potential but minimal effects that have been associated with the use of e-cigarettes 
are nausea, headache, dizziness, and mouth/throat irritation. 
A glass of water will be offered to participants upon arrival and throughout the 
entire duration of the experiment. However, given that all participants will be 
smokers thus accustomed to the use of nicotine and be given nicotine concentrations 
that are below or equal to their habitual ones, adverse effects are unlikely to occur. 
Note, as part of the study’s procedures, participants will be asked to use the device 
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ad libitum (i.e. as much as they desire), thus potential risks associated with adverse 
effects are not greater than those encountered in their everyday lives. In the event 
that adverse effects do occur, it is likely that they will be short-lived. In the unlikely 
event that ill-effects are reported, participants will be strongly recommended to stop 
using the device, and they can rest in a calm and quiet location with the researcher 
by his/her side should they wish to do so.  If required, a taxi home will be offered 
when the participant has been assessed to be well enough to leave the premises. 
 
Prior to the commencement of each testing sessions, checks will be run to minimize 
risks of equipment malfunction (E-cigarettes, batteries, Camera and Smokerlyzer). 
Participants will be given the e-cigarette with verbal and written instructions on how 
to use the device. Participants will be issued with contacts for technical support.  
68. Provide an outline of your debriefing, support and feedback protocol for 
participants involved in the proposed research. This should include, for example, 
where participants may feel the need to discuss thoughts or feelings brought about 
following their participation in the research. This may involve referral to an external 
support or counseling service, where participation in the research has caused 
specific issues for participants. Where medical aftercare may be necessary, this 
should include details of the treatment available to participants. Debriefing may 
involve the disclosure of further information on the aims of the research, the 
participant’s performance and/or the results of the research. (Do not exceed 500 
words) 
 
Given the behaviours we are observing in study 2 will be used as predictors of 
smoking cessation for study 3, we will not disclose the hypotheses of the study to 
participants until the very end of study 3 (12 month follow up).  However, 
debriefing may be earlier for some participants if they have stopped using the e-
cigarettes completely and relapsed to smoking. Debriefing will be done over the 
phone.  Participants will be thanked and debriefed verbally vis-à-vis the rationale 
and the expected impacts of this research in the wider academic, clinical and 
regulatory communities.  Participants will be verbally informed of the aims of the 
study – i.e. a) to look at any changes in puffing patterns and blood nicotine levels as 
the user acquires more experience using the device and how using a lower nicotine 
concentration and different types of device influence puffing patterns; b) to explore 
factors which influence quitting behaviour. Participants will be invited to ask 
questions about their participation and other questions they may have regarding their 
cigarette and e-cigarette use. Participants will also be given the principle 
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investigator’s e-mail address and telephone number should they have any further 
queries at a later date.   
 
 
 
 
 
 
 
PARTICIPANT CONSENT AND WITHDRAWAL 
 
69. Have you attached a copy of your participant information sheet (this should be in 
plain English)? Where the research involves non-English speaking participants, 
please include translated materials. YES☒     NO    
If NO, please indicate what alternative arrangements are in place below: 
 
 
70. Have you attached a copy of your participant consent form (this should be in 
plain English)? Where the research involves non-English speaking participants, 
please include translated materials. 
YES ☒     NO    
If NO, please indicate what alternative arrangements are in place below: 
 
 
71. The following is a participant information sheet checklist covering the various 
points that should be included in this document.  
 
☒ Clear identification of UEL as the sponsor for the research, the schools(s) involved, the 
project title, the Principal Investigator and other researchers along with relevant contact 
details. 
☒Details of what involvement in the proposed research will require (e.g., participation in 
interviews, completion of questionnaire, audio/video-recording of events), estimated time 
commitment and any risks involved. 
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☒A statement confirming that the research has received formal approval from UREC. 
☒ If the sample size is small, advice to participants that this may have implications for 
confidentiality / anonymity. 
N/A A clear statement that where participants are in a dependent relationship with any of 
the researchers that participation in the research will have no impact on assessment / 
treatment / service-use or support. 
☒ Assurance that involvement in the project is voluntary and that participants are free to 
withdraw consent at any time, and to withdraw any unprocessed data previously supplied. 
☒Advice as to arrangements to be made to protect confidentiality of data, including that 
confidentiality of information provided is subject to legal limitations. 
☒A statement that the data generated in the course of the research will be retained in 
accordance with the University’s Data Protection Policy.  
☒Advice that if participants have any concerns about the conduct of the investigator, 
researcher(s) or any other aspect of this research project, they should contact 
researchethics@uel.ac.uk. 
☒Confirmation on any limitations in confidentiality where disclosure of imminent harm to 
self and/or others may occur. 
N/A. For research involving under 16 s or vulnerable groups, where true, a statement has 
been included on all information sheets that the investigators have passed appropriate 
Disclosure and Barring Service checks. 
 
 
72. The following is a consent form checklist covering the various points that should 
be included in this document.  
 
☒University of East London letterhead or logo. 
☒Title of the project (with research degree projects this need not necessarily be the title of 
the thesis) and names of investigators. 
☒Confirmation that the project is research.  
☒Confirmation that involvement in the project is voluntary and that participants are free to 
withdraw at any time, or to withdraw any unprocessed data previously supplied. 
☒Confirmation of particular requirements of participants, including for example whether 
interviews are to be audio-/video-recorded, whether anonymised quotes will be used in 
publications advice of legal limitations to data confidentiality. 
☒ If the sample size is small, confirmation that this may have implications for anonymity any 
other relevant information. 
☒The proposed method of publication or dissemination of the research findings. 
N/A. Details of any external contractors or partner institutions involved in the research. 
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N/A. Details of any funding bodies or research councils supporting the research. 
N/A Confirmation on any limitations in confidentiality where disclosure of imminent harm to 
self and/or others may occur. 
N/A. Separate forms and information sheets requesting parental/guardian consent for 
research involving under age children have been included / attached. 
N/A. Letters requesting consent for the research to be conducted at external sites (e.g.  
Managers/ owners/ head teachers /etc.) where the research will be carried out have been 
included / attached. 
☒Where research is to be published (it is envisaged that this is true in most cases) it has 
been made clear in the information sheet and, or form (preferably both) that both consent to 
take part and to publication is being obtained.  
 
 
 
 
 
CONFIDENTIALITY AND ANONYMITY 
 
73. Below is a checklist covering key points relating to the confidentiality and 
anonymity of participants. Please indicate where relevant to the proposed 
research. 
 
 Participants will be completely anonymised and their identity will not be known by the 
investigator or researcher(s) (i.e. the participants are part of an anonymous randomised 
sample and return responses with no form of personal identification)? 
 The responses are anonymised or are an anonymised sample (i.e. a permanent process 
of coding has been carried out whereby direct and indirect identifiers have been removed 
from data and replaced by a code, with no record retained of how the code relates to the 
identifiers). 
☒The samples and data are de-identified (i.e. direct and indirect identifiers have been 
removed and replaced by a code. The investigator or researchers are able to link the code to 
the original identifiers and isolate the participant to whom the sample or data relates). 
 Participants have the option of being identified in a publication that will arise from the 
research. 
 Participants will be pseudo-anonymised in a publication that will arise from the research. 
 The proposed research will make use of personal sensitive data. 
 Participants consent to be identified in the study and subsequent dissemination of 
research findings and/or publication. 
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74. Participants must be made aware that the confidentiality of the information they 
provide is subject to legal limitations in data confidentiality (i.e. the data may be 
subject to a subpoena, a freedom of information request or mandated reporting by 
some professions).  This only applies to named or de-identified data.  If your 
participants are named or de-identified, please confirm that you will specifically 
state these limitations.   
 
YES ☒    NO    
 
If NO, please indicate why this is the case below: 
 
 
NOTE: WHERE THE PROPOSED RESEARCH INVOLVES A SMALL SAMPLE OR FOCUS 
GROUP, PARTICIPANTS SHOULD BE ADVISED THAT THERE WILL BE DISTINCT 
LIMITATIONS IN THE LEVEL OF ANONYMITY THEY CAN BE AFFORDED.  
 
DATA ACCESS, SECURITY AND MANAGEMENT 
 
75. Will the Principal Investigator be responsible for the security of all data collected 
in connection with the proposed research? YES ☒     NO    
If NO, please indicate what alternative arrangements are in place below: 
 
 
76. In line with the 5th principle of the Data Protection Act (1998), which states that 
personal data shall not be kept for longer than is necessary for that purpose or 
those purposes for which it was collected; please state how long data will be 
retained for. 
 
     ☒  1-2 years   3-5 years   6-10 years  10> years  
 
NOTE: Research Councils UK (RCUK) guidance currently states that data should 
normally be preserved and accessible for 10 years, but for projects of clinical or major 
social, environmental or heritage importance, for 20 years or longer. 
(http://www.rcuk.ac.uk/documents/reviews/grc/grcpoldraft.pdf) 
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77. Below is a checklist which relates to the management, storage and secure 
destruction of data for the purposes of the proposed research. Please indicate 
where relevant to your proposed arrangements. 
 
☒Research data, codes and all identifying information to be kept in separate locked filing 
cabinets. 
☒Access to computer files to be available to research team by password only. 
 Access to computer files to be available to individuals outside the research team by 
password only (See 23.1). 
 Research data will be encrypted and transferred electronically within the European 
Economic Area (EEA). 
 Research data will be encrypted and transferred electronically outside of the European 
Economic Area (EEA). (See 23.2). 
NOTE: Transfer of research data via third party commercial file sharing services, such as 
Google Docs and YouSendIt are not necessarily secure or permanent. These systems may 
also be located overseas and not covered by UK law. If the system is located outside the 
European Economic Area (EEA) or territories deemed to have sufficient standards of data 
protection, transfer may also breach the Data Protection Act (1998). 
☒Use of personal addresses, postcodes, faxes, e-mails or telephone numbers. 
☒Use of personal data in the form of audio or video recordings. 
 Primary data gathered on encrypted mobile devices (i.e. laptops). NOTE: This should be 
transferred to secure UEL servers at the first opportunity. 
☒All electronic data will undergo secure disposal.  
NOTE: For hard drives and magnetic storage devices (HDD or SSD), deleting files does not 
permanently erase the data on most systems, but only deletes the reference to the file. Files 
can be restored when deleted in this way. Research files must be overwritten to ensure they 
are completely irretrievable. Software is available for the secure erasing of files from hard 
drives which meet recognised standards to securely scramble sensitive data. Examples of 
this software are BC Wipe, Wipe File, DeleteOnClick and Eraser for Windows platforms. Mac 
users can use the standard ‘secure empty trash’ option; an alternative is Permanent eraser 
software. 
☒All hardcopy data will undergo secure disposal. 
NOTE: For shredding research data stored in hardcopy (i.e. paper), adopting DIN 3 ensures 
files are cut into 2mm strips or confetti like cross-cut particles of 4x40mm. The UK government 
requires a minimum standard of DIN 4 for its material, which ensures cross cut particles of at 
least 2x15mm. 
 
77.1. Please provide details of individuals outside the research team who will 
be given password protected access to encrypted data for the proposed 
research. 
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N/A 
77.2. Please provide details on the regions and territories where research 
data will be electronically transferred that are external to the European 
Economic Area (EEA). 
 
N/A 
 
 
 
 
 
 
 
 
OVERSEAS TRAVEL FOR RESEARCH 
 
78. Does the proposed research involve travel outside of the UK? YES      NO ☒ 
 
78.1. Have you consulted the Foreign and Commonwealth Office website for 
guidance/travel advice? http://www.fco.gov.uk/en/travel-and-living-abroad/       YES 
     NO    
 
78.2. If you are a non-UK national, have you sought travel advice/guidance from 
the Foreign Office (or equivalent body) of your country? YES      NO     NOT 
APPLICABLE     
    
78.3. Have you completed the overseas travel approval process and enclosed a 
copy of the document with this application?                                                  YES      
NO    
              Details on this process are available here 
http://www.uel.ac.uk/qa/research/fieldwork.htm  
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78.4. Is the research covered by our University’s insurance and indemnity 
provision? 
                                                                                                     YES      NO    
       (Please seek confirmation via researchethics@uel.ac.uk) 
 
NOTE: Where research is undertaken at an off-campus location within the UK or overseas, 
the Risk Assessment policy must be consulted:  
http://dl-cfs-01.uel.ac.uk/hrservices/documents/hshandbook/risk_assess_policy.pdf.  
The Dean of School or Director of Service has overall responsibility for risk assessment 
regarding the health and safety of staff or students conducting research where UEL is the 
sponsor. 
 
 
78.5. Please evidence how compliance with all local research ethics and research 
governance requirements have been assessed for the country(ies) in which the 
research is taking place. 
 
78.6. Will this research be financially supported by the United States Department 
of Health and Human Services or any of its divisions, agencies or programs? YES 
     NO    
 
 
PUBLICATION AND DISSEMINATION OF RESEARCH FINDINGS 
 
79. How will the results of the research be reported and disseminated? (Select all that 
apply) 
 
☒  Peer reviewed journal 
☒  Conference presentation 
  Internal report 
☒  Dissertation/Thesis 
  Other publication 
  Written feedback to research participants 
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☒  Presentation to participants or relevant community groups 
  Other (Please specify below) 
 
 
 
 
 
 
 
 
 
OTHER ETHICAL ISSUES 
 
80. Are there any other ethical issues that have not been addressed which you would 
wish to bring to the attention of University Research Ethics Committee (UREC)? 
 
No 
 
CHECKLIST FOR ATTACHED DOCUMENTS 
 
81. Please check that the following documents are attached to your application. 
 
☒  Recruitment advertisement 
☒ Participant information sheets (including easy-read where relevant) 
☒ Consent forms (including easy-read where relevant) 
  Assent form for children (where relevant) 
  Evidence of any external approvals needed 
☒  Questionnaire 
  Interview Schedule or topic guide 
☒ Risk assessment (where applicable) 
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  Overseas travel approval (where applicable) 
 
81.1. Where it is not possible to attach the above materials, please provide 
an explanation below. 
 
Recruitment will be via social media sites such as twitter/facebook. The researcher 
will seek support from all UEL available channels to reach out to smokers. For 
example advertising through InFocus and Universe newsletters, Plasma screens and 
Student Union webpages, etc. In addition, flyers will be distributed at various points 
throughout London in and outside the university. 
 
 
The recruitment advertisement materials will be based on the following text: 
 
Smokers wanted for a study on e-cigarettes at UEL 
 
• Researchers at UEL are exploring the potential of e-cigarettes as smoking 
cessation aids.   
• The study involves 3 sessions in which you will be asked to use an e-cigarette 
whilst being video-recorded to measure your puffing patterns.  
• You will be given the e-cigarette and ask to report your use for a period 4 
weeks. 
• To take part you must be: 
• Regular smoker (≥ 5 cigarettes/day for at least 1 year) 
• 18 or over 
• Be willing to try and quit smoking and use an e-cigarette for a period 
of at least 2 weeks 
• Be willing to provide saliva samples and report on your cigarette and 
e-cigarette use daily for up to 4 weeks 
 
• If interested contact the researcher: 
• Catherine Kimber at u0951767@uel.ac.uk or C.kimber@uel.ac.uk; 020 8223 
4592 leaving your name and contact details. Find me on Twitter at 
@Cat_kimber 
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APPROVAL LETTER 
14 October 2015 
Dear Catherine  
Project Title:  Cigalikes Versus Tank systems: Effects of Users’ experience, 
Device Characteristics and Nicotine Concentration During a Quit Attempt  
Principal Investigator: Dr Lynne Dawkins Researcher 
Catherine Kimber Reference Number: UREC 1516 04 
I am writing to confirm the outcome of your application to the University 
Research Ethics Committee (UREC), which was considered by UREC on 
Wednesday 16th September 2015. 
The decision made by members of the Committee is Approved. The Committee’s 
response is based on the protocol described in the application form and 
supporting documentation. Your study has received ethical approval from the 
date of this letter. 
Should any significant adverse events or considerable changes occur in 
connection with this research project that may consequently alter relevant ethical 
considerations, this must be reported immediately to UREC. Subsequent to such 
changes an Ethical Amendment Form should be completed and submitted to 
UREC. 
Approved Research Site 
I am pleased to confirm that the approval of the proposed research applies to the 
following research site: 
Research Site Principal Investigator / Local Collaborator 
University of East London premises 
Dr Lynne Dawkins 
Approved Documents 
The final list of documents reviewed and approved by the Committee is as 
follows: 
Document Version Date 
UREC application form 2.0 
08 October 2015 
Participant information sheet 2.0 
08 October 2015 
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Consent form 1.0 
27 August 2015 
Baseline characteristic questionnaire 1.0 
27 August 2015  
Smoking history questionnaire 1.0 
27 August 2015 
Fagerström Test of Nicotine Dependence 1.0 
27 August 2015 
MPSS questionnaire 1.0 
27 August 2015 
Diary – E-cigarette use and Smoking behaviour 1.0 
27 August 2015 
Study 3 - Follow-up Interview questions 1.0 
27 August 2015 
Subjective effects questionnaire 1.0 
27 August 2015 
Approval is given on the understanding that the UEL Code of Good Practice in 
Research is adhered to. 
The University will periodically audit a random sample of applications for ethical 
approval, to ensure that the research study is conducted in compliance with the 
consent given by the ethics Committee and to the highest standards of rigour and 
integrity. 
Please note, it is your responsibility to retain this letter for your records. 
With the Committee’s best wishes for the success of this project. 
Yours sincerely, 
Rosalind Eccles 
University Research Ethics Committee (UREC) 
UREC Servicing Officer 
Email: researchethics@uel.ac.uk 
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RISK ASSESSMENT FOR STUDY 2 
University of East London 
School of Psychology 
 
Risk assessment for testing participants  
 
Puffing Patterns in Electronic Cigarettes: Self-titration of Nicotine   
 
 Testing 
Location(s)  
Possible 
Risk 
Severity 
of 
hazard 
(H, M, 
L) 
Likelihood 
of hazard 
(H, M, L) 
Risk 
(H, 
M, 
L) 
Mitigating Activity 
 
1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.  
 
 
 
 
 
 
 
 
 
 
 
UEL 
clinical 
education 
building, 
Stratford 
campus  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UEL 
clinical 
education 
building, 
Stratford 
campus 
 
 
 
 
 
 
Participants 
experience 
adverse 
effect of 
nicotine  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is possible 
that blood 
samples 
could be 
spilt or 
dropped.   
 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
Low 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Low 
 
Very unlikely as 
participants will be 
given their OWN 
STRENGTH and a 
LOWER strength 
nicotine e-liquid and 
using ad libitum.  
However, should a 
participant feel any 
adverse effects, s/he 
will be advised to 
stop using the e-
cigarette 
immediately and the 
nurse and one of the 
researchers will stay 
with the participant 
until s/he feels better.  
Effects usually wear 
off within an hour.  
If needed, participant 
will be offered a taxi 
home. 
    
 
All care will be taken 
to avoid this by 
ensuring that all the 
correct equipment is 
in place and is easily 
accessible.  Only the 
qualified phlebotomy 
nurse and those with 
full Hepatitis B 
vaccination will 
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4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. 
 
 
 
UEL 
clinical 
education 
building, 
Stratford 
campus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UEL 
clinical 
education 
building, 
Stratford 
campus 
 
 
 
 
 
 
 
Participants 
might feel 
faint  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E-liquid spill 
handle blood 
samples. 
 
 
All participants will 
be screened for 
previous history of 
feeling faint or 
fainting during blood 
samples collection. 
Participants will be 
asked to eat a 
substantial breakfast 
on the morning prior 
to each testing 
session. A telephone 
emergency services 
will be accessible 
and a first aider will 
be present 
throughout the 
duration of the 
experiment to 
intervene if need be. 
 
 
The device we have 
chosen is very easy 
to re-fill and the 
investigator and 
researcher have 
extensive experience 
in using e-liquid 
refills.  We will only 
use 5ml of liquid at a 
time.  In the case of 
accidental spillage or 
contact with the skin, 
the 
participant/researcher 
will use the sink in 
the laboratory to 
wash their hands 
immediately.  No 
reports of adverse 
effects relating to 
exposure of this 
concentration and 
amount of e-liquid to 
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the skin have been 
reported.  
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APPENDIX 17 - PARTICIPANT INVITATION LETTER 
 
UNIVERSITY OF EAST LONDON 
 
School of Psychology 
Stratford Campus 
Water Lane 
London E15 4LZ 
 
 
The Principal Investigator(s) 
Dr Kirstie Soar; E-mail: k.soar@uel.ac.uk; tel: 020 8223 4082 
Dr. Lynne Dawkins; E-mail: l.e.dawkins@uel.ac.uk ; tel: 020 8223 4421 
Catherine Kimber; E-mail:  C.Kimber@uel.ac.uk; tel: 020 8223 4592 
Professor Olivia Corcoran; E-mail:  o.corcoran@uel.ac.uk; tel: 020 8223 4034 
 
Consent to Participate in a Research Study 
The purpose of this letter is to provide you with the information that you need to 
consider in deciding whether to participate in a research study being conducted at the 
University of East London. 
 
Project Title 
 Cigalikes Versus Tank systems: Effects of Users’ experience, device characteristics 
and Nicotine Concentration during a Quit Attempt 
 
Project Description 
 
This study aims to compare e-cigarette puffing behaviour, nicotine delivery and quitting 
behaviour with the use of various e-cigarette brands and nicotine strengths. If you are 
eligible to take part, we would like to see you on three occasions for approximately 1 
hour each time (day 1 and after 1 and 2 weeks). You will be asked to refrain from 
smoking and any nicotine use up to one hour prior to each session.   
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During the first testing session, you will be given an electronic cigarette to keep.  This 
will be either 1) a ‘cigarette-like’ device plus 3 weeks supply of refill cartridges 
(18mg/ml); 2) a ‘curve-mini’ e-cigarette with 18mg/ml refill bottles; or 3) a ‘curve-
mini’ e-cigarette with 6mg/ml refill bottles.  Allocation to one of the three conditions 
will be randomly determined. We request that you use the device that we have provided 
for at least the first three weeks of the study, using your e-cigarette to replace as many 
tobacco cigarettes as you can with the aim of stopping smoking completely. After 3 
weeks, you are free to use other electronic cigarettes or nicotine products or to change 
the flavour/strength of cartridges/e-liquid used but we will ask you to report this 
information to us.   
 
On each of the three testing days, you will first be asked to use a smokerlyser which 
measures your carbon monoxide levels indicating how much you have smoked in the 
last 24 hours. This is a simple, non-invasive breath test which simply requires you to 
hold your breath and then breathe slowly into a tube. You will also be asked to provide 
a saliva sample which will be used to measure how much nicotine you are absorbing. 
You will then be asked to provide some background information about yourself and 
your smoking history and complete a brief questionnaire measuring craving, mood and 
physical symptoms. We will then ask you to use the e-cigarette for 20 minutes, using it 
as much or as little as you want during that time. We will video-record you doing this in 
order to capture your puffing patterns (i.e. puff frequency and duration), after which, 
you will complete 2 questionnaires about your mood state and experience of using the 
e-cigarette. Please note, you are free to take comfort breaks during this time.  
At the end of the first testing session, you will be given a diary in which you will be 
asked to keep a record of your cigarette and e-cigarette use for the next 2 weeks. We 
will then arrange an appointment to see you again after 1 and 2 weeks at which point we 
will ask you more questions about your experience, smoking status and to video-record 
you using the e-cigarette again. Also, please keep all your empty cartridges or bottles 
and return them to us as we will use these to measure how much nicotine you 
consumed. 
 
After the 2 week session, you can keep the e-cigarette and continue to use it to help you 
stop smoking or to help you not to relapse to smoking. We would like to contact you 
again at 4 week, 3 months and 6 months via telephone to ask you about your smoking 
status and e-cigarette use.   
 
 
Study Eligibility and exclusion criteria 
 
To take part you must: 
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• Be a  regular smoker (i.e. smoke more than 5 cigarettes/day for at least 1 year) 
• Fluent in written and spoken English 
• aged 18 or over 
• Willing to use an e-cigarette for up to 4 weeks to try and quit smoking.  
• Willing to provide saliva sample and report on cigarette and e-cigarette use daily 
for 4 weeks  
• available and willing to participate in three one-hour sessions at UEL, Stratford 
• Willing to provide a contact telephone number and e-mail address and to agree 
to be contacted at  4 weeks, 3 and 12 months to report on your smoking status 
and e-cigarette use  
 
You cannot participate, if you: 
• are a non-smoker 
• are under 18 years of age 
• not fluent in written and spoken English 
• are a current e-cigarette user, have used an e-cigarette on more than 5 occasions 
in the past or for  more than a week continuously  
• have any neurobiological or heart conditions 
• are pregnant or a lactating female 
 
 
Confidentiality of the Data 
 
All data generated in the course of the research will be treated confidentially and will be 
retained in accordance with the University’s Data Protection Policy and personal data 
will be kept in accordance with the Data Protection Act. All data will be numerically 
coded, consent forms will be detached and separated from the numerically-coded data 
and your questionnaire data and video recordings will be stored in a locked filing 
cabinet at UEL, analysed by two independent researchers at UEL, entered into a dataset 
then discarded securely. The anonymised data will be used for the current study only. It 
is aimed that the findings will be written up for publication in a peer reviewed journal 
and might be presented at conferences. Should any data be used in subsequent studies 
or for further analysis, the data will still be kept anonymous and confidential. 
Nevertheless, please be aware that the confidentiality of the information provided is 
subject to legal limitations in data confidentiality (i.e. the data may be subject to a 
subpoena, a freedom of information request or mandated reporting by some 
professions). 
 
Providing Body fluids: Saliva Samples 
 
The study involves salivary cotinine testing which is a non-invasive procedure whereby 
you will be instructed to gently place a swab in your mouth for a few minutes until 
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saturated.  Saliva samples will be stored at the University of East London before being 
transported to the Advanced Bioanalysis Service Laboratories Ltd., Welwyn Garden 
City, UK, for analysis of the nicotine content. Samples will not be used for any other 
purposes or studies. Once saliva cotinine levels from all samples have been determined 
and recorded electronically, all samples will be disposed of in accordance MHRA, GLP 
(Good Laboratory Practise) and GCP (Good Clinical Practise) accreditation protocols. 
 
 
Location 
 
The study will be conducted at the University East London, Stratford Campus in our 
research lab on the ground floor of the Arthur Edward building or at a mutually agreed 
location that is suitable. 
 
 
Remuneration 
 
There is no remuneration for taking part in the study, although, you will be given an e-
cigarette device plus sufficient nicotine e-liquid refill bottle/cartridges to use for the first 
1-2 weeks of the study.  
Note, if you are a student, your participation, non-participation or later withdrawal will 
have no impact on your assessments (i.e.: no module credits involved) and learning 
experience at UEL. Equally, if you are a patient, service-user and/or receiving any form 
of treatment or medication, be advised that although e-cigarette use may increase the 
likelihood of a positive outcome in terms of cigarette consumption reduction, do not 
hold the belief that participation in the research guarantees such outcome.  
 
 
Disclaimer 
 
You are not obliged to take part in this study and should not feel coerced. You are free 
to withdraw at any time. Should you choose to withdraw from the study you may do so 
without disadvantage to yourself and without any obligation to give a reason. Your right 
to withdraw from the study includes the right to request the destruction of any of your 
data obtained from the study though you must memorise your personal participant 
number in order for the experimenter to delete your data.  You can email us at any point 
prior stating your participation number, and we will remove your data for you.  
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Following completion of the study, none of your contact information will be retained 
without your specific permission. 
 
Please feel free to ask any questions. If you are happy to continue you will be asked to 
sign a consent form prior to your participation. Please retain this invitation letter for 
reference.  
 
This study has received full approval from the University of East London’s Ethical 
Committee.  If you have any questions or concerns about how the study has been 
conducted, please contact the study’s Principle Investigator: 
 
Dr. Kirstie Soar, School of Psychology, University of East London, Water Lane, 
London E15 4LZ. +44 (0)20 8223 4082. E-mail:  k.soar@uel.ac.uk 
 
Or  
 
Catherine Fieulleteau, Ethics Integrity Manager, Graduate School, EB 1.43 
University of East London, Docklands Campus, London E16 2RD  
(Telephone: 020 8223 6683, Email: researchethics@uel.ac.uk). 
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APPENDIX 18 - CONSENT FORM 
 
UNIVERSITY OF EAST LONDON 
 
Consent to participate in a research study 
 
 
Title 
 
Cigalikes Versus Tank systems: Effects of Users’ experience, device 
characteristics and Nicotine Concentration during a Quit Attempt 
 
I have read the information sheet relating to the above research study and have been 
given a copy to retain. The nature and purpose of the research has been explained to me, 
and I have had the opportunity to discuss the details and ask questions about this 
information. I understand what is being proposed and the procedures in which I will be 
involved have been explained to me.  I understand that I am able to take breaks 
whenever I want and that I am free to leave at any time.  
 
I understand that my involvement in this study, and particular data from this research, 
will remain strictly confidential. Only the researcher(s) involved in the study will have 
access to identifying data. I understand that the findings from this research project may 
be written up, submitted for publication and presented at conferences. I understand that 
all collected data will remain confidential during this process. It has been explained to 
me what will happen once the research study has been completed. 
 
I hereby freely and fully consent to participate in the study which has been fully 
explained to me. Having given this consent, I understand that I have the right to 
withdraw from the study at any time without disadvantage to myself and without being 
obliged to give any reason. 
 
Participant’s Name (BLOCK CAPITALS)  
 
………………………………………………………………………………………. 
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Participant’s Signature  
 
……………………………………………………………………………………….. 
 
Researcher’s Name (BLOCK CAPITALS)  
 
……………………………………………………………………………………….. 
 
Researcher’s Signature  
 
………………………………………………………………………………………… 
 
 
Date: ……………………..……. 
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APPENDIX 19 - SMOKING HISTORY (STUDY 2) 
Participant number: _________ 
Session number: _________ 
Date: _________ 
Condition allocated: _________ 
 
1. How long have you been smoking? ……. 
2. How many cigarettes do you smoke per day?  ………………. 
3. Have you tried to quit smoking before?  ☐ Yes  ☐ No 
i. If yes, how many times have you tried?  ….. 
ii. If yes, did you use a smoking cessation aid?   ☐ Yes  ☐ No 
a. Please state which type ……….. 
 
4. Which of the following describes you? 
☐ I don’t want to stop smoking ☐ I think I should stop smoking but don’t really 
want to ☐ I want to stop smoking but haven’t thought about when  ☐ I REALLY want 
to stop smoking but I don’t know when I will ☐ I want to stop smoking and hope 
to soon ☐ I REALLY want to stop smoking and intend to in the next 3 months
 ☐ I REALLY want to stop smoking and intend to in the next month    ☐ I 
don’t know 
 
5.  How confident are you in succeeding in your quit attempt? 
☐ Not at all confident   ☐ A little confident  ☐ Moderately confident  
 ☐ Fairly confident   ☐ Extremely confident 
 
6. Have you tried an electronic cigarette in the past? 
 ☐ Yes  ☐ No 
i. If yes, how many times?  ….. 
ii. What e-cigarette model did you try?  ☐ Cigalike  ☐ Later generation  ☐ 
Both 
iii. If applicable, add a quick statement on why you did not sustain the use of e-
cigarette (eg. Did not like it, I wanted to try out of curiosity eg. I tried somebody 
else’s) 
…………………………………………………………… 
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A P P E N DI X 2 0  - F A G E R S T R Ö M T E S T  F O R CI G A R E T T E 
D E P E N D E N C E  
 
P arti ci p a nt n u m b er:  _ _ _ _ _ _ _ _ _  
S e ssi o n n u m b er:  _ _ _ _ _ _ _ _ _  
D at e:  _ _ _ _ _ _ _ _ _  
C o n diti o n all o c at e d:  _ _ _ _ _ _ _ _ _  
C O l e v el s: _ _ _ _ _ _ _ _ _  
 
Pl e as e a ns w e r e a c h q u e sti o n b y ti c ki n g t h e r e s p o ns e wit h w hi c h y o u a gr e e m ost  
 
 
1. H o w s o o n aft er y o u w a k e u p d o y o u s m o k e y o ur first ci g ar ett e ?  
 
 Wit hi n 5 mi n ut e s     
 6 - 3 0 mi n ut e s      
 3 1 - 6 0 mi n ut e s     
 Aft er 6 0 mi n ut e s     
 
 
2. D o y o u fi n d it diffi c ult t o r efr ai n fr o m s m o ki n g i n pl a c e s w h er e it i s f or bi d d e n, e. g. i n 
c h ur c h, at t h e li br ar y, i n ci n e m a e t c. ? 
 
 Y e s    N o      
 
 
3. W hi c h ci g ar ett e w o ul d y o u h at e m ost t o gi v e u p ?  
 
   T h e first o n e i n t h e m or ni n g     A n y ot h er o n e   
   
 
4. H o w m a n y ci g ar ett e s a d a y d o y o u s m o k e ?   
 
 1 0 or l e ss     
 1 1 - 2 0      
 2 1 - 3 0      
 3 1 or m or e     
 
 
5. D o y o u s m o k e m or e fr e q u e ntl y d uri n g t h e first h o urs aft er w a ki n g t h a n d uri n g t h e r e st 
of t h e d a y ?  
 
 Y e s    N o    
 
6. D o y o u s m o k e if y o u ar e s o ill t h at y o u ar e i n b e d m ost of t h e d a y ?   
 
 Y e s    N o   
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APPENDIX 21 - E-CIGARETTE USE AND SMOKING BEHAVIOUR 
DIARY 
Participant number: _________ 
Condition allocated: _________ 
Week beginning: _________ 
Date of completion: _________ 
 Monda
y 
Tuesda
y 
Wednesda
y 
Thursda
y 
Frida
y 
Saturda
y 
Sunda
y 
How many 
tobacco 
cigarettes 
have you 
smoked 
today?* 
       
Please try to 
estimate 
how many 
puffs you 
have taken 
on your e-
cig today: 
** 
       
How many 
cartridges/m
l of nicotine 
e-liquid 
have you 
used 
today?*** 
       
How 
satisfying 
did you find 
your e-
cigarette 
today (0-
100%)? 
       
How 
pleasant 
was your e-
cigarette 
today (0-
100%)? 
       
How much 
did your e-
cigarette 
reduce your 
craving for 
smoking 
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today (0-
100%)? 
How much 
of a ‘hit’ 
did you feel 
from the e-
cigarette 
today (0-
100%)? 
       
 
*Place a small vertical line inside the box every time you smoke a tobacco cigarette as 
shown below: 
 
                 would mean you have smoked 7 cigarettes today    
 
**Place a small vertical line inside the box every time you use your e-cigarette and add 
the numbers of puffs underneath the line as shown below: 
           would mean you have used your e-cigarette 4 times today and had 40 puffs 
overall. 
 
***The tank has a 2 mL capacity so if you topped up your tank today and used half of it 
following the top up, you used approximately 3 mL.  
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A P P E N DI X 2 2  - F O L L O W -U P I N T E R VI E W Q U E S T I O N S A T 1 , 3 A N D 6-
M O N T H S ( S T U D Y 3) 
 
 
P arti ci p a nt n u m b er:  _ _ _ _ _ _ _ _ _  
S e ssi o n n u m b er:  _ _ _ _ _ _ _ _ _  
D at e:  _ _ _ _ _ _ _ _ _  
C o n diti o n all o c at e d:  _ _ _ _ _ _ _ _ _  
 
Ci g a r ett es c o ns u m pti o n  
1.  H a v e y o u s m o k e d at all i n t h e l a st 7 d a ys ?  
If Y E S. H o w m a n y ?  … … … … … … … …  
i. H o w m a n y ci g ar ett e s d o y o u s m o k e p er d a y ?  
… … … … … … … … … … …..  
 
b.  If N O. W h e n di d y o u l a st s m o k e  
… … … … … … … … …  
 
iii. H o w di d y o u q uit s m o ki n g ?  
… … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … … …
… … … … … … ….  
 
H a v e y o u us e d a n y s m o ki n g c e ss ati o n ai d s ( N R T s, C o u ns elli n g) i n t h e l a st 1 2 m o nt hs ?  
1.  If y e s pl e a s e st at e w h at t y p e, w h e n, h o w oft e n y o u h a v e 
us e d it  
… … … … … … … … … … … … … ….  
 
If y o u a ns w e r e d N O t o Q u e sti o n I. 1, a n s w e r I. 1. b t h e n g o t o Q u e sti o n I I ( e -
ci g a r ett e us e).  
 
2. H o w s o o n aft er y o u w a k e u p d o y o u s m o k e y o ur first ci g ar ett e ?  
 
 Wit hi n 5 mi n ut e s     
 6 - 3 0 mi n ut e s      
 3 1 - 6 0 mi n ut e s     
 Aft er 6 0 mi n ut e s     
3. D o y o u fi n d it diffi c ult t o r efr ai n fr o m s m o ki n g i n pl a c e s w h er e it i s f or bi d d e n, e. g. i n 
c h ur c h, at t h e li br ar y, i n ci n e m a et c. ?  
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 Y e s    
 N o      
 
 
 
4. W hi c h ci g ar ett e w o ul d y o u h at e m ost t o gi v e u p ?  
 
 T h e first o n e i n t h e m or ni n g     
 A n y ot h er o n e       
 
 
 
5. D o y o u s m o k e m or e fr e q u e ntl y d uri n g t h e first h o urs aft er w a ki n g t h a n d uri n g t h e r e st 
of t h e d a y ?  
 
 Y e s    
 N o    
 
6. D o y o u s m o k e if y o u ar e s o ill t h at y o u ar e i n b e d m ost of t h e d a y ?   Y e s  
  N o   
 
 
 
E -ci g a r ett e us e q u esti o n n ai r e  
 
1.  Ar e y o u still usi n g t h e e -ci g ar ett e w e pr o vi d e d ?  
i. If n o, w h e n di d y o u st o p usi n g t h e d e vi c e ? 
… … … … ….  
ii. Di d y o u st o p usi n g t h e e -ci g ar ett e b e c a us e ? ( C h o os e t h e o pti o n  (o nl y 
o n e ) w hi c h f e el s t h e m ost r el e v a nt) 
a.  M alf u n cti o n i ss u e s T h e e -ci g ar ett e r e q uir e d t o b e c h ar g e d t o o 
oft e n   
b.  W a s n ot c o n v e ni e nt –  f elt a b ur d e n  
c.  T h e e -ci g ar ett e w a s n ot s ati sf yi n g   
d.  Ur g e t o s m o k e w a s t o o gr e at    
e.  I h a v e u p gr a d e d t o a b ett er m o d el  
f. O t h er 
 … … … … … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … … … … … … … … … … … … …
… … … … … … … … … … … … … … … … … …  
 
2.  W hi c h t y p e of d e vi c e d o y o u c urr e ntl y u s e m ost ( pl e a s e cir cl e o n e):  
 
a.  A di s p o s a bl e e -ci g ar ett e ( n o n -r e c h ar g e a bl e) 
 
 
464 
 
b. A rechargeable e-cigarette (sometimes called ‘stick-like’,  ‘cigarette-like’ 
or ‘cartomizers’ without fluid)  
c. A rechargeable e-cigarette (‘stick-like/cigarette-like/cartomizer’ without 
fluid) starter kit 
d. A rechargeable e-cigarette (non cigarette-like with fluid) 
e. A rechargeable e-cigarette (non cigarette-like with fluid) starter kit 
f. A modular system (your own combination of separate parts: battery, 
atomizer, fluid etc). 
g. E-cigar 
 
 
3. Which brand and model of e-cigarette are you currently using the most? 
 
Brand (please state) _________________ 
Model (please state)_________________ 
 
 
4. Which strength(s) of nicotine fluid/cartridge are you currently using? (circle all 
that apply). 
a. 0mg 
b. 4 mg  
c. 6mg 
d. 8mg 
e. 10 mg 
f. 11mg 
g. 15 mg 
h. 16mg 
i. 18mg 
j. 24mg 
k. 36mg  
l. Higher than 36mg 
m. I don’t know 
 
 
5. If you have circled more than one strength, please state which strength you use 
most:  _______________________________ 
 
 
 
6. Please try to estimate the amount you use per day: 
a. In puffs ____________ 
b. In cartridges ___________ 
c. In ml _______________ 
 
 
7. Which is your preferred flavour? (please circle one) 
a. Tobacco 
b. Mint/menthol 
c. Fruit (various) 
d. Coffee 
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e. Vanilla 
f. RY4 
g. Chocolate 
h. Cinnamon 
i. Tea 
j. Alcohol-related 
k. Other (please state) 
 
8. How soon after you wake up do you use your electronic cigarette? 
 
a. Within 5 minutes 
b. 6 – 30 minutes 
c. 31 – 60 minutes 
d. After 60 minutes 
 
9. Do you find it difficult to refrain from using your electronic cigarette in places 
where it is forbidden (e.g. on the train, in a business meeting) 
 
a. Yes 
b. No 
 
10. Which puffs on your e-cigarette would you hate most to give up? 
 
a. The first ones in the morning 
b. Any other one 
 
11. Do you puff more frequently on your e-cigarette during the first hours after 
waking than during the rest of the day? 
 
a. Yes 
b. No 
 
12. Do you use your e-cigarette if you are so ill that you are in bed most of the day? 
 
a. Yes 
b. No 
 
13.    Please rate your addiction to e-cigarettes on a scale of 0 to 
100:______________ 
 
I am NOT addicted at all = 0 
I am extremely addicted = 100 
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14. For you, stopping using the e-cigarette for good would be: 
 
a. Impossible 
b. Very difficult 
c. Fairly difficult 
d. Fairly easy 
e. Very easy 
 
15. How much of the time have you felt the urge to vape (i.e. use your e-cigarette) in 
the past week? (Circle one number) 
 
All the time Almost all 
the time 
A lot of the 
time 
Some of the 
time 
A little of the 
time 
Not at all 
5 4 3 2 1 0 
 
 
16. How strong have the urges been? (Circle one number) 
 
Extremely 
strong 
Very strong Strong Moderate Slight No urges 
5 4 3 2 1 0 
 
 
 
17. Since you started using the electronic cigarette, have you attempted to cut down 
the amount that you use it? 
 
a. Yes  
b. No  
 
If YES:  In your attempt to cut down your use of the electronic cigarette, how successful 
have you been? 
g. Extremely successful: I have stopped using it completely now  
h. Very successful: I only use it occasionally now    
i. Quite successful: I use it much less that I did initially   
j. Not very successful: I have only cut down slightly    
k. Unsuccessful: My use has not changed      
l. Very unsuccessful: I use it more than I did initially  
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18. Is it likely that in one month from now, you will have stopped using the electronic 
cigarette? 
 
a. Very likely 
b. Rather likely 
c. Rather unlikely 
d. Very unlikely 
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APPENDIX 23 - TABLES 3.6 AND 3.7 MEAN (SD) SUBJECTIVE 
EFFECTS STUDY 2 
 
Table 3.6 Mean (SD) per condition in positive effects associated with e-cigarette use. 
 Cigalikes  Tank 18                         Tank 6        
 Mean (%) SE Mean (%) SE Mean (%) SE 
‘Hit’ 47.78 5.74 59.93 4.26 50.10 4.37 
‘Satisfaction’ 42.77 4.12 61.75 3.06 59.29 3.14 
‘Pleasant’ 46.55 6.86 55.46 5.08 64.53 5.22 
‘Tastes good’ 45.02 6.62 46.59 4.91 50.84 5.07 
‘Reduced my craving’ 51.07 5.43 62.36 4.03 58.71 4.14 
‘helped concentration’ 36.83 6.44 41.13 4.77 41.18 4.90 
‘helped me feel 
calmer’ 
48.21 11.27 49.49 8.36 56.73 8.58 
‘feel more awake’ 32.36 5.97 32.33 4.43 32.11 4.54 
‘reduced my hunger’ 23.55 6.14 34.01 4.55 29.56 4.67 
‘tastes like usual 
brand/model’ 
22.52 6.08 22.68 4.51 22.05 4.62 
‘feels like using usual 
brand/model’ 
22.83 5.65 24.49 4.19 27.46 4.30 
Overall mean 38.13 4.12 44.56 3.06 44.78 3.14 
 
Table 3.7 Mean (SD) per condition in adverse effects associated with e-cigarette use 
            Cigalikes           Tank 18               Tank 6 
 Mean (%)  SE Mean (%) SE Mean (%) SE 
‘Confused’ 7.74 2.81 10.58 2.08 8.69 2.14 
‘Dizzy’ 10.49 3.36 8.27 2.49 13.23 2.55 
‘Headache’ 7.13 3.02 7.12 2.59 13.68 2.30 
‘Pounding heart’ 7.80 2.45 8.13 2.10 9.57 1.86 
‘Light headed’ 15.59 3.62 11.59 3.10 15.45 2.76 
Nausea, feeling sick 5.55 2.34 7.93 2.01 11.14 1.78 
‘Nervous’ 5.21 2.08 7.17 1.78 8.23 1.58 
‘Salivation’ 10.21 3.06 9.56 2.62 12.65 2.33 
‘Sweaty’ 5.64 2.41 6.28 2.07 9.73 1.84 
‘Weak’ 10.89 3.39 9.88 2.91 10.35 2.58 
‘Mouth irritation’ 8.98 2.21 9.07 1.90 9.43 1.68 
‘Throat irritation’ 14.68 4.68 18.86 4.00 16.50 3.56 
‘Aching jaws’ 6.58 2.89 7.24 2.48 9.86 2.20 
‘Vomiting’ 5.56 1.65 6.53 1.41 7.29 1.25 
‘Flatulence/Bloating’ 6.47 2.37 10.91 2.03 7.06 1.81 
‘Stomach ache’ 4.84 1.72 6.15 1.47 6.83 1.31 
‘Heartburn’ 7.17 2.11 6.21 1.81 7.50 1.61 
‘Diarrhoea’ 4.66 2.24 8.91 1.92 6.09 1.70 
‘Hiccups’ 4.30 1.59 6.26 1.36 5.99 1.21 
‘Cold hands feet’ 5.88 3.19 6.32 2.73 12 2.43 
‘Palpitations’ 5.49 2.01 7.35 1.72 7.13 1.53 
Overall mean 7.67 2.16 11.60 1.60 9.92 1.64 
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APPENDIX 24 - PRESENTATIONS & CONFERENCES 
 
➢ 22nd February 2019 “Predictors of Smoking Cessation in an E-Cigarette Quit 
Attempt: Device Type, Craving And Cigarette Dependence” at SRNT 25th 
Annual Meeting, Hilton San Francisco Union Square, San Francisco, California 
➢ 8-9th November 2018 “Effects of Device type and Nicotine Concentrations on E-
Cigarette Naïve Smokers’ Puffing Topography in a Two-Week Smoking 
Reduction Attempt” Poster presentation at the Society for the Study of Addiction 
(SSA) at the Crowne Plaza Hotel, Newcastle, UK. 
➢ 7th September 2018 “Changes in puffing topography in e-cigarette naïve smokers 
in the initial two weeks of a cessation attempt” Oral presentation at the Society 
for Nicotine and Tobacco Research Europe (SRNTe), Ludwig-Maximilians-
University psychiatric clinic, Munich, Germany  
➢ 23rd February 2018 "The Early Stage of a Smoking Cessation Attempt Using a 
cigalike Versus a Tank System E-cigarette: Effects on Subjective Symptoms" 
Poster presentation at the Society for Nicotine and Tobacco Research, The Hilton 
hotel, Baltimore, US. 
➢ 8th November 2017 “Cigalikes versus tank system E-cigarettes: Effects on 
smoking behaviours at the early stage of a quit attempt”.  Poster presentation at 
the Society for the Study of Addiction (SSA) at the Crowne Plaza Hotel, 
Newcastle, UK.  
➢ 17th July 2017 Invited speaker at a round table discussion on the role and impact 
of e-cigarettes in the UK and as part of a harm reduction strategy to a delegation 
sent by the Brazilian authorities. This was organised by the Knowledge Exchange 
Action group (KAP) and Nicotine Science and Policy group at the Guildhall, city 
of London Guildhall, Gresham Street, London, EC2V 7HH. 
➢ 15th – 17th June 2017 “Cigalikes vs Tank Systems: Effects on Smoking Reduction, 
Self-reported Satisfaction, Craving and Withdrawal Relief”. Invited speaker at 
the 4th Global Forum on Nicotine (GFN) 2017 at the Marriot Hotel, Warsaw, 
Poland. 
➢ 8th – 11th March 2017 Annual Meeting of the Society for Research on Nicotine 
and Tobacco (SRNT) Lynne Dawkins (LSBU), Catherine Kimber (UEL), Mira 
Doig (ABS labs), Colin Feyerabend (ABS labs) and Olivia Corcoran (UEL), Leon 
Kosmider, Jolanta Kurek (IOM) Compensatory Puffing Behaviour with Lower 
Nicotine Strength E-Liquid can Increase Carbonyl Exposure 
➢ 9th - 10th June 2016  Kimber CF, Kośmider L., Corcoran O., Dawkins L. (2016) 
Liquid Chromatographic Analysis of Carbonyl Compounds in Aerosols from High 
and Low Nicotine E-Cigarette Liquids Mirroring Realistic Puffing Topography. 
Poster presentation at the UK Nicotine & Smoking Cessation Conference 
(UKNSCC) at the Victoria Park Plaza Hotel, London, UK 
➢ 17th - 18th June 2016 Kimber CF, Kośmider L., Corcoran O., Dawkins L. (2016) 
Liquid Chromatographic Analysis of Carbonyl Compounds in Aerosols from High 
and Low Nicotine E-Cigarette Liquids Mirroring Realistic Puffing Topography. 
Poster presentation at the Global Forum on Nicotine (GFN) in Warsaw. 
➢ 26th - 29th July 2015 in Bristol Kimber CF, Kośmider L., Corcoran O., Dawkins 
L. (2015) Do e-cigarette users alter their puffing behaviours when given lower 
nicotine Concentrations?. Journal of Psychopharmacology. Abstract supplement 
29(8) ISSN 0269-8811. Poster presentation at the British Association for 
Psychopharmacology (BAP). 
 
